

National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010)

made under subsections 100(1) and (2) of the

National Health Act 1953

**Compilation No. 113**

**Compilation date:** 1 December 2020

**Includes amendments up to:** PB 115 of 2020

**Registered:** 8 December 2020

**About this compilation**

**This compilation**

This is a compilation of the *National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010)* that shows the text of the law as amended and in force on 1 December 2020 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

**Uncommenced amendments**

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Editorial changes**

For more information about any editorial changes made in this compilation, see the endnotes.

**Modifications**

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

**Self‑repealing provisions**

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary 1

Division 1—General 1

1 Name of Special Arrangement 1

4 Definitions 1

4A Definition of *authorised prescriber* 6

Division 2—HSD pharmaceutical benefits 8

5 Pharmaceutical benefits covered by this Special Arrangement 8

6 Application of Part VII of the Act 8

7 Responsible person 8

8 Prescribing of HSD pharmaceutical benefits—authorised prescribers 9

9 Prescription circumstances 9

9AA Modified prescription circumstances during COVID‑19 pandemic 9

9A HSD pharmaceutical benefits which may be supplied to public hospital admitted patients 10

Division 3—HSD Authority Required procedures 11

10 HSD Authority Required procedures 11

Division 4—Maximum quantity and maximum number of repeats 12

14 Maximum quantity 12

15 Maximum number of repeats 13

Division 5—Section 100 only 14

16 Section 100 only supply 14

Part 2—Supply of HSD pharmaceutical benefits 15

Division 1—General requirements for supply 15

17 Entitlement to HSD pharmaceutical benefits 15

17A Modified application of paragraph 92A(1)(f) conditions of approval 15

18 Supply of HSD pharmaceutical benefits under this Special Arrangement 15

Division 2—Repeat prescriptions 17

19 Application of section 51 of the Regulations 17

20 No repeats for visitors 17

Division 3—Prescribing HSD pharmaceutical benefits that have non‑CAR drugs 18

21 Methods of prescribing HSD pharmaceutical benefits that have non‑CAR drugs 18

22A Information to be kept for prescription of HSD pharmaceutical benefits referred to in section 9A that have non‑CAR drugs 18

Division 4—Prescribing HSD pharmaceutical benefits that have CAR drugs 19

23 Prescriptions for HSD pharmaceutical benefits that have CAR drugs 19

23A Information to be kept for prescription of HSD pharmaceutical benefits referred to in section 9A that have CAR drugs 19

24 HSD pharmaceutical benefits that have CAR drugs—quantity exceptions 19

25 HSD pharmaceutical benefits that have CAR drugs—repeat exceptions 25

26 Application of section 30 of the Regulations in relation to CAR drugs 30

Part 4—Claiming procedures and payment amounts 31

Division 2—Modified section 99AAA claims by approved public hospitals 31

Subdivision 1—General requirements 31

30 How claims to be made—modified section 99AAA claiming 31

31 Limit on number of prescriptions in one claim 31

Subdivision 3—Payment of claims 31

35 Payments to suppliers that are approved hospital authorities for public hospitals 31

Division 3—Payments to suppliers of HSD pharmaceutical benefits that are approved hospital authorities for private hospitals or approved pharmacists or approved medical practitioners 32

36 Payments to certain suppliers of HSD pharmaceutical benefits 32

Part 5—Dispensed price 33

Division 1—Dispensed price for supply of an HSD pharmaceutical benefit by a hospital authority for a public hospital 33

37 The dispensed price—supply by public hospital 33

38 Where quantity is less than a pack quantity 33

Division 2—Dispensed price for supply of HSD pharmaceutical benefit by an approved hospital authority for a private hospital or by an approved pharmacist or approved medical practitioner 34

39 The dispensed price—supply by an approved hospital authority for a private hospital or by an approved pharmacist or approved medical practitioner 34

40 Mark‑up 35

41 Where quantity is less than a pack quantity 36

42 Dispensing fee if quantity of repeated supply directed to be supplied on one occasion 36

Division 3—Dispensed price—other matters 37

44 Rounding up of dispensed price 37

Part 6—Patient contributions 38

46 Patient contributions in relation to approved hospital authorities 38

47 Patient contributions for claims by approved pharmacists or approved medical practitioners 38

48 Additional patient contributions 38

Part 7—Miscellaneous 39

49 Compliance and audit arrangements 39

50 PBS Safety Net 39

51 Application of Act and Part VII instruments to approved suppliers and prescriptions etc 39

Part 8—Approval of certain hospital authorities 41

52 Approval of certain public hospital authorities 41

Part 9—Transitional arrangements 42

53 Approvals of certain hospital authorities of public hospitals 42

54 Transitional arrangements for existing public hospital medication chart prescribing and paperless claiming 42

55 Transitional arrangements for existing non‑medication chart public hospital paperless claiming 42

56 Transitional arrangements for repeat prescriptions 43

Schedule 1—Pharmaceutical benefits covered by this Special Arrangement and related information 44

Schedule 2—Responsible Person Codes 121

Schedule 3—Circumstances and Purposes Codes 123

Schedule 3 Part 1—General statement for drugs for the treatment of hepatitis C 532

Schedule 4—Patient contributions 537

Schedule 5—HSD pharmaceutical benefits with modified prescription circumstances during COVID‑19 pandemic 538

Endnotes 541

Endnote 1—About the endnotes 541

Endnote 2—Abbreviation key 542

Endnote 3—Legislation history 543

Endnote 4—Amendment history 549

Part 1—Preliminary

Division 1—General

1 Name of Special Arrangement

(1) This Special Arrangement is the *National Health (Highly specialised drugs program) Special Arrangement 2010*.

(2) This Special Arrangement may also be cited as PB 116 of 2010.

4 Definitions

In this Special Arrangement:

***ABN*** has the same meaning as in the *A New Tax System (Australian Business Number) Act 1999*.

***accredited prescriber of medication for the treatment of hepatitis B*** means a medical practitioner, or an authorised nurse practitioner, approved by a State or Territory to prescribe medication for the treatment of hepatitis B for this Special Arrangement.

***accredited prescriber of medication for the treatment of hepatitis C*** means a medical practitioner, or an authorised nurse practitioner, approved by a State or Territory to prescribe medication for the treatment of hepatitis C for this Special Arrangement.

***accredited prescriber of medication for the treatment of HIV or AIDS*** means a medical practitioner, or an authorised nurse practitioner, approved by a State or Territory to prescribe medication for the treatment of HIV or AIDS for this Special Arrangement.

***accredited prescriber of medication for the treatment of schizophrenia*** means a medical practitioner approved by a State or Territory to prescribe medication for the treatment of schizophrenia for this Special Arrangement.

***Act*** means the *National Health Act 1953*.

***affiliated specialist medical practitioner*** means a medical practitioner who:

(a) is affiliated with the hospital at or from which the patient is receiving treatment; and

(b) is either:

(i) a staff hospital specialist; or

(ii) a visiting or consulting specialist of the hospital.

***approved hospital authority***, for a hospital, means the hospital authority for the hospital that:

(a) is approved:

(i) by the Minister under section 94 of the Act; or

(ii) by the Secretary under section 52 of this Special Arrangement; or

(b) was approved under section 52 of the *National Health (Highly specialised drugs program for public hospitals) Special Arrangements Instrument 2010* and the approval:

(i) is not suspended; or

(ii) has not been revoked.

Note: The Instrument mentioned in paragraph (b) is also known as PB 63 of 2010.

***approved private hospital*** means a private hospital that has an approved hospital authority.

***approved public hospital*** means a public hospital that has an approved hospital authority.

***authorised nurse practitioner*** has the same meaning as in Part VII of the Act.

***authorised prescriber*** has the meaning given by section 4A.

***benefit card*** means any of the following:

(a) a PBS Entitlement Card;

(b) a PBS Safety Net Concession Card;

(c) a Pensioner Concession Card;

(d) a Health Care Card (including Low Income Health Care Card and Foster Child Health Care Card);

(e) a Commonwealth Seniors Health Card;

(f) a Cleft Lip and Palate Card;

(g) a DVA Gold Card;

(h) a DVA White Card;

(i) a DVA Orange Card;

(j) War Widow/Widower Transport Card;

(k) a card or voucher approved by the Chief Executive Medicare for this paragraph.

***CAR drug*** (Complex Authority Required drug) means any of the following highly specialised drugs:

(a)          abatacept

(b)          adalimumab

(c)          ambrisentan

(d)          azacitidine

(e)          benralizumab

(f)           bosentan

(g)          eculizumab

(h)          eltrombopag

(i)            epoprostenol

(j)            etanercept

(k)          iloprost

(l)            infliximab

(m)        ivacaftor

(n)          lenalidomide

(o)          lumacaftor with ivacaftor

(p)          macitentan

(q)          mepolizumab

(r)           midostaurin

(s)           nusinersen

(t)            omalizumab

(u)          pasireotide

(v)          pegvisomant

(w)        pomalidomide

(x)          riociguat

(y)          rituximab

(z)          romiplostim

(aa)       sildenafil

(bb)      tadalafil

(cc)       teduglutide

(dd)      tezacaftor with ivacaftor and ivacaftor

(ee)       tocilizumab

(ff)         ustekinumab

(gg)       vedolizumab

***circumstances code*** means the letter ‘C’ followed by a number.

***Department*** means the Department administered by the Minister who administers the *National Health Act 1953*.

***dispensed price***:

(a) for the supply of an HSD pharmaceutical benefit by a hospital authority for a public hospital—has the meaning given by section 37; and

(b) for the supply of an HSD pharmaceutical benefit by an approved hospital authority for a private hospital or by an approved pharmacist—has the meaning given by section 39.

***eligible medical practitioner****,* for the prescription of an HSD pharmaceutical benefit under this Special Arrangement to an eligible patient, means a person:

(a) who is an affiliated specialist medical practitioner; or

(bb) who is, for the prescription of medication for the treatment of schizophrenia—an accredited prescriber of medication for the treatment of schizophrenia; or

(d) who is, for the prescription of medication for maintenance therapy if it is impractical to obtain a prescription from the treating affiliated specialist medical practitioner and the treating staff hospital specialist has agreed to the prescription—a medical practitioner; or

(e) who is, for the prescription of medication for maintenance therapy—a medical practitioner whom the Commonwealth and the State or Territory Government has agreed may give such a prescription.

***eligible patient*** means a person who

(a) is, or is to be treated as, an eligible person within the meaning of the Health Insurance Act 1973; and

(b) if receiving treatment at or from a public hospital, is receiving medical treatment by a medical practitioner as:

(i) a non‑admitted patient; or

(ii) a day admitted patient; or

(iii) a patient on discharge; or

(iv) an admitted patient who has been prescribed a HSD pharmaceutical benefit referred to in section 9A.

***entitlement number***, for a patient, means the number listed on the patient’s benefit card.

***General Statement for drugs for the treatment of hepatitis C*** means the statement set out in Schedule 3 Part 1.

***highly specialised drug*** means a listed drug mentioned in Schedule 1.

Note: Special Arrangements under section 100 of the Act apply to pharmaceutical benefits with drugs that have been declared by the Minister under subsection 85(2) of the Act. The drugs in Schedule 1 have all been so declared.

***hospital authority*** means:

(a) for a public hospital—the governing body of the hospital; or

(b) for a private hospital—the proprietor of the hospital.

***HSD pharmaceutical benefit*** means a pharmaceutical benefit mentioned in Schedule 1.

***item code***, for a drug that has a particular form, manner of administration and brand, means the code for the form, manner of administration and brand for the drug set out in the Department’s website.

Note: The website address is http://www.pbs.gov.au.

***medication chart prescription*** has the meaning given in the Regulations, but does not include a medication chart prescription for a person receiving treatment in a residential care service.

***medication for the treatment of hepatitis B*** means any of the following:

(a) adefovir

(b) entecavir

(c) interferon alfa‑2a

(e) lamivudine

(g) tenofovir

***medication for the treatment of hepatitis C*** means medication mentioned in the table in paragraph 3 of the General Statement for drugs for the treatment of hepatitis C.

***medication for the treatment of HIV or AIDS*** means any of the following:

(a) abacavir

(b) abacavir with lamivudine

(c) abacavir with lamivudine and zidovudine

(d) atazanavir

(e) atazanavir with cobicistat

(f) azithromycin

(g) bictegravir with emtricitabine with tenofovir alafenamide

(h) darunavir

(i) darunavir with cobicistat

(j) dolutegravir

(k) dolutegravir with abacavir and lamivudine

(l) dolutegravir with lamivudine

(m) dolutegravir with rilpivirine

(n) doxorubicin ‑ pegylated liposomal

(o) efavirenz

(p) emtricitabine with rilpivirine with tenofovir alafenamide

(q) emtricitabine with tenofovir alafenamide

(r) enfuvirtide

(s) etravirine

(t) fosamprenavir

(u) ganciclovir

(v) lamivudine

(w) lamivudine with zidovudine

(x) lopinavir with ritonavir

(y) maraviroc

(z) nevirapine

(aa) raltegravir

(bb) rifabutin

(cc) rilpivirine

(dd) ritonavir

(ee) saquinavir

(ff) tenofovir

(gg) tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat

(hh) tenofovir with emtricitabine

(ii) tenofovir with emtricitabine and efavirenz

(jj) tipranavir

(kk) valganciclovir

(ll) zidovudine

***medication for the treatment of schizophrenia*** means clozapine.

***non‑CAR drug*** means a highly specialised drug that is not a complex authority required (CAR) drug.

***other Special Arrangement*** means another Special Arrangement under section 100 of the Act.

***purposes code*** means the letter ‘P’ followed by a number.

***residential care service*** has the meaning given by the Regulations.

***Regulations*** means the *National Health (Pharmaceutical Benefit) Regulations 2017*.

***streamlined authority code*** means the number mentioned in subsection 13(1).

***under co‑payment data*** means information relating to a supply of a HSD pharmaceutical benefit by an approved pharmacist, approved medical practitioner or approved hospital authority for a hospital where a claim is not payable as the dispensed price for the supply of the HSD pharmaceutical benefit does not exceed the amount that the supplier was entitled to charge under subsection 46(2) or subsection 47(2) of this Special Arrangement.

Note: Terms used in this Special Arrangement have the same meaning as in the Act—see section 13 of the *Legislative Instruments Act 2003*. These terms include:

• approved ex‑manufacturer price

* approved medical practitioner

• approved pharmacist

• claimed price

• hospital

• medical practitioner

• Chief Executive Medicare

• pack quantity

• pharmaceutical benefit

• pharmaceutical item

• private hospital

• proportional ex‑manufacturer price

• public hospital.

4A Definition of *authorised prescriber*

(1) An eligible medical practitioner for the prescription of an HSD pharmaceutical benefit under this Special Arrangement to an eligible patient is an ***authorised prescriber*** for the HSD pharmaceutical benefit.

(2) A medical practitioner is an ***authorised prescriber*** for each of the following HSD pharmaceutical benefits for the purpose of the treatment of hepatitis C:

(a) grazoprevir with elbasvir;

(b) ledipasvir with sofosbuvir; and

(c) ribavirin.

(3) A person mentioned in column 1 of an item of the following table is an ***authorised prescriber*** for an HSD pharmaceutical benefit mentioned in column 2 of the item.

| Authorised prescribers for certain HSD pharmaceutical benefits | | |
| --- | --- | --- |
| Item | Column 1  Person | Column 2  HSD pharmaceutical benefit |
| 1 | An accredited prescriber of medication for the treatment of hepatitis B | A medication for the treatment of hepatitis B |
| 2 | An accredited prescriber of medication for the treatment of hepatitis C | A medication for the treatment of hepatitis C |
| 3 | An accredited prescriber of medication for the treatment of HIV or AIDS | A medication for the treatment of HIV or AIDS |

Division 2—HSD pharmaceutical benefits

5 Pharmaceutical benefits covered by this Special Arrangement

(1) This Special Arrangement applies to each HSD pharmaceutical benefit mentioned in Schedule 1.

(2) Each HSD pharmaceutical benefit to which this Special Arrangement applies is a brand of a listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Note: Each listed drug mentioned in Schedule 1 is a highly specialised drug—see definition of ***highly specialised drug*** in section 4. Each listed drug has been declared by the Minister under subsection 85(2) of the Act. The form, manner of administration and brand mentioned in Schedule 1 have been determined by the Minister under subsections 85(3), (5) and (6) of the Act respectively.

6 Application of Part VII of the Act

(1) Each HSD pharmaceutical benefit supplied in accordance with this Special Arrangement is supplied under Part VII of the Act.

(2) A provision of Part VII of the Act, or of regulations or other instruments made for Part VII of the Act, applies subject to this Special Arrangement.

Note: See subsection 100(3) of the Act.

7 Responsible person

(1) If a code is mentioned in the column in Schedule 1 headed ‘Responsible Person’ for a brand of a pharmaceutical item, the person mentioned in paragraph (2)(a) is the responsible person for the brand of the pharmaceutical item.

(2) For subsection (1):

(a) the person is the person mentioned in Schedule 2 for the code, with the ABN, if any, mentioned in Schedule 2 for the person; and

(b) the pharmaceutical item is the listed drug mentioned in Schedule 1:

(i) in the form mentioned in Schedule 1 for the listed drug; and

(ii) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Note: An HSD pharmaceutical benefit mentioned in Schedule 1 is a brand of a pharmaceutical item.

Note: A person identified by a code in the column headed ‘Responsible Person’ in Schedule 1 has been determined by the Minister, under section 84AF of the Act, to be the responsible person for the brand of the pharmaceutical item.

8 Prescribing of HSD pharmaceutical benefits—authorised prescribers

(1) For the purposes of subsection 88(1) of the Act applying to a medical practitioner who is an authorised prescriber for an HSD pharmaceutical benefit, the benefit is determined.

(2) For the purposes of subsection 88(1E) of the Act applying to an authorised nurse practitioner who is an authorised prescriber for an HSD pharmaceutical benefit, the benefit is determined.

(4) For subsection (1), the HSD pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

(5) Subsection 9(1A) of the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012* (which provides for the pharmaceutical benefits for which medical practitioners are authorised to write prescriptions) does not apply to an HSD pharmaceutical benefit other than a medication for the treatment of hepatitis C.

(6) Subsections (1) and (2) do not apply to an HSD pharmaceutical benefit mentioned in Part 2 of Schedule 1 to the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012* (PB 71 of 2012) (ready‑prepared pharmaceutical benefits for supply only).

9 Prescription circumstances

(1) If at least 1 circumstances code is mentioned in the column in Schedule 1 headed ‘Circumstances’ for an HSD pharmaceutical benefit, the circumstances mentioned in Schedule 3 for the code are the circumstances in which a prescription for the supply of the HSD pharmaceutical benefit may be written.

(2) For subsection (1), the HSD pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

(3) This section has effect subject to section 9AA (which temporarily modifies the circumstances mentioned in Schedule 3 for circumstances codes for HSD pharmaceutical benefits that are pharmaceutical items described in Schedule 5).

9AA Modified prescription circumstances during COVID‑19 pandemic

(1) This section affects the circumstances in which a prescription may be written by an authorised prescriber for the supply of an HSD pharmaceutical benefit that is a listed brand of a pharmaceutical item described in Schedule 5 to a person (the ***patient***) if the authorised prescriber is satisfied the patient has, in accordance with this Special Arrangement, already been supplied with the benefit on the basis of a prescription written in circumstances determined by subsection 9(1) unaffected by this section.

(2) For the purposes of subsection 9(1), Schedule 3 has effect as if each circumstances code for the HSD pharmaceutical benefit:

(a) did not mention any circumstance that, having regard to the patient’s situation and the state of affairs associated with precautions against the spread of the coronavirus known as COVID‑19, it is not reasonably practicable to establish in relation to the patient; and

(b) mentioned the circumstance that the authorised prescriber keeps a written record of the reason it is not practicable to establish the circumstance described in paragraph (a).

(3) This section, subsection 9(3) and Schedule 5 are repealed at the start of 1 April 2021.

9A HSD pharmaceutical benefits which may be supplied to public hospital admitted patients

The HSD pharmaceutical benefits which may be supplied to public hospital admitted patients under this Special Arrangement are referred to in the table below:

(a) if a drug is referred to in the table below and paragraphs (b), (c) and (d) do not apply – all HSD pharmaceutical benefits containing that drug;

(b) if a form of the drug is referred to in the table below and paragraphs (c) and (d) do not apply – all HSD pharmaceutical benefits containing that drug in that form;

(c) if a manner of administration of that form of the drug is referred to in the table below and paragraph (d) does not apply – all HSD pharmaceutical benefits containing that drug in that form with that manner of administration;

(d) if a brand of a drug in that form with that manner of administration is referred to in the table below – that brand of HSD pharmaceutical benefit containing that drug in that form with that manner of administration;

(e) if one or more circumstances and/or purposes code is identified in the table below – the HSD pharmaceutical benefit must be prescribed for one of those circumstances and/or purposes.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Drug | Form | Manner of Administration | Brand | Circumstances  Code | Purposes  Code |
| eculizumab |  |  |  |  |  |

Note: A circumstances and/or purposes code mentioned in the above table is the same circumstances and/or purposes code referred to in section 9 (circumstances code) or section 14 or section 15 (purposes code).

Division 3—HSD Authority Required procedures

10 HSD Authority Required procedures

(1) This section applies to an HSD pharmaceutical benefit if the circumstances mentioned in Schedule 3 for a circumstances code mentioned in Schedule 1 for the HSD pharmaceutical benefit includes:

(a) Compliance with Authority Required procedures;

(b) Compliance with Written Authority Required procedures;

(c) Compliance with Written or Telephone Authority Required procedures;

(d) Compliance with modified Authority Required procedures.

(1A) If the circumstances mentioned in Schedule 3 for a circumstances code mentioned in Schedule 1 for a HSD pharmaceutical benefit include ‘Compliance with Written or Telephone Authority Required procedures’ then treat as if the words used are ‘Compliance with Authority Required procedures’.

(2) The Authority Required procedures as provided for in sections 11 to 14 of the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012* are to be followed.

(3) In addition to the requirements of subsection (2), where ‘Compliance with modified Authority Required procedures’ appears in the circumstances mentioned in Schedule 3 for the code, in addition to ‘Compliance with Written or Telephone Authority Required procedures’, any other requirement included in the circumstances is to be followed as part of the Authority Required procedures.

Division 4—Maximum quantity and maximum number of repeats

14 Maximum quantity

(1) The maximum quantity or number of units of the pharmaceutical item in an HSD pharmaceutical benefit that may, in 1 prescription for the supply of the HSD pharmaceutical benefit, be directed to be supplied by an authorised prescriber for the HSD pharmaceutical benefit is the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ for the HSD pharmaceutical benefit.

(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for an HSD pharmaceutical benefit, the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ is the maximum for the particular purposes mentioned in Schedule 3 for each code.

(3) If no purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’, the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same HSD pharmaceutical benefit.

(4) For subsection (1), the pharmaceutical item is the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

(5) For this section, the HSD pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

(6) Subsection (1) applies, in relation to an HSD pharmaceutical benefit that has a CAR drug, subject to section 24.

Note: The maximum quantities and numbers of units mentioned in the column headed ‘Maximum quantity’ in Schedule 1 have been determined by the Minister under paragraph 85A(2)(a) of the Act.

Note: See also section 26.

(7) A determination made under paragraph 85A(2)(a) of the Act does not apply to an HSD pharmaceutical benefit supplied in accordance with this Special Arrangement in relation to the maximum quantity of the HSD pharmaceutical benefit that can be supplied under this Special Arrangement if the maximum quantity mentioned in the determination differs from the maximum quantity mentioned in this section.

15 Maximum number of repeats

(1) The maximum number of occasions an authorised prescriber for the HSD pharmaceutical benefit may, in 1 prescription, direct that the supply of the pharmaceutical benefit be repeated is the number in the column in Schedule 1 headed ‘Number of Repeats’ for the pharmaceutical benefit.

(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for the pharmaceutical benefit, the number of repeats mentioned in the column in Schedule 1 headed ‘Number of Repeats’ is the maximum number for the particular purposes mentioned in Schedule 3 for each code.

(3) If no purposes code is mentioned in the column headed ‘Purposes’, the number of repeats mentioned in the column headed ‘Number of Repeats’ is the maximum number for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.

(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

(a) in the form mentioned in Schedule 1 for the listed drug; and

(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

(5) Subsection (1) applies, in relation to an HSD pharmaceutical benefit that has a CAR drug, subject to section 25.

Note: See also section 26.

(6) A determination made under paragraph 85A(2)(b) of the Act does not apply to an HSD pharmaceutical benefit supplied in accordance with this Special Arrangement in relation to the maximum number of occasions an authorised prescriber for the HSD pharmaceutical benefit may, in 1 prescription, direct, under this Special Arrangement, that the supply of the HSD pharmaceutical benefit be repeated if the maximum number mentioned in the determination differs from the maximum number mentioned in this section.

Division 5—Section 100 only

16 Section 100 only supply

(1) If the letter ‘D’ is mentioned in the column in Schedule 1 headed ‘Section 100 only’ for a listed drug, the listed drug may be supplied only in accordance with this Special Arrangement and any other Special Arrangement relating to the listed drug.

(2) An HSD pharmaceutical benefit that has a drug mentioned in subsection (1) is not available for general supply on the Pharmaceutical Benefits Scheme.

Note: The Minister has declared, under subsection 85(2A) of the Act, that the listed drug can only be supplied under a section 100 Special Arrangement.

(3) If the letters ‘PB’ are mentioned in the column in Schedule 1 headed ‘Section 100 only’ for an HSD pharmaceutical benefit, the HSD pharmaceutical benefit may be supplied only in accordance with this Special Arrangement and any other Special Arrangement relating to the pharmaceutical benefit.

(4) An HSD pharmaceutical benefit mentioned in subsection (3) is not available for general supply on the Pharmaceutical Benefits Scheme.

Note: The Minister has determined, under paragraph 85(8)(a) of the Act, that this HSD pharmaceutical benefit can only be supplied under a section 100 Special Arrangement.

(5) If the letter ‘C’ is mentioned in the column in Schedule 1 headed ‘Section 100 only’ for an HSD pharmaceutical benefit, the HSD pharmaceutical benefit may be supplied in the circumstances mentioned in Schedule 3 for the circumstances code in the column headed ‘Circumstances’ only in accordance with this Special Arrangement and any other Special Arrangement relating to the HSD pharmaceutical benefit.

(6) An HSD pharmaceutical benefit mentioned in subsection (5) is not available in the circumstances mentioned in subsection (5) for general supply on the Pharmaceutical Benefits Scheme.

Note: The Minister has determined, under paragraph 85(8)(b) of the Act, that 1 or more of the circumstances in which a prescription for the supply of the HSD pharmaceutical benefit may be written are circumstances in which the benefit can only be supplied under a section 100 Special Arrangement.

Part 2—Supply of HSD pharmaceutical benefits

Division 1—General requirements for supply

17 Entitlement to HSD pharmaceutical benefits

Subject to this Special Arrangement, an eligible patient is entitled to be supplied an HSD pharmaceutical benefit under this Special Arrangement without payment or other consideration, other than a charge made in accordance with Part 6.

17A Modified application of paragraph 92A(1)(f) conditions of approval

(1) Section 8 of the conditions of approval for approved pharmacists under paragraph 92A(1)(f) of the Act does not apply to the supply of a HSD pharmaceutical benefit, once prepared as a final product ready for infusion to a person, when the HSD pharmaceutical benefit has a physical, chemical or biological stability restricting its clinically effective shelf life to 8 hours or less.

(2) For the purposes of this section, shelf life means the period of time that a medicine can be stored and still be considered safe and effective for use.

18 Supply of HSD pharmaceutical benefits under this Special Arrangement

(1) Subject to subsection (2), this Special Arrangement only applies to the supply of an HSD pharmaceutical benefit:

(a) by an approved hospital authority for a public hospital to an eligible patient receiving treatment at or from an approved public hospital; or

(b) by an approved hospital authority for a private hospital to an eligible patient receiving treatment at or from an approved private hospital; or

(c) by an approved pharmacist to an eligible patient receiving treatment at or from a private hospital; or

(d) if the HSD pharmaceutical benefit has a CAR drug—by an approved pharmacist to an eligible patient receiving treatment at or from an approved public hospital or an approved private hospital.

(2) Where an eligible patient receives treatment in or at or outside of an approved public hospital or an approved private hospital, then a supplier listed in paragraph (a) may supply, to the eligible patient, HSD pharmaceutical benefits that are referred to in paragraph (b):

(a) The suppliers are:

i. an approved pharmacist; or

ii. an approved medical practitioner; or

iii. an approved hospital authority;

(b) The HSD pharmaceutical benefits are:

i. medication for the treatment of hepatitis B;

ii. medication for the treatment of HIV or AIDS, other than the pharmaceutical benefits containing the drugs azithromycin, doxorubicin ‑ pegylated liposomal and rifabutin; and

iii. medication for the treatment of schizophrenia when used in continuing therapy.

(3) This section does not require an approved hospital authority or an approved pharmacist to supply the HSD pharmaceutical benefit directly to a patient.

(4) The HSD pharmaceutical benefit may be supplied by the approved hospital authority or approved pharmacist through an agent.

(5) Section 94 of the Act applies in a modified manner to pharmaceutical benefits supplied by an approved hospital authority under this Special Arrangement.

Division 2—Repeat prescriptions

19 Application of section 51 of the Regulations

Section 51 of the Regulations does not apply to the supply of HSD pharmaceutical benefits.

20 No repeats for visitors

An authorised prescriber for an HSD pharmaceutical benefit must not write a repeat prescription for the HSD pharmaceutical benefit for a person who is a visitor to Australia even if the person is, in accordance with section 7 of the *Health Insurance Act 1973*, to be treated as an eligible person within the meaning of that Act.

Division 3—Prescribing HSD pharmaceutical benefits that have non‑CAR drugs

21 Methods of prescribing HSD pharmaceutical benefits that have non‑CAR drugs

An authorised prescriber for an HSD pharmaceutical benefit that has a non‑CAR drug may prescribe the HSD pharmaceutical benefit under this Special Arrangement by:

(a) writing a prescription for the HSD pharmaceutical benefit in accordance with section 40 of the Regulations; or

(b) preparing a medication chart prescription for the HSD pharmaceutical benefit in accordance with section 41 of the Regulations.

Note: An authorised prescriber for an HSD pharmaceutical benefit that has a non‑CAR drug may prescribe more than the maximum quantity, or more than the maximum number of repeats, of the HSD pharmaceutical benefit only in accordance with section 30 of the Regulations.

22A Information to be kept for prescription of HSD pharmaceutical benefits referred to in section 9A that have non‑CAR drugs

(1) If an authorised prescriber for an HSD pharmaceutical benefit referred to in section 9A prescribes the HSD pharmaceutical benefit for supply under Part VII of the Act, and the HSD pharmaceutical benefit has a non‑CAR drug, then either the:

(a) authorised prescriber; or

(b) approved hospital authority treating the eligible patient;

must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes.

(2) These records must be kept for 2 years after the date the prescription to which the records relate is written.

Division 4—Prescribing HSD pharmaceutical benefits that have CAR drugs

23 Prescriptions for HSD pharmaceutical benefits that have CAR drugs

An authorised prescriber for an HSD pharmaceutical benefit that has a CAR drug may prescribe the HSD pharmaceutical benefit by writing a prescription for the HSD pharmaceutical benefit in accordance with section 40 of the Regulations.

23A Information to be kept for prescription of HSD pharmaceutical benefits referred to in section 9A that have CAR drugs

(1) If an authorised prescriber for an HSD pharmaceutical benefit referred to in section 9A prescribes the HSD pharmaceutical benefit for supply under Part VII of the Act, and the HSD pharmaceutical benefit has a CAR drug, then either the:

(a) authorised prescriber; or

(b) approved hospital authority treating the eligible patient;

must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes.

(2) These records must be kept for 2 years after the date the prescription to which the records relate is written.

24 HSD pharmaceutical benefits that have CAR drugs—quantity exceptions

(1) An authorised prescriber for an HSD pharmaceutical benefit that has a CAR drug mentioned in subsection (2) may write a prescription for the HSD pharmaceutical benefit to be supplied to an eligible patient on any one occasion only in accordance with the limitation mentioned in subsection (2) for the drug.

(2) The drugs and limitations are as follows:

(a) for HSD pharmaceutical benefits that have the drug ambrisentan, bosentan, epoprostenol, etanercept, iloprost, sildenafil or tadalafil—a quantity of units sufficient for up to 1 month of treatment with the drug;

(b) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of an adult with severe active rheumatoid arthritis—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 3 milligrams per kilogram;

(c) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of an adult with active ankylosing spondylitis, severe active psoriatic arthritis or severe chronic plaque psoriasis—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 5 milligrams per kilogram;

(d) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of a patient with refractory Crohn disease or fistulating Crohn disease—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 5 milligrams per kilogram;

(da) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of a patient with moderate to severe ulcerative colitis—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 5 milligrams per kilogram.

(db) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of an adult with severe Crohn disease—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 5 milligrams per kilogram.

(e) for HSD pharmaceutical benefits that have the drug rituximab—a quantity of units sufficient to provide for a single dose;

(f) for HSD pharmaceutical benefits that have the drug abatacept—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose;

(g) for HSD pharmaceutical benefits that have the drug tocilizumab, for the treatment of adult patients with severe active rheumatoid arthritis—a quantity of units that are sufficient, based on the weight of the patient and taking into account whether any other strength injections will contribute part of the dose, to provide for the whole or part of a single dose of 8 mg per kg;

(h) for HSD pharmaceutical benefits that have the drug adalimumab—a quantity of units that are sufficient, based on the weight of the patient, to provide for 2 doses;

(i) for HSD pharmaceutical benefits that have the drug lenalidomide, for the treatment of a patient with multiple myeloma:

(i) with the form Capsule 5 mg—up to 84 tablets;

(ii) with the form Capsule 10 mg—up to 42 tablets;

(iii) with the form Capsule 15 mg—up to 21 tablets;

(iv) with the form Capsule 25 mg—up to 21 tablets;

(j) for HSD pharmaceutical benefits that have the drug lenalidomide, for the treatment of a patient with myelodysplastic syndrome:

(i) with the form Capsule 5 mg—up to 21 tablets;

(ii) with the form Capsule 10 mg—up to 21 tablets;

(k) for HSD pharmaceutical benefits that have the drug azacitidine with the form Powder for injection 100mg—up to 14 units.

(l) for HSD pharmaceutical benefits that have the drug romiplostim, for initial treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP):

(i) at the time of the initial written authority application—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 1 microgram per kilogram;

(ii) during the initial period of dose titration—a quantity of units sufficient to provide for a single dose;

(iii) for a patient whose dose has been stable for a period of 4 weeks—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.

(m) for HSD pharmaceutical benefits that have the drug romiplostim, for initial PBS‑subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with Romiplostim prior to 1 April 2011 and in whom the criteria for initial treatment in the circumstances can be demonstrated to have been met at the time his or her treatment with Romiplostim was commenced:

(i) at the time of the initial written authority application—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 1 microgram per kilogram;

(ii) during the initial period of dose titration—a quantity of units sufficient to provide for a single dose;

(iii) for a patient in the titration phase of treatment whose dose has been stable for a period of 4 weeks—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks;

(iv) for a patient whose dose had been stable for a period of at least 4 weeks at the time of the initial application for PBS‑subsidy—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks of treatment.

(n) for HSD pharmaceutical benefits that have the drug romiplostim, for the first period of continuing treatment or re‑initiation of interrupted PBS subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with Romiplostim during the initial period of PBS‑subsidised treatment—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks treatment.

(o) for HSD pharmaceutical benefits that have the drug romiplostim, for the second and subsequent periods of continuing treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who continues to display a sustained platelet response to treatment with Romiplostim—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks of treatment.

(p) for HSD pharmaceutical benefits that have the drug omalizumab, for initial treatment of uncontrolled severe allergic asthma—a quantity of units that are sufficient to provide for 28 weeks treatment;

(r) for HSD pharmaceutical benefits that have the drug omalizumab, for continuing treatment—a quantity of units that are sufficient to provide for 24 weeks treatment.

(ra) for HSD pharmaceutical benefits that have the drug omalizumab, for the treatment of severe chronic spontaneous urticaria:

(i) for initial treatment—a quantity of units that are sufficient to provide for 12 weeks treatment;

(ii) for initial PBS‑subsidised treatment in a patient who has previously received non‑PBS‑subsidised therapy with omalizumab (grandfathered patients)—a quantity of units that are sufficient to provide for 24 weeks treatment;

(iii) for continuing treatment—a quantity of units that are sufficient to provide for 24 weeks treatment.

(s) for HSD pharmaceutical benefits that have the drug eltrombopag, for initial PBS‑subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP):

(i) with the form Tablet 25 mg (as olamine)—up to 28 tablets;

(ii) with the form Tablet 50 mg (as olamine)—up to 28 tablets;

—a quantity of units that are sufficient for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.

(t) for HSD pharmaceutical benefits that have the drug eltrombopag, for initial PBS‑subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with Eltrombopag prior to 1 November 2011 and in whom the criteria for initial treatment in the circumstances can be demonstrated to have been met at the time his or her treatment with Eltrombopag was commenced):

(i) with the form Tablet 25 mg (as olamine)—up to 28 tablets;

(ii) with the form Tablet 50 mg (as olamine)—up to 28 tablets;

—a quantity of units that are sufficient for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.

(u) for HSD pharmaceutical benefits that have the drug eltrombopag, for the first period of continuing treatment or re‑initiation of interrupted PBS subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with Eltrombopag during the initial period of PBS‑subsidised treatment:

(i) with the form Tablet 25 mg (as olamine)—up to 28 tablets;

(ii) with the form Tablet 50 mg (as olamine)—up to 28 tablets;

—a quantity of units that are sufficient for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.

(v) for HSD pharmaceutical benefits that have the drug eltrombopag, for the second and subsequent periods of continuing treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who continues to display a sustained platelet response to treatment with Eltrombopag:

(i) with the form Tablet 25 mg (as olamine)—up to 28 tablets;

(ii) with the form Tablet 50 mg (as olamine)—up to 28 tablets;

—a quantity of units that are sufficient for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.

(w) for HSD pharmaceutical benefits that have the drug tocilizumab, for the treatment of patients with severe active systemic juvenile idiopathic arthritis—a quantity of units sufficient for up to 1 month of treatment with the drug.

(x) for HSD pharmaceutical benefits that have the drug riociguat, for the treatment of Chronic thromboembolic pulmonary hypertension (CTEPH):

(ii) for Initial treatment—prescriptions for dose titration must provide sufficient quantity for dose titrations by 0.5 mg increments at 2‑week intervals to achieve up to a maximum of 2.5 mg three times daily.  Approvals for subsequent authority prescriptions will be limited to 1 month of treatment.

(iii) for Continuing treatment—the maximum quantity per prescription will be limited to provide sufficient supply for 1 month of treatment.

(y) for HSD pharmaceutical benefits that have the drug riociguat, for balance of supply for patient who has received insufficient therapy with this agent:

(ii) for Initial treatment—maximum of 20 weeks of treatment.

(iii) for Continuing treatment—maximum of 24 weeks of treatment—the treatment must provide no more than the balance up to 20 or 24 weeks of treatment available under the above respective restriction.

(z) for HSD pharmaceutical benefits that have the drug riociguat, for the treatment of Pulmonary arterial hypertension (PAH):

(i) for Initial 1(new patients), Initial 2 (new patients) and Initial 3 (change or re‑commencement of therapy for all patients) – prescriptions for dose titration will provide sufficient quantity for dose titrations by 0.5 mg increments at 2‑week intervals to achieve up to a maximum of 2.5 mg three times daily. Approvals for subsequent authority prescriptions will be limited to 1 month of treatment.

(ii) for First Continuing treatment and Subsequent Continuing treatment – the maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.

(iii) for Initial 1 (new patients) or Initial 2 (new patients) or Initial 3 (change or re‑commencement of therapy for all patients) or First Continuing treatment – Balance of supply – the treatment must provide no more than the balance of up to six months treatment.

(za) for HSD pharmaceutical benefits that have the drug pasireotide, for the treatment of acromegaly:

(i) with the form Injection (modified release) 20 mg (as embonate), vial and diluent syringe—up to 2 vials and diluent syringes;

(ii) with the form Injection (modified release) 40 mg (as embonate), vial and diluent syringe—up to 2 vials and diluent syringes;

(iii) with the form Injection (modified release) 60 mg (as embonate), vial and diluent syringe—up to 2 vials and diluent syringes.

(zb) for HSD pharmaceutical benefits that have the drug pegvisomant, for the treatment of acromegaly:

(i) for initial treatment, for the 80 mg loading dose—4 x injection set containing powder for injection 20 mg, 1 and diluent, 1;

(ii) for initial treatment (subsequent doses)—1 x injection set containing powder for injection 10 mg, 15 mg or 20 mg, 30 and diluent, 30;

(iii) for initial PBS‑subsidised treatment in a patient who has previously received non‑PBS‑subsidised therapy with pegvisomant—1 x injection set containing powder for injection 10 mg, 15 mg or 20 mg, 30 and diluent, 30;

(iv) for continuing treatment—1 x injection set containing powder for injection 10 mg, 15 mg or 20 mg, 30 and diluent, 30.

(zc) for HSD pharmaceutical benefits that have the drug ustekinumab, for the treatment of severe Crohn disease:

(i) for initial treatment, for a weight‑based loading dose—up to 4 vials of Solution for I.V. infusion 130 mg in 26 mL;

(ii) for a change or re‑commencement of treatment, for a weight‑based loading dose—up to 4 vials of Solution for I.V. infusion 130 mg in 26 mL.

(zd) for HSD pharmaceutical benefits that have the drug vedolizumab, for the treatment of moderate to severe ulcerative colitis—the appropriate number of vials to provide for a single infusion of 300 mg per dose.

(ze) for HSD pharmaceutical benefits that have the drug vedolizumab, for the treatment of severe Crohn disease— the appropriate number of vials to provide for a single infusion of 300 mg.

(zf) for HSD pharmaceutical benefits that have the drug nusinersen, for PBS‑subsidised treatment of spinal muscular atrophy:

(i) for initial treatment with loading doses at days 0, 14, 28 and 63—up to 2 x solution for injection 12 mg in 5 mL for days 0 and 14; up to 1 x solution for injection 12 mg in 5 mL for day 28 or 63.

(ii) for continuing treatment—0 repeat supplies

25 HSD pharmaceutical benefits that have CAR drugs—repeat exceptions

(1) An authorised prescriber for an HSD pharmaceutical benefit that has a CAR drug mentioned in subsection (2) may authorise the repeat supply of the HSD pharmaceutical benefit only in accordance with the limitations mentioned in subsection (2) for the drug.

(2) The drugs and limitations are as follows:

(a) for bosentan:

(i) if the prescription is for the balance of a 6 month course of initial treatment for a patient who has been issued with an authority prescription for the first month of the 6 month course—up to 4 repeat supplies; or

(ii) if the prescription is for continuing treatment of a patient who has achieved a response to his or her most recent course of PBS‑subsidised treatment—up to 5 repeat supplies;

(b) for etanercept:

(i) for the initial treatment of severe polyarticular course juvenile chronic arthritis—up to 3 repeat supplies; or

(ii) for the continuing treatment of severe polyarticular course juvenile chronic arthritis—up to 5 repeat supplies;

(c) for infliximab, for the treatment of an adult with severe active rheumatoid arthritis:

(i) if the circumstances permit a course of up to a maximum of 22 weeks of treatment to be authorised—up to 3 repeat supplies; or

(ii) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 2 repeat supplies;

(d) for infliximab, for the treatment of an adult with severe active psoriatic arthritis:

(i) if the circumstances permit a course of up to a maximum of 22 weeks of treatment to be authorised—up to 3 repeat supplies; or

(ii) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 2 repeat supplies;

(e) for infliximab, for the treatment of an adult with active ankylosing spondylitis—up to 3 repeat supplies;

(f) for infliximab, for the treatment of a patient with refractory Crohn disease or fistulating Crohn disease—up to 2 repeat supplies;

(g) for infliximab, for the treatment of an adult with severe chronic plaque psoriasis:

(i) if the circumstances permit a course of up to a maximum of 22 weeks of treatment to be authorised—up to 3 repeat supplies; or

(ii) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 2 repeat supplies;

(ga) for infliximab, for the treatment of a patient with moderate to severe ulcerative colitis:

(i) for initial treatment (new patient or re‑commencement of treatment after more than 5 years break in therapy)—up to 2 repeat supplies;

(ii) for a change or re‑commencement of treatment after a break in therapy—up to 2 repeat supplies;

(iii) for continuing treatment—up to 2 repeat supplies.

(gb) for infliximab, for the treatment of an adult with severe Crohn disease:

(i) for initial treatment (new patient – initial 1)—up to 2 repeat supplies;

(ii) for a change or re‑commencement of treatment (initial 2)—up to 2 repeat supplies;

(iii) for continuing treatment—up to 2 repeat supplies.

(h) for abatacept, for the treatment of an adult with severe active rheumatoid arthritis:

(i) if the circumstances permit a course of up to a maximum of 16 weeks of treatment to be authorised—up to 4 repeat supplies; or

(ii) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies;

(i) for rituximab—1 repeat supply;

(j) for ambrisentan:

(i) for the initial PBS‑subsidised treatment of a patient who was receiving non‑PBS‑subsidised treatment with ambrisentan for less than 6 months before 1 December 2009—sufficient repeat supplies to allow the patient to complete a period of combined PBS‑subsidised and non‑PBS‑subsidised therapy of up to 6 months duration in total; or

(ii) if subparagraph (i) does not apply—up to 5 repeat supplies;

(k) for lenalidomide, for the treatment of a patient with multiple myeloma—up to 2 repeat supplies;

(l) for lenalidomide, for the treatment of a patient with myelodysplastic syndrome—up to 3 repeat supplies;

(m) for epoprostenol, iloprost, sildenafil, or tadalafil—up to 5 repeat supplies;

(n) for tocilizumab, for the treatment of adults with severe active rheumatoid arthritis:

(i) if the circumstances permit a course of up to a maximum of 16 weeks of treatment to be authorised—up to 3 repeat supplies;

(ii) If the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies;

(o) for adalimumab for the treatment of a patient with juvenile idiopathic arthritis:

(i) if the circumstances permit a course of up to a maximum of 16 weeks of treatment to be authorised—up to 3 repeat supplies;

(ii) if the circumstances permit a course of up to a maximum of 24 weeks treatment to be authorised—up to 5 repeat supplies;

(p) for azacitidine:

(i) for initial treatment—up to 2 repeat supplies;

(ii) for continuing treatment—up to 5 repeat supplies.

(q) for romiplostim for initial treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP):

(i) at the time of the initial written authority application—1 repeat supply;

(ii) during the initial period of dose titration—1 repeat supply;

(iii) for a patient whose dose has been stable for a period of 4 weeks—up to 4 repeat supplies.

(r) for romiplostim for initial PBS‑subsidised treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with Romiplostim prior to 1 April 2011 and in whom the criteria for initial treatment in the circumstances can be demonstrated to have been met at the time his or her treatment with romplostin was commenced:

(i) at the time of the initial written authority application—1 repeat supply;

(ii) during the initial period of dose titration—1 repeat supply;

(iii) for a patient in the titration phase of treatment whose dose has been stable for a period of 4 weeks—up to 4 repeat supplies;

(iv) for a patient whose dose had been stable for a period of at least 4 weeks at the time of the initial application for PBS‑subsidy—up to 5 repeat supplies.

(s) for romiplostim for the first period of continuing treatment or re‑initiation of interrupted PBS‑subsidised treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpure (ITP) who has displayed a sustained platelet response to treatment with Romiplostim during the initial period of PBS‑subsidised treatment:

(i) at the time of the initial written authority application—up to 5 repeat supplies;

(ii) where less than 5 repeat supplies are requested in the initial written authority application—sufficient repeat supplies to complete a maximum of 24 weeks treatment.

(t) for romiplostim for the second and subsequent periods of continuing treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpure (ITP) who continues to display a sustained platelet response to treatment with Romiplostim—up to 5 repeat supplies.

(u) for omalizumab—where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the authority application—sufficient repeat supplies to complete 24 weeks of treatment.

(v) for omalizumab—where at least 24 weeks treatment was requested at the time of the application—0 repeat supplies.

(va) for omalizumab, for the treatment of severe chronic spontaneous urticaria:

(i) for initial treatment—where the patient has received a quantity of units that are sufficient to provide for 12 weeks treatment—0 repeat supplies;

(ii) for initial PBS‑subsidised treatment in a patient who has previously received non‑PBS‑subsidised therapy with omalizumab (grandfathered patients)—where the patient has received a quantity of units that are sufficient to provide for 24 weeks treatment—0 repeat supplies;

(iii) for continuing treatment—where the patient has received a quantity of units that are sufficient to provide for 24 weeks treatment—0 repeat supplies;

(w) for eltrombopag for initial treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP):

(i) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies.

(x) for eltrombopag for initial PBS‑subsidised treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with eltrombopag prior to 1 November 2011 and in whom the criteria for initial treatment in the circumstances can be demonstrated to have been met at the time his or her treatment with eltrombopag was commenced:

(i) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies.

(y) for eltrombopag for the first period of continuing treatment or re‑initiation of interrupted PBS‑subsidised treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpure (ITP) who has displayed a sustained platelet response to treatment with eltrombopag during the initial period of PBS‑subsidised treatment:

(i) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies;

(ii) where less than 5 repeat supplies are requested in the initial written authority application—sufficient repeat supplies to complete a maximum of 24 weeks treatment.

(z) for eltrombopag for the second and subsequent periods of continuing treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpure (ITP) who continues to display a sustained platelet response to treatment with eltrombopag—up to 5 repeat supplies.

(za) for tocilizumab, for the treatment of patients with severe active systemic juvenile idiopathic arthritis:

(i) if the circumstances permit a course of up to a maximum of 16 weeks of treatment to be authorised—up to 3 repeat supplies;

(ii) If the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies.

(zb) for riociguat, for the treatment of Chronic thromboembolic pulmonary hypertension (CTEPH):

(ii) for initial treatment—up to 3 repeat supplies.

(iii) for continuing treatment—up to 5 repeat supplies.

(zc) for riociguat, for the treatment of Pulmonary arterial hypertension (PAH):

(i) for Initial 1 (new patients), Initial 2 (new patients) and Initial 3 (change or re‑commencement of therapy for all patients) – up to 4 repeat supplies.

(ii) for First Continuing treatment and Subsequent Continuing treatment – up to 5 repeat supplies.

(zd) for pasireotide—up to 5 repeat supplies.

(ze) for pegvisomant:

(i) for initial treatment, for the 80 mg loading dose—0 repeat supplies;

(ii) for intitial treatment (subsequent doses)—up to 5 repeat supplies;

(iii) for initial PBS‑subsidised treatment in a patient who has previously received non‑PBS‑subsidised therapy with pegvisomant—up to 5 repeat supplies;

(iv) for continuing treatment—up to 5 repeat supplies.

(zf) for ustekinumab:

(i) for initial treatment, for a weight‑based loading dose—0 repeat supplies;

(ii) for a change or re‑commencement of treatment, for a weight‑based loading dose——0 repeat supplies.

(zg) for vedolizumab, for the treatment of severe Crohn disease:

(i) for initial treatment (new patient – initial 1)—up to 2 repeat supplies;

(ii) for a change or re‑commencement of treatment (initial 2)—up to 2 repeat supplies;

(iii) for initial PBS‑subsidised treatment (grandfather)—up to 2 repeat supplies;

(iv) for continuing treatment—up to 2 repeat supplies.

(zh) for vedolizumab, for the treatment of moderate to severe ulcerative colitis:

(i) for initial treatment (new patient – initial 1)—up to 2 repeat supplies;

(ii) for a change or re‑commencement of treatment after a break in therapy (initial 2)—up to 2 repeat supplies;

(iii) for initial PBS‑subsidised treatment (grandfather patient)—up to 2 repeat supplies;

(iv) for continuing treatment—up to 2 repeat supplies.

(zi) for nusinersen, for the treatment of spinal muscular atrophy:

(i) for initial treatment loading doses —up to 1 x solution for injection 12 mg in 5 mL

(ii) for continuing treatment—up to 1 x solution for injection 12 mg in 5 mL

(3) In this section, ***circumstances*** means circumstances mentioned in Schedule 3 for the circumstances code mentioned in the column in Schedule 1 headed ‘Circumstances’ for the HSD pharmaceutical benefit that has the drug.

26 Application of section 30 of the Regulations in relation to CAR drugs

Section 30 of the Regulations does not apply in relation to a prescription for an HSD pharmaceutical benefit that has a CAR drug supplied under this Special Arrangement.

Part 4—Claiming procedures and payment amounts

Division 2—Modified section 99AAA claims by approved public hospitals

Subdivision 1—General requirements

30 How claims to be made—modified section 99AAA claiming

An approved hospital authority for a public hospital may make a claim for payment for the supply of an HSD pharmaceutical benefit in accordance with the rules made by the Minister under subsection 99AAA(8) of the Act, as modified by this Division.

Note: An approved hospital authority for a public hospital that may make a modified section 99AAA claim may choose instead to make the claim in accordance with the rules made by the Minister under subsection 99AAA(8) of the Act.

31 Limit on number of prescriptions in one claim

The claim for payment must not contain more than 3 500 prescriptions.

Subdivision 3—Payment of claims

35 Payments to suppliers that are approved hospital authorities for public hospitals

(1) An approved hospital authority for a public hospital is entitled to be paid the amount, if any, by which the dispensed price for the supply of the HSD pharmaceutical benefit exceeds the amount that the approved hospital authority was entitled to charge under subsection 46(2).

(2) The dispensed price is to be worked out in accordance with Division 1 of Part 5.

(3) No mark ups may be added to the cost of an HSD pharmaceutical benefit for which payment is claimed under this Division.

Division 3—Payments to suppliers of HSD pharmaceutical benefits that are approved hospital authorities for private hospitals or approved pharmacists or approved medical practitioners

36 Payments to certain suppliers of HSD pharmaceutical benefits

(1) An approved hospital authority for a private hospital is entitled to be paid by the Commonwealth the amount, if any, by which the dispensed price for its supply of the HSD pharmaceutical benefit is greater than the amount that the approved hospital authority was entitled to charge under subsection 46(2).

(2) An approved pharmacist or an approved medical practitioner is entitled to be paid by the Commonwealth the amount, if any, by which the dispensed price for the supply of an HSD pharmaceutical benefit is greater than the amount that the approved pharmacist or approved medical practitioner was entitled to charge under subsection 47(2).

(3) The dispensed price for the supply of an HSD pharmaceutical benefit by an approved hospital authority for a private hospital or by an approved pharmacist or by an approved medical practitioner is to be worked out under Division 2 of Part 5.

Note: An approved hospital authority for a private hospital or an approved pharmacist may make claims for payment in accordance with rules made by the Minister under subsection 99AAA(8) of the Act—see section 99AAA(2) of the Act.

Part 5—Dispensed price

Division 1—Dispensed price for supply of an HSD pharmaceutical benefit by a hospital authority for a public hospital

37 The dispensed price—supply by public hospital

Subject to section 43, the dispensed price for the supply of an HSD pharmaceutical benefit, by a hospital authority for a public hospital, is as follows:

(a) if the quantity of the HSD pharmaceutical benefit that is ordered and supplied is equal to a multiple of a pack quantity of the benefit—the sum of the approved ex‑manufacturer price or the proportional ex‑manufacturer price for each pack quantity;

(b) if the quantity of the HSD pharmaceutical benefit that is ordered and supplied is less than a pack quantity of the benefit—the amount calculated in accordance with section 38;

(c) if the quantity of the HSD pharmaceutical benefit that is ordered and supplied is more than a multiple of a pack quantity of the benefit—the sum of:

(i) the approved ex‑manufacturer price or the proportional ex‑manufacturer price for each pack quantity; and

(ii) the amount calculated in accordance with section 38 for the remainder of the quantity supplied that is less than a pack quantity.

38 Where quantity is less than a pack quantity

If the quantity of an HSD pharmaceutical benefit that is ordered and supplied is less than a pack quantity of the benefit (a ***broken quantity***), the amount mentioned in paragraph 37(b) and subparagraph 37(c)(ii) is to be calculated by:

(a) dividing the quantity or number of units in the broken quantity by the pack quantity, expressed as a percentage to 2 decimal places; and

(b) applying that percentage to the approved ex‑manufacturer price or proportional ex‑manufacturer price for the pack quantity.

Division 2—Dispensed price for supply of HSD pharmaceutical benefit by an approved hospital authority for a private hospital or by an approved pharmacist or approved medical practitioner

39 The dispensed price—supply by an approved hospital authority for a private hospital or by an approved pharmacist or approved medical practitioner

(1) The ***dispensed price*** for the supply of an HSD pharmaceutical benefit by an approved hospital authority for a private hospital, or by an approved pharmacist, or by an approved medical practitioner, is as follows:

(a) if the quantity of the HSD pharmaceutical benefit that is ordered and supplied is equal to a multiple of a pack quantity, the sum of:

(i) the approved ex‑manufacturer price or the proportional ex‑manufacturer price for each pack quantity, plus the mark‑up mentioned in section 40, taken to the nearest cent, with one half cent being rounded up to 1 cent; and

(ii) either:

(A) a dispensing fee equal to the dispensing fee for the supply of a ready prepared pharmaceutical benefit, mentioned in the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or

(B) if the HSD pharmaceutical benefit has a drug mentioned in subsection (2) in the form mentioned in that subsection for the drug—the extemporaneously‑prepared dispensing fee mentioned in the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or

(b) if a quantity of the HSD pharmaceutical benefit that is ordered and supplied is less than a pack quantity, the sum of:

(i) the amount calculated in accordance with section 41; and

(ii) either:

(A) a dispensing fee equal to the dispensing fee for the supply of a ready prepared pharmaceutical benefit, mentioned in the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or

(B) if the HSD pharmaceutical benefit has a drug mentioned in subsection (2) in the form mentioned in that subsection for the drug—the extemporaneously‑prepared dispensing fee mentioned in the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or

(c) if a quantity of the HSD pharmaceutical benefit that is ordered and supplied is more than a multiple of a pack quantity, the sum of:

(i) for each pack quantity, the approved ex‑manufacturer price or the proportional ex‑manufacturer price for the pack quantity, plus the mark‑up mentioned in section 40, taken to the nearest cent, with one half cent being counted as 1 cent; and

(ii) the amount calculated in accordance with section 41 for the remainder of the quantity supplied that is less than a pack quantity; and

(iii) either:

(A) a dispensing fee equal to the dispensing fee for the supply of a ready prepared pharmaceutical benefit, mentioned in the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or

(B) if the HSD pharmaceutical benefit has the drug mentioned in subsection (2) in the form mentioned in that subsection for the drug—the extemporaneously‑prepared dispensing fee set out in the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit.

(2) For sub‑subparagraphs (1)(a)(ii)(B), (1)(b)(ii)(B) and (1)(c)(iii)(B), the drugs and the forms for the drugs are as follows:

(a) mycophenolic acid as a powder for oral suspension containing mycophenolate mofetil 1g per 5 mL, 165mL;

(c) valganciclovir as a powder for oral solution 50mg (as hydrocholoride) per mL, 100 mL.

40 Mark‑up

For subparagraphs 39(1)(a)(i) and 39(1)(c)(i) and paragraph 41(a), the mark‑up for a pack quantity of a ready‑prepared pharmaceutical benefit is:

(a) if the pack quantity for which a mark‑up is to be calculated under this section is equal to a maximum quantity of the HSD pharmaceutical benefit, the mark‑up is the amount mentioned in the table below for the approved ex‑manufacturer price (AEMP) or proportional ex‑manufacturer price (PEMP) for that quantity.

| Item | AEMP or PEMP for Maximum Quantity | Mark‑up for Maximum Quantity |
| --- | --- | --- |
| 1 | < $40 | 10% of AEMP or PEMP |
| 2 | ≥ $40, ≤ $100 | $4.00 |
| 3 | > $100, ≤ $1,000 | 4% of AEMP or PEMP |
| 4 | > $1,000 | $40.00 |

(b) if the pack quantity for which a mark‑up is to be calculated under this section is not equal to a maximum quantity of the HSD pharmaceutical benefit, the mark‑up is worked out as follows:

(i) if the mark‑up that would apply to the maximum quantity is shown in the table in paragraph (a) as a monetary amount—the mark‑up for the pack quantity is that monetary amount reduced proportionately for the relative quantities; and

(ii) if the mark‑up that would apply to the maximum quantity is shown in the table in paragraph (a) as a percentage of AEMP or PEMP—the mark‑up for the pack quantity is that percentage of the AEMP or PEMP for the pack quantity.

41 Where quantity is less than a pack quantity

If the quantity of an HSD pharmaceutical benefit that is ordered and supplied is less than a pack quantity of the benefit (a broken quantity), the amount mentioned in subparagraph 39(b)(i) and 39(c)(ii) is to be calculated by:

(a) adding the mark‑up mentioned in section 40 to the approved ex‑manufacturer price or the proportional ex‑manufacturer price for the pack quantity, taking the result to the nearest cent, with one half cent being counted as 1 cent; and

(b) dividing the quantity or number of units in the broken quantity by the pack quantity, expressed as a percentage to 2 decimal places; and

(c) applying the percentage worked out under subparagraph (b) to the amount worked out under subparagraph (a).

42 Dispensing fee if quantity of repeated supply directed to be supplied on one occasion

If an authorised prescriber for an HSD pharmaceutical benefit, instead of directing a repeated supply of the HSD pharmaceutical benefit, directs the supply on one occasion of a quantity or number of units of the HSD pharmaceutical benefit, not exceeding the total quantity or number of units that could be prescribed if the authorised prescriber directed a repeated supply, the dispensed price for the supply of the HSD pharmaceutical benefit will include only one dispensing fee.

Note: See section 49 of the Regulations for the circumstances in which such a supply may be directed.

Division 3—Dispensed price—other matters

44 Rounding up of dispensed price

The dispensed price for the supply of an HSD pharmaceutical benefit will in each case be taken to the nearest cent, one half cent being counted as one cent.

Part 6—Patient contributions

46 Patient contributions in relation to approved hospital authorities

(1) This section applies to an approved hospital authority for a public hospital or a private hospital that supplies an HSD pharmaceutical benefit.

(2) The approved hospital authority may charge the patient an amount equivalent to the amount that may be charged under section 87 of the Act for the supply of a pharmaceutical benefit to the patient.

(3) For section 87 of the Act, the amount that is equal to the special patient contribution for the supply of an HSD pharmaceutical benefit that is a brand of a pharmaceutical item is the amount mentioned in section 48 if the HSD pharmaceutical benefit is mentioned in Schedule 4.

47 Patient contributions for claims by approved pharmacists or approved medical practitioners

(1) This section applies if an approved pharmacists or an approved medical practitioner supplies an HSD pharmaceutical benefit to an eligible patient and makes a claim for payment.

(2) The approved pharmacist or the approved medical practitioner may charge the patient an amount equivalent to the amount that may be charged under section 87 of the Act for the supply of a pharmaceutical benefit to the patient.

(3) For section 87 of the Act, the amount that is equal to the special patient contribution for the supply of an HSD pharmaceutical benefit that is a brand of a pharmaceutical item is the amount mentioned in section 48 if the HSD pharmaceutical benefit is mentioned in Schedule 4.

48 Additional patient contributions

For subsections 46(3) and 47(3), the amount is the amount that is the difference between:

(a) the price that would have been the dispensed price for the quantity of the HSD pharmaceutical benefit supplied if that dispensed price had been based on the claimed price mentioned for the benefit in the column in Schedule 4 headed ‘Claimed Price’; and

(b) the dispensed price for that quantity of the HSD pharmaceutical benefit.

Part 7—Miscellaneous

49 Compliance and audit arrangements

(1) If an approved supplier supplies HSD pharmaceutical benefits under this Special Arrangement, the approved supplier that supplies the HSD pharmaceutical benefits must keep adequate, secure and auditable records of all supplied HSD pharmaceutical benefits for which a claim is made.

(2) The records must be kept in systems that are able to be audited by the Chief Executive Medicare on reasonable notice being given to the approved supplier.

50 PBS Safety Net

(2) An amount paid by a person because of a charge made by an approved hospital authority under subsection 46(2) counts towards the person’s PBS safety net if it is equivalent to the amount chargeable under subsection 87(5) of the Act for the supply of the HSD pharmaceutical benefit less the amount chargeable under that subsection because of subsection 87(2A) of the Act.

(3) An amount paid by a person because of a charge made by an approved pharmacist or approved medical practitioner under subsection 47(2) counts towards the person’s PBS safety net, other than an amount equivalent to the amount chargeable under subsection 87(2A) of the Act for the supply of the HSD pharmaceutical benefit to the person.

Note: Division 1A of Part VII of the Act contains provisions about safety net concession cards.

51 Application of Act and Part VII instruments to approved suppliers and prescriptions etc

For the application of Part VII of the Act, or of regulations or other instruments made for Part VII of the Act:

(a) a reference in the Act or other instrument to an approved supplier or an approved hospital authority includes a reference to a hospital authority approved under:

(i) subsection 52(2) of this Special Arrangement; or

(ii) subsection 52(2) of the *National Health (Highly specialised drugs program for public hospitals) Special Arrangements Instrument 2010 (PB 63 of 2010)*; and

(b) a reference in the Act or other instrument to a number allotted to an approval under section 16 includes a reference to a number allotted to an approval under:

(i) subsection 52(3) of this Special Arrangement; and

(ii) subsection 52(3) of the *National Health (Highly specialised drugs program for public hospitals) Special Arrangements Instrument 2010 (PB 63 of 2010)*; and

(c) a medication chart prescription may be written for an eligible patient receiving treatment from a hospital; and

(f) the rules made under subsection 98AC(4) of the Act apply to a supply of a HSD pharmaceutical benefit by an approved pharmacist, approved medical practitioneror approved hospital authority for a hospital under this Special Arrangement as if the definition of under co‑payment data appearing in those rules was replaced with the definition of under co‑payment data in section 4 of this Special Arrangement.

Note: Section 84 of the Act defines ***approved hospital authority*** and ***approved supplier*** for Part VII of the Act.

Note: The rules made by the Minister under subsection 99AAA(8) of the Act are instruments made under Part VII of the Act.

Part 8—Approval of certain hospital authorities

52 Approval of certain public hospital authorities

(1) A hospital authority for a public hospital, that must not be approved under section 94 of the Act because of subsection 94(5) of the Act, may apply, in writing, to the Secretary for approval under this Part for the purpose of its supplying HSD pharmaceutical benefits under this Special Arrangement to eligible patients receiving treatment at or from the hospital of which it is the governing body.

(2) The Secretary may, in writing, approve the hospital authority for this Special Arrangement.

(3) If the Secretary approves the hospital authority, he or she may allot a number to the approval.

(4) A number allotted to a hospital authority under either of the following provisions is to be treated as having been allotted by the Secretary under subsection 16(4) of the Regulations:

(a) subsection (3) of this section;

(b) subsection 52(3) of the *National Health (Highly specialised drugs program for public hospitals) Special Arrangements Instrument 2010*.

(5) The approval may be subject to any conditions the Secretary determines.

(6) The Secretary must, in writing, notify the hospital authority of his or her decision on the hospital authority’s application.

(7) The Secretary may, at any time, by notice in writing to the hospital authority, vary, suspend or revoke the approval.

Note: An approval under this Part may only be made for a hospital authority for a public hospital and does not constitute an approval under section 94 of the Act.

Part 9—Transitional arrangements

53 Approvals of certain hospital authorities of public hospitals

Despite the revocation of the *National Health (Highly specialised drugs program for public hospitals) Special Arrangements Instrument 2010 (PB 63 of 2010)*, an approval that was in force under subsection 52(2) of that Instrument immediately before the commencement of this section continues in force under this Special Arrangement as if it were an approval under subsection 52(2) of this Special Arrangement.

54 Transitional arrangements for existing public hospital medication chart prescribing and paperless claiming

(1) An eligible medical practitioner at a public hospital may prescribe a HSD pharmaceutical benefit that has a non‑CAR drug under this Special Arrangement, before 1 April 2017, by following the requirements for prescribing from a medication chart in the *National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010* as in force immediately before 1 April 2015.

(2) An approved hospital authority for a public hospital can supply a HSD pharmaceutical benefit prescribed under subsection (1).

(3) The requirements for prescribing, supplying and claiming from a medication chart set out in the *National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010* as in force immediately before 1 April 2015, continue to apply in relation to a medication chart prepared under subsection (1).

(4) However, this section does not apply if the public hospital referred to in subsections (1) and (2) is a listed approved hospital under regulation 59 of the *National Health (Pharmaceutical Benefits) Regulations 1960* as in force immediately before the commencement of the Regulations.

(5) However, if this section applies, the supply certification referred to in subrule 5(1A) of the rules made under subsections 98AC(4) and 99AAA(8) of the Act is allowed, and then required, as indicated in transitional rule 12 of those rules.

55 Transitional arrangements for existing non‑medication chart public hospital paperless claiming

(1) An approved hospital authority for a public hospital may supply a HSD pharmaceutical benefit that has a non‑CAR drug before 1 April 2017, from a prescription other than a medication chart, in accordance with Part 4, Division 2, Subdivision 2 of the *National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010* as in force immediately before 1 April 2015.

(2) However, if this section applies, the supply certification referred to in subrule 5(1A) of the rules made under subsections 98AC(4) and 99AAA(8) of the Act is allowed, and then required, as indicated in transitional rule 12 of those rules.

56 Transitional arrangements for repeat prescriptions

(1) Where an authorised prescriber has issued a repeat prescription prior to 1 July 2015, the new arrangements apply to the supply of the repeat pharmaceutical benefits.

(2) In this section ***new arrangements*** mean the *National Health (Highly specialised drugs program) Special Arrangement 2010* as in force on 1 July 2015.

Schedule 1—Pharmaceutical benefits covered by this Special Arrangement and related information

(sections 5, 7, 8, 9, 10, 14, 15, 16 and 25)

| **Listed Drug** | **Form** | **Manner of Administration** | **Brand** | **Responsible Person** | **Circumstances** | **Purposes** | **Maximum Quantity** | **Number of Repeats** | **Section 100 only** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Abacavir | Tablet 300 mg (as sulfate) | Oral | Ziagen | VI | C4454 C4512 |  | 120 | 5 | D |
|  | Oral solution 20 mg (as sulfate) per mL, 240 mL | Oral | Ziagen | VI | C4454 C4512 |  | 8 | 5 | D |
| Abacavir with Lamivudine | Tablet containing abacavir 600 mg (as hydrochloride) with lamivudine 300 mg | Oral | Abacavir/Lamivudine GH 600/300 | GQ | C4527 C4528 |  | 60 | 5 | D |
|  | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | ABACAVIR/LAMIVUDINE 600/300 SUN | RA | C4527 C4528 |  | 60 | 5 | D |
|  |  |  | Abacavir/ Lamivudine Mylan | AF | C4527 C4528 |  | 60 | 5 | D |
|  |  |  | Kivexa | VI | C4527 C4528 |  | 60 | 5 | D |
| Abacavir with Lamivudine and Zidovudine | Tablet containing abacavir 300 mg (as sulfate) with lamivudine 150 mg and zidovudine 300 mg | Oral | Trizivir | VI | C4480 C4495 |  | 120 | 5 | D |
| Abatacept | Powder for I.V. infusion 250 mg | Injection | Orencia | BQ | C8627 C8638 C8655 C8688 C8748 C8759 |  | See Note 1 | See Note 2 | PB |
| Adalimumab | Injection 20 mg in 0.4 mL pre‑filled syringe | Injection | Humira | VE | C9384 C9417 C10582 C10583 C10600 C10619 |  | See Note 1 | See Note 2 | C |
|  | Injection 40 mg in 0.8 mL pre‑filled syringe | Injection | Humira | VE | C9384 C9417 C10582 C10583 C10600 C10619 |  | See Note 1 | See Note 2 | C |
|  | Injection 40 mg in 0.8 mL pre‑filled pen | Injection | Humira | VE | C9384 C9417 C10582 C10583 C10600 C10619 |  | See Note 1 | See Note 2 | C |
| Adefovir | Tablet containing adefovir dipivoxil 10 mg | Oral | APO‑Adefovir | TX | C4490 C4510 |  | 60 | 5 | D |
| Alemtuzumab | Solution concentrate for I.V. infusion 12 mg in 1.2 mL | Injection | Lemtrada | GZ | C6847 C7714 C9589 C9636 | P6847 P9589 | 3 | 0 | D |
|  |  |  |  |  | C6847 C7714 C9589 C9636 | P7714 P9636 | 5 | 0 | D |
| Ambrisentan | Tablet 5 mg | Oral | Ambrisentan Mylan | AF | C10228 C10236 C10285 C10728 C10845 C10846 C10850 C10869 C11007 C11008 C11010 C11024 C11037 |  | See Note 1 | See Note 2 | D |
|  |  |  | Cipla Ambrisentan | LR | C10228 C10236 C10285 C10728 C10845 C10846 C10850 C10869 C11007 C11008 C11010 C11024 C11037 |  | See Note 1 | See Note 2 | D |
|  |  |  | Volibris | GK | C10228 C10236 C10285 C10728 C10845 C10846 C10850 C10869 C11007 C11008 C11010 C11024 C11037 |  | See Note 1 | See Note 2 | D |
|  | Tablet 10 mg | Oral | Ambrisentan Mylan | AF | C10228 C10236 C10285 C11007 C11008 C11010 C11024 C11037 |  | See Note 1 | See Note 2 | D |
|  |  |  | Cipla Ambrisentan | LR | C10228 C10236 C10285 C11007 C11008 C11010 C11024 C11037 |  | See Note 1 | See Note 2 | D |
|  |  |  | Volibris | GK | C10228 C10236 C10285 C11007 C11008 C11010 C11024 C11037 |  | See Note 1 | See Note 2 | D |
| Anakinra | Injection 100 mg in 0.67 mL single use pre‑filled syringe | Injection | Kineret | FK | C5450 |  | 28 | 5 | D |
| Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 20 mg in 2 mL | Injection | Movapo | TD | C4833 C9561 |  | 360 | 5 | PB |
|  | Injection containing apomorphine hydrochloride hemihydrate 50 mg in 5 mL | Injection | Movapo | TD | C4833 C9561 |  | 180 | 5 | PB |
|  | Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL | Injection | Apomine Solution for Infusion | PF | C10830 C10863 |  | 90 | 5 | C |
|  | Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre-filled syringe | Injection | Movapo PFS | TD | C4833 C9561 |  | 180 | 5 | PB |
|  | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre-filled pen | Injection | Apomine Intermittent | PF | C10830 C10863 |  | 100 | 5 | C |
|  |  |  | Movapo Pen | TD | C10830 C10863 |  | 100 | 5 | C |
| Atazanavir | Capsule 200 mg (as sulfate) | Oral | Atazanavir Mylan | AF | C4454 C4512 |  | 120 | 5 | D |
|  |  |  | Reyataz | BQ | C4454 C4512 |  | 120 | 5 | D |
|  | Capsule 300 mg (as sulfate) | Oral | Atazanavir Mylan | AF | C4454 C4512 |  | 60 | 5 | D |
|  |  |  | Reyataz | BQ | C4454 C4512 |  | 60 | 5 | D |
| Atazanavir with cobicistat | Tablet containing 300 mg atazanavir and 150 mg cobicistat | Oral | Evotaz | BQ | C4454 C4512 |  | 60 | 5 | D |
| Azacitidine | Powder for injection 100 mg | Injection | Azacitidine Accord | OC | C6132 C6143 C6144 C6177 C6186 C6199 |  | See Note 1 | See Note 2 | D |
|  |  |  | AZACITIDINE DR.REDDY’S | RI | C6132 C6143 C6144 C6177 C6186 C6199 |  | See Note 1 | See Note 2 | D |
|  |  |  | Azacitidine Juno | JO | C6132 C6143 C6144 C6177 C6186 C6199 |  | See Note 1 | See Note 2 | D |
|  |  |  | Azacitidine‑Teva | TB | C6132 C6143 C6144 C6177 C6186 C6199 |  | See Note 1 | See Note 2 | D |
|  |  |  | Azadine | RZ | C6132 C6143 C6144 C6177 C6186 C6199 |  | See Note 1 | See Note 2 | D |
|  |  |  | Celazadine | JU | C6132 C6143 C6144 C6177 C6186 C6199 |  | See Note 1 | See Note 2 | D |
|  |  |  | Vidaza | CJ | C6132 C6143 C6144 C6177 C6186 C6199 |  | See Note 1 | See Note 2 | D |
| Azithromycin | Tablet 600 mg (as dihydrate) | Oral | Zithromax | PF | C6356 C9604 |  | 16 | 5 | PB |
| Baclofen | Intrathecal injection 10 mg in 5 mL | Injection | Bacthecal | DZ | C6911 C6925 C6939 C6940 C9488 C9489 C9524 C9637 |  | 10 | 0 | PB |
|  |  |  | Lioresal Intrathecal | NV | C6911 C6925 C6939 C6940 C9488 C9489 C9524 C9637 |  | 10 | 0 | PB |
|  |  |  | Sintetica Baclofen Intrathecal | BZ | C6911 C6925 C6939 C6940 C9488 C9489 C9524 C9637 |  | 10 | 0 | PB |
|  | Intrathecal injection 40 mg in 20 mL | Injection | Sintetica Baclofen Intrathecal | BZ | C7134 C7148 C7152 C7153 C9525 C9562 C9606 C9638 |  | 2 | 0 | PB |
| Benralizumab | Injection 30 mg in 1 mL single dose pre-filled pen | Injection | Fasenra Pen | AP | C9887 C10264 C10281 C10314 | P9887 | 1 | 0 | D |
|  |  |  |  |  | C9887 C10264 C10281 C10314 | P10281 | 1 | 2 | D |
|  |  |  |  |  | C9887 C10264 C10281 C10314 | P10264 P10314 | 1 | 4 | D |
|  | Injection 30 mg in 1 mL single dose pre‑filled syringe | Injection | Fasenra | AP | C9887 C10264 C10281 C10314 | P9887 | 1 | 0 | D |
|  |  |  |  |  | C9887 C10264 C10281 C10314 | P10281 | 1 | 2 | D |
|  |  |  |  |  | C9887 C10264 C10281 C10314 | P10264 P10314 | 1 | 4 | D |
| Bictegravir with emtricitabine with tenofovir alafenamide | Tablet containing bictegravir 50 mg with emtricitabine 200 mg with tenofovir alafenamide 25 mg | Oral | Biktarvy | GI | C4470 C4522 |  | 60 | 5 | D |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | Bosentan APO | GX | C10228 C10238 C10924 C10945 C11004 C11022 C11023 C11044 C11064 |  | See Note 1 | See Note 2 | D |
|  |  |  | BOSENTAN DR. REDDY’S | RI | C10228 C10238 C10924 C10945 C11004 C11022 C11023 C11044 C11064 |  | See Note 1 | See Note 2 | D |
|  |  |  | Bosentan Mylan | AF | C10228 C10238 C10924 C10945 C11004 C11022 C11023 C11044 C11064 |  | See Note 1 | See Note 2 | D |
|  |  |  | Bosentan RBX | RA | C10228 C10238 C10924 C10945 C11004 C11022 C11023 C11044 C11064 |  | See Note 1 | See Note 2 | D |
|  |  |  | Bosentan Sandoz | SZ | C10228 C10238 C10924 C10945 C11004 C11022 C11023 C11044 C11064 |  | See Note 1 | See Note 2 | D |
|  |  |  | BOSLEER | RW | C10228 C10238 C10924 C10945 C11004 C11022 C11023 C11044 C11064 |  | See Note 1 | See Note 2 | D |
|  |  |  | Tracleer | JC | C10228 C10238 C10924 C10945 C11004 C11022 C11023 C11044 C11064 |  | See Note 1 | See Note 2 | D |
|  | Tablet 125 mg (as monohydrate) | Oral | Bosentan APO | GX | C10228 C10924 C10945 C11004 C11022 C11023 C11036 C11044 |  | See Note 1 | See Note 2 | D |
|  |  |  | BOSENTAN DR. REDDY’S | RI | C10228 C10924 C10945 C11004 C11022 C11023 C11036 C11044 |  | See Note 1 | See Note 2 | D |
|  |  |  | Bosentan GH | GQ | C10228 C10924 C10945 C11004 C11022 C11023 C11036 C11044 |  | See Note 1 | See Note 2 | D |
|  |  |  | Bosentan Mylan | AF | C10228 C10924 C10945 C11004 C11022 C11023 C11036 C11044 |  | See Note 1 | See Note 2 | D |
|  |  |  | Bosentan RBX | RA | C10228 C10924 C10945 C11004 C11022 C11023 C11036 C11044 |  | See Note 1 | See Note 2 | D |
|  |  |  | Bosentan Sandoz | SZ | C10228 C10924 C10945 C11004 C11022 C11023 C11036 C11044 |  | See Note 1 | See Note 2 | D |
|  |  |  | BOSLEER | RW | C10228 C10924 C10945 C11004 C11022 C11023 C11036 C11044 |  | See Note 1 | See Note 2 | D |
|  |  |  | Tracleer | JC | C10228 C10924 C10945 C11004 C11022 C11023 C11036 C11044 |  | See Note 1 | See Note 2 | D |
| Ciclosporin | Capsule 10 mg | Oral | Neoral 10 | NV | C6631 C6638 C6643 C6660 C6676 C9694 C9695 C9742 C9763 C9764 |  | 120 | 5 | C |
|  | Capsule 25 mg | Oral | Cyclosporin Sandoz | SZ | C6631 C6638 C6643 C6660 C6676 C9694 C9695 C9742 C9763 C9764 |  | 120 | 5 | C |
|  |  |  | Neoral 25 | NV | C6631 C6638 C6643 C6660 C6676 C9694 C9695 C9742 C9763 C9764 |  | 120 | 5 | C |
|  | Capsule 50 mg | Oral | Cyclosporin Sandoz | SZ | C6631 C6638 C6643 C6660 C6676 C9694 C9695 C9742 C9763 C9764 |  | 120 | 5 | C |
|  |  |  | Neoral 50 | NV | C6631 C6638 C6643 C6660 C6676 C9694 C9695 C9742 C9763 C9764 |  | 120 | 5 | C |
|  | Capsule 100 mg | Oral | Cyclosporin Sandoz | SZ | C6631 C6638 C6643 C6660 C6676 C9694 C9695 C9742 C9763 C9764 |  | 120 | 5 | C |
|  |  |  | Neoral 100 | NV | C6631 C6638 C6643 C6660 C6676 C9694 C9695 C9742 C9763 C9764 |  | 120 | 5 | C |
|  | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | NV | C6631 C6638 C6643 C6660 C6676 C9694 C9695 C9742 C9763 C9764 |  | 4 | 5 | C |
|  | Solution concentrate for I.V. infusion 50 mg in 1 mL | Injection | Sandimmun | NV | C6628 C9831 |  | 10 | 0 | PB |
| Cinacalcet | Tablet 30 mg (as hydrochloride) | Oral | Pharmacor Cinacalcet | CR | C10063 C10067 C10073 |  | 56 | 5 | C |
|  | Tablet 60 mg (as hydrochloride) | Oral | Pharmacor Cinacalcet | CR | C10063 C10067 C10073 |  | 56 | 5 | C |
|  | Tablet 90 mg (as hydrochloride) | Oral | Pharmacor Cinacalcet | CR | C10063 C10067 C10073 |  | 56 | 5 | C |
| Clozapine | Tablet 25 mg | Oral | Clopine 25 | PF | C4998 C5015 C9490 |  | 200 | 0 | D |
|  |  |  | Clozaril 25 | GO | C4998 C5015 C9490 |  | 200 | 0 | D |
|  | Tablet 50 mg | Oral | Clopine 50 | PF | C4998 C5015 C9490 |  | 200 | 0 | D |
|  | Tablet 100 mg | Oral | Clopine 100 | PF | C4998 C5015 C9490 |  | 200 | 0 | D |
|  |  |  | Clozaril 100 | GO | C4998 C5015 C9490 |  | 200 | 0 | D |
|  | Tablet 200 mg | Oral | Clopine 200 | PF | C4998 C5015 C9490 |  | 200 | 0 | D |
|  | Oral liquid 50 mg per mL, 100 mL | Oral | Clopine Suspension | PF | C4998 C5015 C9490 |  | 1 | 0 | D |
|  |  |  | Versacloz | PF | C4998 C5015 C9490 |  | 1 | 0 | D |
| Darbepoetin Alfa | Injection 10 micrograms in 0.4 mL pre‑filled syringe | Injection | Aranesp | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 20 micrograms in 0.5 mL pre‑filled syringe | Injection | Aranesp | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 20 micrograms in 0.5 mL pre‑filled injection pen | Injection | Aranesp SureClick | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 30 micrograms in 0.3 mL pre‑filled syringe | Injection | Aranesp | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 40 micrograms in 0.4 mL pre‑filled syringe | Injection | Aranesp | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 40 micrograms in 0.4 mL pre‑filled injection pen | Injection | Aranesp SureClick | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 50 micrograms in 0.5 mL pre‑filled syringe | Injection | Aranesp | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 60 micrograms in 0.3 mL pre‑filled syringe | Injection | Aranesp | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 60 micrograms in 0.3 mL pre‑filled injection pen | Injection | Aranesp SureClick | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 80 micrograms in 0.4 mL pre‑filled syringe | Injection | Aranesp | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 80 micrograms in 0.4 mL pre‑filled injection pen | Injection | Aranesp SureClick | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 100 micrograms in 0.5 mL pre‑filled syringe | Injection | Aranesp | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 100 micrograms in 0.5 mL pre‑filled injection pen | Injection | Aranesp SureClick | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 150 micrograms in 0.3 mL pre‑filled syringe | Injection | Aranesp | AN | C6294 C9688 |  | 8 | 5 | D |
|  | Injection 150 micrograms in 0.3 mL pre‑filled injection pen | Injection | Aranesp SureClick | AN | C6294 C9688 |  | 8 | 5 | D |
| Darunavir | Tablet 150 mg (as ethanolate) | Oral | Prezista | JC | C5094 |  | 240 | 5 | D |
|  | Tablet 600 mg (as ethanolate) | Oral | Prezista | JC | C5094 |  | 120 | 5 | D |
|  | Tablet 800mg (as ethanolate) | Oral | Prezista | JC | C4313 |  | 60 | 5 | D |
| Darunavir with cobicistat | Tablet containing darunavir 800mg with cobicistat 150 mg | Oral | Prezcobix | JC | C6377 C6413 C6428 |  | 60 | 5 | D |
| Darunavir with cobicistat, emtricitabine and tenofovir alafenamide | Tablet containing darunavir  800 mg with cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg | Oral | Symtuza | JC | C10317 C10324 |  | 60 | 5 | D |
| Deferasirox | Tablet 90 mg | Oral | Jadenu | NM | C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 | P7385 P8326 P8328 P8329 P9222 P9258 P9302 | 180 | 2 | D |
|  |  |  |  |  | C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 | P7374 P7375 | 180 | 5 | D |
|  | Tablet 180 mg | Oral | Jadenu | NM | C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 | P7385 P8326 P8328 P8329 P9222 P9258 P9302 | 180 | 2 | D |
|  |  |  |  |  | C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 | P7374 P7375 | 180 | 5 | D |
|  | Tablet 360 mg | Oral | Jadenu | NM | C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 | P7385 P8326 P8328 P8329 P9222 P9258 P9302 | 180 | 2 | D |
|  |  |  |  |  | C7374 C7375 C7385 C8326 C8328 C8329 C9222 C9258 C9302 | P7374 P7375 | 180 | 5 | D |
| Deferiprone | Tablet 500 mg | Oral | Ferriprox | EU | C6403 C6448 C9228 C9286 |  | 300 | 5 | D |
|  | Tablet 1000 mg | Oral | Ferriprox | EU | C6403 C6448 C9590 C9623 |  | 300 | 5 | D |
|  | Oral solution 100 mg per mL, 250 mL | Oral | Ferriprox | EU | C6403 C6448 C9228 C9286 |  | 5 | 5 | D |
| Desferrioxamine | Powder for injection containing desferrioxamine mesilate 500 mg | Injection | DBL Desferrioxamine Mesilate | PF | C6394 C9696 |  | 400 | 5 | D |
|  | Powder for injection containing desferrioxamine mesilate 2 g | Injection | DBL Desferrioxamine Mesilate | PF | C6394 C9696 |  | 60 | 5 | D |
| Dolutegravir | Tablet 50mg (as sodium) | Oral | Tivicay | VI | C4454 C4512 |  | 60 | 5 | D |
| Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | VI | C9981 C10116 |  | 60 | 5 | D |
| Dolutegravir with lamivudine | Tablet containing dolutegravir  50 mg (as sodium) with lamivudine 300 mg | Oral | Dovato | VI | C9987 C11066 |  | 60 | 5 | D |
| Dolutegravir with rilpivirine | Tablet containing dolutegravir 50 mg (as sodium) with rilpivirine 25 mg (as hydrochloride) | Oral | Juluca | VI | C8214 C8226 |  | 60 | 5 | D |
| Dornase Alfa | Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL | Inhalation | Pulmozyme | RO | C5634 C5635 C5740 C9591 C9592 C9624 |  | 60 | 5 | D |
| Doxorubicin ‑  Pegylated Liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | Injection | Caelyx | JC | C6234 C6274 C9223 C9287 |  | 4 | 5 | D |
|  |  |  | Liposomal Doxorubicin SUN | RA | C6234 C6274 C9223 C9287 |  | 4 | 5 | D |
| Eculizumab | Solution concentrate for I.V. infusion 300 mg in 30 mL | Injection | Soliris | XI | C6626 C6637 C6642 C6668 C6686 C6687 C6688 | P6626 | 1 | 0 | D |
|  |  |  |  |  | C6626 C6637 C6642 C6668 C6686 C6687 C6688 | P6642 | 1 | 4 | D |
|  |  |  |  |  | C6626 C6637 C6642 C6668 C6686 C6687 C6688 | P6668 P6686  P6687 P6688 | 1 | 5 | D |
|  |  |  |  |  | C6626 C6637 C6642 C6668 C6686 C6687 C6688 | P6637 | 1 | 6 | D |
| Efavirenz | Tablet 200 mg | Oral | Stocrin | MK | C4454 C4512 |  | 180 | 5 | D |
|  | Tablet 600 mg | Oral | Stocrin | MK | C4454 C4512 |  | 60 | 5 | D |
|  | Oral solution 30 mg per mL, 180 mL | Oral | Stocrin | MK | C4454 C4512 |  | 7 | 5 | D |
| Eltrombopag | Tablet 25 mg (as olamine) | Oral | Revolade | NV | C6724 C6725 C6738 C6739 C6790 |  | See Note 1 | See Note 2 | D |
|  | Tablet 50 mg (as olamine) | Oral | Revolade | NV | C6724 C6725 C6738 C6739 C6790 |  | See Note 1 | See Note 2 | D |
| Emtricitabine with rilpivirine with tenofovir alafenamide | Tablet containing emtricitabine 200 mg with rilpivirine 25 mg with tenofovir alafenamide 25 mg | Oral | Odefsey | GI | C4470 C4522 |  | 60 | 5 | D |
| Emtricitabine with tenofovir alafenamide | Tablet containing emtricitabine 200 mg with tenofovir alafenamide 10 mg | Oral | Descovy | GI | C4454 C4512 |  | 60 | 5 | D |
|  | Tablet containing emtricitabine 200 mg with tenofovir alafenamide 25 mg | Oral | Descovy | GI | C4454 C4512 |  | 60 | 5 | D |
| Enfuvirtide | Pack containing 60 vials powder for injection 90 mg with 60 vials water for injections 1.1 mL (with syringes and swabs) | Injection | Fuzeon | RO | C5014 |  | 2 | 5 | D |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Baraclude | BQ | C4993 C5036 |  | 60 | 5 | D |
|  |  |  | ENTAC | LR | C4993 C5036 |  | 60 | 5 | D |
|  |  |  | Entecavir Amneal | EA | C4993 C5036 |  | 60 | 5 | D |
|  |  |  | ENTECAVIR APO | GX | C4993 C5036 |  | 60 | 5 | D |
|  |  |  | Entecavir APOTEX | TX | C4993 C5036 |  | 60 | 5 | D |
|  |  |  | Entecavir GH | GQ | C4993 C5036 |  | 60 | 5 | D |
|  |  |  | Entecavir Mylan | AF | C4993 C5036 |  | 60 | 5 | D |
|  |  |  | ENTECAVIR RBX | RA | C4993 C5036 |  | 60 | 5 | D |
|  |  |  | Entecavir Sandoz | SZ | C4993 C5036 |  | 60 | 5 | D |
|  |  |  | ENTECLUDE | RW | C4993 C5036 |  | 60 | 5 | D |
|  | Tablet 1 mg (as monohydrate) | Oral | Baraclude | BQ | C5037 C5044 |  | 60 | 5 | D |
|  |  |  | ENTAC | LR | C5037 C5044 |  | 60 | 5 | D |
|  |  |  | Entecavir Amneal | EA | C5037 C5044 |  | 60 | 5 | D |
|  |  |  | ENTECAVIR APO | GX | C5037 C5044 |  | 60 | 5 | D |
|  |  |  | Entecavir APOTEX | TX | C5037 C5044 |  | 60 | 5 | D |
|  |  |  | Entecavir GH | GQ | C5037 C5044 |  | 60 | 5 | D |
|  |  |  | Entecavir Mylan | AF | C5037 C5044 |  | 60 | 5 | D |
|  |  |  | ENTECAVIR RBX | RA | C5037 C5044 |  | 60 | 5 | D |
|  |  |  | Entecavir Sandoz | SZ | C5037 C5044 |  | 60 | 5 | D |
|  |  |  | ENTECLUDE | RW | C5037 C5044 |  | 60 | 5 | D |
| Epoetin Alfa | Injection 1,000 units in 0.5 mL pre‑filled syringe | Injection | Eprex 1000 | JC | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 2,000 units in 0.5 mL pre‑filled syringe | Injection | Eprex 2000 | JC | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 3,000 units in 0.3 mL pre‑filled syringe | Injection | Eprex 3000 | JC | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 4,000 units in 0.4 mL pre‑filled syringe | Injection | Eprex 4000 | JC | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 5,000 units in 0.5 mL pre‑filled syringe | Injection | Eprex 5000 | JC | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 6,000 units in 0.6 mL pre‑filled syringe | Injection | Eprex 6000 | JC | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 8,000 units in 0.8 mL pre‑filled syringe | Injection | Eprex 8000 | JC | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 10,000 units in 1 mL pre‑filled syringe | Injection | Eprex 10000 | JC | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 20,000 units in 0.5 mL pre‑filled syringe | Injection | Eprex 20,000 | JC | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 40,000 units in 1 mL pre‑filled syringe | Injection | Eprex 40,000 | JC | C6294 C9688 |  | 2 | 5 | D |
| Epoetin Beta | Injection 2,000 units in 0.3 mL pre‑filled syringe | Injection | NeoRecormon | RO | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 3,000 units in 0.3 mL pre‑filled syringe | Injection | NeoRecormon | RO | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 4,000 units in 0.3 mL pre‑filled syringe | Injection | NeoRecormon | RO | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 5,000 units in 0.3 mL pre‑filled syringe | Injection | NeoRecormon | RO | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 6,000 units in 0.3 mL pre‑filled syringe | Injection | NeoRecormon | RO | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 10,000 units in 0.6 mL pre‑filled syringe | Injection | NeoRecormon | RO | C6294 C9688 |  | 12 | 5 | D |
| Epoetin lambda | Injection 1,000 units in 0.5 mL pre‑filled syringe | Injection | Novicrit | SZ | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 2,000 units in 1 mL pre‑filled syringe | Injection | Novicrit | SZ | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 3,000 units in 0.3 mL pre‑filled syringe | Injection | Novicrit | SZ | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 4,000 units in 0.4 mL pre‑filled syringe | Injection | Novicrit | SZ | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 5,000 units in 0.5 mL pre‑filled syringe | Injection | Novicrit | SZ | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 6,000 units in 0.6 mL pre‑filled syringe | Injection | Novicrit | SZ | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 8,000 units in 0.8 mL pre‑filled syringe | Injection | Novicrit | SZ | C6294 C9688 |  | 12 | 5 | D |
|  | Injection 10,000 units in 1 mL pre‑filled syringe | Injection | Novicrit | SZ | C6294 C9688 |  | 12 | 5 | D |
| Epoprostenol | Powder for I.V. infusion 500 micrograms (as sodium) | Injection | EPOPROSTENOL SUN | RA | C10228 C10240 C10241 |  | See Note 1 | See Note 2 | D |
|  |  |  | Veletri | JC | C10228 C10240 C10241 |  | See Note 1 | See Note 2 | D |
|  | Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL | Injection | Flolan | GK | C10228 C10240 C10241 |  | See Note 1 | See Note 2 | D |
|  | Powder for I.V. infusion 1.5 mg (as sodium) | Injection | EPOPROSTENOL SUN | RA | C10228 C10240 C10241 |  | See Note 1 | See Note 2 | D |
|  |  |  | Veletri | JC | C10228 C10240 C10241 |  | See Note 1 | See Note 2 | D |
|  | Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL | Injection | Flolan | GK | C10228 C10240 C10241 |  | See Note 1 | See Note 2 | D |
| Etanercept | Injection set containing 4 vials powder for injection 25 mg and 4 pre‑filled syringes solvent 1 mL | Injection | Enbrel | PF | C9384 C9417 C10548 C10578 C10579 C10599 |  | See Note 1 | See Note 2 | C |
|  | Injections 50 mg in 1 mL single use pre‑filled syringes, 4 | Injection | Enbrel | PF | C9384 C9417 C10548 C10578 C10579 C10599 |  | See Note 1 | See Note 2 | C |
|  | Injection 50 mg in 1 mL single use auto‑injector, 4 | Injection | Enbrel | PF | C9384 C9417 C10548 C10578 C10579 C10599 |  | See Note 1 | See Note 2 | C |
| Etravirine | Tablet 200 mg | Oral | Intelence | JC | C5014 |  | 120 | 5 | D |
| Everolimus | Tablet 0.25 mg | Oral | Certican | NV | C5554 C5795 C9691 C9693 |  | 120 | 5 | C |
|  | Tablet 0.5 mg | Oral | Certican | NV | C5554 C5795 C9691 C9693 |  | 120 | 5 | C |
|  | Tablet 0.75 mg | Oral | Certican | NV | C5554 C5795 C9691 C9693 |  | 240 | 5 | C |
|  | Tablet 1 mg | Oral | Certican | NV | C5554 C5795 C9691 C9693 |  | 240 | 5 | C |
| Filgrastim | Injection 120 micrograms in 0.2 mL single‑use pre‑filled syringe | Injection | Nivestim | PF | C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 |  | 20 | 11 | D |
|  | Injection 300 micrograms in 0.5 mL single‑use pre‑filled syringe | Injection | Neupogen | AN | C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 |  | 20 | 11 | D |
|  |  |  | Nivestim | PF | C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 |  | 20 | 11 | D |
|  |  |  | Zarzio | SZ | C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 |  | 20 | 11 | D |
|  | Injection 300 micrograms in 1 mL | Injection | Neupogen | AN | C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 |  | 20 | 11 | D |
|  | Injection 480 micrograms in 0.5 mL single‑use pre‑filled syringe | Injection | Neupogen | AN | C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 |  | 20 | 11 | D |
|  |  |  | Nivestim | PF | C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 |  | 20 | 11 | D |
|  |  |  | Zarzio | SZ | C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 |  | 20 | 11 | D |
|  | Injection 480 micrograms in 1.6 mL | Injection | Neupogen | AN | C6621 C6640 C6653 C6654 C6655 C6679 C6680 C7822 C7843 C8667 C8668 C8669 C8670 C8671 C8672 C8673 C8674 C8696 |  | 20 | 11 | D |
| Fosamprenavir | Tablet 700 mg (as calcium) | Oral | Telzir | VI | C4454 C4512 |  | 120 | 5 | D |
| Ganciclovir | Powder for I.V. infusion 500 mg (as sodium) | Injection | Cymevene | PB | C4972 C4999 C5000 C9404 C9526 |  | 10 | 1 | D |
|  |  |  | GANCICLOVIR SXP | HN | C4972 C4999 C5000 C9404 C9526 |  | 10 | 1 | D |
| Glecaprevir with pibrentasvir | Tablet containing 100 mg glecaprevir with 40 mg pibrentasvir | Oral | Maviret | VE | C7593 C7615C10268 | P7593 | 84 | 1 |  |
|  |  |  |  |  | C7593 C7615C10268 | P7615 | 84 | 2 |  |
|  |  |  |  |  | C7593 C7615C10268 | P10268 | 84 | 3 |  |
| Grazoprevir with elbasvir | Tablet containing grazoprevir 100 mg with elbasvir 50 mg | Oral | Zepatier | MK | C5969 C6625 | P5969 | 28 | 2 |  |
|  |  |  |  |  | C5969 C6625 | P6625 | 28 | 3 |  |
| Ibandronic acid | Concentrated injection for I.V. infusion 6 mg (as ibandronate sodium monohydrate) in 6 mL | Injection | Bondronat | IX | C5291 C9333 |  | 1 | 11 | PB |
| Iloprost | Solution for inhalation 20 micrograms (as trometamol) in 2 mL | Inhalation | Ventavis | BN | C10228 C10229 C10284 |  | See Note 1 | See Note 2 | D |
| Infliximab | Powder for I.V. infusion 100 mg | Injection | Inflectra | PF | C4524 C7777 C8296 C8644 C8645 C8646 C8715 C8743 C8744 C8745 C8755 C8800 C8801 C8844 C8881 C8883 C8885 C8886 C8940 C8941 C8962 C8983 C9065 C9067 C9068 C9110 C9111 C9169 C9188 C9191 C9400 C9401 C9402 C9472 C9481 C9487 C9558 C9559 C9584 C9587 C9602 C9621 C9632 C9668 C9669 C9675 C9676 C9677 C9719 C9721 C9731 C9732 C9733 C9751 C9752 C9754 C9756 C9759 C9775 C9776 C9778 C9779 C9781 C9783 C9785 C9787 C9788 C9799 C9800 C9803 C9806 C9877 C9900 C9975 C9994 |  | See Note 1 | See Note 2 | D |
|  |  |  | Remicade | JC | C4524 C7777 C8296 C8644 C8645 C8646 C8715 C8743 C8744 C8745 C8800 C8801 C8881 C8883 C8885 C8886 C8941 C8962 C8983 C9065 C9067 C9068 C9110 C9111 C9169 C9191 C9400 C9401 C9402 C9487 C9558 C9559 C9587 C9632 C9669 C9675 C9676 C9677 C9719 C9721 C9751 C9752 C9754 C9756 C9759 C9776 C9778 C9779 C9781 C9783 C9788 C9799 C9800 C9803 C9877 C9900 C9994 |  | See Note 1 | See Note 2 | D |
|  |  |  | Renflexis | OQ | C4524 C7777 C8296 C8644 C8645 C8646 C8715 C8743 C8744 C8745 C8755 C8800 C8801 C8844 C8881 C8883 C8885 C8886 C8940 C8941 C8962 C8983 C9065 C9067 C9068 C9110 C9111 C9169 C9188 C9191 C9400 C9401 C9402 C9472 C9481 C9487 C9558 C9559 C9584 C9587 C9602 C9621 C9632 C9668 C9669 C9675 C9676 C9677 C9719 C9721 C9731 C9732 C9733 C9751 C9752 C9754 C9756 C9759 C9775 C9776 C9778 C9779 C9781 C9783 C9785 C9787 C9788 C9799 C9800 C9803 C9806 C9877 C9900 C9975 C9994 |  | See Note 1 | See Note 2 | D |
| Interferon Alfa‑2a | Injection 3,000,000 I.U. in 0.5 mL single dose pre‑filled syringe | Injection | Roferon‑A | RO | C4993 C5036 C5042 C9259 |  | 30 | 5 | C |
|  | Injection 9,000,000 I.U. in 0.5 mL single dose pre‑filled syringe | Injection | Roferon‑A | RO | C4993 C5036 C5042 C9259 |  | 30 | 5 | C |
| Interferon Gamma‑1b | Injection 2,000,000 I.U. in 0.5 mL | Injection | Imukin | EU | C6222 C9639 |  | 12 | 11 | D |
| Ivacaftor | Sachet containing granules 50 mg | Oral | Kalydeco | VR | C9889 C9890 |  | 56 | 5 | D |
|  | Sachet containing granules 75 mg | Oral | Kalydeco | VR | C9889 C9890 |  | 56 | 5 | D |
|  | Tablet 150 mg | Oral | Kalydeco | VR | C9889 C9890 |  | 56 | 5 | D |
| Lamivudine | Tablet 100 mg | Oral | Zeffix | RW | C4993 C5036 |  | 56 | 5 | D |
|  |  |  | Zetlam | AF | C4993 C5036 |  | 56 | 5 | D |
|  | Tablet 150 mg | Oral | 3TC | VI | C4454 C4512 |  | 120 | 5 | D |
|  |  |  | Lamivudine Alphapharm | AF | C4454 C4512 |  | 120 | 5 | D |
|  | Tablet 300 mg | Oral | 3TC | VI | C4454 C4512 |  | 60 | 5 | D |
|  |  |  | Lamivudine Alphapharm | AF | C4454 C4512 |  | 60 | 5 | D |
|  | Oral solution 10 mg per mL, 240 mL | Oral | 3TC | VI | C4454 C4512 |  | 8 | 5 | D |
| Lamivudine with Zidovudine | Tablet 150 mg‑300 mg | Oral | Combivir | VI | C4454 C4512 |  | 120 | 5 | D |
|  |  |  | Lamivudine 150 mg + Zidovudine 300 mg Alphapharm | AF | C4454 C4512 |  | 120 | 5 | D |
| Lanreotide | Injection 60 mg (as acetate) in single dose pre‑filled syringe | Injection | Somatuline Autogel | IS | C4575 C7025 C7509 C7532 C9260 C9261 |  | 2 | 5 | D |
|  | Injection 90 mg (as acetate) in single dose pre‑filled syringe | Injection | Somatuline Autogel | IS | C4575 C7025 C7509 C7532 C9260 C9261 |  | 2 | 5 | D |
|  | Injection 120 mg (as acetate) in single dose pre‑filled syringe | Injection | Somatuline Autogel | IS | C4575 C7025 C7509 C7532 C9260 C9261 C10061 C10075 C10077 |  | 2 | 5 | D |
|  | Powder for suspension for injection 30 mg (as acetate) with diluent | Injection | Somatuline LA | IS | C7042 C9225 |  | 2 | 11 | D |
| Lanthanum | Tablet, chewable, 500 mg (as carbonate hydrate) | Oral | Fosrenol | TK | C5530 C9762 |  | 180 | 5 | C |
|  | Tablet, chewable, 750 mg (as carbonate hydrate) | Oral | Fosrenol | TK | C5530 C9762 |  | 180 | 5 | C |
|  | Tablet, chewable, 1000 mg (as carbonate hydrate) | Oral | Fosrenol | TK | C5530 C9762 |  | 180 | 5 | C |
| Ledipasvir with sofosbuvir | Tablet containing 90 mg ledipasvir with 400 mg sofosbuvir | Oral | Harvoni | GI | C5944 C5969 C5972 | P5944 | 28 | 1 |  |
|  |  |  |  |  | C5944 C5969 C5972 | P5969 | 28 | 2 |  |
|  |  |  |  |  | C5944 C5969 C5972 | P5972 | 28 | 5 |  |
| Lenalidomide | Capsule 5 mg | Oral | Revlimid | CJ | C4282 C4287 C10334 C10335 C10349 C10350 C10373 C10427 C10428 C10429 C10452 C10453 |  | See Note 1 | See Note 2 | D |
|  | Capsule 10 mg | Oral | Revlimid | CJ | C4282 C4287 C10334 C10335 C10349 C10350 C10373 C10427 C10428 C10429 C10452 C10453 |  | See Note 1 | See Note 2 | D |
|  | Capsule 15 mg | Oral | Revlimid | CJ | C10334 C10335 C10349 C10350 C10373 C10427 C10428 C10429 C10452 C10453 |  | See Note 1 | See Note 2 | D |
|  | Capsule 25 mg | Oral | Revlimid | CJ | C10349 C10350 C10373 C10427 C10428 C10429 C10452 C10453 |  | See Note 1 | See Note 2 | D |
| Lenograstim | Powder for injection 13,400,000 I.U. (105 micrograms) | Injection | Granocyte 13 | PF | C6502 C6507 C6516 C6522 C6523 C6532 C6535 C6634 C6644 C6653 C6654 C6657 C6673 C6682 C9226 C9227 C9229 C9230 C9231 C9263 C9264 C9265 C9266 C9314 C9324 C9325 C9326 C9327 |  | 20 | 11 | D |
|  | Powder for injection 33,600,000 I.U. (263 micrograms) | Injection | Granocyte 34 | PF | C6502 C6507 C6516 C6522 C6523 C6532 C6535 C6634 C6644 C6653 C6654 C6657 C6673 C6682 C9226 C9227 C9229 C9230 C9231 C9263 C9264 C9265 C9266 C9314 C9324 C9325 C9326 C9327 |  | 20 | 11 | D |
| Levodopa with carbidopa | Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg per mL,  100 mL | Intra‑ intestinal | Duodopa | VE | C10138 C10161 C10363 C10375 | P10138 P10161 | 28 | 5 | C |
|  |  |  |  |  | C10138 C10161 C10363 C10375 | P10363 P10375 | 56 | 5 | C |
| Lipegfilgrastim | Injection 6 mg in 0.6 mL single use pre‑filled syringe | Injection | Lonquex | TB | C7822 C7843 C9224 C9322 |  | 1 | 11 | D |
| Lopinavir with Ritonavir | Tablet 100 mg‑25 mg | Oral | Kaletra | VE | C4454 C4512 |  | 120 | 5 | D |
|  | Tablet 200 mg‑50 mg | Oral | Kaletra | VE | C4454 C4512 |  | 240 | 5 | D |
|  | Oral liquid 400 mg‑100 mg per 5 mL, 60 mL | Oral | Kaletra | VE | C4454 C4512 |  | 10 | 5 | D |
| Lumacaftor with ivacaftor | Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg | Oral | Orkambi | VR | C10005 C10007 |  | 56 | 5 | D |
|  | Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg | Oral | Orkambi | VR | C10005 C10007 |  | 56 | 5 | D |
|  | Tablet containing lumacaftor  100 mg with ivacaftor 125 mg | Oral | Orkambi | VR | C9891 C9920 |  | 112 | 5 | D |
|  | Tablet containing lumacaftor  200 mg with ivacaftor 125 mg | Oral | Orkambi | VR | C9857 C9943 |  | 112 | 5 | D |
| Macitentan | Tablet 10 mg | Oral | Opsumit | JC | C10228 C10236 C10285 C11021 C11033 C11034 C11043 C11071 |  | 30 | 5 | D |
| Mannitol | Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers | Inhalation by mouth | bronchitol | XA | C7362 C7367 C9527 C9593 |  | 4 | 5 | D |
| Maraviroc | Tablet 150 mg | Oral | Celsentri | VI | C5008 |  | 120 | 5 | D |
|  | Tablet 300 mg | Oral | Celsentri | VI | C5008 |  | 120 | 5 | D |
| Mepolizumab | Injection 100 mg in 1 mL single dose pre-filled pen | Injection | Nucala | GK | C9885 C10221 C10222 C10280 C10483 C10484 | P9885 | 1 | 0 | D |
|  |  |  |  |  | C9885 C10221 C10222 C10280 C10483 C10484 | P10280 P10483 P10484 | 1 | 5 | D |
|  |  |  |  |  | C9885 C10221 C10222 C10280 C10483 C10484 | P10221 P10222 | 1 | 7 | D |
|  | Powder for injection 100 mg | Injection | Nucala | GK | C9885 C10221 C10222 C10280 | P9885 | 1 | 0 | D |
|  |  |  |  |  | C9885 C10221 C10222 C10280 | P10280 | 1 | 5 | D |
|  |  |  |  |  | C9885 C10221 C10222 C10280 | P10221 P10222 | 1 | 7 | D |
| Methoxsalen | Solution for blood fraction 20 microgram per mL, 10 mL | Extracorporeal Circulation | Uvadex | TQ | C10971 C10985 C10988 C10989 | P10988 P10989 | 1 | 5 | D |
|  |  |  |  |  | C10971 C10985 C10988 C10989 | P10971 P10985 | 2 | 6 | D |
| Methoxy polyethylene glycol‑epoetin beta | Injection 30 micrograms in 0.3 mL pre‑filled syringe | Injection | Mircera | RO | C6294 C9688 |  | 2 | 5 | D |
|  | Injection 50 micrograms in 0.3 mL pre‑filled syringe | Injection | Mircera | RO | C6294 C9688 |  | 2 | 5 | D |
|  | Injection 75 micrograms in 0.3 mL pre‑filled syringe | Injection | Mircera | RO | C6294 C9688 |  | 2 | 5 | D |
|  | Injection 100 micrograms in 0.3 mL pre‑filled syringe | Injection | Mircera | RO | C6294 C9688 |  | 2 | 5 | D |
|  | Injection 120 micrograms in 0.3 mL pre‑filled syringe | Injection | Mircera | RO | C6294 C9688 |  | 2 | 5 | D |
|  | Injection 200 micrograms in 0.3 mL pre‑filled syringe | Injection | Mircera | RO | C6294 C9688 |  | 2 | 5 | D |
|  | Injection 360 micrograms in 0.6 mL pre‑filled syringe | Injection | Mircera | RO | C6294 C9688 |  | 2 | 5 | D |
| Midostaurin | Capsule 25 mg | Oral | Rydapt | NV | C8138 C8177 C8193 C8218 | P8193 | 56 | 2 | D |
|  |  |  |  |  | C8138 C8177 C8193 C8218 | P8218 | 112 | 1 | D |
|  |  |  |  |  | C8138 C8177 C8193 C8218 | P8138 P8177 | 112 | 2 | D |
| Mycophenolic Acid | Tablet (enteric coated) containing mycophenolate sodium equivalent to 180 mg mycophenolic acid | Oral | Myfortic | NV | C4084 C4095 C9692 C9809 |  | 240 | 5 | C |
|  | Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid | Oral | Myfortic | NV | C4084 C4095 C9692 C9809 |  | 240 | 5 | C |
|  | Capsule containing mycophenolate mofetil 250 mg | Oral | APO‑Mycophenolate | TX | C5600 C5653 C9689 C9690 |  | 600 | 5 | C |
|  |  |  | CellCept | RO | C5600 C5653 C9689 C9690 |  | 600 | 5 | C |
|  |  |  | Ceptolate | AF | C5600 C5653 C9689 C9690 |  | 600 | 5 | C |
|  |  |  | Mycophenolate Sandoz | SZ | C5600 C5653 C9689 C9690 |  | 600 | 5 | C |
|  |  |  | Pharmacor Mycophenolate 250 | CR | C5600 C5653 C9689 C9690 |  | 600 | 5 | C |
|  | Tablet containing mycophenolate mofetil 500 mg | Oral | APO‑Mycophenolate | TX | C5554 C5795 C9691 C9693 |  | 300 | 5 | C |
|  |  |  | CellCept | RO | C5554 C5795 C9691 C9693 |  | 300 | 5 | C |
|  |  |  | Ceptolate | AF | C5554 C5795 C9691 C9693 |  | 300 | 5 | C |
|  |  |  | MycoCept | RF | C5554 C5795 C9691 C9693 |  | 300 | 5 | C |
|  |  |  | Mycophenolate AN | EA | C5554 C5795 C9691 C9693 |  | 300 | 5 | C |
|  |  |  | Mycophenolate APOTEX | GX | C5554 C5795 C9691 C9693 |  | 300 | 5 | C |
|  |  |  | Mycophenolate GH | GQ | C5554 C5795 C9691 C9693 |  | 300 | 5 | C |
|  |  |  | Mycophenolate Sandoz | SZ | C5554 C5795 C9691 C9693 |  | 300 | 5 | C |
|  |  |  | Pharmacor Mycophenolate 500 | CR | C5554 C5795 C9691 C9693 |  | 300 | 5 | C |
|  | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL | Oral | CellCept | RO | C5554 C5795 C9691 C9693 |  | 2 | 5 | C |
| Natalizumab | Solution concentrate for I.V. infusion 300 mg in 15 mL | Injection | Tysabri | BD | C9744 C9818 |  | 1 | 5 | D |
| Nevirapine | Tablet 200 mg | Oral | Nevirapine Alphapharm | AF | C4454 C4512 |  | 120 | 5 | D |
|  | Tablet 400 mg (extended release) | Oral | Nevirapine XR APOTEX | TX | C4454 C4526 |  | 60 | 5 | D |
|  |  |  | Viramune XR | BY | C4454 C4526 |  | 60 | 5 | D |
|  | Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL | Oral | Viramune | BY | C4454 C4512 |  | 10 | 5 | D |
| Nusinersen | Solution for injection 12 mg in 5 mL | Injection | Spinraza | BD | C11049 C11050 C11058 |  | See Note 1 | See Note 2 | D |
| Ocrelizumab | Solution concentrate for I.V. infusion 300 mg in 10 mL | Injection | Ocrevus | RO | C7386 C7699 C9523 C9635 |  | 2 | 0 | D |
| Octreotide | Injection 50 micrograms (as acetate) in 1 mL | Injection | Octreotide GH | HQ | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  |  |  | Octreotide MaxRx | GQ | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  |  |  | Octreotide (SUN) | RA | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  |  |  | Sandostatin 0.05 | NV | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  | Injection 100 micrograms (as acetate) in 1 mL | Injection | Octreotide GH | HQ | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  |  |  | Octreotide MaxRx | GQ | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  |  |  | Octreotide (SUN) | RA | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  |  |  | Sandostatin 0.1 | NV | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  | Injection 500 micrograms (as acetate) in 1 mL | Injection | Octreotide GH | HQ | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  |  |  | Octreotide MaxRx | GQ | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  |  |  | Octreotide (SUN) | RA | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  |  |  | Sandostatin 0.5 | NV | C6369 C6390 C8165 C9232 C9233 C9289 |  | 90 | 11 | D |
|  | Injection (modified release) 10 mg (as acetate), vial and diluent syringe | Injection | Sandostatin LAR | NV | C5901 C5906 C8161 C8197 C8198 C8208 C9262 C9288 C9313 |  | 2 | 5 | D |
|  | Injection (modified release) 20 mg (as acetate), vial and diluent syringe | Injection | Sandostatin LAR | NV | C5901 C5906 C8161 C8197 C8198 C8208 C9262 C9288 C9313 |  | 2 | 5 | D |
|  | Injection (modified release) 30 mg (as acetate), vial and diluent syringe | Injection | Sandostatin LAR | NV | C5901 C5906 C8161 C8197 C8198 C8208 C9262 C9288 C9313 C10061 C10075 C10077 |  | 2 | 5 | D |
| Omalizumab | Injection 75 mg in 0.5 mL single dose pre‑filled syringe | Injection | Xolair | NV | C9855 C10219 C10223 C10226 C10265 C10279 C10299 |  | See Note 1 | See Note 2 | D |
|  | Injection 150 mg in 1 mL single dose pre‑filled syringe | Injection | Xolair | NV | C7046 C7055 C9855 C10219 C10223 C10226 C10265 C10279 C10299 |  | See Note 1 | See Note 2 | D |
| Pamidronic Acid | Concentrated injection containing pamidronate disodium 15 mg in 5 mL | Injection | Pamisol | PF | C4433 C9234 |  | 4 | 2 | C |
|  | Concentrated injection containing pamidronate disodium 30 mg in 10 mL | Injection | Pamisol | PF | C4433 C9234 |  | 2 | 2 | C |
|  | Concentrated injection containing pamidronate disodium 60 mg in 10 mL | Injection | Pamisol | PF | C4433 C9234 |  | 1 | 2 | C |
|  | Concentrated injection containing pamidronate disodium 90 mg in 10 mL | Injection | Pamisol | PF | C4433 C5218 C5291 C9234 C9315 C9335 |  | 1 | 11 | PB |
| Pasireotide | Injection (modified release) 20 mg (as embonate), vial and diluent syringe | Injection | Signifor LAR | RJ | C9088 C9089 |  | See Note 1 | See Note 2 | D |
|  | Injection (modified release) 40 mg (as embonate), vial and diluent syringe | Injection | Signifor LAR | RJ | C9088 C9089 |  | See Note 1 | See Note 2 | D |
|  | Injection (modified release) 60 mg (as embonate), vial and diluent syringe | Injection | Signifor LAR | RJ | C9088 C9089 |  | See Note 1 | See Note 2 | D |
| Pegfilgrastim | Injection 6 mg in 0.6 mL single use pre‑filled syringe | Injection | Fulphila | AF | C7822 C7843 C9235 C9303 |  | 1 | 11 | D |
|  |  |  | Neulasta | JU | C7822 C7843 C9235 C9303 |  | 1 | 11 | D |
|  |  |  | Pelgraz | OC | C7822 C7843 C9235 C9303 |  | 1 | 11 | D |
|  |  |  | Ristempa | JO | C7822 C7843 C9235 C9303 |  | 1 | 11 | D |
|  |  |  | Tezmota | JX | C7822 C7843 C9235 C9303 |  | 1 | 11 | D |
|  |  |  | Ziextenzo | SZ | C7822 C7843 C9235 C9303 |  | 1 | 11 | D |
| Peginterferon alfa‑2a | Injection 135 micrograms in 0.5 mL single use pre‑filled syringe | Injection | Pegasys | RO | C5004 C9603 |  | 8 | 5 | C |
|  | Injection 180 micrograms in 0.5 mL single use pre‑filled syringe | Injection | Pegasys | RO | C5004 C9603 |  | 8 | 5 | C |
| Pegvisomant | Injection set containing powder for injection 10 mg, 30 and diluent, 30 | Injection | Somavert | PF | C7087 C9041 |  | See Note 1 | See Note 2 | D |
|  | Injection set containing powder for injection 15 mg, 30 and diluent, 30 | Injection | Somavert | PF | C7087 C9041 |  | See Note 1 | See Note 2 | D |
|  | Injection set containing powder for injection 20 mg, 1 and diluent, 1 | Injection | Somavert | PF | C9041 |  | See Note 1 | See Note 2 | D |
|  | Injection set containing powder for injection 20 mg, 30 and diluent, 30 | Injection | Somavert | PF | C7087 C9041 |  | See Note 1 | See Note 2 | D |
| Plerixafor | Injection 24 mg in 1.2 mL | Injection | Mozobil | GZ | C4549 C9329 |  | 1 | 1 | D |
| Pomalidomide | Capsule 3 mg | Oral | Pomalyst | CJ | C7791 C7952 |  | 21 | 0 | D |
|  | Capsule 4 mg | Oral | Pomalyst | CJ | C7791 C7952 |  | 21 | 0 | D |
| Raltegravir | Tablet 25 mg (as potassium) | Oral | Isentress | MK | C4274 C4275 |  | 360 | 5 | D |
|  | Tablet 100 mg (as potassium) | Oral | Isentress | MK | C4274 C4275 |  | 360 | 5 | D |
|  | Tablet 400 mg (as potassium) | Oral | Isentress | MK | C4454 C4512 |  | 120 | 5 | D |
|  | Tablet 600 mg (as potassium) | Oral | Isentress HD | MK | C4454 C4512 |  | 120 | 5 | D |
| Ribavirin | Tablet 400 mg | Oral | Ibavyr | IX | C5957 C5958 | P5957 | 28 | 2 |  |
|  |  |  |  |  | C5957 C5958 | P5958 | 28 | 5 |  |
|  | Tablet 600 mg | Oral | Ibavyr | IX | C5957 C5958 | P5957 | 28 | 2 |  |
|  |  |  |  |  | C5957 C5958 | P5958 | 28 | 5 |  |
| Rifabutin | Capsule 150 mg | Oral | Mycobutin | PF | C6350 C6356 C9560 C9622 |  | 120 | 5 | D |
| Rilpivirine | Tablet 25 mg (as hydrochloride) | Oral | Edurant | JC | C4454 C4512 |  | 60 | 5 | D |
| Riociguat | Tablet 500 micrograms | Oral | Adempas | BN | C6645 C6664 C7629 C10231 C10243 C10245 |  | See note 1 | See note 2 | D |
|  | Tablet 1 mg | Oral | Adempas | BN | C6645 C6664 C7629 C10231 C10243 C10245 |  | See note 1 | See note 2 | D |
|  | Tablet 1.5 mg | Oral | Adempas | BN | C6645 C6664 C7629 C10231 C10243 C10245 |  | See note 1 | See note 2 | D |
|  | Tablet 2 mg | Oral | Adempas | BN | C6645 C6664 C7629 C10231 C10243 C10245 |  | See note 1 | See note 2 | D |
|  | Tablet 2.5 mg | Oral | Adempas | BN | C6645 C6664 C7629 C10231 C10243 C10245 |  | See note 1 | See note 2 | D |
| Ritonavir | Tablet 100 mg | Oral | Norvir | VE | C4454 C4512 |  | 720 | 5 | D |
| Rituximab | Solution for I.V. infusion 100 mg in 10 mL | Injection | Mabthera | RO | C7021 C7022 C9344 C9511 |  | See Note 1 | See Note 2 | PB |
|  |  |  | Riximyo | SZ | C7021 C7022 C9336 C9344 C9511 C9539 C9640 C9641 |  | See Note 1 | See Note 2 | PB |
|  |  |  | Truxima | EW | C7021 C7022 C9336 C9344 C9511 C9539 C9640 C9641 |  | See Note 1 | See Note 2 | PB |
|  | Solution for I.V. infusion 500 mg in 50 mL | Injection | Mabthera | RO | C7021 C7022 C9340 C9344 C9448 C9449 C9450 C9511 C9512 |  | See Note 1 | See Note 2 | PB |
|  |  |  | Riximyo | SZ | C7021 C7022 C9336 C9340 C9344 C9446 C9448 C9449 C9450 C9511 C9512 C9539 C9611 C9640 C9641 |  | See Note 1 | See Note 2 | PB |
|  |  |  | Truxima | EW | C7021 C7022 C9336 C9340 C9344 C9446 C9448 C9449 C9450 C9511 C9512 C9539 C9611 C9640 C9641 |  | See Note 1 | See Note 2 | PB |
| Romiplostim | Powder for injection 375 micrograms | Injection | Nplate | AN | C6694 C6737 C6738 C6766 C6789 |  | See Note 1 | See Note 2 | D |
|  | Powder for injection 625 micrograms | Injection | Nplate | AN | C6694 C6737 C6738 C6766 C6789 |  | See Note 1 | See Note 2 | D |
| Saquinavir | Tablet 500 mg (as mesilate) | Oral | Invirase | RO | C4454 C4512 |  | 240 | 5 | D |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | Sevelamer Apotex | TX | C5530 C9762 |  | 360 | 5 | C |
|  |  |  | Sevelamer Lupin | GQ | C5530 C9762 |  | 360 | 5 | C |
|  | Tablet containing sevelamer hydrochloride 800 mg | Oral | Renagel | GZ | C5530 C9762 |  | 360 | 5 | C |
| Sildenafil | Tablet 20 mg (as citrate) | Oral | APO‑Sildenafil PHT | TX | C10228 C10234 C10304 C10998 C11012 C11020 C11032 C11045 |  | See Note 1 | See Note 2 | D |
|  |  |  | Revatio | UJ | C10228 C10234 C10304 C10998 C11012 C11020 C11032 C11045 |  | See Note 1 | See Note 2 | D |
|  |  |  | SILDATIO PHT | RW | C10228 C10234 C10304 C10998 C11012 C11020 C11032 C11045 |  | See Note 1 | See Note 2 | D |
|  |  |  | Sildenafil AN PHT 20 | EA | C10228 C10234 C10304 C10998 C11012 C11020 C11032 C11045 |  | See Note 1 | See Note 2 | D |
|  |  |  | Sildenafil Sandoz PHT 20 | SZ | C10228 C10234 C10304 C10998 C11012 C11020 C11032 C11045 |  | See Note 1 | See Note 2 | D |
| Sirolimus | Tablet 0.5 mg | Oral | Rapamune | PF | C5795 C9914 |  | 200 | 5 | C |
|  | Tablet 1 mg | Oral | Rapamune | PF | C5795 C9914 |  | 200 | 5 | C |
|  | Tablet 2 mg | Oral | Rapamune | PF | C5795 C9914 |  | 200 | 5 | C |
|  | Oral solution 1 mg per mL, 60 mL | Oral | Rapamune | PF | C5795 C9914 |  | 2 | 5 | C |
| Sofosbuvir | Tablet 400 mg | Oral | Sovaldi | GI | C5969 C5972 | P5969 | 28 | 2 |  |
| C5969 C5972 | P5972 | 28 | 5 |  |
| Sofosbuvir with velpatasvir | Tablet containing 400 mg sofosbuvir with 100 mg velpatasvir | Oral | Epclusa | GI | C5969 |  | 28 | 2 |  |
| Sofosbuvir with velpatasvir and voxilaprevir | Tablet containing 400 mg sofosbuvir with 100 mg velpatasvir and 100 mg voxilaprevir | Oral | Vosevi | GI | C10248 |  | 28 | 2 |  |
| Sucroferric oxyhydroxide | Tablet, chewable, 2.5 g (equivalent to 500 mg iron) | Oral | Velphoro | VL | C5530 C9762 |  | 180 | 5 | C |
| Tacrolimus | Capsule 0.5 mg | Oral | Pacrolim | AF | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | Pharmacor Tacrolimus 0.5 | CR | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | Prograf | LL | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | Tacrograf | RW | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | TACROLIMUS APOTEX | TX | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | Tacrolimus Sandoz | SZ | C5569 C9697 |  | 200 | 5 | C |
|  | Capsule 0.5 mg (once daily prolonged release) | Oral | ADVAGRAF XL | LQ | C5569 C9697 |  | 60 | 5 | C |
|  | Capsule 0.75 mg | Oral | Tacrolimus Sandoz | SZ | C5569 C9697 |  | 200 | 5 | C |
|  | Capsule 1 mg | Oral | Pacrolim | AF | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | Pharmacor Tacrolimus 1 | CR | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | Prograf | LL | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | Tacrograf | RW | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | TACROLIMUS APOTEX | TX | C5569 C9697 |  | 200 | 5 | C |
|  |  |  | Tacrolimus Sandoz | SZ | C5569 C9697 |  | 200 | 5 | C |
|  | Capsule 1 mg (once daily prolonged release) | Oral | ADVAGRAF XL | LQ | C5569 C9697 |  | 120 | 5 | C |
|  | Capsule 2 mg | Oral | Tacrolimus Sandoz | SZ | C5569 C9697 |  | 200 | 5 | C |
|  | Capsule 3 mg (once daily prolonged release) | Oral | ADVAGRAF XL | LQ | C5569 C9697 |  | 100 | 3 | C |
|  | Capsule 5 mg | Oral | Pacrolim | AF | C5569 C9697 |  | 100 | 5 | C |
|  |  |  | Pharmacor Tacrolimus 5 | CR | C5569 C9697 |  | 100 | 5 | C |
|  |  |  | Prograf | LL | C5569 C9697 |  | 100 | 5 | C |
|  |  |  | Tacrograf | RW | C5569 C9697 |  | 100 | 5 | C |
|  |  |  | TACROLIMUS APOTEX | TX | C5569 C9697 |  | 100 | 5 | C |
|  |  |  | Tacrolimus Sandoz | SZ | C5569 C9697 |  | 100 | 5 | C |
|  | Capsule 5 mg (once daily prolonged release) | Oral | ADVAGRAF XL | LQ | C5569 C9697 |  | 60 | 5 | C |
| Tadalafil | Tablet 20 mg | Oral | Adcirca | LY | C10228 C10234 C10304 C10998 C11012 C11020 C11032 C11045 |  | See Note 1 | See Note 2 | D |
|  |  |  | Tadalca | CR | C10228 C10234 C10304 C10998 C11012 C11020 C11032 C11045 |  | See Note 1 | See Note 2 | D |
|  |  |  | TADALIS 20 | LR | C10228 C10234 C10304 C10998 C11012 C11020 C11032 C11045 |  | See Note 1 | See Note 2 | D |
| Teduglutide | Powder for injection 5 mg with diluent | Injection | Revestive | TK | C9515 C9569 C9687 C9740 C9793 C9829 |  | See Note 1 | See Note 2 | D |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir APOTEX | TX | C6980 C6982 C6983 C6984 C6992 C6998 C10362 | P10362 | 60 | 2 | D |
|  |  |  | Viread | GI | C6980 C6982 C6983 C6984 C6992 C6998 C10362 | P10362 | 60 | 2 | D |
|  |  |  | Tenofovir APOTEX | TX | C6980 C6982 C6983 C6984 C6992 C6998 C10362 | P6980 P6982 P6983 P6984 P6992 P6998 | 60 | 5 | D |
|  |  |  | Viread | GI | C6980 C6982 C6983 C6984 C6992 C6998 C10362 | P6980 P6982 P6983 P6984 P6992 P6998 | 60 | 5 | D |
|  | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Mylan | AF | C6980 C6982 C6983 C6984 C6992 C6998 C10362 | P10362 | 60 | 2 | D |
|  |  |  |  |  | C6980 C6982 C6983 C6984 C6992 C6998 C10362 | P6980 P6982 P6983 P6984 P6992 P6998 | 60 | 5 | D |
|  | Tablet containing tenofovir disoproxil phosphate 291 mg | Oral | Tenofovir GH | GQ | C6980 C6982 C6983 C6984 C6992 C6998 C10362 | P10362 | 60 | 2 | D |
|  |  |  |  |  | C6980 C6982 C6983 C6984 C6992 C6998 C10362 | P6980 P6982 P6983 P6984 P6992 P6998 | 60 | 5 | D |
| Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat | Tablet containing tenofovir alafenamide 10 mg with emtricitabine 200 mg, elvitegravir 150 mg and cobicistat 150 mg | Oral | Genvoya | GI | C4470 C4522 |  | 60 | 5 | D |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine 300/200 APOTEX | TX | C6985 C6986 |  | 60 | 5 | C |
|  | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | Tenofovir Disoproxil Emtricitabine Mylan 300/200 | AF | C6985 C6986 |  | 60 | 5 | C |
|  | Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg | Oral | Tenofovir EMT GH | GQ | C6985 C6986 |  | 60 | 5 | C |
| Tenofovir with emtricitabine and efavirenz | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg and efavirenz 600 mg | Oral | Tenofovir Disoproxil/Emtricitabine/Efavirenz Mylan 300/200/600 | AF | C4470 C4522 |  | 60 | 5 | D |
| Tezacaftor with ivacaftor and ivacaftor | Pack containing 28 tablets tezacaftor 100 mg with ivacaftor 150 mg and 28 tablets ivacaftor 150 mg | Oral | Symdeko | VR | C9880 C9961 C10064 C10069 |  | See Note 1 | See Note 2 | D |
| Thalidomide | Capsule 50 mg | Oral | Thalomid | CJ | C5914 C9290 |  | 112 | 0 | D |
|  | Capsule 100 mg | Oral | Thalomid | CJ | C5914 C9290 |  | 56 | 0 | D |
| Tipranavir | Capsule 250 mg | Oral | Aptivus | BY | C5764 |  | 240 | 5 | D |
| Tocilizumab | Concentrate for injection 80 mg in 4 mL | Injection | Actemra | RO | C8627 C8635 C8636 C8637 C8638 C8709 C9380 C9384 C9386 C9407 C9417 C9494 C9495 C9496 C10532 C10535 C10536 C10541 C10542 C10545 C10567 C10570 C10571 C10616 |  | See Note 1 | See Note 2 | PB |
|  | Concentrate for injection 200 mg in 10 mL | Injection | Actemra | RO | C8627 C8635 C8636 C8637 C8638 C8709 C9380 C9384 C9386 C9407 C9417 C9494 C9495 C9496 C10532 C10535 C10536 C10541 C10542 C10545 C10567 C10570 C10571 C10616 |  | See Note 1 | See Note 2 | PB |
|  | Concentrate for injection 400 mg in 20 mL | Injection | Actemra | RO | C8627 C8635 C8636 C8637 C8638 C8709 C9380 C9384 C9386 C9407 C9417 C9494 C9495 C9496 C10532 C10535 C10536 C10541 C10542 C10545 C10567 C10570 C10571 C10616 |  | See Note 1 | See Note 2 | PB |
| Ustekinumab | Solution for I.V. infusion 130 mg in 26 mL | Injection | Stelara | JC | C9655 C9656 C9710 |  | See Note 1 | See Note 2 | PB |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | APO‑Valaciclovir | TX | C5975 C9267 |  | 500 | 2 | C |
|  |  |  | Valaciclovir APOTEX | GX | C5975 C9267 |  | 500 | 2 | C |
|  |  |  | Valaciclovir RBX | RA | C5975 C9267 |  | 500 | 2 | C |
|  |  |  | Valtrex | RW | C5975 C9267 |  | 500 | 2 | C |
| Valganciclovir | Tablet 450 mg (as hydrochloride) | Oral | Valcyte | RO | C4980 C4989 C9316 |  | 120 | 5 | D |
|  |  |  | Valganciclovir Mylan | AF | C4980 C4989 C9316 |  | 120 | 5 | D |
|  |  |  | Valganciclovir Sandoz | SZ | C4980 C4989 C9316 |  | 120 | 5 | D |
|  | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL | Oral | Valcyte | RO | C4980 C4989 C9316 |  | 11 | 5 | D |
| Vedolizumab | Powder for injection 300 mg | Injection | Entyvio | TK | C9682 C9683 C9708 C9738 C9739 C9771 C9792 C9796 C9815 C9825 |  | See Note 1 | See Note 2 | D |
| Zidovudine | Capsule 100 mg | Oral | Retrovir | VI | C4454 C4512 |  | 400 | 5 | D |
|  | Capsule 250 mg | Oral | Retrovir | VI | C4454 C4512 |  | 240 | 5 | D |
|  | Syrup 10 mg per mL, 200 mL | Oral | Retrovir | VI | C4454 C4512 |  | 15 | 5 | D |
| Zoledronic acid | Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL | Injection | APO‑Zoledronic Acid | TX | C5605 C5703 C5704 C5735 C9268 C9304 C9317 C9328 |  | 1 | 11 | PB |
|  |  |  | DBL Zoledronic Acid | PF | C5605 C5703 C5704 C5735 C9268 C9304 C9317 C9328 |  | 1 | 11 | PB |
|  |  |  | DEZTRON | DZ | C5605 C5703 C5704 C5735 C9268 C9304 C9317 C9328 |  | 1 | 11 | PB |
|  |  |  | Zometa | NV | C5605 C5703 C5704 C5735 C9268 C9304 C9317 C9328 |  | 1 | 11 | PB |
|  | Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL | Injection | DBL Zoledronic Acid | PF | C5605 C5703 C5704 C5735 C9268 C9304 C9317 C9328 |  | 1 | 11 | PB |

Note 1: The quantity or number of units of the HSD pharmaceutical benefit that may be directed in a prescription to be supplied to an eligible patient on any 1 occasion may only be in accordance with the limitations set out in section 24.

Note 2: The maximum number of repeats that may be authorised in a repeated supply of the HSD pharmaceutical benefit is set out in section 25.

Schedule 2—Responsible Person Codes

| Code | Responsible Person | Australian Business Number |
| --- | --- | --- |
| AF | Alphapharm Pty Ltd | 93 002 359 739 |
| AN | Amgen Australia Pty Limited | 31 051 057 428 |
| AP | AstraZeneca Pty Ltd | 54 009 682 311 |
| BD | Biogen Australia Pty Ltd | 30 095 760 115 |
| BN | Bayer Australia Ltd | 22 000 138 714 |
| BQ | Bristol‑Myers Squibb Australia Pty Ltd | 33 004 333 322 |
| BY | Boehringer Ingelheim Pty Ltd | 52 000 452 308 |
| BZ | Boucher & Muir Pty Ltd | 58 000 140 474 |
| CJ | Celgene Pty Limited | 42 118 998 771 |
| CR | Pharmacor Pty Limited | 58 121 020 835 |
| DZ | Medsurge Healthcare Pty Ltd | 92 124 728 892 |
| EA | Amneal Pharmaceuticals Pty Ltd | 11 163 167 851 |
| EU | Chiesi Australia Pty Ltd | 72 145 180 865 |
| EW | Celltrion Healthcare Australia Pty Ltd | 66 625 407 105 |
| FK | A. Menarini Australia Pty Limited | 62 116 935 758 |
| GI | Gilead Sciences Pty Limited | 71 072 611 708 |
| GK | GlaxoSmithKline Australia Pty Ltd | 47 100 162 481 |
| GO | Mylan Health Pty Ltd | 29 601 608 771 |
| GQ | Generic Health Pty Ltd | 93 110 617 859 |
| GX | Apotex Pty Ltd | 52 096 916 148 |
| GZ | sanofi‑aventis Australia Pty Ltd | 31 008 558 807 |
| HN | Horizon Hospital Healthcare Pty Ltd | 60 148 910 883 |
| HQ | Generic Health Pty Ltd | 93 110 617 859 |
| IS | Ipsen Pty Ltd | 47 095 036 909 |
| IX | Clinect Pty Ltd | 76 150 558 473 |
| JC | Janssen‑Cilag Pty Ltd | 47 000 129 975 |
| JO | Juno Pharmaceuticals Pty Ltd | 55 156 303 650 |
| JU | Juno Pharmaceuticals Pty Ltd | 55 156 303 650 |
| JX | Juno Pharmaceuticals Pty Ltd | 55 156 303 650 |
| LL | Astellas Pharma Australia Pty Ltd | 81 147 915 482 |
| LQ | Astellas Pharma Australia Pty Ltd | 81 147 915 482 |
| LR | Cipla Australia Pty Ltd | 46 132 155 063 |
| LY | Eli Lilly Australia Pty Ltd | 39 000 233 992 |
| MK | Merck Sharp & Dohme (Australia) Pty Ltd | 14 000 173 508 |
| NM | Novartis Pharmaceuticals Australia Pty Limited | 18 004 244 160 |
| NV | Novartis Pharmaceuticals Australia Pty Limited | 18 004 244 160 |
| OC | Accord Healthcare Pty Ltd | 49 110 502 513 |
| OQ | Organon Pharma Pty Ltd | 54 637 107 512 |
| PB | Pharmaco (Australia) Limited | 89 113 383 501 |
| PF | Pfizer Australia Pty Ltd | 50 008 422 348 |
| RA | Sun Pharma ANZ Pty Ltd | 17 110 871 826 |
| RF | Arrow Pharma Pty Ltd | 35 605 909 920 |
| RI | Dr Reddy’s Laboratories (Australia) Pty Ltd | 16 120 092 408 |
| RJ | Recordati Rare Diseases Australia Pty. Ltd | 26 627 263 094 |
| RO | Roche Products Pty Ltd | 70 000 132 865 |
| RW | Arrow Pharma Pty Ltd | 35 605 909 920 |
| RZ | Dr Reddy’s Laboratories (Australia) Pty Ltd | 16 120 092 408 |
| SZ | Sandoz Pty Ltd | 60 075 449 553 |
| TB | Teva Pharma Australia Pty Limited | 41 169 715 664 |
| TD | Stada Pharmaceuticals Australia Pty Limited | 73 154 966 944 |
| TK | Takeda Pharmaceuticals Australia Pty Ltd | 71 095 610 870 |
| TQ | Terumo BCT Australia Pty Limited | 87 130 046 865 |
| TX | Apotex Pty Ltd | 52 096 916 148 |
| UJ | Upjohn Australia Pty Ltd | 50 629 389 911 |
| VE | AbbVie Pty Ltd | 48 156 384 262 |
| VI | ViiV Healthcare Pty Ltd | 46 138 687 448 |
| VL | Vifor Pharma Pty Limited | 87 086 114 043 |
| VR | Vertex Pharmaceuticals (Australia) Pty Ltd | 34 160 157 157 |
| XA | Pharmaxis Ltd | 75 082 811 630 |
| XI | Alexion Pharmaceuticals Australasia Pty Ltd | 59 132 343 036 |

Schedule 3—Circumstances and Purposes Codes

(sections 9, 14, 15, 16 and 25)

| **Listed Drug** | **Circumstances Code** | **Purposes Code** | **Circumstances and Purposes** | **Authority Requirements ‑ Part of Circumstances** |
| --- | --- | --- | --- | --- |
| Abacavir | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Abacavir with Lamivudine | C4527 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents; Patient must be aged 12 years or older; AND Patient must weigh 40 kg or more | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4527 |
|  | C4528 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents; Patient must be aged 12 years or older; AND Patient must weigh 40 kg or more | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4528 |
| Abacavir with Lamivudine and Zidovudine | C4480 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; Patient must be aged 12 years or older; AND Patient must weigh 40 kg or more | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4480 |
|  | C4495 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; Patient must be aged 12 years or older; AND Patient must weigh 40 kg or more | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4495 |
| Abatacept | C8627 |  | Severe active rheumatoid arthritis Continuing Treatment ‑ balance of supply. Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction. | Compliance with Authority Required procedures |
|  | C8638 |  | Severe active rheumatoid arthritis Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) ‑ balance of supply Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | Compliance with Authority Required procedures |
|  | C8655 |  | Severe active rheumatoid arthritis Continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C8688 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 3 (re‑commencement of treatment after a break in biological medicine of more than 24 months) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 24 months or more from the most recent PBS‑subsidised biological medicine for this condition; AND Patient must not have failed to respond to previous PBS‑subsidised treatment with this drug for this condition; AND Patient must not have already failed , or ceased to respond to, PBS‑subsidised biological medicine treatment for this condition 5 times; AND The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; OR The condition must have a C‑reactive protein (CRP) level greater than 15 mg per L; AND The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND Patient must not receive more than 16 weeks of treatment under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C8748 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 2 (change or re‑commencement of treatment after a break in biological medicine of less than 24 months). Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must not have failed to respond to previous PBS‑subsidised treatment with this drug for this condition; AND Patient must not have already failed , or ceased to respond to, PBS‑subsidised biological medicine treatment for this condition 5 times; AND Patient must not receive more than 16 weeks of treatment under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). An application for a patient who has received PBS‑subsidised treatment with this drug and who wishes to re‑commence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised treatment with this drug, within the timeframes specified below. Where the most recent course of PBS‑subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. At the time of authority application, medical practitioners should request the appropriate number of vials to provide sufficient drug, based on the weight of the patient, for a single infusion. Up to a maximum of 4 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. A patient who has demonstrated a response to a course of rituximab must have a PBS‑subsidised biological therapy treatment‑free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine. | Compliance with Written Authority Required procedures |
|  | C8759 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 1 (new patient) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must not have received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti‑rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)‑approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA‑approved Product Information or cannot be tolerated at the doses specified above, must include at least 3 months continuous treatment with each of at least 2 DMARDs, with one or more of the following DMARDs being used in place of the DMARDS which are contraindicated or not tolerated: (i) azathioprine at a dose of at least 1 mg/kg per day; and/or (ii) cyclosporin at a dose of at least 2 mg/kg/day; and/or (iii) sodium aurothiomalate at a dose of 50 mg weekly; AND Patient must not receive more than 16 weeks of treatment under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. If methotrexate is contraindicated according to the TGA‑approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable. The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C‑reactive protein (CRP) level greater than 15 mg per L; AND either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active joints from the following list of major joints: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. At the time of authority application, medical practitioners should request the appropriate number of vials to provide sufficient drug, based on the weight of the patient, for a single infusion. Up to a maximum of 4 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
| Adalimumab | C9384 |  | Severe active juvenile idiopathic arthritis Continuing treatment ‑ balance of supply Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction. | Compliance with Authority Required procedures |
|  | C9417 |  | Severe active juvenile idiopathic arthritis Initial treatment ‑ Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) ‑ balance of supply Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) restriction to complete 16 weeks treatment; AND The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | Compliance with Authority Required procedures |
|  | C10582 |  | Severe active juvenile idiopathic arthritis Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND Patient must not receive more than 16 weeks of treatment under this restriction. An adequate response to treatment is defined as: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). At the time of authority application, medical practitioners must request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient who fails to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. A patient may re-trial this drug after a minimum of 12 months have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the initial 3 treatment restriction. If a patient fails to respond to PBS-subsidised biological medicine treatment 3 times (once with each agent) they will not be eligible to receive further PBS-subsidised biological medicine therapy in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C10583 |  | Severe active juvenile idiopathic arthritis Initial treatment - Initial 1 (new patient) Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have demonstrated severe intolerance of, or toxicity due to, methotrexate; OR Patient must have demonstrated failure to achieve an adequate response to 1 or more of the following treatment regimens: (i) oral or parenteral methotrexate at a dose of at least 20 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or (ii) oral methotrexate at a dose of at least 10 mg per square metre weekly together with at least 1 other disease modifying anti-rheumatic drug (DMARD), alone or in combination with corticosteroids, for a minimum of 3 months; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be under 18 years of age. Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant non-steroidal anti-inflammatory drugs (NSAIDs) on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours. Toxicity due to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis. If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application. If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, details of this toxicity must be provided at the time of application. The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: (a) an active joint count of at least 20 active (swollen and tender) joints; OR (b) at least 4 active joints from the following list: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The joint count assessment must be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. At the time of authority application, medical practitioners must request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 3 repeats will be authorised. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C10600 |  | Severe active juvenile idiopathic arthritis Continuing treatment Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction. An adequate response to treatment is defined as: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Determination of whether a response has been demonstrated to initial and subsequent courses of treatment will be based on the baseline measurement of joint count submitted with the initial treatment application. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. At the time of authority application, medical practitioners must request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 5 repeats will be authorised. Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re-trial this drug after a minimum of 12 months have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. If a patient fails to respond to PBS-subsidised biological medicine treatment 3 times (once with each agent) they will not be eligible to receive further PBS-subsidised biological medicine therapy in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C10619 |  | Severe active juvenile idiopathic arthritis Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have had a break in treatment of 12 months or more from the most recently approved PBS-subsidised biological medicine for this condition; AND The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND Patient must not receive more than 16 weeks of treatment under this restriction. Active joints are defined as: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). All measures of joint count must be no more than 4 weeks old at the time of this application. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of active joints, the response must be demonstrated on the total number of active joints. At the time of authority application, medical practitioners must request the appropriate number of injections of appropriate strength, based on the weight of the patient, to provide sufficient for two doses. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
| Adefovir | C4490 |  | Chronic hepatitis B infection Patient must not have cirrhosis; AND Patient must have failed antihepadnaviral therapy; AND Patient must have repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration, in conjunction with documented chronic hepatitis B infection; OR Patient must have repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months whilst on previous antihepadnaviral therapy, except in patients with evidence of poor compliance. | Compliance with Authority Required procedures - Streamlined Authority Code 4490 |
|  | C4510 |  | Chronic hepatitis B infection Patient must have cirrhosis; AND Patient must have failed antihepadnaviral therapy; AND Patient must have detectable HBV DNA. Patients with Child’s class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy. | Compliance with Authority Required procedures - Streamlined Authority Code 4510 |
| Alemtuzumab | C6847 | P6847 | Multiple sclerosis Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must not show continuing progression of disability while on treatment with this drug; AND Patient must not receive more than one PBS-subsidised treatment per year; AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must have demonstrated compliance with, and an ability to tolerate this therapy. Must be treated by a neurologist. | Compliance with Authority Required procedures - Streamlined Authority Code 6847 |
|  | C7714 | P7714 | Multiple sclerosis Initial treatment The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis by magnetic resonance imaging of the brain and/or spinal cord; OR The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis by accompanying written certification provided by a radiologist that a magnetic resonance imaging scan is contraindicated because of the risk of physical (not psychological) injury to the patient; AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years of commencing a PBS-subsidised disease modifying therapy for this condition; AND Patient must be ambulatory (without assistance or support). Must be treated by a neurologist. Where applicable, the date of the magnetic resonance imaging scan must be recorded in the patient's medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 7714 |
|  | C9589 | P9589 | Multiple sclerosis Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must not show continuing progression of disability while on treatment with this drug; AND Patient must not receive more than one PBS-subsidised treatment per year; AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must have demonstrated compliance with, and an ability to tolerate this therapy. Must be treated by a neurologist. | Compliance with Authority Required procedures - Streamlined Authority Code 9589 |
|  | C9636 | P9636 | Multiple sclerosis Initial treatment The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis by magnetic resonance imaging of the brain and/or spinal cord; OR The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis by accompanying written certification provided by a radiologist that a magnetic resonance imaging scan is contraindicated because of the risk of physical (not psychological) injury to the patient; AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years of commencing a PBS-subsidised disease modifying therapy for this condition; AND Patient must be ambulatory (without assistance or support). Must be treated by a neurologist. Where applicable, the date of the magnetic resonance imaging scan must be recorded in the patient's medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 9636 |
| Ambrisentan | C10228 |  | Pulmonary arterial hypertension (PAH) Continuing treatment Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent for this condition; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10236 |  | Pulmonary arterial hypertension (PAH) Initial 2 (change) Patient must have documented WHO Functional Class II PAH, or WHO Functional Class III PAH, or WHO Functional Class IV PAH; AND Patient must have had their most recent course of PBS-subsidised treatment for this condition with a PAH agent other than this agent; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment (monotherapy) with 1 of these 8 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent’s restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap between the 8 PAH agents must be made under the relevant initial treatment (monotherapy) restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10285 |  | Pulmonary arterial hypertension (PAH) Initial 1 (new patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have WHO Functional Class II PAH, or WHO Functional Class III PAH, or WHO Functional Class IV PAH; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C10728 |  | Pulmonary arterial hypertension (PAH) Continuing treatment (dual therapy) Patient must have received their most recent course of PBS-subsidised dual therapy with this PAH agent and a phosphodiesterase-5 inhibitor (PDE-5i) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10845 |  | Pulmonary arterial hypertension (PAH) Initial 1 (dual therapy - previously untreated patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must currently have WHO Functional Class III PAH or WHO Functional Class IV PAH; AND The treatment must be in combination with a PBS-subsidised phosphodiesterase-5 inhibitor (PDE-5i) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C10846 |  | Pulmonary arterial hypertension (PAH) Grandfathered patients (dual therapy) Patient must be receiving dual therapy with this non PBS-subsidised pulmonary arterial hypertension (PAH) agent and a non PBS-subsidised phosphodiesterase-5 inhibitor (PDE-5i) for this condition prior to 1 October 2020; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it was not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC could not be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests were able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC could not be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria for dual therapy for this condition. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C10850 |  | Pulmonary arterial hypertension (PAH) Initial 3 (dual therapy - change) Patient must have had their most recent course of PBS-subsidised dual therapy with a phosphodiesterase-5 inhibitor (PDE-5i) and an endothelin receptor antagonist (ERA) other than this agent for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once patients are approved dual therapy with a PAH agent from the PDE-5i class; or a PAH agent from the ERA class, they may swap between PAH agents within the same class. This means that patients may commence treatment with another PAH agent in the same class, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap within a PAH agent class must be made under the relevant initial treatment restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10869 |  | Pulmonary arterial hypertension (PAH) Initial 2 (dual therapy - previously treated patients) Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH; AND Patient must have documented a failure to achieve or maintain WHO Functional Class II status with prior PBS-subsidised monotherapy treatment with a phosphodiesterase-5 inhibitor (PDE-5i) for this condition; AND The treatment must be in combination with the PBS-subsidised PDE-5i for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. The results and date of the RHC, ECHO and 6 MWT as applicable must be included in the patient's medical record. Where a RHC cannot be performed on clinical grounds, the written confirmation of the reasons why must also be included in the patient's medical record. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11007 |  | Pulmonary arterial hypertension (PAH) Continuing treatment (dual therapy) Patient must have received their most recent course of PBS-subsidised dual therapy with this PAH agent and a phosphodiesterase-5 inhibitor (PDE-5i) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, and macitentan. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11008 |  | Pulmonary arterial hypertension (PAH) Grandfathered patients (dual therapy) Patient must be receiving dual therapy with this non PBS-subsidised pulmonary arterial hypertension (PAH) agent and a non PBS-subsidised phosphodiesterase-5 inhibitor (PDE-5i) for this condition prior to 1 December 2020; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, and macitentan. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it was not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC could not be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests were able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC could not be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria for dual therapy for this condition. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C11010 |  | Pulmonary arterial hypertension (PAH) Initial 3 (dual therapy - change) Patient must have had their most recent course of PBS-subsidised dual therapy with a phosphodiesterase-5 inhibitor (PDE-5i) and an endothelin receptor antagonist (ERA) other than this agent for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, and macitentan. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once patients are approved dual therapy with a PAH agent from the PDE-5i class; or a PAH agent from the ERA class, they may swap between PAH agents within the same class. This means that patients may commence treatment with another PAH agent in the same class, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap within a PAH agent class must be made under the relevant initial treatment restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11024 |  | Pulmonary arterial hypertension (PAH) Initial 2 (dual therapy - previously treated patients) Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH; AND Patient must have documented a failure to achieve or maintain WHO Functional Class II status with prior PBS-subsidised monotherapy treatment with a phosphodiesterase-5 inhibitor (PDE-5i) for this condition; AND The treatment must be in combination with the PBS-subsidised PDE-5i for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, and macitentan. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. The results and date of the RHC, ECHO and 6 MWT as applicable must be included in the patient's medical record. Where a RHC cannot be performed on clinical grounds, the written confirmation of the reasons why must also be included in the patient's medical record. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11037 |  | Pulmonary arterial hypertension (PAH) Initial 1 (dual therapy - previously untreated patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must currently have WHO Functional Class III PAH or WHO Functional Class IV PAH; AND The treatment must be in combination with a PBS-subsidised phosphodiesterase-5 inhibitor (PDE-5i) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, and macitentan. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
| Anakinra | C5450 |  | Moderate to severe cryopyrin associated periodic syndromes (CAPS) Must be treated by a rheumatologist or in consultation with a rheumatologist; OR Must be treated by a clinical immunologist or in consultation with a clinical immunologist. A diagnosis of CAPS must be documented in the patient’s medical records. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5450 |
| Apomorphine | C4833 |  | Parkinson disease Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4833 |
|  | C9561 |  | Parkinson disease Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9561 |
|  | C10830 |  | Parkinson disease Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND The treatment must be commenced in a specialist unit in a hospital setting. | Compliance with Authority Required procedures - Streamlined Authority Code 10830 |
|  | C10863 |  | Parkinson disease Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND The treatment must be commenced in a specialist unit in a hospital setting. | Compliance with Authority Required procedures - Streamlined Authority Code 10863 |
| Atazanavir | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Atazanavir with cobicistat | C4454 |  | HIV infection Continuing Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial Patient must be antiretroviral treatment naive; AND The treatment must be in combination with other antiretroviral agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Azacitidine | C6132 |  | Chronic Myelomonocytic Leukaemia Initial treatment The condition must have 10% to 29% marrow blasts without Myeloproliferative Disorder. The first authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Azacitidine PBS Authority Application ‑ Supporting Information Form; and (c) a copy of the bone marrow biopsy report demonstrating that the patient has chronic myelomonocytic leukaemia ; and (d) a copy of the full blood examination report; and (e) a signed patient acknowledgement. No more than 3 cycles will be authorised. | Compliance with Written Authority Required procedures |
|  | C6143 |  | Acute Myeloid Leukaemia Initial treatment The condition must have 20% to 30% marrow blasts and multi‑lineage dysplasia, according to World Health Organisation (WHO) Classification. The first authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Azacitidine PBS Authority Application ‑ Supporting Information Form; and (c) a copy of the bone marrow biopsy report demonstrating that the patient has acute myeloid leukaemia; and (d) a copy of the full blood examination report; and (e) a signed patient acknowledgement. No more than 3 cycles will be authorised. | Compliance with Written Authority Required procedures |
|  | C6144 |  | Chronic Myelomonocytic Leukaemia Continuing treatment The condition must have 10% to 29% marrow blasts without Myeloproliferative Disorder; AND Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must not have progressive disease. Applications for continuing therapy may be made by telephone. Up to 6 cycles will be authorised. | Compliance with Authority Required procedures |
|  | C6177 |  | Myelodysplastic syndrome Initial treatment The condition must be classified as Intermediate‑2 according to the International Prognostic Scoring System (IPSS); OR The condition must be classified as high risk according to the International Prognostic Scoring System (IPSS). Classification of the condition as Intermediate‑2 requires a score of 1.5 to 2.0 on the IPSS, achieved with the possible combinations: a. 11% to 30% marrow blasts with good karyotypic status (normal, ‑Y alone, del(5q) alone, del(20q) alone), and 0 to 1 cytopenias; OR b. 11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 0 to 1 cytopenias; OR c. 11% to 20% marrow blasts with good karyotypic status (normal, ‑Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR d. 5% to 10% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR e. 5% to 10% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias; OR f. Less than 5% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), and 2 to 3 cytopenias. Classification of the condition as high risk requires a score of 2.5 or more on the IPSS, achieved with the possible combinations: a. 21% to 30% marrow blasts with good karyotypic status (normal, ‑Y alone, del(5q) alone, del(20q) alone), and 2 to 3 cytopenias; OR b. 21% to 30% marrow blasts with intermediate (other abnormalities) or poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR c. 11% to 20% marrow blasts with poor karyotypic status (3 or more abnormalities or chromosome 7 anomalies), regardless of cytopenias; OR d. 11% to 20% marrow blasts with intermediate karyotypic status (other abnormalities), and 2 to 3 cytopenias. The first authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Azacitidine PBS Authority Application ‑ Supporting Information Form; and (c) a copy of the bone marrow biopsy report demonstrating that the patient has myelodysplastic syndrome; and (d) a copy of the full blood examination report; and (e) a copy of the pathology report detailing the cytogenetics demonstrating intermediate‑2 or high risk disease according to the International Prognostic Scoring System (IPSS); and (f) a signed patient acknowledgment form. No more than 3 cycles will be authorised. | Compliance with Written Authority Required procedures |
|  | C6186 |  | Acute Myeloid Leukaemia Continuing treatment The condition must have 20% to 30% marrow blasts and multi‑lineage dysplasia, according to World Health Organisation (WHO) Classification; AND Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must not have progressive disease. Applications for continuing therapy may be made by telephone. Up to 6 cycles will be authorised. | Compliance with Authority Required procedures |
|  | C6199 |  | Myelodysplastic syndrome Continuing treatment The condition must be classified as Intermediate‑2 according to the International Prognostic Scoring System (IPSS); OR The condition must be classified as high risk according to the International Prognostic Scoring System (IPSS); AND Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must not have progressive disease. Applications for continuing therapy may be made by telephone. Up to 6 cycles will be authorised. | Compliance with Authority Required procedures |
| Azithromycin | C6356 |  | Mycobacterium avium complex infection  The treatment must be for prophylaxis; AND  Patient must be human immunodeficiency virus (HIV) positive; AND  Patient must have CD4 cell counts of less than 75 per cubic millimetre. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6356 |
|  | C9604 |  | Mycobacterium avium complex infection The treatment must be for prophylaxis; AND Patient must be human immunodeficiency virus (HIV) positive; AND Patient must have CD4 cell counts of less than 75 per cubic millimetre. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9604 |
| Baclofen | C6911 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity due to spinal cord disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6911 |
|  | C6925 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity of cerebral origin. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6925 |
|  | C6939 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity due to multiple sclerosis. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6939 |
|  | C6940 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity due to spinal cord injury. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6940 |
|  | C7134 |  | Severe chronic spasticity  Patient must have failed to respond to treatment with oral antispastic agents; OR  Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND  Patient must have chronic spasticity due to multiple sclerosis. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7134 |
|  | C7148 |  | Severe chronic spasticity  Patient must have failed to respond to treatment with oral antispastic agents; OR  Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND  Patient must have chronic spasticity due to spinal cord disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7148 |
|  | C7152 |  | Severe chronic spasticity  Patient must have failed to respond to treatment with oral antispastic agents; OR  Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND  Patient must have chronic spasticity of cerebral origin. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7152 |
|  | C7153 |  | Severe chronic spasticity  Patient must have failed to respond to treatment with oral antispastic agents; OR  Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND  Patient must have chronic spasticity due to spinal cord injury. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7153 |
|  | C9488 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity of cerebral origin. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9488 |
|  | C9489 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity due to spinal cord injury. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9489 |
|  | C9524 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity due to spinal cord disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9524 |
|  | C9525 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity due to multiple sclerosis. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9525 |
|  | C9562 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity of cerebral origin. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9562 |
|  | C9606 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity due to spinal cord disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9606 |
|  | C9637 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity due to multiple sclerosis. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9637 |
|  | C9638 |  | Severe chronic spasticity Patient must have failed to respond to treatment with oral antispastic agents; OR Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND Patient must have chronic spasticity due to spinal cord injury. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9638 |
| Benralizumab | C9887 | P9887 | Uncontrolled severe eosinophilic asthma Balance of supply Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must received insufficient therapy with this drug under the Initial 1 (new patients or recommencement of treatment in a new treatment cycle) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Initial 2 (change of treatment) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND The treatment must not provide more than the balance of up to 32 weeks of treatment if the most recent authority approval was made under an Initial treatment restriction; OR The treatment must not provide more than the balance of up to 24 weeks of treatment if the most recent authority approval was made under the Continuing treatment restriction. | Compliance with Authority Required procedures |
|  | C10264 | P10264 | Uncontrolled severe eosinophilic asthma Initial treatment ‑ Initial 2 (Change of treatment) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must have received prior PBS‑subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND Patient must not have failed, or ceased to respond to, PBS‑subsidised treatment with this drug for severe asthma during the current treatment cycle; AND Patient must have had a blood eosinophil count greater than or equal to 300 cells per microlitre and that is no older than 12 months immediately prior to commencing PBS‑subsidised biological medicine treatment for severe asthma; OR Patient must have had a blood eosinophil count greater than or equal to 150 cells per microlitre while receiving treatment with oral corticosteroids and that is no older than 12 months immediately prior to commencing PBS‑subsidised biological medicine treatment for severe asthma; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Eosinophilic Asthma (mepolizumab/benralizumab) Initial PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) Asthma Control Questionnaire (ACQ‑5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and (ii) the details of prior biological medicine treatment including the details of date and duration of treatment; and (iii) eosinophil count and date; and (iv) the dose of the maintenance oral corticosteroid (where the response criteria or baseline is based on corticosteroid dose); and (v) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). An application for a patient who has received PBS‑subsidised biological medicine treatment for severe asthma who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ‑5 assessment of the patient’s most recent course of PBS‑subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine. An ACQ‑5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS‑subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment at around 28 weeks, which will be used to determine eligibility for the first continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this biological medicine. At the time of the authority application, medical practitioners should request up to 4 repeats to provide for an initial course sufficient for up to 32 weeks of therapy, based on a dose of 30 mg every 4 weeks for the first three doses (weeks 0, 4, and 8) then 30 mg every eight weeks thereafter (refer to the TGA‑approved Product Information). A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. | Compliance with Written Authority Required procedures |
|  | C10281 | P10281 | Uncontrolled severe eosinophilic asthma Continuing treatment Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must have demonstrated or sustained an adequate response to PBS‑subsidised treatment with this drug for this condition; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 12 years or older. An adequate response to this biological medicine is defined as: (a) a reduction in the Asthma Control Questionnaire (ACQ‑5) score of at least 0.5 from baseline, OR (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ‑5 score from baseline or an increase in ACQ‑5 score from baseline less than or equal to 0.5. All applications for second and subsequent continuing treatments with this drug must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient’s response to the prior course of treatment or the assessment of oral corticosteroid dose, should be made at around 20 weeks after the first dose of PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. The assessment should, where possible, be completed by the same physician who initiated treatment with this drug. This assessment, which will be used to determine eligibility for continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this drug. Where treatment was ceased for clinical reasons despite the patient experiencing improvement, an assessment of the patient’s response to treatment made at the time of treatment cessation or retrospectively will be considered to determine whether the patient demonstrated or sustained an adequate response to treatment. A patient who fails to respond to treatment with this biological medicine for uncontrolled severe asthma will not be eligible to receive further PBS subsidised treatment with this biological medicine for severe asthma within the current treatment cycle. At the time of the authority application, medical practitioners should request the appropriate number of repeats to provide for a continuing course of this drug sufficient for up to 24 weeks of therapy. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Eosinophilic Asthma Continuing PBS Authority Application ‑ Supporting Information Form which includes: (i) details of maintenance oral corticosteroid dose; or (ii) a completed Asthma Control Questionnaire (ACQ‑5) score. | Compliance with Written Authority Required procedures |
|  | C10314 | P10314 | Uncontrolled severe eosinophilic asthma Initial treatment ‑ Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must not have received PBS‑subsidised treatment with a biological medicine for severe asthma; OR Patient must have had a break in treatment from the most recently approved PBS‑subsidised biological medicine for severe asthma; AND Patient must have a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by the following standard clinical features: (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma; AND Patient must have a duration of asthma of at least 1 year; AND Patient must have blood eosinophil count greater than or equal to 300 cells per microlitre in the last 12 months; OR Patient must have blood eosinophil count greater than or equal to 150 cells per microlitre while receiving treatment with oral corticosteroids in the last 12 months; AND Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. Optimised asthma therapy includes: (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long‑acting beta‑2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated; AND (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated. If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA‑approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application. The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application: (a) an Asthma Control Questionnaire (ACQ‑5) score of at least 2.0, as assessed in the previous month, AND (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician. The Asthma Control Questionnaire (5 item version) assessment of the patient’s response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment, which will be used to determine eligibility for the first continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within the same treatment cycle. A treatment break in PBS‑subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 3 biological medicines within the same treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with a PBS‑subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle. There is no limit to the number of treatment cycles that a patient may undertake in their lifetime. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. At the time of the authority application, medical practitioners should request up to 4 repeats to provide for an initial course of benralizumab sufficient for up to 32 weeks of therapy, at a dose of 30 mg every 4 weeks for the first three doses (weeks 0, 4, and 8) then 30 mg every eight weeks thereafter. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Eosinophilic Asthma Initial PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) details of prior optimised asthma drug therapy (date of commencement and duration of therapy); and (ii) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and (iii) the eosinophil count and date; and (iv) Asthma Control Questionnaire (ACQ‑5) score. | Compliance with Written Authority Required procedures |
| Bictegravir with emtricitabine with tenofovir alafenamide | C4470 |  | HIV infection Continuing Patient must have previously received PBS‑subsidised therapy for HIV infection. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4470 |
| C4522 |  | HIV infection Initial Patient must be antiretroviral treatment naive. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4522 |
| Bosentan | C10228 |  | Pulmonary arterial hypertension (PAH) Continuing treatment Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent for this condition; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10238 |  | Pulmonary arterial hypertension (PAH) Cessation of treatment (all patients) Patient must be receiving PBS-subsidised treatment with this PAH agent; AND The treatment must be for the purpose of gradual dose reduction prior to ceasing therapy. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment. Treatment beyond 1 month will not be approved. | Compliance with Authority Required procedures |
|  | C10924 |  | Pulmonary arterial hypertension (PAH) Initial 2 (change) Patient must have documented WHO Functional Class II PAH, or WHO Functional Class III PAH, or WHO Functional Class IV PAH; AND Patient must have had their most recent course of PBS-subsidised treatment for this condition with a PAH agent other than this agent; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment (monotherapy) with 1 of these 8 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap between the 8 PAH agents must be made under the relevant initial treatment (monotherapy) restriction. If patients will be taking 62.5mg for the first month then 125 mg, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information and no repeats. Prescribers should request the second authority prescription of therapy with the 125 mg tablet strengths, with a quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. If patients will be taking 62.5mg for longer than 1 month, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment and a maximum of 5 repeats based on the dosage recommendations in the TGA-approved Product Information. | Compliance with Authority Required procedures |
|  | C10945 |  | Pulmonary arterial hypertension (PAH) Initial 1 (new patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have WHO Functional Class II PAH, or WHO Functional Class III PAH, or WHO Functional Class IV PAH; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) two completed authority prescription forms; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. If patients will be taking 62.5mg for the first month then 125 mg, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information and no repeats. Prescribers should request the second authority prescription of therapy with the 125 mg tablet strengths, with a quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. If patients will be taking 62.5mg for longer than 1 month, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment and a maximum of 5 repeats based on the dosage recommendations in the TGA-approved Product Information. | Compliance with Written Authority Required procedures |
|  | C11004 |  | Pulmonary arterial hypertension (PAH) Grandfathered patients (dual therapy) Patient must be receiving dual therapy with this non PBS-subsidised pulmonary arterial hypertension (PAH) agent and a non PBS-subsidised phosphodiesterase-5 inhibitor (PDE-5i) for this condition prior to 1 October 2020; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it was not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC could not be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests were able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC could not be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria for dual therapy for this condition. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C11022 |  | Pulmonary arterial hypertension (PAH) Initial 3 (dual therapy - change) Patient must have had their most recent course of PBS-subsidised dual therapy with a phosphodiesterase-5 inhibitor (PDE-5i) and an endothelin receptor antagonist (ERA) other than this agent for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once patients are approved dual therapy with a PAH agent from the PDE-5i class; or a PAH agent from the ERA class, they may swap between PAH agents within the same class. This means that patients may commence treatment with another PAH agent in the same class, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap within a PAH agent class must be made under the relevant initial treatment restriction. If patients will be taking 62.5mg for the first month then 125 mg, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information and no repeats. Prescribers should request the second authority prescription of therapy with the 125 mg tablet strengths, with a quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. If patients will be taking 62.5mg for longer than 1 month, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment and a maximum of 5 repeats based on the dosage recommendations in the TGA-approved Product Information. | Compliance with Authority Required procedures |
|  | C11023 |  | Pulmonary arterial hypertension (PAH) Continuing treatment (dual therapy) Patient must have received their most recent course of PBS-subsidised dual therapy with this PAH agent and a phosphodiesterase-5 inhibitor (PDE-5i) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11036 |  | Pulmonary arterial hypertension (PAH) Initial 1 (dual therapy - previously untreated patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must currently have WHO Functional Class III PAH or WHO Functional Class IV PAH; AND The treatment must be in combination with a PBS-subsidised phosphodiesterase-5 inhibitor (PDE-5i) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. If patients will be taking 62.5mg for the first month then 125 mg, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information and no repeats. Prescribers should request the second authority prescription of therapy with the 125 mg tablet strengths, with a quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. If patients will be taking 62.5mg for longer than 1 month, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment and a maximum of 5 repeats based on the dosage recommendations in the TGA-approved Product Information. | Compliance with Written Authority Required procedures |
|  | C11044 |  | Pulmonary arterial hypertension (PAH) Initial 2 (dual therapy - previously treated patients) Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH; AND Patient must have documented a failure to achieve or maintain WHO Functional Class II status with prior PBS-subsidised monotherapy treatment with a phosphodiesterase-5 inhibitor (PDE-5i) for this condition; AND The treatment must be in combination with the PBS-subsidised PDE-5i for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. The results and date of the RHC, ECHO and 6 MWT as applicable must be included in the patient's medical record. Where a RHC cannot be performed on clinical grounds, the written confirmation of the reasons why must also be included in the patient's medical record. If patients will be taking 62.5mg for the first month then 125 mg, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information and no repeats. Prescribers should request the second authority prescription of therapy with the 125 mg tablet strengths, with a quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. If patients will be taking 62.5mg for longer than 1 month, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment and a maximum of 5 repeats based on the dosage recommendations in the TGA-approved Product Information. | Compliance with Authority Required procedures |
|  | C11064 |  | Pulmonary arterial hypertension (PAH) Initial 1 (dual therapy - previously untreated patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must currently have WHO Functional Class III PAH or WHO Functional Class IV PAH; AND The treatment must be in combination with a PBS-subsidised phosphodiesterase-5 inhibitor (PDE-5i) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. If patients will be taking 62.5mg for the first month then 125 mg, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information and no repeats. Prescribers should request the second authority prescription of therapy with the 125 mg tablet strengths, with a quantity for one month of treatment, based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. If patients will be taking 62.5mg for longer than 1 month, prescribers should request the first authority prescription of therapy with the 62.5 mg tablet strength, with the quantity for one month of treatment and a maximum of 5 repeats based on the dosage recommendations in the TGA-approved Product Information. | Compliance with Written Authority Required procedures |
| Ciclosporin | C6628 |  | Management of transplant rejection  The treatment must be used by organ or tissue transplant recipients. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6628 |
|  | C6631 |  | Nephrotic syndrome  Management (initiation, stabilisation and review of therapy)  Patient must have failed prior treatment with steroids and cytostatic drugs; OR Patient must be intolerant to treatment with steroids and cytostatic drugs; OR The condition must be considered inappropriate for treatment with steroids and cytostatic drugs; AND Patient must not have renal impairment. Must be treated by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6631 |
|  | C6638 |  | Severe active rheumatoid arthritis  Management (initiation, stabilisation and review of therapy)  The condition must have been ineffective to prior treatment with classical slow‑acting anti‑rheumatic agents (including methotrexate); OR The condition must be considered inappropriate for treatment with slow‑acting anti‑rheumatic agents (including methotrexate). Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6638 |
|  | C6643 |  | Management of transplant rejection  Management (initiation, stabilisation and review of therapy)  Patient must have had an organ or tissue transplantation; AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6643 |
|  | C6660 |  | Severe atopic dermatitis  Management (initiation, stabilisation and review of therapy)  Must be treated by a dermatologist; OR Must be treated by a clinical immunologist. The condition must be ineffective to other systemic therapies; OR The condition must be inappropriate for other systemic therapies. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6660 |
|  | C6676 |  | Severe psoriasis  Management (initiation, stabilisation and review of therapy)  The condition must be ineffective to other systemic therapies; OR The condition must be inappropriate for other systemic therapies; AND The condition must have caused significant interference with quality of life. Must be treated by a dermatologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6676 |
|  | C9694 |  | Nephrotic syndrome Management (initiation, stabilisation and review of therapy) Patient must have failed prior treatment with steroids and cytostatic drugs; OR Patient must be intolerant to treatment with steroids and cytostatic drugs; OR The condition must be considered inappropriate for treatment with steroids and cytostatic drugs; AND Patient must not have renal impairment. Must be treated by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9694 |
|  | C9695 |  | Severe atopic dermatitis Management (initiation, stabilisation and review of therapy) Must be treated by a dermatologist; OR Must be treated by a clinical immunologists. The condition must be ineffective to other systemic therapies; OR The condition must be inappropriate for other systemic therapies. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9695 |
|  | C9742 |  | Severe active rheumatoid arthritis Management (initiation, stabilisation and review of therapy) The condition must have been ineffective to prior treatment with classical slow‑acting anti‑rheumatic agents (including methotrexate); OR The condition must be considered inappropriate for treatment with slow‑acting anti‑rheumatic agents (including methotrexate). Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9742 |
|  | C9763 |  | Severe psoriasis Management (initiation, stabilisation and review of therapy) The condition must be ineffective to other systemic therapies; OR The condition must be inappropriate for other systemic therapies; AND The condition must have caused significant interference with quality of life. Must be treated by a dermatologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9763 |
|  | C9764 |  | Management of transplant rejection Management (initiation, stabilisation and review of therapy) Patient must have had an organ or tissue transplantation; AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9764 |
|  | C9831 |  | Management of transplant rejection The treatment must be used by organ or tissue transplant recipients. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9831 |
| Cinacalcet | C10063 |  | Secondary hyperparathyroidism Continuing treatment Must be treated by a nephrologist. Patient must have chronic kidney disease; AND Patient must be on dialysis; AND Patient must have previously received PBS‑subsidised treatment with this drug for this condition. During the maintenance phase, iPTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration. During the maintenance phase, prescribers should request approval to allow sufficient supply for 4 weeks treatment up to a maximum of 6 months supply, with doses between 30 and 180 mg per day according to the patient’s response and tolerability. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10063 |
|  | C10067 |  | Secondary hyperparathyroidism Continuing treatment Must be treated by a nephrologist. Patient must have chronic kidney disease; AND Patient must be on dialysis; AND Patient must have previously received PBS‑subsidised treatment with this drug for this condition. During the maintenance phase, iPTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration. During the maintenance phase, prescribers should request approval to allow sufficient supply for 4 weeks treatment up to a maximum of 6 months supply, with doses between 30 and 180 mg per day according to the patient’s response and tolerability. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10067 |
|  | C10073 |  | Secondary hyperparathyroidism Initial treatment Must be treated by a nephrologist. Patient must have chronic kidney disease; AND Patient must be on dialysis; AND Patient must have failed to respond to conventional therapy; AND Patient must have sustained hyperparathyroidism with iPTH of at least 50 pmol per L; OR Patient must have sustained hyperparathyroidism with iPTH of at least 15 pmol per L and less than 50 pmol per L and an (adjusted) serum calcium concentration at least 2.6 mmol per L. During the titration phase, intact PTH (iPTH) should be monitored 4 weekly (measured at least 12 hours post dose) and dose titrated until an appropriate iPTH concentration is achieved. During the titration phase, prescribers should request approval to allow sufficient supply for 4 weeks treatment at a time, with doses between 30 and 180 mg per day according to the patient’s response and tolerability. | Compliance with Authority Required procedures |
| Clozapine | C4998 |  | Schizophrenia Continuing treatment Must be treated by a psychiatrist; OR Must be treated by an authorised medical practitioner, with the agreement of the treating psychiatrist. Patient must have previously received PBS-subsidised therapy with this drug for this condition; AND Patient must have completed at least 18 weeks therapy; AND Patient must be on a clozapine dosage considered stable by a treating psychiatrist; AND The treatment must be under the supervision and direction of a psychiatrist reviewing the patient at regular intervals. A medical practitioner should request a quantity sufficient for up to one month’s supply. Up to 5 repeats will be authorised. | Compliance with Authority Required procedures - Streamlined Authority Code 4998 |
|  | C5015 |  | Schizophrenia Initial treatment Must be treated by a psychiatrist or in consultation with the psychiatrist affiliated with the hospital or specialised unit managing the patient. Patient must be non-responsive to other neuroleptic agents; OR Patient must be intolerant of other neuroleptic agents. Patients must complete at least 18 weeks of initial treatment under this restriction before being able to qualify for treatment under the continuing restriction. The name of the consulting psychiatrist should be included in the patient’s medical records. A medical practitioner should request a quantity sufficient for up to one month’s supply. Up to 5 repeats will be authorised. | Compliance with Authority Required procedures - Streamlined Authority Code 5015 |
|  | C9490 |  | Schizophrenia Initial treatment Must be treated by a psychiatrist or in consultation with the psychiatrist affiliated with the hospital or specialised unit managing the patient. Patient must be non‑responsive to other neuroleptic agents; OR Patient must be intolerant of other neuroleptic agents. Patients must complete at least 18 weeks of initial treatment under this restriction before being able to qualify for treatment under the continuing restriction. The name of the consulting psychiatrist should be included in the patient’s medical records. A medical practitioner should request a quantity sufficient for up to one month’s supply. Up to 5 repeats will be authorised. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9490 |
| Darbepoetin Alfa | C6294 |  | Anaemia associated with intrinsic renal disease  Patient must require transfusion; AND  Patient must have a haemoglobin level of less than 100 g per L; AND  Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6294 |
|  | C9688 |  | Anaemia associated with intrinsic renal disease Patient must require transfusion; AND Patient must have a haemoglobin level of less than 100 g per L; AND Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9688 |
| Darunavir | C4313 |  | Human immunodeficiency virus (HIV) infection  The treatment must be in addition to optimised background therapy, AND  The treatment must be in combination with other antiretroviral agents, AND  The treatment must be co‑administered with 100 mg ritonavir, AND  Patient must have experienced virological failure or clinical failure or genotypic resistance after at least one antiretroviral regimen, AND  Patient must not have demonstrated darunavir resistance associated mutations detected on resistance testing.  Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment‑limiting toxicity. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4313 |
|  | C5094 |  | Human immunodeficiency virus (HIV) infection  The treatment must be in addition to optimised background therapy, AND  The treatment must be in combination with other antiretroviral agents, AND  The treatment must be co‑administered with 100 mg ritonavir twice daily, AND  Patient must have experienced virological failure or clinical failure or genotypic resistance after at least one antiretroviral regimen.  Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment‑limiting toxicity. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5094 |
| Darunavir with cobicistat | C6377 |  | Human immunodeficiency virus (HIV) infection  The treatment must be in addition to optimised background therapy; AND  The treatment must be in combination with other antiretroviral agents; AND  The treatment must not be in combination with ritonavir; AND  Patient must have experienced virological failure or clinical failure or genotypic resistance after at least one antiretroviral regimen.  Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment‑limiting toxicity. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6377 |
|  | C6413 |  | Human immunodeficiency virus (HIV) infection  Initial treatment  Patient must be antiretroviral treatment naive; AND  The treatment must be in combination with other antiretroviral agents; AND  The treatment must not be in combination with ritonavir. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6413 |
|  | C6428 |  | Human immunodeficiency virus (HIV) infection  Continuing treatment  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND  The treatment must be in combination with other antiretroviral agents; AND  The treatment must not be in combination with ritonavir. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6428 |
| Darunavir with cobicistat, emtricitabine and tenofovir alafenamide | C10317 |  | HIV infection Continuing treatment Must be treated by a medical practitioner or an authorised nurse practitioner in consultation with a medical practitioner. Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must not be in combination with ritonavir. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10317 |
|  | C10324 |  | HIV infection Initial treatment Must be treated by a medical practitioner or an authorised nurse practitioner in consultation with a medical practitioner. Patient must be antiretroviral treatment naive; OR Patient must have experienced virological failure or clinical failure or genotypic resistance after at least one antiretroviral regimen; AND The treatment must not be in combination with ritonavir. Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment‑limiting toxicity. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10324 |
| Deferasirox | C7374 | P7374 | Chronic iron overload  Initial treatment  Patient must not be transfusion dependent; AND  The condition must be thalassaemia. | Compliance with Authority Required procedures |
|  | C7375 | P7375 | Chronic iron overload  Initial treatment  Patient must be transfusion dependent; AND  Patient must not have a malignant disorder of erythropoiesis. | Compliance with Authority Required procedures |
|  | C7385 | P7385 | Chronic iron overload  Initial treatment  Patient must be red blood cell transfusion dependent; AND  Patient must have a serum ferritin level of greater than 1000 microgram/L; AND  Patient must have a malignant disorder of haemopoiesis; AND  Patient must have a median life expectancy exceeding five years. | Compliance with Authority Required procedures |
|  | C8326 | P8326 | Chronic iron overload Continuing treatment Patient must be red blood cell transfusion dependent; AND Patient must have a malignant disorder of haemopoieisis; AND Patient must have previously received PBS‑subsidised therapy with deferasirox for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8326 |
|  | C8328 | P8328 | Chronic iron overload Continuing treatment Patient must be transfusion dependent; AND Patient must not have a malignant disorder of erythropoiesis; AND Patient must have previously received PBS‑subsidised therapy with deferasirox for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8328 |
|  | C8329 | P8329 | Chronic iron overload Continuing treatment Patient must not be transfusion dependent; AND The condition must be thalassaemia; AND Patient must have previously received PBS‑subsidised therapy with deferasirox for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8329 |
|  | C9222 | P9222 | Chronic iron overload Continuing treatment Patient must not be transfusion dependent; AND The condition must be thalassaemia; AND Patient must have previously received PBS‑subsidised therapy with deferasirox for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9222 |
|  | C9258 | P9258 | Chronic iron overload Continuing treatment Patient must be red blood cell transfusion dependent; AND Patient must have a malignant disorder of haemopoieisis; AND Patient must have previously received PBS‑subsidised therapy with deferasirox for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9258 |
|  | C9302 | P9302 | Chronic iron overload Continuing treatment Patient must be transfusion dependent; AND Patient must not have a malignant disorder of erythropoiesis; AND Patient must have previously received PBS‑subsidised therapy with deferasirox for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9302 |
| Deferiprone | C6403 |  | Iron overload  Patient must have thalassaemia major; AND  Patient must be one in whom desferrioxamine therapy has proven ineffective. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6403 |
|  | C6448 |  | Iron overload  Patient must have thalassaemia major; AND  Patient must be unable to take desferrioxamine therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6448 |
|  | C9228 |  | Iron overload Patient must have thalassaemia major; AND Patient must be one in whom desferrioxamine therapy has proven ineffective. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9228 |
|  | C9286 |  | Iron overload Patient must have thalassaemia major; AND Patient must be unable to take desferrioxamine therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9286 |
|  | C9590 |  | Iron overload Patient must have thalassaemia major; AND Patient must be one in whom desferrioxamine therapy has proven ineffective. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9590 |
|  | C9623 |  | Iron overload Patient must have thalassaemia major; AND Patient must be unable to take desferrioxamine therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9623 |
| Desferrioxamine | C6394 |  | Disorders of erythropoiesis  The condition must be associated with treatment‑related chronic iron overload. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6394 |
|  | C9696 |  | Disorders of erythropoiesis The condition must be associated with treatment‑related chronic iron overload. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9696 |
| Dolutegravir | C4454 |  | HIV infection  Continuing  Patient must have previously received PBS subsidised therapy for HIV infection; AND  The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Dolutegravir with abacavir and lamivudine | C9981 |  | HIV infection Initial treatment Patient must be antiretroviral treatment naive. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9981 |
|  | C10116 |  | HIV infection Continuing treatment Patient must have previously received PBS‑subsidised therapy for HIV infection. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10116 |
| Dolutegravir with lamivudine | C9987 |  | HIV infection Initial treatment Patient must be antiretroviral treatment naive; AND Patient must not have suspected resistance to either antiretroviral component. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9987 |
|  | C11066 |  | HIV infection Continuing or change of treatment Patient must have previously received PBS-subsidised therapy for HIV infection. | Compliance with Authority Required procedures - Streamlined Authority Code 11066 |
| Dolutegravir with rilpivirine | C8214 |  | HIV infection Initial treatment Patient must be virologically suppressed on a stable antiretroviral regimen for at least 6 months; AND The treatment must be the sole PBS‑subsidised therapy for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8214 |
|  | C8226 |  | HIV infection Continuing treatment Patient must have previously received PBS‑subsidised therapy with this drug for this condition; AND The treatment must be the sole PBS‑subsidised therapy for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8226 |
| Dornase alfa | C5634 |  | Cystic fibrosis Patient must have a severe clinical course with frequent respiratory exacerbations or chronic respiratory symptoms (including chronic or recurrent cough, wheeze or tachypnoea) requiring hospital admissions more frequently than 3 times per year; OR Patient must have significant bronchiectasis on chest high resolution computed tomography scan; OR Patient must have severe cystic fibrosis bronchiolitis with persistent wheeze non‑responsive to conventional medicines; OR Patient must have severe physiological deficit measure by forced oscillation technique or multiple breath nitrogen washout and failure to respond to conventional therapy. Patient must be less than 5 years of age. Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit. Following an initial 6 months therapy, a comprehensive assessment must be undertaken and documented. Treatment with this drug should cease if there is not agreement of benefit, as there is always the possibility of harm from unnecessary use. Further reassessments must be undertaken and documented at six‑monthly intervals. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5634 |
|  | C5635 |  | Cystic fibrosis Continuing treatment Patient must have initiated treatment with dornase alfa at an age of less than 5 years,AND Patient must have undergone a comprehensive assessment which documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Patient must be 5 years of age or older. Further reassessments must be undertaken and documented at six‑monthly intervals. Treatment with this drug should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5635 |
|  | C5740 |  | Cystic fibrosis Patient must be 5 years of age or older. Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit. Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease. Initial therapy is limited to 3 months treatment with dornase alfa at a dose of 2.5 mg daily. To be eligible for continued PBS‑subsidised treatment with this drug following 3 months of initial treatment: (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND (2) the patient or the patient’s family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient. Further reassessments must be undertaken and documented at six‑monthly intervals. Therapy with this drug should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5740 |
|  | C9591 |  | Cystic fibrosis Patient must have a severe clinical course with frequent respiratory exacerbations or chronic respiratory symptoms (including chronic or recurrent cough, wheeze or tachypnoea) requiring hospital admissions more frequently than 3 times per year; OR Patient must have significant bronchiectasis on chest high resolution computed tomography scan; OR Patient must have severe cystic fibrosis bronchiolitis with persistent wheeze non‑responsive to conventional medicines; OR Patient must have severe physiological deficit measure by forced oscillation technique or multiple breath nitrogen washout and failure to respond to conventional therapy. Patient must be less than 5 years of age. Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit. Following an initial 6 months therapy, a comprehensive assessment must be undertaken and documented. Treatment with this drug should cease if there is not agreement of benefit, as there is always the possibility of harm from unnecessary use. Further reassessments must be undertaken and documented at six‑monthly intervals. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9591 |
|  | C9592 |  | Cystic fibrosis Continuing treatment Patient must have initiated treatment with dornase alfa at an age of less than 5 years; AND Patient must have undergone a comprehensive assessment which documents agreement that dornase alfa treatment is continuing to produce worthwhile benefit. Patient must be 5 years of age or older. Further reassessments must be undertaken and documented at six‑monthly intervals. Treatment with this drug should cease if there is not agreement of benefit as there is always the possibility of harm from unnecessary use. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9592 |
|  | C9624 |  | Cystic fibrosis Patient must be 5 years of age or older. Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit. Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease. Initial therapy is limited to 3 months treatment with dornase alfa at a dose of 2.5 mg daily. To be eligible for continued PBS‑subsidised treatment with this drug following 3 months of initial treatment: (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND (2) the patient or the patient’s family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient. Further reassessments must be undertaken and documented at six‑monthly intervals. Therapy with this drug should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9624 |
| Doxorubicin ‑  Pegylated Liposomal | C6234 |  | Kaposi sarcoma The condition must be AIDS‑related; AND Patient must have a CD4 cell count of less than 200 per cubic millimetre; AND The condition must include extensive mucocutaneous involvement. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6234 |
|  | C6274 |  | Kaposi sarcoma The condition must be AIDS‑related; AND Patient must have a CD4 cell count of less than 200 per cubic millimetre; AND The condition must include extensive visceral involvement. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6274 |
|  | C9223 |  | Kaposi sarcoma The condition must be AIDS‑related; AND Patient must have a CD4 cell count of less than 200 per cubic millimetre; AND The condition must include extensive visceral involvement. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9223 |
|  | C9287 |  | Kaposi sarcoma The condition must be AIDS‑related; AND Patient must have a CD4 cell count of less than 200 per cubic millimetre; AND The condition must include extensive mucocutaneous involvement. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9287 |
| Eculizumab | C6626 | P6626 | Atypical haemolytic uraemic syndrome (aHUS)  Initial treatment  Patient must have active and progressing thrombotic microangiopathy (TMA) caused by aHUS; AND  Patient must have ADAMTS‑13 activity of greater than or equal to 10% on a blood sample taken prior to plasma exchange or infusion; or, if ADAMTS‑13 activity was not collected prior to plasma exchange or infusion, patient must have platelet counts of greater than 30x10^9/L and a serum creatinine of greater than 150 mol/L; AND  Patient must have a confirmed negative STEC (Shiga toxin‑producing E.Coli) result if the patient has had diarrhoea in the preceding 14 days; AND  Patient must have clinical features of active organ damage or impairment; AND  Patient must not receive more than 4 weeks of treatment under this restriction.  Must be treated by a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist, or, must be in consultation with a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist.  Evidence of active and progressing TMA is defined by the following:  (1) a platelet count of less than 150x10^9/L; and evidence of two of the following:  (i) presence of schistocytes on blood film;  (ii) low or absent haptoglobin;  (iii) lactate dehydrogenase (LDH) above normal range;  OR  (2) in recipients of a kidney transplant for end‑stage kidney disease due to aHUS, a kidney biopsy confirming TMA;  AND  (3) evidence of at least one of the following clinical features of active TMA‑related organ damage or impairment is defined as below:  (a) kidney impairment as demonstrated by one of the following:  (i) a decline in estimated Glomerular Filtration Rate (eGFR) of greater than 20% in a patient who has pre‑existing kidney impairment; and/or  (ii) a serum creatinine (sCr) of greater than the upper limit of normal (ULN) in a patient who has no history of pre‑existing kidney impairment; or  (iii) a sCr of greater than the age‑appropriate ULN in paediatric patients; or  (iv) a renal biopsy consistent with aHUS;  (b) onset of TMA‑related neurological impairment;  (c) onset of TMA‑related cardiac impairment;  (d) onset of TMA‑related gastrointestinal impairment;  (e) onset of TMA‑related pulmonary impairment.  Claims of non‑renal TMA‑related organ damage should be made at the point of application for initial PBS‑subsidised eculizumab (where possible), and should be supported by objective clinical measures. The prescriber’s cover letter should establish that the observed organ damage is directly linked to active and progressing TMA, particularly when indirect causes such as severe thrombocytopenia, hypertension and acute renal failure are present at the time of the initial organ impairment.  Serial haematological results (every 3 months while the patient is receiving treatment) must be provided with every subsequent application for treatment.  The authority application must be in writing and must include:  (1) A completed authority prescription form; and  (2) A completed aHUS eculizumab Authority Application Supporting Information Form ‑ Initial PBS‑subsidised eculizumab treatment; and  (3) A signed patient acknowledgement or an acknowledgement signed by a parent or authorised guardian, if applicable; and  (4) A detailed cover letter from the prescriber; and  (5) A copy of a current Certificate of vaccination or a statement that vaccination has or will be administered and appropriate antibiotic prophylaxis has been prescribed; and  (6) A measurement of body weight at the time of application; and  (7) The result of ADAMTS‑13 activity on a blood sample taken prior to plasma exchange or infusion; the date and time that the sample for the ADAMTS‑13 assay was collected, and the dates and times of any plasma exchanges or infusions that were undertaken in the two weeks prior to collection of the ADAMTS‑13 assay; and  (8) In the case that a sample for ADAMTS‑13 assay was not collected prior to plasma exchange or infusion, measurement of ADAMTS‑13 activity must be taken 1‑2 weeks following the last plasma exchange or infusion. The ADAMTS‑13 result must be submitted to the Department of Human Services within 27 days of commencement of eculizumab treatment in order for the patient to be considered as eligible for further PBS‑subsidised eculizumab treatment, underInitial treatment 1‑balance of supply; and  (9) A confirmed negative STEC result if the patient has had diarrhoea in the preceding 14 days; and  (10) Evidence of active and progressing TMA, including pathology results where relevant. Evidence of the onset of TMA‑related neurological, cardiac, gastrointestinal or pulmonary impairment requires a supporting statement with clinical evidence in patient records. All tests must have been performed within one month of application; and  (11) For all patients, a recent measurement of eGFR, platelets and two of either LDH, haptoglobin or schistocytes of no more than 1 week old at the time of application. | Compliance with Written Authority Required procedures |
|  | C6637 | P6637 | Atypical haemolytic uraemic syndrome (aHUS)  Extended initial treatment ‑ Assessment phase  Patient must have received treatment under the initial restriction with PBS subsidised eculizumab for this condition; AND  Patient must have demonstrated on‑going treatment response of PBS‑subsidised eculizumab treatment for this condition; AND  Patient must not have experienced treatment failure with eculizumab including PBS‑subsidised eculizumab for this condition; AND  Patient must not receive more than 56 weeks of treatment under this restriction.  Must be treated by a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist, or, must be in consultation with a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist.  A treatment response is defined as:  (1) Normalisation of haematology as demonstrated by at least 2 of the following: platelet count, haptoglobin, and LDH; AND  (2) One of the following:  a) An increase in eGFR of > 25% from baseline, where the baseline is the eGFR measurement immediately prior to commencing treatment with eculizumab or  b) an eGFR within +/‑ 25% from baseline; or  c) an avoidance of dialysis‑dependence but worsening of kidney function with a reduction in eGFR 25% from baseline.  PBS‑subsidised treatment with eculizumab will not be permitted if a patient has experienced treatment failure.  A treatment failure is defined as a patient who is:  (1) dialysis‑dependent at the time of application and has failed to demonstrate significant resolution of extra‑renal complications if originally presented; or  (2) on dialysis and has been on dialysis for 4 months of the previous 6 months while receiving PBS‑subsidised eculizumab and has failed to demonstrate significant resolution of extra‑renal complications if originally presented.  A maximum of up to 56 weeks of treatment is allowed under this restriction, however an application must be submitted at 6 months, 12 months, 18 months and 24 months following commencing PBS‑subsidised eculizumab.  The authority application must include the following measures of response to the prior course of treatment, including serial haematological results (every 3 months while the patient is receiving treatment).  The authority application must be in writing and must include:  (1) A completed authority prescription form; and  (2) A completed aHUS eculizumab Authority Application Supporting Information Form for Extended Initial treatment; and  (3) A detailed cover letter from the prescriber; and  (4) A copy of a current Certificate of vaccination or a statement that vaccination has or will be administered and appropriate antibiotic prophylaxis has been prescribed; and  (5) A measurement of body weight at the time of application; and  (6) An identified genetic mutation, if applicable; and  (7) A family history of aHUS, if applicable; and  (8) A history of multiple episodes of aHUS before commencing eculizumab treatment, if applicable; and  (9) A history of kidney transplant, if applicable, (especially if required due to aHUS); and  (10) An inclusion of the individual consequences of recurrent disease, if applicable; and  (11) Evidence that the patient has had a treatment response including haematological results of no more than 1 week old at the time of application (platelet count, haptoglobin and LDH); and an eGFR level of no more than 1 week old at the time of application; and  (12) Evidence that the patient has not experienced treatment failure, including a supporting statement with clinical evidence that the patient does not require dialysis, unless the indication for continuing eculizumab is severe extra‑renal complications that have significantly improved; and  (13) If the indication for continuing eculizumab is severe extra‑renal complications, then a supporting statement with clinical evidence that any initial extra‑renal complications of TMA have significantly improved is required.  This assessment must be submitted no later than 4 weeks from the cessation of the prior treatment. Where a response assessment is not undertaken and submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with eculizumab. | Compliance with Written Authority Required procedures |
|  | C6642 | P6642 | Atypical haemolytic uraemic syndrome (aHUS) Initial treatment - Balance of Supply Must be treated by a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist, or, must be in consultation with a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist. Patient must have received PBS-subsidised initial supply of eculizumab for this condition; AND Patient must have ADAMTS-13 activity of greater than or equal to 10% on a blood sample; AND Patient must not receive more than 20 weeks supply under this restriction. ADAMTS-13 activity result must have been submitted to the Department of Human Services. In the case that a sample for ADAMTS-13 activity taken prior to plasma exchange or infusion was not available at the time of application for Initial Treatment, ADAMTS-13 activity must have been measured 1-2 weeks following the last plasma exchange or infusion, and must have been submitted to the Department of Human Services within 27 days of commencement of eculizumab. The date and time that the sample for the ADAMTS-13 assay was collected, and the dates and times of the last, if any, plasma exchange or infusion that was undertaken in the two weeks prior to collection of the ADAMTS-13 assay must also have been provided to Department of Human Services. Serial haematological results (every 3 months while the patient is receiving treatment) must be provided with every subsequent application for treatment. | Compliance with Written Authority Required procedures |
|  | C6668 | P6668 | Atypical haemolytic uraemic syndrome (aHUS)  Continuing treatment  Patient must have received treatment under Extended Initial restriction with PBS subsidised eculizumab for this condition; AND  Patient must have demonstrated on‑going treatment response of PBS‑subsidised eculizumab treatment for this condition; AND  Patient must not have experienced treatment failure with eculizumab including PBS‑subsidised eculizumab for this condition; AND  Patient must not receive more than 24 weeks of treatment under this restriction.  Must be treated by a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist, or, must be in consultation with a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist.  A treatment response is defined as:  (1) Normalisation of haematology as demonstrated by at least 2 of the following: platelet count, haptoglobin, and LDH; AND  (2) One of the following:  a) An increase in eGFR of > 25% from baseline, where the baseline is the eGFR measurement immediately prior to commencing treatment with eculizumab or  b) an eGFR within +/‑ 25% from baseline; or  c) an avoidance of dialysis‑dependence but worsening of kidney function with a reduction in eGFR 25% from baseline.  PBS‑subsidised treatment with eculizumab will not be permitted if a patient has experienced treatment failure.  A treatment failure is defined as a patient who is:  (1) dialysis‑dependent at the time of application and has failed to demonstrate significant resolution of extra‑renal complications if originally presented; or  (2) on dialysis and has been on dialysis for 4 months of the previous 6 months while receiving PBS‑subsidised eculizumab and has failed to demonstrate significant resolution of extra‑renal complications if originally presented.  The authority application must include the following measures of response to the prior course of treatment, including serial haematological results (every 3 months while the patient is receiving treatment).  The authority application must be in writing and must include:  (1) A completed authority prescription form; and  (2) A completed aHUS eculizumab Authority Application Supporting Information Form for Continuing treatment; and  (3) A detailed cover letter from the prescriber; and  (4) A copy of a current Certificate of vaccination or a statement that vaccination has or will be administered and appropriate antibiotic prophylaxis has been prescribed; and  (5) A measurement of body weight at the time of application; and  (6) An identified genetic mutation, if applicable; and  (7) A family history of aHUS, if applicable; and  (8) A history of multiple episodes of aHUS before recommencing eculizumab treatment, if applicable; and  (9) A history of kidney transplant if applicable (especially if required due to aHUS); and  (10) An inclusion of the individual consequences of recurrent disease, if applicable; and  (11) Evidence that the patient has had a treatment response including haematological results of no more than 1 week old at the time of application (platelet count, haptoglobin and LDH); and an eGFR level of no more than 1 week old at the time of application; and  (12) Evidence that the patient has not experienced treatment failure, including a supporting statement with clinical evidence that the patient does not require dialysis, unless the indication for continuing eculizumab is severe extra‑renal complications that have significantly improved; and  (13) If the indication for continuing eculizumab is severe extra‑renal complications, then a supporting statement with clinical evidence that any initial extra‑renal complications of TMA have significantly improved is required.  This assessment must be submitted no later than 4 weeks from the cessation of the prior treatment. Where a response assessment is not undertaken and submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with eculizumab. | Compliance with Written Authority Required procedures |
|  | C6686 | P6686 | Atypical haemolytic uraemic syndrome (aHUS)  Extended Continuing treatment  Patient must have received treatment under the Continuing treatment with PBS‑subsidised eculizumab for this condition; AND  Patient must have demonstrated on‑going treatment response with PBS‑subsidised eculizumab for this condition; AND  Patient must not have ever experienced treatment failure with eculizumab including PBS‑subsidised eculizumab for this condition; AND  Patient must have a TMA‑related cardiomyopathy as evidenced by left ventricular ejection fraction < 40% on current objective measurement; OR  Patient must have severe TMA‑related neurological impairment; OR  Patient must have severe TMA‑related gastrointestinal impairment; OR  Patient must have severe TMA‑related pulmonary impairment on current objective measurement; OR  Patient must have grade 4 or 5 chronic kidney disease (eGFR of less than 30 mL/min); OR  Patient must have a high risk of aHUS recurrence in the short term in the absence of continued treatment with eculizumab; AND  Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction.  Must be treated by a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist, or, must be in consultation with a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist.  A treatment response is defined as:  (1) Normalisation of haematology as demonstrated by at least 2 of the following: platelet count, haptoglobin, and LDH; AND  (2) One of the following:  a) An increase in eGFR of > 25% from baseline, where the baseline is the eGFR measurement immediately prior to commencing treatment with eculizumab or  b) an eGFR within +/‑ 25% from baseline; or  c) an avoidance of dialysis‑dependence but worsening of kidney function with a reduction in eGFR 25% from baseline.  PBS‑subsidised treatment with eculizumab will not be permitted if a patient has experienced treatment failure. A treatment failure is defined as a patient who is:  (1) dialysis‑dependent at the time of application and has failed to demonstrate significant resolution of extra‑renal complications if originally presented; or  (2) on dialysis and has been on dialysis for 4 months of the previous 6 months while receiving PBS‑subsidised eculizumab and has failed to demonstrate significant resolution of extra‑renal complications if originally presented.  The authority application must include the following measures of response to the prior course of treatment, including serial haematological results (every 3 months while the patient is receiving treatment).  The authority application must be in writing and must include:  (1) A completed authority prescription form; and  (2) A completed aHUS eculizumab Authority Application Supporting Information Form for Continuing treatment; and  (3) A detailed cover letter from the prescriber; and  (4) A copy of a current Certificate of vaccination or a statement that vaccination has or will be administered and appropriate antibiotic prophylaxis has been prescribed; and  (5) A measurement of body weight at the time of application; and  (6) An identified genetic mutation, if applicable; and  (7) A family history of aHUS, if applicable; and  (8) A history of multiple episodes of aHUS before commencing eculizumab treatment, if applicable; and  (9) A history of kidney transplant, if applicable (especially if required due to aHUS); and  (10) An inclusion of the individual consequences of recurrent disease; and  (11) A supporting statement with clinical evidence of severe TMA‑related cardiomyopathy (including current LVEF result), neurological impairment, gastrointestinal impairment or pulmonary impairment; and  (12) Evidence that the patient has had a treatment response including haematological results of no more than 1 month old at the time of application (platelet count, haptoglobin and LDH); and an eGFR level of no more than 1 month old at the time of application; and  (13) Evidence that the patient has not experienced treatment failure, including a supporting statement with clinical evidence that the patient does not require dialysis, unless the indication for continuing eculizumab is severe extra‑renal complications that have significantly improved; and  (14) If the indication for continuing eculizumab is severe extra‑renal complications, then a supporting statement with clinical evidence that any initial extra‑renal complications of TMA have significantly improved is required.  This assessment must be submitted no later than 4 weeks from the cessation of the prior treatment. Where a response assessment is not undertaken and submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with eculizumab. | Compliance with Written Authority Required procedures |
|  | C6687 | P6687 | Atypical haemolytic uraemic syndrome (aHUS)  Recommencement of treatment  Patient must have demonstrated treatment response to previous treatment with PBS‑subsidised eculizumab for this condition; AND  Patient must not have ever experienced treatment failure with eculizumab including PBS‑subsidised eculizumab for this condition; AND  Patient must have the following clinical conditions:(i) either significant haemolysis as measured by low/absent haptoglobin; or presence of schistocytes on the blood film; or lactate dehydrogenase (LDH) above normal;AND(ii) either platelet consumption as measured by either 25% decline from patient baseline or thrombocytopenia (platelet count <150 x 10^9/L);OR(iii) TMA‑related organ impairment including on recent biopsy; AND  Patient must not receive more than 24 weeks of treatment under this restriction.  Must be treated by a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist, or, must be in consultation with a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist.  A treatment response is defined as:  (1) Normalisation of haematology as demonstrated by at least 2 of the following: platelet count, haptoglobin, and LDH; AND  (2) One of the following:  a) An increase in eGFR of > 25% from baseline, where the baseline is the eGFR measurement immediately prior to commencing treatment with eculizumab or  b) an eGFR within +/‑ 25% from baseline; or  c) an avoidance of dialysis‑dependence but worsening of kidney function with a reduction in eGFR 25% from baseline.  PBS‑subsidised treatment with eculizumab will not be permitted if a patient has experienced treatment failure. A treatment failure is defined as a patient who is:  (1) dialysis‑dependent at the time of application and has failed to demonstrate significant resolution of extra‑renal complications if originally presented; or  (2) on dialysis and has been on dialysis for 4 months of the previous 6 months while receiving PBS‑subsidised eculizumab and has failed to demonstrate significant resolution of extra‑renal complications if originally presented.  The authority application must include the following measures of response to the prior course of treatment, including serial haematological results (every 3 months while the patient is receiving treatment).  The authority application must be in writing and must include:  (1) A completed authority prescription form(s); and  (2) A completed aHUS eculizumab Authority Application Supporting Information Form for Recommencement of treatment; and  (3) A signed patient acknowledgement or an acknowledgement signed by a parent or authorised guardian, if applicable; and  (4) A detailed cover letter from the prescriber; and  (5) A copy of a current Certificate of vaccination or a statement that vaccination has or will be administered and appropriate antibiotic prophylaxis has been prescribed; and  (6) A measurement of body weight at the time of application, and  (7) An identified genetic mutation, if applicable; and  (8) A family history of aHUS if applicable; and  (9) A history of multiple episodes of aHUS following the treatment break, if applicable; and  (10) A history of kidney transplant if applicable (especially if required due to aHUS); and  (11) An inclusion of the individual consequences of recurrent disease; and  (12) A supporting statement with clinical evidence of TMA‑related organ damage including current (within one week of application) haematological results (platelet count, haptoglobin and LDH), eGFR level, and, if applicable, on recent biopsy;  (13) Evidence that the patient has had a treatment response to their previous treatment with eculizumab; and  (14) Evidence that the patient has not experienced treatment failure, including a supporting statement with clinical evidence that the patient does not require dialysis, unless the indication for continuing eculizumab is severe extra‑renal complications that have significantly improved; and  (15) If the indication for continuing eculizumab is severe extra‑renal complications, then a supporting statement with clinical evidence that any initial extra‑renal complications of TMA have significantly improved is required.  This assessment must be submitted no later than 4 weeks from the cessation of the prior treatment. Where a response assessment is not undertaken and submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with eculizumab. | Compliance with Written Authority Required procedures |
|  | C6688 | P6688 | Atypical haemolytic uraemic syndrome (aHUS)  Continuing recommencement of treatment  Patient must have received treatment under Recommencement of treatment restriction with PBS‑subsidised eculizumab for this condition; AND  Patient must have demonstrated ongoing treatment response to the previous 24 weeks of PBS‑subsidised eculizumab for this condition; AND  Patient must not have experienced treatment failure with eculizumab including PBS‑subsidised eculizumab for this condition; AND  Patient must not receive more than 24 weeks of treatment under this restriction.  Must be treated by a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist, or, must be in consultation with a paediatric nephrologist, a nephrologist, a paediatric haematologist or a haematologist.  A treatment response is defined as:  (1) Normalisation of haematology as demonstrated by at least 2 of the following: platelet count, haptoglobin, and LDH; AND  (2) One of the following:  a) An increase in eGFR of > 25% from baseline, where the baseline is the eGFR measurement immediately prior to commencing treatment with eculizumab or  b) an eGFR within +/‑ 25% from baseline; or  c) an avoidance of dialysis‑dependence but worsening of kidney function with a reduction in eGFR 25% from baseline.  PBS‑subsidised treatment with eculizumab will not be permitted if a patient has experienced treatment failure. A treatment failure is defined as a patient who is:  (1) dialysis‑dependent at the time of application and has failed to demonstrate significant resolution of extra‑renal complications if originally presented; or  (2) on dialysis and has been on dialysis for 4 months of the previous 6 months while receiving PBS‑subsidised eculizumab and has failed to demonstrate significant resolution of extra‑renal complications if originally presented.  The authority application must include the following measures of response to the prior course of treatment, including serial haematological results (every 3 months while the patient is receiving treatment).  The authority application must be in writing and must include:  (1) A completed authority prescription form; and  (2) A completed aHUS eculizumab Authority Application Supporting Information Form for Continuing treatment; and  (3) A detailed cover letter from the prescriber; and  (4) A copy of a current Certificate of vaccination or a statement that vaccination has or will be administered and appropriate antibiotic prophylaxis has been prescribed; and  (5) A measurement of body weight at the time of application; and  (6) An identified genetic mutation, if applicable; and  (7) A family history of aHUS, if applicable; and  (8) A history of multiple episodes of aHUS before recommencing eculizumab treatment, if applicable; and  (9) A history of kidney transplant if applicable (especially if required due to aHUS); and  (10) An inclusion of the individual consequences of recurrent disease, if applicable; and  (11) Evidence that the patient has had a treatment response including haematological results of no more than 1 week old at the time of application (platelet count, haptoglobin and LDH); and an eGFR level of no more than 1 week old at the time of application; and  (12) Evidence that the patient has not experienced treatment failure, including a supporting statement with clinical evidence that the patient does not require dialysis, unless the indication for continuing eculizumab is severe extra‑renal complications that have significantly improved; and  (13) If the indication for continuing eculizumab is severe extra‑renal complications, then a supporting statement with clinical evidence that any initial extra‑renal complications of TMA have significantly improved is required.  This assessment must be submitted no later than 4 weeks from the cessation of the prior treatment. Where a response assessment is not undertaken and submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with eculizumab. | Compliance with Written Authority Required procedures |
| Efavirenz | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Eltrombopag | C6724 |  | Severe thrombocytopenia  Initial treatment 2 ‑ New patient  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  Patient must not have had a splenectomy; AND  Patient must have failed to acheive an adequate response to, or be intolerant to, corticosteroid therapy at a dose equivalent to 0.5‑2 mg/kg/day of prednisone for at least 4‑6 weeks; AND  Patient must have failed to acheive an adequate response to, or be intolerant to, immunoglobulin therapy; AND  Patient must be unsuitable for splenectomy due to medical reasons; AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition.  Patient must be an adult.  The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of initial application;  (a) a platelet count of less than or equal to 20,000 million per L; OR  (b) a platelet count of 20,000 million to 30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.  The authority application must be made in writing and must include:  (1) a completed authority prescription form,  (2) a signed patient acknowledgement,  (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application ‑ Supporting Information Form,  (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and  (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.  The full blood count must be no more than 1 month old at the time of application.  A maximum of 24 weeks of treatment with this drug will be authorised under this criterion. | Compliance with Written Authority Required procedures |
|  | C6725 |  | Severe thrombocytopenia  First Continuing treatment or Re‑initiation of interrupted treatment  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  Patient must have previously received PBS‑subsidised initial treatment with this drug for this condition; AND  Patient must have demonstrated a sustained platelet response to PBS‑subsidised treatment with this drug for this condition under the Initial treatment restriction; AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition.  Patient must be an adult.  For the purposes of this restriction, a sustained platelet response is defined as:  (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS‑subsidised treatment with this drug,  AND either of the following:  (b) a platelet count greater than or equal to 50,000 million per L on at least four (4) occasions, each at least one week apart;  OR  (c) a platelet count greater than 30,000 million per L and which is double the baseline (pre‑treatment) platelet count on at least four (4) occasions, each at least one week apart.  Applications for the First continuing PBS‑subsidised treatment or Re‑initiation of interrupted PBS‑subsidised treatment must be made in writing and must include:  (1) a completed authority prescription form, and  (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application ‑ Supporting Information Form , and  (3) copies of the platelet count pathology reports (unless previously provided for patients re‑initiating therapy).  The platelet count must be no more than one month old at the time of application.  A maximum of 24 weeks of treatment with this drug will be authorised under this criterion. | Compliance with Written Authority Required procedures |
|  | C6738 |  | Severe thrombocytopenia  Initial 1, Initial 2, First Continuing treatment or Re‑initiation of interrupted treatment, and Second and Subsequent Continuing treatment ‑ balance of supply  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition; AND  Patient must have received insufficient therapy with this drug for this condition under the Initial 1 restriction to complete 24 weeks treatment; OR  Patient must have received insufficient therapy with this drug for this condition under the Initial 2 restriction to complete 24 weeks treatment; OR  Patient must have received insufficient therapy with this drug for this condition under the First Continuing treatment or Re‑initiation of interrupted treatment restriction to complete 24 weeks treatment; OR  Patient must have received insufficient therapy with this drug for this condition under the Second and subsequent Continuing treatment restriction to complete 24 weeks treatment; AND  The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.  Patient must be an adult. | Compliance with Authority Required procedures |
|  | C6739 |  | Severe thrombocytopenia  Initial treatment 1 ‑ New patient  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  Patient must have had a splenectomy; AND  Patient must have failed to acheive an adequate response to, or be intolerant to, corticosteroid therapy following the splenectomy; AND  Patient must have failed to acheive an adequate response to, or be intolerant to, immunoglobulin therapy following the splenectomy; AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition.  Patient must be an adult.  The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of initial application;  (a) a platelet count of less than or equal to 20,000 million per L; OR  (b) a platelet count of 20,000 million to 30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.  The authority application must be made in writing and must include:  (1) a completed authority prescription form,  (2) a signed patient acknowledgement,  (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application ‑ Supporting Information Form,  (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and  (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.  The full blood count must be no more than 1 month old at the time of application.  A maximum of 24 weeks of treatment with this drug will be authorised under this criterion. | Compliance with Written Authority Required procedures |
|  | C6790 |  | Severe thrombocytopenia  Second or subsequent Continuing treatment  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND  Patient must have demonstrated a continuing response to treatment with this drug; AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition.  Patient must be an adult.  For the purpose of this restriction, a continuing response to treatment with drug is defined as:  (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS‑subsidised treatment with this drug  AND either of the following:  (b) a platelet count greater than or equal to 50,000 million per L  OR  (c) a platelet count greater than 30,000 million per L and which is double the baseline platelet count.  The platelet count must be no more than one month old at the time of application.  Authority applications for second and subsequent periods of continuing therapy may be made by telephone | Compliance with Authority Required procedures |
| Emtricitabine with rilpivirine with tenofovir alafenamide | C4470 |  | HIV infection Continuing Patient must have previously received PBS‑subsidised therapy for HIV infection. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4470 |
|  | C4522 |  | HIV infection Initial Patient must be antiretroviral treatment naive. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4522 |
| Emtricitabine with tenofovir alafenamide | C4454 |  | HIV infection Continuing Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial Patient must be antiretroviral treatment naive; AND The treatment must be in combination with other antiretroviral agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Enfuvirtide | C5014 |  | HIV infection The treatment must be in addition to optimised background therapy, AND The treatment must be in combination with other antiretroviral agents, AND Patient must be antiretroviral experienced, AND Patient must have experienced virological failure or clinical failure or genotypic resistance after each of at least 3 different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes. Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment‑limiting toxicity. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5014 |
| Entecavir | C4993 |  | Chronic hepatitis B infection Patient must not have cirrhosis, AND Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection, AND Patient must have evidence of chronic liver injury determined by confirmed elevated serum ALT or liver biopsy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4993 |
|  | C5036 |  | Chronic hepatitis B infection Patient must have cirrhosis, AND Patient must have detectable HBV DNA. Patients with Child’s class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5036 |
|  | C5037 |  | Chronic hepatitis B infection Patient must have cirrhosis, AND Patient must have failed lamivudine, AND Patient must have detectable HBV DNA. Patients with Child’s class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5037 |
|  | C5044 |  | Chronic hepatitis B infection Patient must not have cirrhosis, AND Patient must have failed lamivudine, AND Patient must have repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration, in conjunction with documented chronic hepatitis B infection; OR Patient must have repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months whilst on previous antihepadnaviral therapy, except in patients with evidence of poor compliance. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5044 |
| Epoetin Alfa | C6294 |  | Anaemia associated with intrinsic renal disease Patient must require transfusion; AND Patient must have a haemoglobin level of less than 100 g per L; AND Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6294 |
|  | C9688 |  | Anaemia associated with intrinsic renal disease Patient must require transfusion; AND Patient must have a haemoglobin level of less than 100 g per L; AND Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9688 |
| Epoetin Beta | C6294 |  | Anaemia associated with intrinsic renal disease Patient must require transfusion; AND Patient must have a haemoglobin level of less than 100 g per L; AND Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6294 |
|  | C9688 |  | Anaemia associated with intrinsic renal disease Patient must require transfusion; AND Patient must have a haemoglobin level of less than 100 g per L; AND Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9688 |
| Epoetin lambda | C6294 |  | Anaemia associated with intrinsic renal disease  Patient must require transfusion; AND  Patient must have a haemoglobin level of less than 100 g per L; AND  Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6294 |
|  | C9688 |  | Anaemia associated with intrinsic renal disease Patient must require transfusion; AND Patient must have a haemoglobin level of less than 100 g per L; AND Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9688 |
| Epoprostenol | C10228 |  | Pulmonary arterial hypertension (PAH) Continuing treatment Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent for this condition; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10240 |  | Pulmonary arterial hypertension (PAH) Initial 1 (new patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have WHO Functional Class IV PAH; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the Therapeutic Goods Administration (TGA) approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C10241 |  | Pulmonary arterial hypertension (PAH) Initial 2 (change) Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH; AND Patient must have had their most recent course of PBS-subsidised treatment for this condition with a PAH agent other than this agent; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment (monotherapy) with 1 of these 8 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent’s restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap between the 8 PAH agents must be made under the relevant initial treatment (monotherapy) restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
| Etanercept | C9384 |  | Severe active juvenile idiopathic arthritis Continuing treatment ‑ balance of supply Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction. | Compliance with Authority Required procedures |
|  | C9417 |  | Severe active juvenile idiopathic arthritis Initial treatment ‑ Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) ‑ balance of supply Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) restriction to complete 16 weeks treatment; AND The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | Compliance with Authority Required procedures |
|  | C10548 |  | Severe active juvenile idiopathic arthritis Initial treatment - Initial 1 (new patient) Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have demonstrated severe intolerance of, or toxicity due to, methotrexate; OR Patient must have demonstrated failure to achieve an adequate response to 1 or more of the following treatment regimens: (i) oral or parenteral methotrexate at a dose of at least 20 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or (ii) oral methotrexate at a dose of at least 10 mg per square metre weekly together with at least 1 other disease modifying anti-rheumatic drug (DMARD), alone or in combination with corticosteroids, for a minimum of 3 months; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be under 18 years of age. Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant non-steroidal anti-inflammatory drugs (NSAIDs) on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours. Toxicity due to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis. If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application. If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, details of this toxicity must be provided at the time of application. The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: (a) an active joint count of at least 20 active (swollen and tender) joints; OR (b) at least 4 active joints from the following list: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The joint count assessment must be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. At the time of authority application, medical practitioners must request the appropriate number of injections to provide sufficient for four weeks of treatment. Up to a maximum of 3 repeats will be authorised. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C10578 |  | Severe active juvenile idiopathic arthritis Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND Patient must not receive more than 16 weeks of treatment under this restriction. An adequate response to treatment is defined as: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). At the time of authority application, medical practitioners must request the appropriate number of injections to provide sufficient for four weeks of treatment. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient who fails to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. A patient may re-trial this drug after a minimum of 12 months have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the initial 3 treatment restriction. If a patient fails to respond to PBS-subsidised biological medicine treatment 3 times (once with each agent) they will not be eligible to receive further PBS-subsidised biological medicine therapy in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C10579 |  | Severe active juvenile idiopathic arthritis Continuing treatment Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction. An adequate response to treatment is defined as: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Determination of whether a response has been demonstrated to initial and subsequent courses of treatment will be based on the baseline measurement of joint count submitted with the initial treatment application. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. At the time of authority application, medical practitioners must request the appropriate number of injections to provide sufficient for four weeks of treatment. Up to a maximum of 5 repeats will be authorised. Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re-trial this drug after a minimum of 12 months have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. If a patient fails to respond to PBS-subsidised biological medicine treatment 3 times (once with each agent) they will not be eligible to receive further PBS-subsidised biological medicine therapy in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C10599 |  | Severe active juvenile idiopathic arthritis Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have had a break in treatment of 12 months or more from the most recently approved PBS-subsidised biological medicine for this condition; AND The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND Patient must not receive more than 16 weeks of treatment under this restriction. Active joints are defined as: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). All measures of joint count must be no more than 4 weeks old at the time of this application. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of active joints, the response must be demonstrated on the total number of active joints. At the time of authority application, medical practitioners must request the appropriate number of injections to provide sufficient for four weeks of treatment. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
| Etravirine | C5014 |  | HIV infection  The treatment must be in addition to optimised background therapy, AND The treatment must be in combination with other antiretroviral agents, AND Patient must be antiretroviral experienced, AND Patient must have experienced virological failure or clinical failure or genotypic resistance after each of at least 3 different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes. Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment‑limiting toxicity. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5014 |
| Everolimus | C5554 |  | Management of cardiac allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of cardiac allograft rejection, AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5554 |
|  | C5795 |  | Management of renal allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of renal allograft rejection, AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5795 |
|  | C9691 |  | Management of renal allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of renal allograft rejection; AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9691 |
|  | C9693 |  | Management of cardiac allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of cardiac allograft rejection; AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9693 |
| Filgrastim | C6621 |  | Severe chronic neutropenia Patient must have an absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart; OR Patient must have neutrophil dysfunction; AND Patient must have experienced a life‑threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months; OR Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6621 |
|  | C6640 |  | Chronic cyclical neutropenia Patient must have an absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles; AND Patient must have experienced a life‑threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics; OR Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6640 |
|  | C6653 |  | Mobilisation of peripheral blood progenitor cells The treatment must be to facilitate harvest of peripheral blood progenitor cells for autologous transplantation into a patient with a non‑myeloid malignancy who has had myeloablative or myelosuppressive therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6653 |
|  | C6654 |  | Mobilisation of peripheral blood progenitor cells The treatment must be in a normal volunteer for use in allogeneic transplantation. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6654 |
|  | C6655 |  | Assisting autologous peripheral blood progenitor cell transplantation The treatment must be following marrow‑ablative chemotherapy for non‑myeloid malignancy prior to the transplantation. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6655 |
|  | C6679 |  | Assisting bone marrow transplantation Patient must be receiving marrow‑ablative chemotherapy prior to the transplantation. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6679 |
|  | C6680 |  | Severe congenital neutropenia Patient must have an absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart; AND Patient must have had a bone marrow examination that has shown evidence of maturational arrest of the neutrophil lineage. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6680 |
|  | C7822 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must be at greater than 20% risk of developing febrile neutropenia; OR Patient must be at substantial risk (greater than 20%) of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7822 |
|  | C7843 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7843 |
|  | C8667 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8667 |
|  | C8668 |  | Mobilisation of peripheral blood progenitor cells The treatment must be in a normal volunteer for use in allogeneic transplantation. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8668 |
|  | C8669 |  | Severe congenital neutropenia Patient must have an absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart; AND Patient must have had a bone marrow examination that has shown evidence of maturational arrest of the neutrophil lineage. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8669 |
|  | C8670 |  | Severe chronic neutropenia Patient must have an absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart; OR Patient must have neutrophil dysfunction; AND Patient must have experienced a life‑threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months; OR Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8670 |
|  | C8671 |  | Assisting bone marrow transplantation Patient must be receiving marrow‑ablative chemotherapy prior to the transplantation. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8671 |
|  | C8672 |  | Mobilisation of peripheral blood progenitor cells The treatment must be to facilitate harvest of peripheral blood progenitor cells for autologous transplantation into a patient with a non‑myeloid malignancy who has had myeloablative or myelosuppressive therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8672 |
|  | C8673 |  | Chronic cyclical neutropenia Patient must have an absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles; AND Patient must have experienced a life‑threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics; OR Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8673 |
|  | C8674 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must be at greater than 20% risk of developing febrile neutropenia; OR Patient must be at substantial risk (greater than 20%) of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8674 |
|  | C8696 |  | Assisting autologous peripheral blood progenitor cell transplantation The treatment must be following marrow‑ablative chemotherapy for non‑myeloid malignancy prior to the transplantation. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8696 |
| Fosamprenavir | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Ganciclovir | C4972 |  | Cytomegalovirus disease Prophylaxis Patient must be a bone marrow transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4972 |
|  | C4999 |  | Cytomegalovirus disease Prophylaxis Patient must be a solid organ transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4999 |
|  | C5000 |  | Cytomegalovirus retinitis Patient must be severely immunocompromised, including due to HIV infection. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5000 |
|  | C9404 |  | Cytomegalovirus disease Prophylaxis Patient must be a bone marrow transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9404 |
|  | C9526 |  | Cytomegalovirus disease Prophylaxis Patient must be a solid organ transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9526 |
| Glecaprevir with pibrentasvir | C7593 | P7593 | Chronic hepatitis C infection  Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 8 weeks. | Compliance with Authority Required procedures |
|  | C7615 | P7615 | Chronic hepatitis C infection  Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 12 weeks. | Compliance with Authority Required procedures |
|  | C10268 | P10268 | Chronic hepatitis C infection Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 16 weeks. The application must include details of the prior treatment regimen containing an NS5A inhibitor. | Compliance with Authority Required procedures |
| Grazoprevir with elbasvir | C5969 | P5969 | Chronic hepatitis C infection  Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND  Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND  The treatment must be limited to a maximum duration of 12 weeks. | Compliance with Authority Required procedures |
|  | C6625 | P6625 | Chronic hepatitis C infection  Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND  Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND  The treatment must be limited to a maximum duration of 16 weeks. | Compliance with Authority Required procedures |
| Ibandronic acid | C5291 |  | Bone metastases The condition must be due to breast cancer. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5291 |
|  | C9333 |  | Bone metastases The condition must be due to breast cancer. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9333 |
| Iloprost | C10228 |  | Pulmonary arterial hypertension (PAH) Continuing treatment Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent for this condition; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10229 |  | Pulmonary arterial hypertension (PAH) Initial 2 (change) Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH; AND Patient must have had their most recent course of PBS-subsidised treatment for this condition with a PAH agent other than this agent; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment (monotherapy) with 1 of these 8 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent’s restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap between the 8 PAH agents must be made under the relevant initial treatment (monotherapy) restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10284 |  | Pulmonary arterial hypertension (PAH) Initial 1 (new patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have WHO Functional Class III drug and toxins induced PAH, or WHO Functional Class IV PAH; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the Therapeutic Goods Administration (TGA) approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
| Infliximab | C4524 |  | Acute severe ulcerative colitis Must be treated by a gastroenterologist; OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology, or general medicine specialising in gastroenterology]. Patient must have received an infusion of infliximab for the treatment of this condition as a hospital inpatient no more than two weeks prior to the date of the authority application; AND Patient must be an adult aged 18 years or older, and prior to initiation of infliximab treatment in hospital must have been experiencing six or more bloody stools per day, plus at least one of the following: (i) Temperature greater than 37.8 degrees Celsius; (ii) Pulse rate greater than 90 beats per minute; (iii) Haemoglobin less than 105 g/L; (iv) Erythrocyte sedimentation rate greater than 30 mm/h; OR Patient must be a child aged 6 to 17 years inclusive, and prior to initiation of infliximab treatment in hospital must have had a Paediatric Ulcerative Colitis Activity Index (PUCAI) greater than or equal to 65, with the diagnosis confirmed by a gastroenterologist, or a consultant physician as specified below; AND Patient must have failed to achieve an adequate response to at least 72 hours treatment with intravenous corticosteroids prior to initiation of infliximab treatment in hospital. Patient must be 6 years of age or older. For adults aged 18 years or older, failure to achieve an adequate response to intravenous corticosteroid treatment is defined by the Oxford criteria where: (i) If assessed on day 3, patients pass 8 or more stools per day or 3 or more stools per day with a C‑reactive protein (CRP) greater than 45 mg/L (ii) If assessed on day 7, patients pass 3 or more stools per day with visible blood. For children aged 6 to 17 years, failure to achieve an adequate response to intravenous corticosteroids means a PUCAI score greater than 45 at 72 hours. At the time of authority application, prescribers should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Before administering infliximab to a child aged 6 to 17 years, the treating clinician must have consulted with a paediatric gastroenterologist or with an institution experienced in performance of paediatric colectomy. The name of the specialist or institution must be included in the patient’s medical records. Evidence that the patient meets the PBS restriction criteria must be recorded in the patient’s medical records. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4524 |
|  | C7777 |  | Complex refractory Fistulising Crohn disease  Balance of supply  Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received insufficient therapy with this drug for this condition under the Initial treatment (new patient or Recommencement of treatment after more than 5 years break in therapy ‑ Initial 1) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Change or Re‑commencement of treatment after a break in therapy of less than 5 years (Initial 2) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment or subsequent continuing treatment restrictions to complete 24 weeks of treatment; AND The treatment must provide no more than the balance of up to 3 doses (Initial 1 or Initial 2 treatment) or 2 repeats (first Continuing or Subsequent Continuing treatment). | Compliance with Authority Required procedures |
|  | C8296 |  | Severe chronic plaque psoriasis Continuing treatment, Whole body or Continuing treatment, Face, hand, foot ‑ balance of supply Patient must have received insufficient therapy with this drug under the first continuing treatment, Whole body restriction to complete 24 weeks treatment; OR Patient must have received insufficient therapy with this drug under the first continuing treatment, Face, hand, foot restriction to complete 24 weeks treatment; OR Patient must have received insufficient therapy with this drug under the subsequent continuing treatment Authority Required (in writing), Whole body restriction to complete 24 weeks treatment; OR Patient must have received insufficient therapy with this drug under the subsequent continuing treatment Authority Required (in writing), Face, hand, foot restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND The treatment must be as systemic monotherapy (other than methotrexate). Must be treated by a dermatologist. | Compliance with Authority Required procedures |
|  | C8644 |  | Severe active rheumatoid arthritis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg. Up to a maximum of 2 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C8645 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 3 (re‑commencement of treatment after a break in biological medicine of more than 24 months) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 24 months or more from the most recent PBS‑subsidised biological medicine for this condition; AND Patient must not have failed to respond to previous PBS‑subsidised treatment with this drug for this condition; AND Patient must not have already failed , or ceased to respond to, PBS‑subsidised biological medicine treatment for this condition 5 times; AND The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; OR The condition must have a C‑reactive protein (CRP) level greater than 15 mg per L; AND The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND Patient must not receive more than 22 weeks of treatment under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C8646 |  | Severe active rheumatoid arthritis Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) ‑ balance of supply Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 22 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 22 weeks treatment; AND The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions. Patient must be aged 18 years or older. | Compliance with Authority Required procedures |
|  | C8715 |  | Severe active rheumatoid arthritis Initial 1 (new patient) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must not have received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti‑rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)‑approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA‑approved Product Information or cannot be tolerated at the doses specified above, must include at least 3 months continuous treatment with each of at least 2 DMARDs, with one or more of the following DMARDs being used in place of the DMARDS which are contraindicated or not tolerated: (i) azathioprine at a dose of at least 1 mg/kg per day; and/or (ii) cyclosporin at a dose of at least 2 mg/kg/day; and/or (iii) sodium aurothiomalate at a dose of 50 mg weekly; AND Patient must not receive more than 22 weeks of treatment under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. If methotrexate is contraindicated according to the TGA‑approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable. The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C‑reactive protein (CRP) level greater than 15 mg per L; AND either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active joints from the following list of major joints: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C8743 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 2 (change or re‑commencement of treatment after a break in biological medicine of less than 24 months) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must not have failed to respond to previous PBS‑subsidised treatment with this drug for this condition; AND Patient must not have already failed , or ceased to respond to, PBS‑subsidised biological medicine treatment for this condition 5 times; AND Patient must not receive more than 22 weeks of treatment under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). An application for a patient who has received PBS‑subsidised treatment with this drug and who wishes to re‑commence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised treatment with this drug, within the timeframes specified below. Where the most recent course of PBS‑subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. A patient who has demonstrated a response to a course of rituximab must have a PBS‑subsidised biological therapy treatment‑free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine. | Compliance with Written Authority Required procedures |
|  | C8744 |  | Severe active rheumatoid arthritis First continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg. Up to a maximum of 2 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C8745 |  | Severe active rheumatoid arthritis Continuing Treatment ‑ balance of supply. Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions. Patient must be aged 18 years or older. | Compliance with Authority Required procedures |
|  | C8755 |  | Severe active rheumatoid arthritis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8755 |
|  | C8800 |  | Severe chronic plaque psoriasis Initial treatment ‑ Initial 3, Whole body (re‑commencement of treatment after a break in biological medicine of more than 5 years) Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND The condition must have a current Psoriasis Area and Severity Index (PASI) score of greater than 15; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 22 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. The most recent PASI assessment must be no more than 1 month old at the time of application. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient’s condition. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Demonstration of response should be provided within this timeframe. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C8801 |  | Severe chronic plaque psoriasis Initial treatment ‑ Initial 1, Face, hand, foot (new patient) Patient must have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; AND Patient must not have received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 4 treatments: (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 22 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. Where treatment with methotrexate, cyclosporin or acitretin is contraindicated according to the relevant TGA‑approved Product Information, or where phototherapy is contraindicated, details must be provided at the time of application. Where intolerance to treatment with phototherapy, methotrexate, cyclosporin or acitretin developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application. Regardless of if a patient has a contraindication to treatment with either methotrexate, cyclosporin, acitretin or phototherapy, the patient is still required to trial 2 of these prior therapies until a failure to achieve an adequate response is met. The following criterion indicates failure to achieve an adequate response to prior treatment and must be demonstrated in the patient at the time of the application: (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment. (c) The most recent PASI assessment must be no more than 1 month old at the time of application. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient’s condition; and (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Demonstration of response should be provided within this timeframe. The PASI assessment for first continuing or subsequent continuing treatment must be performed on the same affected area as assessed at baseline. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C8844 |  | Severe chronic plaque psoriasis Subsequent continuing treatment, Whole body Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as: A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the baseline value for this treatment cycle. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. Determination of response must be based on the PASI assessment of response to the most recent course of treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8844 |
|  | C8881 |  | Severe chronic plaque psoriasis Subsequent continuing treatment, Face, hand, foot Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing: (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the baseline values; or (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the baseline value for this treatment cycle. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams including the date of the assessment of the patient’s condition. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Approval will be based on the PASI assessment of response to the most recent course of treatment with this drug. The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline. The most recent PASI assessment must be no more than 1 month old at the time of application. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C8883 |  | Severe chronic plaque psoriasis First continuing treatment, Face, hand, foot Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing: (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the baseline values; or (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the baseline value for this treatment cycle. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams including the date of the assessment of the patient’s condition. The most recent PASI assessment must be no more than 1 month old at the time of application. Approval will be based on the PASI assessment of response to the most recent course of treatment with this drug. The PASI assessment for first continuing or subsequent continuing treatment must be performed on the same affected area assessed at baseline. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures |
|  | C8885 |  | Severe chronic plaque psoriasis Initial 1 ‑ Whole body (new patient) Patient must have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis; AND Patient must not have received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 2 of the following 4 treatments: (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 22 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. Where treatment with methotrexate, cyclosporin or acitretin is contraindicated according to the relevant TGA‑approved Product Information, or where phototherapy is contraindicated, details must be provided at the time of application. Where intolerance to treatment with phototherapy, methotrexate, cyclosporin or acitretin developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application. Regardless of if a patient has a contraindication to treatment with either methotrexate, cyclosporin, acitretin or phototherapy, the patient is still required to trial 2 of these prior therapies until a failure to achieve an adequate response is met. The following criterion indicates failure to achieve an adequate response to prior treatment and must be demonstrated in the patient at the time of the application: (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment. (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment. (c) The most recent PASI assessment must be no more than 1 month old at the time of application. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient’s condition; and (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Demonstration of response should be provided within this timeframe. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C8886 |  | Severe chronic plaque psoriasis Initial 1, Whole body or Face, hand, foot (new patient) or Initial 2, Whole body or Face, hand, foot (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3, Whole body or Face, hand, foot (re‑commencement of treatment after a break in biological medicine of more than 5 years) ‑ balance of supply Patient must have received insufficient therapy with this drug for this condition under the Initial 1, Whole body (new patient) restriction to complete 22 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2, Whole body (change or recommencement of treatment after a break in biological medicine of less than 5 years ) restriction to complete 22 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3, Whole body (re‑commencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 22 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 1, Face, hand, foot (new patient) restriction to complete 22 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2, Face, hand, foot (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 22 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3, Face, hand, foot (re‑commencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 22 weeks treatment; AND The treatment must be as systemic monotherapy (other than methotrexate); AND The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions. Must be treated by a dermatologist. | Compliance with Authority Required procedures |
|  | C8940 |  | Severe chronic plaque psoriasis Subsequent continuing treatment, Face, hand, foot Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing: (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the baseline values; or (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the baseline value for this treatment cycle. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. Determination of response must be based on the PASI assessment of response to the most recent course of treatment with this drug. The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8940 |
|  | C8941 |  | Severe chronic plaque psoriasis Subsequent continuing treatment, Whole body Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as: A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the baseline value for this treatment cycle. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the completed Psoriasis Area and Severity Index (PASI) calculation sheet including the date of the assessment of the patient’s condition. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Approval will be based on the PASI assessment of response to the most recent course of treatment with this drug. The most recent PASI assessment must be no more than 1 month old at the time of application. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C8962 |  | Severe chronic plaque psoriasis First continuing treatment, Whole body Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as: A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the baseline value for this treatment cycle. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the completed Psoriasis Area and Severity Index (PASI) calculation sheet including the date of the assessment of the patient’s condition. The most recent PASI assessment must be no more than 1 month old at the time of application. Approval will be based on the PASI assessment of response to the most recent course of treatment with this drug. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C8983 |  | Severe chronic plaque psoriasis Initial treatment ‑ Initial 3, Face, hand, foot (re‑commencement of treatment after a break in biological medicine of more than 5 years) Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND The condition must be classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where: (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe; or (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 22 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. The most recent PASI assessment must be no more than 1 month old at the time of application. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient’s condition. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Demonstration of response should be provided within this timeframe. The PASI assessment for first continuing or subsequent continuing treatment must be performed on the same affected area as assessed at baseline. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C9065 |  | Severe psoriatic arthritis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C‑reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following major active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Severe Psoriatic Arthritis PBS Authority Application ‑ Supporting Information Form. Where the most recent course of PBS‑subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9067 |  | Severe psoriatic arthritis First continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C‑reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following major active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Severe Psoriatic Arthritis PBS Authority Application ‑ Supporting Information Form. Where the most recent course of PBS‑subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9068 |  | Severe psoriatic arthritis Continuing treatment ‑ balance of supply Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions. | Compliance with Authority Required procedures |
|  | C9110 |  | Severe psoriatic arthritis Initial treatment ‑ Initial 1 (new patient) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. Patient must not have received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; OR Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND Patient must not receive more than 22 weeks of treatment under this restriction. Patient must be aged 18 years or older. Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA‑approved Product Information, details must be provided at the time of application. Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application. The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C‑reactive protein (CRP) level greater than 15 mg per L; and either (a) an active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active joints from the following list of major joints: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Severe Psoriatic Arthritis PBS Authority Application ‑ Supporting Information Form. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C9111 |  | Severe psoriatic arthritis Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) ‑ balance of supply Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 22 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 22 weeks treatment; AND The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions. | Compliance with Authority Required procedures |
|  | C9169 |  | Severe psoriatic arthritis Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; OR The condition must have a C‑reactive protein (CRP) level greater than 15 mg per L; AND The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND Patient must not receive more than 22 weeks of treatment under this restriction. Patient must be aged 18 years or older. Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Severe Psoriatic Arthritis PBS Authority Application ‑ Supporting Information Form. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C9188 |  | Severe psoriatic arthritis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C‑reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following major active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments. The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient’s medical records. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9188 |
|  | C9191 |  | Severe psoriatic arthritis Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; AND Patient must not receive more than 22 weeks of treatment under this restriction. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C‑reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following major active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Severe Psoriatic Arthritis PBS Authority Application ‑ Supporting Information Form. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9400 |  | Ankylosing spondylitis Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; AND Patient must not receive more than 18 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ankylosing Spondylitis PBS Authority Application ‑ Supporting Information Form. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following: (a) an ESR measurement no greater than 25 mm per hour; or (b) a CRP measurement no greater than 10 mg per L; or (c) an ESR or CRP measurement reduced by at least 20% from baseline. Where only 1 acute phase reactant measurement is supplied in the first application for PBS‑subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications. All measurements provided must be no more than 1 month old at the time of application. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9401 |  | Ankylosing spondylitis Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND The condition must be radiographically (plain X‑ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender; AND Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0‑10 scale that is no more than 4 weeks old at the time of application; AND Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; OR Patient must have a C‑reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; OR Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND Patient must not receive more than 18 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ankylosing Spondylitis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and (ii) a completed BASDAI Assessment Form. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. Up to a maximum of 3 repeats will be authorised. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C9402 |  | Ankylosing spondylitis First continuing treatment Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ankylosing Spondylitis PBS Authority Application ‑ Supporting Information Form. An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following: (a) an ESR measurement no greater than 25 mm per hour; or (b) a CRP measurement no greater than 10 mg per L; or (c) an ESR or CRP measurement reduced by at least 20% from baseline. Where only 1 acute phase reactant measurement is supplied in the first application for PBS‑subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications. All measurements provided must be no more than 1 month old at the time of application. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9472 |  | Severe psoriatic arthritis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C‑reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following major active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments. The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient’s medical records. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9472 |
|  | C9481 |  | Ankylosing spondylitis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following: (a) an ESR measurement no greater than 25 mm per hour; or (b) a CRP measurement no greater than 10 mg per L; or (c) an ESR or CRP measurement reduced by at least 20% from baseline. Where only 1 acute phase reactant measurement is supplied in the first application for PBS‑subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9481 |
|  | C9487 |  | Ankylosing spondylitis Continuing treatment ‑ balance of supply Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions. Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis. | Compliance with Authority Required procedures |
|  | C9558 |  | Ankylosing spondylitis Initial treatment ‑ Initial 1 (new patient) The condition must be radiographically (plain X‑ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND Patient must not have received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender; AND Patient must have failed to achieve an adequate response following treatment with at least 2 non‑steroidal anti‑inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND Patient must not receive more than 18 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis. The application must include details of the NSAIDs trialled, their doses and duration of treatment. If the NSAID dose is less than the maximum recommended dose in the relevant TGA‑approved Product Information, the application must include the reason a higher dose cannot be used. If treatment with NSAIDs is contraindicated according to the relevant TGA‑approved Product Information, the application must provide details of the contraindication. If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application: (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0‑10 scale; AND (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C‑reactive protein (CRP) level greater than 10 mg per L. The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application. Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ankylosing Spondylitis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and (ii) a completed BASDAI Assessment Form; and (iii) a completed Exercise Program Self Certification Form included in the supporting information form. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. Up to a maximum of 3 repeats will be authorised. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C9559 |  | Ankylosing spondylitis Initial treatment ‑ Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) ‑ balance of supply Patient must have received insufficient therapy with this drug under the Initial 1 (new patient) restriction to complete 18 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 weeks treatment; AND The treatment must provide no more than the balance of up to 18 weeks treatment available under the above restrictions. Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis. | Compliance with Authority Required procedures |
|  | C9584 |  | Severe chronic plaque psoriasis Subsequent continuing treatment, Face, hand, foot Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing: (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the baseline values; or (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the baseline value for this treatment cycle. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. Determination of response must be based on the PASI assessment of response to the most recent course of treatment with this drug. The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9584 |
|  | C9587 |  | Ankylosing spondylitis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ankylosing Spondylitis PBS Authority Application ‑ Supporting Information Form. An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following: (a) an ESR measurement no greater than 25 mm per hour; or (b) a CRP measurement no greater than 10 mg per L; or (c) an ESR or CRP measurement reduced by at least 20% from baseline. Where only 1 acute phase reactant measurement is supplied in the first application for PBS‑subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications. All measurements provided must be no more than 1 month old at the time of application. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. Each application for subsequent continuing treatment with this drug must include an assessment of the patient’s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9602 |  | Severe chronic plaque psoriasis Subsequent continuing treatment, Whole body Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as: A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the baseline value for this treatment cycle. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. Determination of response must be based on the PASI assessment of response to the most recent course of treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9602 |
|  | C9621 |  | Ankylosing spondylitis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following: (a) an ESR measurement no greater than 25 mm per hour; or (b) a CRP measurement no greater than 10 mg per L; or (c) an ESR or CRP measurement reduced by at least 20% from baseline. Where only 1 acute phase reactant measurement is supplied in the first application for PBS‑subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9621 |
|  | C9632 |  | Acute severe ulcerative colitis Must be treated by a gastroenterologist; OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology, or general medicine specialising in gastroenterology]. Patient must have received an infusion of infliximab for the treatment of this condition as a hospital inpatient no more than two weeks prior to the date of the authority application; AND Patient must be an adult aged 18 years or older, and prior to initiation of infliximab treatment in hospital must have been experiencing six or more bloody stools per day, plus at least one of the following: (i) Temperature greater than 37.8 degrees Celsius; (ii) Pulse rate greater than 90 beats per minute; (iii) Haemoglobin less than 105 g/L; (iv) Erythrocyte sedimentation rate greater than 30 mm/h; OR Patient must be a child aged 6 to 17 years inclusive, and prior to initiation of infliximab treatment in hospital must have had a Paediatric Ulcerative Colitis Activity Index (PUCAI) greater than or equal to 65, with the diagnosis confirmed by a gastroenterologist, or a consultant physician as specified below; AND Patient must have failed to achieve an adequate response to at least 72 hours treatment with intravenous corticosteroids prior to initiation of infliximab treatment in hospital. Patient must be 6 years of age or older. For adults aged 18 years or older, failure to achieve an adequate response to intravenous corticosteroid treatment is defined by the Oxford criteria where: (i) If assessed on day 3, patients pass 8 or more stools per day or 3 or more stools per day with a C‑reactive protein (CRP) greater than 45 mg/L (ii) If assessed on day 7, patients pass 3 or more stools per day with visible blood. For children aged 6 to 17 years, failure to achieve an adequate response to intravenous corticosteroids means a PUCAI score greater than 45 at 72 hours. At the time of authority application, prescribers should request the appropriate number of vials, based on the weight of the patient, to provide sufficient for a single infusion at a dose of 5 mg per kg. Before administering infliximab to a child aged 6 to 17 years, the treating clinician must have consulted with a paediatric gastroenterologist or with an institution experienced in performance of paediatric colectomy. The name of the specialist or institution must be included in the patient’s medical records. Evidence that the patient meets the PBS restriction criteria must be recorded in the patient’s medical records. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9632 |
|  | C9668 |  | Moderate to severe Crohn disease Subsequent continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have a reduction in PCDAI Score by at least 15 points from baseline value; AND Patient must have a total PCDAI score of 30 points or less; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 6 to 17 years inclusive. The PCDAI assessment must be no more than 1 month old at the time of prescribing. The PCDAI score must be documented in the patient’s medical notes as the measurement of response to the prior course of therapy. Patients are only eligible to receive subsequent continuing PBS‑subsidised treatment with this drug in courses of up to 24 weeks at a dose of 5 mg per kg per dose providing they continue to sustain the response. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9668 |
|  | C9669 |  | Moderate to severe Crohn disease Balance of supply for paediatric patient Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment or subsequent continuing treatment restrictions to complete 24 weeks of treatment; AND The treatment must provide no more than the balance of up to 14 weeks therapy available under Initial 1, 2 or 3 treatment; OR The treatment must provide no more than the balance of up to 24 weeks therapy available under Continuing treatment. | Compliance with Authority Required procedures |
|  | C9675 |  | Moderate to severe ulcerative colitis Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; OR Patient must have previously received PBS‑subsidised treatment with a biological medicine (adalimumab or infliximab) for this condition in this treatment cycle if aged 6 to 17 years; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; OR Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle more than once if aged 6 to 17 years. Patient must be 6 years of age or older. Application for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ulcerative Colitis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Mayo clinic or partial Mayo clinic or Paediatric Ulcerative Colitis Activity Index (PUCAI) calculation sheet including the date of assessment of the patient’s condition if relevant; and (ii) the details of prior biological medicine treatment including the details of date and duration of treatment. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for golimumab, infliximab and vedolizumab and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient who fails to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS‑subsidised treatment with this drug in this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the initial 3 treatment restriction. If patients aged 6 to 17 years fail to respond to PBS‑subsidised biological medicine treatment 3 times (twice with one agent) they will not be eligible to receive further PBS‑subsidised biological medicine therapy in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C9676 |  | Severe Crohn disease First continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have an adequate response to this drug defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150 if assessed by CDAI or if affected by extensive small intestine disease; OR Patient must have an adequate response to this drug defined as (a) an improvement of intestinal inflammation as demonstrated by: (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C‑reactive protein (CRP) level no greater than 15 mg per L; or (ii) faeces: normalisation of lactoferrin or calprotectin level; or (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or (b) reversal of high faecal output state; or (c) avoidance of the need for surgery or total parenteral nutrition (TPN), if affected by short gut syndrome, extensive small intestine or is an ostomy patient; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient’s condition, if relevant; or (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy for patients with short gut syndrome, extensive small intestine disease or an ostomy, if relevant; and (iii) the date of clinical assessment. All assessments, pathology tests, and diagnostic imaging studies must be made within 1 month of the date of application. The application for first continuing treatment with this drug must include an assessment of the patient’s response to the initial course of treatment. The assessment must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated. This assessment must be submitted no later than 4 weeks from the cessation of that treatment course. Where a response assessment is not undertaken and submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks treatment may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the continuing treatment period. | Compliance with Written Authority Required procedures |
|  | C9677 |  | Complex refractory Fistulising Crohn disease Subsequent continuing treatment Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug. Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. An adequate response is defined as: (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Fistulising Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes a completed Fistula Assessment form including the date of the assessment of the patient’s condition. The most recent fistula assessment must be no more than 1 month old at the time of application. Each application for subsequent continuing treatment with this drug must include an assessment of the patient’s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. Patients are eligible to receive continuing treatment with this drug in courses of up to 24 weeks providing they continue to sustain the response. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. | Compliance with Written Authority Required procedures |
|  | C9719 |  | Moderate to severe Crohn disease Subsequent continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have a reduction in PCDAI Score by at least 15 points from baseline value; AND Patient must have a total PCDAI score of 30 points or less; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 6 to 17 years inclusive. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Paediatric Crohn Disease PBS Authority Application ‑ Supporting Information Form, which includes the completed Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient’s condition. The PCDAI assessment must be no more than 1 month old at the time of application. Each application for subsequent continuing treatment with this drug must include an assessment of the patient’s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. Patients are only eligible to receive subsequent continuing PBS‑subsidised treatment with this drug in courses of up to 24 weeks at a dose of 5 mg per kg per dose providing they continue to sustain the response. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks treatment may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the continuing treatment period. | Compliance with Written Authority Required procedures |
|  | C9721 |  | Moderate to severe Crohn disease First continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have a reduction in PCDAI Score by at least 15 points from baseline value; AND Patient must have a total PCDAI score of 30 points or less; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 6 to 17 years inclusive. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Paediatric Crohn Disease PBS Authority Application ‑ Supporting Information Form, which includes the completed Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet along with the date of the assessment of the patient’s condition. The PCDAI assessment must be no more than 1 month old at the time of application. The application for first continuing treatment with this drug must include a PCDAI assessment of the patient’s response to the initial course of treatment. The assessment must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated. This assessment must be submitted no later than 4 weeks from the cessation of that treatment course. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks treatment may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the continuing treatment period. | Compliance with Written Authority Required procedures |
|  | C9731 |  | Severe Crohn disease Subsequent continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have an adequate response to this drug defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150 if assessed by CDAI or if affected by extensive small intestine disease; OR Patient must have an adequate response to this drug defined as (a) an improvement of intestinal inflammation as demonstrated by: (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C‑reactive protein (CRP) level no greater than 15 mg per L; or (ii) faeces: normalisation of lactoferrin or calprotectin level; or (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or (b) reversal of high faecal output state; or (c) avoidance of the need for surgery or total parenteral nutrition (TPN), if affected by short gut syndrome, extensive small intestine or is an ostomy patient; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9731 |
|  | C9732 |  | Complex refractory Fistulising Crohn disease Subsequent continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received this drug as their most recent course of PBS‑subsidised biological agent treatment for this condition in this treatment cycle; AND Patient must have demonstrated an adequate response to treatment with this drug. An adequate response is defined as: (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. Patients are eligible to receive subsequent continuing treatment with this drug in courses of up to 24 weeks at a dose of 5 mg per kg per dose providing they continue to sustain the response. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9732 |
|  | C9733 |  | Severe Crohn disease Subsequent continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have an adequate response to this drug defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150 if assessed by CDAI or if affected by extensive small intestine disease; OR Patient must have an adequate response to this drug defined as (a) an improvement of intestinal inflammation as demonstrated by: (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C‑reactive protein (CRP) level no greater than 15 mg per L; or (ii) faeces: normalisation of lactoferrin or calprotectin level; or (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or (b) reversal of high faecal output state; or (c) avoidance of the need for surgery or total parenteral nutrition (TPN), if affected by short gut syndrome, extensive small intestine or is an ostomy patient; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9733 |
|  | C9751 |  | Moderate to severe Crohn disease Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition more than once in the current treatment cycle; AND The treatment must not exceed a total of 3 doses to be administered at weeks 0, 2 and 6 under this restriction. Patient must be aged 6 to 17 years inclusive. Application for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Paediatric Crohn Disease PBS Authority Application ‑Supporting Information Form which includes the following: (i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) Score calculation sheet; and (ii) details of prior biological medicine treatment including details of date and duration of treatment. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. If the response assessment to the previous course of biological medicine treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of biological medicine. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of this drug may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. A PCDAI assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for the first continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. | Compliance with Written Authority Required procedures |
|  | C9752 |  | Moderate to severe Crohn disease Initial treatment ‑ Initial 1 (new patient) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have confirmed diagnosis of Crohn disease, defined by standard clinical, endoscopic and/or imaging features including histological evidence; AND Patient must have failed to achieve an adequate response to 2 of the following 3 conventional prior therapies including: (i) a tapered course of steroids, starting at a dose of at least 1 mg per kg or 40 mg (whichever is the lesser) prednisolone (or equivalent), over a 6 week period; (ii) an 8 week course of enteral nutrition; or (iii) immunosuppressive therapy including azathioprine at a dose of at least 2 mg per kg daily for 3 or more months, or, 6‑mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more months, or, methotrexate at a dose of at least 10 mg per square metre weekly for 3 or more months; OR Patient must have a documented intolerance of a severity necessitating permanent treatment withdrawal or a contra‑indication to each of prednisolone (or equivalent), azathioprine, 6‑mercaptopurine and methotrexate; AND Patient must have a Paediatric Crohn Disease Activity Index (PCDAI) Score greater than or equal to 30 preferably whilst still on treatment; AND The treatment must not exceed a total of 3 doses to be administered at weeks 0, 2 and 6 under this restriction. Patient must be aged 6 to 17 years inclusive. Application for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Paediatric Crohn Disease PBS Authority Application ‑Supporting Information Form which includes the following: (i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet including the date of assessment of the patient’s condition which must be no more than one month old at the time of application; and (ii) details of previous systemic drug therapy [dosage, date of commencement and duration of therapy] or dates of enteral nutrition. The PCDAI score should preferably be obtained whilst on conventional treatment but must be obtained within one month of the last conventional treatment dose. If treatment with any of the specified prior conventional drugs is contraindicated according to the relevant TGA‑approved Product Information, please provide details at the time of application. If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, details of this toxicity must be provided at the time of application. Details of the accepted toxicities including severity can be found on the Department of Human Services website. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of this drug may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. A PCDAI assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for the first continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. | Compliance with Written Authority Required procedures |
|  | C9754 |  | Moderate to severe ulcerative colitis Balance of supply Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks of treatment; AND The treatment must provide no more than the balance of up to 3 doses therapy available under Initial 1, 2 or 3 treatment; OR The treatment must provide no more than the balance of up to 24 weeks therapy available under Continuing treatment. | Compliance with Authority Required procedures |
|  | C9756 |  | Severe Crohn disease Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; AND The treatment must not exceed a total of 3 doses to be administered at weeks 0, 2 and 6 under this restriction. Patient must be aged 18 years or older. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of assessment of the patient’s condition if relevant; or (ii) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy for patients with short gut syndrome, extensive small intestine disease or an ostomy, if relevant; and (iii) the date of clinical assessment; and (iv) the details of prior biological medicine treatment including the details of date and duration of treatment. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab or ustekinumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and vedolizumab and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. If the response assessment to the previous course of biological medicine treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of biological medicine. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of this drug may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. The assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for the first continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9759 |  | Severe Crohn disease Subsequent continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have an adequate response to this drug defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150 if assessed by CDAI or if affected by extensive small intestine disease; OR Patient must have an adequate response to this drug defined as (a) an improvement of intestinal inflammation as demonstrated by: (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C‑reactive protein (CRP) level no greater than 15 mg per L; or (ii) faeces: normalisation of lactoferrin or calprotectin level; or (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or (b) reversal of high faecal output state; or (c) avoidance of the need for surgery or total parenteral nutrition (TPN), if affected by short gut syndrome, extensive small intestine or is an ostomy patient; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 18 years or older. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed Crohn Disease Activity Index (CDAI) Score; or (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy for patients with short gut syndrome, extensive small intestine disease or an ostomy, if relevant; and (iii) the date of the most recent clinical assessment. All assessments, pathology tests, and diagnostic imaging studies must be made within 1 month of the date of application. Each application for subsequent continuing treatment with this drug must include an assessment of the patient’s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. Patients are eligible to receive continuing treatment with this drug in courses of up to 24 weeks providing they continue to sustain the response. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks treatment may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the continuing treatment period. | Compliance with Written Authority Required procedures |
|  | C9775 |  | Moderate to severe Crohn disease Subsequent continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have a reduction in PCDAI Score by at least 15 points from baseline value; AND Patient must have a total PCDAI score of 30 points or less; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 6 to 17 years inclusive. The PCDAI assessment must be no more than 1 month old at the time of prescribing. The PCDAI score must be documented in the patient’s medical notes as the measurement of response to the prior course of therapy. Patients are only eligible to receive subsequent continuing PBS‑subsidised treatment with this drug in courses of up to 24 weeks at a dose of 5 mg per kg per dose providing they continue to sustain the response. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9775 |
|  | C9776 |  | Moderate to severe ulcerative colitis Initial treatment ‑ Initial 1 (new patient) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have failed to achieve an adequate response to a 5‑aminosalicylate oral preparation in a standard dose for induction of remission for 3 or more consecutive months or have intolerance necessitating permanent treatment withdrawal; AND Patient must have failed to achieve an adequate response to azathioprine at a dose of at least 2 mg per kg daily for 3 or more consecutive months or have intolerance necessitating permanent treatment withdrawal; OR Patient must have failed to achieve an adequate response to 6‑mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more consecutive months or have intolerance necessitating permanent treatment withdrawal; OR Patient must have failed to achieve an adequate response to a tapered course of oral steroids, starting at a dose of at least 40 mg (for a child, 1 to 2 mg/kg up to 40 mg) prednisolone (or equivalent), over a 6 week period or have intolerance necessitating permanent treatment withdrawal, and followed by a failure to achieve an adequate response to 3 or more consecutive months of treatment of an appropriately dosed thiopurine agent; AND Patient must have a Mayo clinic score greater than or equal to 6 if an adult patient; OR Patient must have a partial Mayo clinic score greater than or equal to 6, provided the rectal bleeding and stool frequency subscores are both greater than or equal to 2 (endoscopy subscore is not required for a partial Mayo clinic score); OR Patient must have a Paediatric Ulcerative Colitis Activity Index (PUCAI) Score greater than or equal to 30 if aged 6 to 17 years; OR Patient must have previously received induction therapy with this drug for an acute severe episode of ulcerative colitis in the last 4 months and demonstrated an adequate response to induction therapy by achieving and maintaining a partial Mayo clinic score less than or equal to 2, with no subscore greater than 1, or a PUCAI score less than 10 (if aged 6 to 17 years). Patient must be 6 years of age or older. Application for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ulcerative Colitis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Mayo clinic or partial Mayo clinic or Paediatric Ulcerative Colitis Activity Index (PUCAI) calculation sheet including the date of assessment of the patient’s condition; and (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, or to be administered at 8‑weekly intervals for patients who have received prior treatment for an acute severe episode, will be authorised. All tests and assessments should be performed preferably whilst still on treatment, but no longer than 4 weeks following cessation of the most recent prior conventional treatment. The most recent Mayo clinic, partial Mayo clinic or Paediatric Ulcerative Colitis Activity Index (PUCAI) score must be no more than 4 weeks old at the time of application. Where treatment for an acute severe episode has occurred, an adequate response to induction therapy needs to be demonstrated by achieving and maintaining a partial Mayo clinic score less than or equal to 2, with no subscore greater than 1, or a Paediatric Ulcerative Colitis Activity Index (PUCAI) score less than 10 (if aged 6 to 17 years), within the first 12 weeks of receiving this drug for acute severe ulcerative colitis. A partial Mayo clinic or Paediatric Ulcerative Colitis Activity Index (PUCAI) assessment of the patient’s response to this initial course of treatment must be made following a minimum of 12 weeks of treatment for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for golimumab, infliximab and vedolizumab so that there is adequate time for a response to be demonstrated. If treatment with any of the above‑mentioned drugs is contraindicated according to the relevant TGA‑approved Product Information, details must be provided at the time of application. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. Details of the accepted toxicities including severity can be found on the Department of Human Services website. | Compliance with Written Authority Required procedures |
|  | C9778 |  | Severe Crohn disease Initial treatment ‑ Initial 1 (new patient) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must be aged 18 years or older. Patient must have confirmed severe Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician; AND Patient must have failed to achieve an adequate response to prior systemic therapy with a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; AND The treatment must not exceed a total of 3 doses to be administered at weeks 0, 2 and 6 under this restriction; AND Patient must have failed to achieve adequate response to prior systemic immunosuppressive therapy with azathioprine at a dose of at least 2 mg per kg daily for 3 or more consecutive months; OR Patient must have failed to achieve adequate response to prior systemic immunosuppressive therapy with 6‑mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more consecutive months; OR Patient must have failed to achieve adequate response to prior systemic immunosuppressive therapy with methotrexate at a dose of at least 15 mg weekly for 3 or more consecutive months; AND Patient must have a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as evidence of failure to achieve an adequate response to prior systemic therapy; OR Patient must have short gut syndrome with diagnostic imaging or surgical evidence, or have had an ileostomy or colostomy; and must have evidence of intestinal inflammation; and must have evidence of failure to achieve an adequate response to prior systemic therapy as specified below; OR Patient must have extensive intestinal inflammation affecting more than 50 cm of the small intestine as evidenced by radiological imaging; and must have a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220; and must have evidence of failure to achieve an adequate response to prior systemic therapy as specified below. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient’s condition if relevant; and (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and (iii) the reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and (iv) the date of the most recent clinical assessment. Evidence of failure to achieve an adequate response to prior therapy must include at least one of the following: (a) patient must have evidence of intestinal inflammation; (b) patient must be assessed clinically as being in a high faecal output state; (c) patient must be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of this drug, if affected by short gut syndrome, extensive small intestine disease or is an ostomy patient. Evidence of intestinal inflammation includes: (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C‑reactive protein (CRP) level greater than 15 mg per L; or (ii) faeces: higher than normal lactoferrin or calprotectin level; or (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery. All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application and should be performed preferably whilst still on conventional treatment, but no longer than 1 month following cessation of the most recent prior treatment If treatment with any of the specified prior conventional drugs is contraindicated according to the relevant TGA‑approved Product Information, please provide details at the time of application. If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, details of this toxicity must be provided at the time of application. Details of the accepted toxicities including severity can be found on the Department of Human Services website. Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the first or subsequent continuing treatment restrictions. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS‑subsidised therapy. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of this drug may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. The assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for the first continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C9779 |  | Severe Crohn disease Balance of supply Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks of treatment; AND The treatment must provide no more than the balance of up to 14 weeks therapy available under Initial 1, 2 or 3 treatment; OR The treatment must provide no more than the balance of up to 24 weeks therapy available under Continuing treatment. | Compliance with Authority Required procedures |
|  | C9781 |  | Severe Crohn disease Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND Patient must have confirmed severe Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician; AND Patient must have a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 that is no more than 4 weeks old at the time of application; OR Patient must have a documented history of intestinal inflammation and have diagnostic imaging or surgical evidence of short gut syndrome if affected by the syndrome or has an ileostomy or colostomy; OR Patient must have a documented history and radiological evidence of intestinal inflammation if the patient has extensive small intestinal disease affecting more than 50 cm of the small intestine, together with a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220 and that is no more than 4 weeks old at the time of application; AND Patient must have evidence of intestinal inflammation; OR Patient must be assessed clinically as being in a high faecal output state; OR Patient must be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of this drug, if affected by short gut syndrome, extensive small intestine disease or is an ostomy patient; AND The treatment must not exceed a total of 3 doses to be administered at weeks 0, 2 and 6 under this restriction. Patient must be aged 18 years or older. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient’s condition if relevant; and (ii) the reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and (iii) the date of the most recent clinical assessment. Evidence of intestinal inflammation includes: (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C‑reactive protein (CRP) level greater than 15 mg per L; or (ii) faeces: higher than normal lactoferrin or calprotectin level; or (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of this drug may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the first or subsequent continuing treatment restrictions. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS‑subsidised therapy. The assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9783 |  | Complex refractory Fistulising Crohn disease First continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug. An adequate response is defined as: (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Fistulising Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes a completed Fistula Assessment form including the date of the assessment of the patient’s condition. The most recent fistula assessment must be no more than 1 month old at the time of application. The application for first continuing treatment with this drug must include an assessment of the patient’s response to the initial course of treatment. The assessment must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated. This assessment must be submitted no later than 4 weeks from the cessation of that treatment course. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. A maximum of 24 weeks of treatment with this drug will be authorised under this restriction. At the time of the authority application, medical practitioners should request the appropriate number of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. | Compliance with Written Authority Required procedures |
|  | C9785 |  | Moderate to severe ulcerative colitis Continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have demonstrated or sustained an adequate response to treatment by having a partial Mayo clinic score less than or equal to 2, with no subscore greater than 1 while receiving treatment with this drug; OR Patient must have demonstrated or sustained an adequate response to treatment by having a Paediatric Ulcerative Colitis Activity Index (PUCAI) score of less than 10 while receiving treatment with this drug, if aged 6 to 17 years. Patient must be 6 years of age or older. Patients who have failed to maintain a partial Mayo clinic score of less than or equal to 2, with no subscore greater than 1, or, patients who have failed to maintain a Paediatric Ulcerative Colitis Activity Index (PUCAI) score of less than 10 (if aged 6 to 17 years) with continuing treatment with this drug, will not be eligible to receive further PBS‑subsidised treatment with this drug. Patients are only eligible to receive continuing PBS‑subsidised treatment with this drug in courses of up to 24 weeks at a dose of 5 mg per kg per dose providing they continue to sustain the response. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. If patients aged 6 to 17 years fail to respond to PBS‑subsidised biological medicine treatment 3 times (twice with one agent) they will not be eligible to receive further PBS‑subsidised biological medicine therapy in this treatment cycle. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9785 |
|  | C9787 |  | Complex refractory Fistulising Crohn disease Subsequent continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received this drug as their most recent course of PBS‑subsidised biological agent treatment for this condition in this treatment cycle; AND Patient must have demonstrated an adequate response to treatment with this drug. An adequate response is defined as: (a) a decrease from baseline in the number of open draining fistulae of greater than or equal to 50%; and/or (b) a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. Patients are eligible to receive subsequent continuing treatment with this drug in courses of up to 24 weeks at a dose of 5 mg per kg per dose providing they continue to sustain the response. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9787 |
|  | C9788 |  | Moderate to severe ulcerative colitis Continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have demonstrated or sustained an adequate response to treatment by having a partial Mayo clinic score less than or equal to 2, with no subscore greater than 1 while receiving treatment with this drug; OR Patient must have demonstrated or sustained an adequate response to treatment by having a Paediatric Ulcerative Colitis Activity Index (PUCAI) score of less than 10 while receiving treatment with this drug, if aged 6 to 17 years. Patient must be 6 years of age or older. Patients who have failed to maintain a partial Mayo clinic score of less than or equal to 2, with no subscore greater than 1, or, patients who have failed to maintain a Paediatric Ulcerative Colitis Activity Index (PUCAI) score of less than 10 (if aged 6 to 17 years) with continuing treatment with this drug, will not be eligible to receive further PBS‑subsidised treatment with this drug. Patients are only eligible to receive continuing PBS‑subsidised treatment with this drug in courses of up to 24 weeks at a dose of 5 mg per kg per dose providing they continue to sustain the response. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly. Up to a maximum of 2 repeats will be authorised. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. If patients aged 6 to 17 years fail to respond to PBS‑subsidised biological medicine treatment 3 times (twice with one agent) they will not be eligible to receive further PBS‑subsidised biological medicine therapy in this treatment cycle. | Compliance with Authority Required procedures |
|  | C9799 |  | Moderate to severe Crohn disease Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND Patient must have confirmed diagnosis of Crohn disease, defined by standard clinical, endoscopic and/or imaging features including histological evidence; AND Patient must have a Paediatric Crohn Disease Activity Index (PCDAI) Score greater than or equal to 30; AND The treatment must not exceed a total of 3 doses to be administered at weeks 0, 2 and 6 under this restriction. Patient must be aged 6 to 17 years inclusive. Application for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Paediatric Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Paediatric Crohn Disease Activity Index (PCDAI) calculation sheet including the date of assessment of the patient’s condition which must be no more than one month old at the time of application. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of this drug may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. A PCDAI assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for the first continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. | Compliance with Authority Required procedures |
|  | C9800 |  | Moderate to severe ulcerative colitis Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have had a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND Patient must have a Mayo clinic score greater than or equal to 6 if an adult patient; OR Patient must have a partial Mayo clinic score greater than or equal to 6, provided the rectal bleeding and stool frequency subscores are both greater than or equal to 2 (endoscopy subscore is not required for a partial Mayo clinic score); OR Patient must have a Paediatric Ulcerative Colitis Activity Index (PUCAI) Score greater than or equal to 30 if aged 6 to 17 years; OR Patient must have previously received induction therapy with this drug for an acute severe episode of ulcerative colitis in the last 4 months and demonstrated an adequate response to induction therapy by achieving and maintaining a partial Mayo clinic score less than or equal to 2, with no subscore greater than 1, or a PUCAI score less than 10 (if aged 6 to 17 years). Patient must be 6 years of age or older. Application for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ulcerative Colitis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Mayo clinic or partial Mayo clinic or Paediatric Ulcerative Colitis Activity Index (PUCAI) calculation sheet including the date of assessment of the patient’s condition; and (ii) the details of prior biological medicine treatment including the details of date and duration of treatment. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, or to be administered at 8‑weekly intervals for patients who have received prior treatment for an acute severe episode, will be authorised. All tests and assessments should be performed preferably whilst still on treatment, but no longer than 4 weeks following cessation of the most recent prior conventional treatment. The most recent Mayo clinic, partial Mayo clinic or Paediatric Ulcerative Colitis Activity Index (PUCAI) score must be no more than 4 weeks old at the time of application. Where treatment for an acute severe episode has occurred, an adequate response to induction therapy needs to be demonstrated by achieving and maintaining a partial Mayo clinic score less than or equal to 2, with no subscore greater than 1, or a Paediatric Ulcerative Colitis Activity Index (PUCAI) score less than 10 (if aged 6 to 17 years), within the first 12 weeks of receiving this drug for acute severe ulcerative colitis. A partial Mayo clinic or Paediatric Ulcerative Colitis Activity Index (PUCAI) assessment of the patient’s response to this initial course of treatment must be made following a minimum of 12 weeks of treatment for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for golimumab, infliximab and vedolizumab so that there is adequate time for a response to be demonstrated. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. Details of the accepted toxicities including severity can be found on the Department of Human Services website. | Compliance with Written Authority Required procedures |
|  | C9803 |  | Complex refractory Fistulising Crohn disease Change or Recommencement of treatment after a break in therapy of less than 5 years (Initial 2) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have failed PBS‑subsidised therapy with this drug for this condition more than once in the current treatment cycle. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Fistulising Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) a completed current Fistula Assessment Form including the date of assessment of the patient’s condition; and (ii) details of prior biological medicine treatment including details of date and duration of treatment. The most recent fistula assessment must be no more than 1 month old at the time of application. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of biological medicine therapy within the timeframes specified in the relevant restriction. If the response assessment to the previous course of biological medicine treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of biological medicine. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. An assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for the first continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. | Compliance with Written Authority Required procedures |
|  | C9806 |  | Moderate to severe ulcerative colitis Continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; OR Must be treated by a paediatrician; OR Must be treated by a specialist paediatric gastroenterologist. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have demonstrated or sustained an adequate response to treatment by having a partial Mayo clinic score less than or equal to 2, with no subscore greater than 1 while receiving treatment with this drug; OR Patient must have demonstrated or sustained an adequate response to treatment by having a Paediatric Ulcerative Colitis Activity Index (PUCAI) score of less than 10 while receiving treatment with this drug, if aged 6 to 17 years. Patient must be 6 years of age or older. Patients who have failed to maintain a partial Mayo clinic score of less than or equal to 2, with no subscore greater than 1, or, patients who have failed to maintain a Paediatric Ulcerative Colitis Activity Index (PUCAI) score of less than 10 (if aged 6 to 17 years) with continuing treatment with this drug, will not be eligible to receive further PBS‑subsidised treatment with this drug. Patients are only eligible to receive continuing PBS‑subsidised treatment with this drug in courses of up to 24 weeks at a dose of 5 mg per kg per dose providing they continue to sustain the response. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. If patients aged 6 to 17 years fail to respond to PBS‑subsidised biological medicine treatment 3 times (twice with one agent) they will not be eligible to receive further PBS‑subsidised biological medicine therapy in this treatment cycle. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9806 |
|  | C9877 |  | Severe chronic plaque psoriasis Initial treatment ‑ Initial 2, Face, hand, foot (change or recommencement of treatment after a break in biological medicine of less than 5 years) Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 22 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing: (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the baseline values; or (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the baseline value for this treatment cycle. An application for a patient who has received PBS‑subsidised treatment with this drug and who wishes to re‑commence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised treatment with this drug, within the timeframes specified below. Where the most recent course of PBS‑subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Demonstration of response should be provided within this timeframe. The PASI assessment for first continuing or subsequent continuing treatment must be performed on the same affected area as assessed at baseline. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient’s condition; and (ii) details of prior biological treatment, including dosage, date and duration of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9900 |  | Complex refractory Fistulising Crohn disease Initial treatment (new patient or Recommencement of treatment after more than 5 years break in therapy ‑ Initial 1) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have confirmed Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician; AND Patient must have an externally draining enterocutaneous or rectovaginal fistula. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Fistulising Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) a completed current Fistula Assessment Form including the date of assessment of the patient’s condition. The most recent fistula assessment must be no more than 1 month old at the time of application. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised. An assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (up to 6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for the first continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. | Compliance with Written Authority Required procedures |
|  | C9975 |  | Severe active rheumatoid arthritis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9975 |
|  | C9994 |  | Severe chronic plaque psoriasis Initial treatment ‑ Initial 2, Whole body (change or recommencement of treatment after a break in biological medicine of less than 5 years) Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; AND The treatment must be as systemic monotherapy (other than methotrexate); AND Patient must not receive more than 22 weeks of treatment under this restriction. Patient must be aged 18 years or older. Must be treated by a dermatologist. An adequate response to treatment is defined as: A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the baseline value for this treatment cycle. An application for a patient who has received PBS‑subsidised treatment with this drug and who wishes to re‑commence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised treatment with this drug, within the timeframes specified below. Where the most recent course of PBS‑subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Demonstration of response should be provided within this timeframe. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient’s condition; and (ii) details of prior biological treatment, including dosage, date and duration of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
| Interferon alfa‑2a | C4993 |  | Chronic hepatitis B infection Patient must not have cirrhosis, AND Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection, AND Patient must have evidence of chronic liver injury determined by confirmed elevated serum ALT or liver biopsy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4993 |
|  | C5036 |  | Chronic hepatitis B infection Patient must have cirrhosis, AND Patient must have detectable HBV DNA. Patients with Child’s class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5036 |
|  | C5042 |  | Chronic Myeloid Leukaemia (CML) The condition must be Philadelphia chromosome positive. | Compliance with Authority Required procedures - Streamlined Authority Code 5042 |
|  | C9259 |  | Chronic Myeloid Leukaemia (CML) The condition must be Philadelphia chromosome positive. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9259 |
| Interferon Gamma‑1b | C6222 |  | Chronic granulomatous disease Patient must have frequent and severe infections despite adequate prophylaxis with antimicrobial agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6222 |
|  | C9639 |  | Chronic granulomatous disease Patient must have frequent and severe infections despite adequate prophylaxis with antimicrobial agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9639 |
| Ivacaftor | C9889 |  | Cystic fibrosis Continuing treatment Patient must be assessed through a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis. If attendance at such a unit is not possible because of geographical isolation, management (including prescribing) may be in consultation with such a unit; AND Patient must have received PBS‑subsidised initial therapy with ivacaftor, given concomitantly with standard therapy, for this condition; AND Patient must not receive more than 24 weeks of treatment under this restriction; AND The treatment must be given concomitantly with standard therapy for this condition. Patient must be aged 12 months or older. Patients receiving PBS‑subsidised ivacaftor must be registered in the Australian Cystic Fibrosis Database Registry. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. Patients who have an acute infective exacerbation at the time of assessment for continuing therapy may receive an additional one month’s supply in order to enable the assessment to be repeated following resolution of the exacerbation. Dosage of ivacaftor must not exceed the dose of one tablet (150 mg) or one sachet twice a week, if the patient is concomitantly receiving one of the following strong CYP3A4 drugs inhibitors: boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole. Where a patient is concomitantly receiving a strong CYP3A4 inhibitor, a single supply of 56 tablets or sachets of ivacaftor will last for 28 weeks. Dosage of ivacaftor must not exceed the dose of one tablet (150 mg) or one sachet once daily, if the patient is concomitantly receiving one of the following moderate CYP3A4 inhibitors: amprenavir, aprepitant, atazanavir, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil. Where a patient is concomitantly receiving a moderate CYP3A4 inhibitor, a single supply of 56 tablets or sachets of ivacaftor will last for 8 weeks. Ivacaftor is not PBS‑subsidised for this condition as a sole therapy. Ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis Ivacaftor Authority Continuing Application Supporting Information Form; and (3) the result of a FEV1 measurement performed within one month prior to the date of application, if aged 6 years or older. Note: FEV1, must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1 is measured; and (4) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (5) height and weight measurements at the time of application; and (6) a measurement of number of days of CF‑related hospitalisation (including hospital in the home) in the previous 6 months. | Compliance with Written Authority Required procedures |
|  | C9890 |  | Cystic fibrosis Initial treatment ‑ New patients Patient must be assessed through a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis. If attendance at such a unit is not possible because of geographical isolation, management (including prescribing) may be in consultation with such a unit; AND Patient must have G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on at least 1 allele; OR Patient must have other gating (class III) mutation in the CFTR gene on at least 1 allele; AND Patient must have a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis; AND Patient must not receive more than 24 weeks of treatment under this restriction; AND The treatment must be given concomitantly with standard therapy for this condition. Patient must be aged 12 months or older. Patients receiving PBS‑subsidised ivacaftor must be registered in the Australian Cystic Fibrosis Database Registry. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. Dosage of ivacaftor must not exceed the dose of one tablet (150 mg) or one sachet twice a week, if the patient is concomitantly receiving one of the following strong CYP3A4 drugs inhibitors: boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole. Where a patient is concomitantly receiving a strong CYP3A4 inhibitor, a single supply of 56 tablets or sachets of ivacaftor will last for 28 weeks. Dosage of ivacaftor must not exceed the dose of one tablet (150 mg) or one sachet once daily, if the patient is concomitantly receiving one of the following moderate CYP3A4 inhibitors: amprenavir, aprepitant, atazanavir, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil. Where a patient is concomitantly receiving a moderate CYP3A4 inhibitor, a single supply of 56 tablets or sachets of ivacaftor will last for 8 weeks. Ivacaftor is not PBS‑subsidised for this condition as a sole therapy. Ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis Ivacaftor Authority Application Supporting Information Form; and (3) a copy of the pathology report detailing the molecular testing for G551D mutation or other gating (class III) mutation on the CFTR gene; and (4) the result of a FEV1 measurement performed within a month prior to the date of application, if aged from 6 years or older. Note: FEV1, must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1 is measured; and (5) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (6) sweat chloride result; and (7) height and weight measurements at the time of application; and (8) a baseline measurement of the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 12 months. | Compliance with Written Authority Required procedures |
| Lamivudine | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
|  | C4993 |  | Chronic hepatitis B infection Patient must not have cirrhosis, AND Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection, AND Patient must have evidence of chronic liver injury determined by confirmed elevated serum ALT or liver biopsy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4993 |
|  | C5036 |  | Chronic hepatitis B infection Patient must have cirrhosis, AND Patient must have detectable HBV DNA. Patients with Child’s class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5036 |
| Lamivudine with zidovudine | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Lanreotide | C4575 |  | Functional carcinoid tumour  The condition must be causing intractable symptoms; AND  Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti‑histamines, anti‑serotonin agents and anti‑diarrhoea agents; AND Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months’ therapy at a dose of 120 mg every 28 days  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4575 |
|  | C7025 |  | Acromegaly  The condition must be active; AND  Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre; AND  The treatment must be after failure of other therapy including dopamine agonists; OR  The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; OR  The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated; AND  The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose); AND  The treatment must cease if IGF1 is not lower after 3 months of treatment; AND  The treatment must not be given concomitantly with PBS‑subsidised pegvisomant.  In a patient treated with radiotherapy, lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7025 |
|  | C7042 |  | Acromegaly  The condition must be active; AND  Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre; AND  The treatment must be after failure of other therapy including dopamine agonists; OR  The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; OR  The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated; AND  The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (6 weeks after the last dose); AND  The treatment must cease if IGF1 is not lower after 3 months of treatment; AND  The treatment must not be given concomitantly with PBS‑subsidised pegvisomant.  In a patient treated with radiotherapy, lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7042 |
|  | C7509 |  | Functional carcinoid tumour  Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND  The condition must be causing intractable symptoms; AND  Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti‑histamines, anti‑serotonin agents and anti‑diarrhoea agents; AND  Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND  The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months’ therapy at a dose of 120 mg every 28 days.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7509 |
|  | C7532 |  | Acromegaly  Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND  The condition must be active; AND  Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre; AND  The treatment must be after failure of other therapy including dopamine agonists; OR  The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; OR  The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated; AND  The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose); AND  The treatment must cease if IGF1 is not lower after 3 months of treatment; AND  The treatment must not be given concomitantly with PBS‑subsidised pegvisomant.  In a patient treated with radiotherapy, lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7532 |
|  | C9225 |  | Acromegaly The condition must be active; AND Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre; AND The treatment must be after failure of other therapy including dopamine agonists; OR The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; OR The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated; AND The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (6 weeks after the last dose); AND The treatment must cease if IGF1 is not lower after 3 months of treatment; AND The treatment must not be given concomitantly with PBS‑subsidised pegvisomant. In a patient treated with radiotherapy, lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9225 |
|  | C9260 |  | Functional carcinoid tumour The condition must be causing intractable symptoms; AND Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti‑histamines, anti‑serotonin agents and anti‑diarrhoea agents; AND Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months’ therapy at a dose of 120 mg every 28 days. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9260 |
|  | C9261 |  | Acromegaly The condition must be active; AND Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre; AND The treatment must be after failure of other therapy including dopamine agonists; OR The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; OR The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated; AND The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after lanreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose); AND The treatment must cease if IGF1 is not lower after 3 months of treatment; AND The treatment must not be given concomitantly with PBS‑subsidised pegvisomant. In a patient treated with radiotherapy, lanreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9261 |
|  | C10061 |  | Non‑functional gastroenteropancreatic neuroendocrine tumour (GEP‑NET) The condition must be unresectable locally advanced disease or metastatic disease; AND The condition must be World Health Organisation (WHO) grade 1 or 2; AND The treatment must be the sole PBS‑subsidised therapy for this condition. Patient must be aged 18 years or older. WHO grade 1 of GEP‑NET is defined as a mitotic count (10HPF) of less than 2 and Ki‑67 index (%) of less than or equal to 2. WHO grade 2 of GEP‑NET is defined as a mitotic count (10HPF) of 2‑20 and Ki‑67 index (%) of 3‑20. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10061 |
|  | C10075 |  | Non‑functional gastroenteropancreatic neuroendocrine tumour (GEP‑NET) Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND The condition must be unresectable locally advanced disease or metastatic disease; AND The condition must be World Health Organisation (WHO) grade 1 or 2; AND The treatment must be the sole PBS‑subsidised therapy for this condition. Patient must be aged 18 years or older. WHO grade 1 of GEP‑NET is defined as a mitotic count (10HPF) of less than 2 and Ki‑67 index (%) of less than or equal to 2. WHO grade 2 of GEP‑NET is defined as a mitotic count (10HPF) of 2‑20 and Ki‑67 index (%) of 3‑20. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10075 |
|  | C10077 |  | Non‑functional gastroenteropancreatic neuroendocrine tumour (GEP‑NET) The condition must be unresectable locally advanced disease or metastatic disease; AND The condition must be World Health Organisation (WHO) grade 1 or 2; AND The treatment must be the sole PBS‑subsidised therapy for this condition. Patient must be aged 18 years or older. WHO grade 1 of GEP‑NET is defined as a mitotic count (10HPF) of less than 2 and Ki‑67 index (%) of less than or equal to 2. WHO grade 2 of GEP‑NET is defined as a mitotic count (10HPF) of 2‑20 and Ki‑67 index (%) of 3‑20. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10077 |
| Lanthanum | C5530 |  | Hyperphosphataemia Initiation and stabilisation The condition must not be adequately controlled by calcium; AND Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; OR The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy; AND The treatment must not be used in combination with any other non-calcium phosphate binding agents. Patient must be undergoing dialysis for chronic kidney disease. | Compliance with Authority Required procedures - Streamlined Authority Code 5530 |
|  | C9762 |  | Hyperphosphataemia Initiation and stabilisation The condition must not be adequately controlled by calcium; AND Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; OR The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy; AND The treatment must not be used in combination with any other non‑calcium phosphate binding agents. Patient must be undergoing dialysis for chronic kidney disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9762 |
| Ledipasvir with sofosbuvir | C5944 | P5944 | Chronic hepatitis C infection Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 8 weeks. | Compliance with Authority Required procedures |
|  | C5969 | P5969 | Chronic hepatitis C infection Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 12 weeks. | Compliance with Authority Required procedures |
|  | C5972 | P5972 | Chronic hepatitis C infection Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 24 weeks. | Compliance with Authority Required procedures |
| Lenalidomide | C4282 |  | Myelodysplastic syndrome Continuing treatment Patient must be classified as Low risk or Intermediate-1 according to the International Prognostic Scoring System (IPSS); AND Patient must have a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities; AND Patient must have received PBS-subsidised initial therapy with lenalidomide for myelodysplastic syndrome; AND Patient must have achieved and maintained transfusion independence; or least a 50% reduction in red blood cell unit transfusion requirements compared with the four month period prior to commencing initial PBS-subsidised therapy with lenalidomide; AND Patient must not have progressive disease. Patients receiving lenalidomide under the PBS listing must be registered in the i-access risk management program. The first authority application for continuing supply must be made in writing. Subsequent authority applications for continuing supply may be made by telephone. The following evidence of response must be provided at each application: (i) a haemoglobin level taken within the last 4 weeks; and (ii) the date of the last transfusion; and (iii) a statement of the number of units of red cells transfused in the 4 months immediately preceding this application; and (iv) a statement confirming that the patient has not progressed to acute myeloid leukaemia. | Compliance with Written Authority Required procedures |
|  | C4287 |  | Myelodysplastic syndrome Initial treatment The treatment must be limited to a maximum duration of 16 weeks; AND Patient must be classified as Low risk or Intermediate-1 according to the International Prognostic Scoring System (IPSS); AND Patient must have a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities; AND Patient must be red blood cell transfusion dependent. Classification of a patient as Low risk requires a score of 0 on the IPSS, achieved with the following combination: less than 5% marrow blasts with good karyotypic status (normal, -Y alone, -5q alone, -20q alone), and 0/1 cytopenias. Classification of a patient as Intermediate-1 requires a score of 0.5 to 1 on the IPSS, achieved with the following possible combinations: 1. 5%-10% marrow blasts with good karyotypic status (normal, -Y alone, -5q alone, -20q alone), and 0/1 cytopenias; OR 2. less than 5% marrow blasts with intermediate karyotypic status (other abnormalities), and 0/1 cytopenias; OR 3. less than 5% marrow blasts with good karyotypic status (normal, -Y alone, -5q alone, -20q alone), and 2/3 cytopenias; OR 4. less than 5% marrow blasts with intermediate karyotypic status (other abnormalities), and 2/3 cytopenias; OR 5. 5%-10% marrow blasts with intermediate karyotypic status (other abnormalities), and 0/1 cytopenias; OR 6. 5%-10% marrow blasts with good karyotypic status (normal, -Y alone, -5q alone, -20q alone), and 2/3 cytopenias; OR 7. less than 5% marrow blasts with poor karyotypic status (complex, greater than 3 abnormalities), and 0/1 cytopenias. Classification of a patient as red blood cell transfusion dependent requires that: (i) the patient has been transfused within the last 8 weeks; and (ii) the patient has received at least 8 units of red blood cell in the last 6 months prior to commencing PBS-subsidised therapy with lenalidomide; and would be expected to continue this requirement without lenalidomide treatment. Patients receiving lenalidomide under the PBS listing must be registered in the i-access risk management program. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Myelodysplastic Syndrome Lenalidomide Authority Application - Supporting Information Form; and (c) a copy of the bone marrow biopsy report demonstrating that the patient has myelodysplastic syndrome; and (d) a copy of the full blood examination report; and (e) a copy of the pathology report detailing the cytogenetics demonstrating Low risk or Intermediate-1 disease according to the IPSS (note: using Fluorescence in Situ Hybridization (FISH) to demonstrate MDS -5q is acceptable); and (f) details of transfusion requirements including: (i) the date of most recent transfusion and the number of red blood cell units transfused; and (ii) the total number of red cell units transfused in the 4 and 6 months preceding the date of this application; and (g) a signed patient acknowledgement form. | Compliance with Written Authority Required procedures |
|  | C10334 |  | Multiple myeloma Initial treatment with lenalidomide monotherapy in newly diagnosed disease The treatment must be as monotherapy; AND The condition must be confirmed by a histological diagnosis; AND Patient must have undergone an autologous stem cell transplant (ASCT) as part of frontline therapy for newly diagnosed multiple myeloma; AND Patient must not have progressive disease following autologous stem cell transplant (ASCT). The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Multiple Myeloma lenalidomide Authority Application ‑ Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, the date the autologous stem cell transplant was performed, and nomination of which disease activity parameters will be used to assess progression. To enable confirmation of eligibility for treatment, the results of current diagnostic reports of at least one of the following must be provided: (a) the level of serum monoclonal protein; or (b) Bence‑Jones proteinuria ‑ the results of 24‑hour urinary light chain M protein excretion; or (c) the serum level of free kappa and lambda light chains; or (d) bone marrow aspirate or trephine; or (e) if present, the size and location of lytic bone lesions (not including compression fractures); or (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT‑scan; or (g) if present, the level of hypercalcaemia, corrected for albumin concentration. As these parameters will be used to determine progression, results for either (a) or (b) or (c) should be provided for all patients. Where the patient has oligo‑secretory or non‑secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo‑secretory or non‑secretory multiple myeloma with free light chain assays, evidence of the oligo‑secretory or non‑secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be provided. Patients receiving this drug under the PBS listing must be registered in the i‑access risk management program. | Compliance with Written Authority Required procedures |
|  | C10335 |  | Multiple myeloma Continuing treatment with lenalidomide monotherapy following initial treatment with lenalidomide therapy in newly diagnosed disease Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must not have demonstrated progressive disease; AND The treatment must be as monotherapy. Progressive disease is defined as at least 1 of the following: (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause). Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein. Patients receiving this drug under the PBS listing must be registered in the i-access risk management program. | Compliance with Authority Required procedures |
|  | C10349 |  | Multiple myeloma Continuing treatment as monotherapy or dual combination therapy with dexamethasone following initial treatment for progressive disease Patient must have previously received PBS-subsidised treatment with this drug for relapsed or refractory multiple myeloma; AND The treatment must be as monotherapy; OR The treatment must be in combination with dexamethasone; AND Patient must not be receiving concomitant PBS-subsidised bortezomib, carfilzomib or thalidomide or its analogues. Patients receiving lenalidomide under the PBS listing must be registered in the i-access risk management program. | Compliance with Authority Required procedures |
|  | C10350 |  | Multiple myeloma Initial treatment as monotherapy or dual combination therapy with dexamethasone for progressive disease The condition must be confirmed by a histological diagnosis; AND The treatment must be as monotherapy; OR The treatment must be in combination with dexamethasone; AND Patient must have progressive disease after at least one prior therapy; AND Patient must have undergone or be ineligible for a primary stem cell transplant; AND Patient must not be receiving concomitant PBS-subsidised bortezomib, carfilzomib or thalidomide or its analogues. Progressive disease is defined as at least 1 of the following: (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause). Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Multiple Myeloma lenalidomide Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, prior treatments including name(s) of drug(s) and date of most recent treatment cycle and record of prior stem cell transplant or ineligibility for prior stem cell transplant; details of the basis of the diagnosis of progressive disease or failure to respond; and nomination of which disease activity parameters will be used to assess response; and (3) a signed patient acknowledgment. To enable confirmation of eligibility for treatment, current diagnostic reports of at least one of the following must be provided: (a) the level of serum monoclonal protein; or (b) Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or (c) the serum level of free kappa and lambda light chains; or (d) bone marrow aspirate or trephine; or (e) if present, the size and location of lytic bone lesions (not including compression fractures); or (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or (g) if present, the level of hypercalcaemia, corrected for albumin concentration. As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be provided. Patients receiving lenalidomide under the PBS listing must be registered in the i-access risk management program. | Compliance with Written Authority Required procedures |
|  | C10373 |  | Multiple myeloma Initial treatment in combination with dexamethasone, of newly diagnosed disease in a patient ineligible for stem cell transplantation The condition must be newly diagnosed; AND The condition must be confirmed by a histological diagnosis; AND Patient must be ineligible for a primary stem cell transplantation; AND Patient must not be receiving concomitant PBS-subsidised bortezomib, thalidomide or its analogues; AND The treatment must be in combination with dexamethasone. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Multiple Myeloma lenalidomide Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, and ineligibility for prior stem cell transplant; and nomination of which disease activity parameters will be used to assess response; and (3) a signed patient acknowledgement. To enable confirmation of eligibility for treatment, current diagnostic reports of at least one of the following must be provided: (a) the level of serum monoclonal protein; or (b) Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or (c) the serum level of free kappa and lambda light chains; or (d) bone marrow aspirate or trephine; or (e) if present, the size and location of lytic bone lesions (not including compression fractures); or (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or (g) if present, the level of hypercalcaemia, corrected for albumin concentration. As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be provided. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be provided. Patients receiving this drug under the PBS listing must be registered in the i-access risk management program. | Compliance with Written Authority Required procedures |
|  | C10427 |  | Multiple myeloma Continuing treatment until progression in patients initiated on dual combination therapy (lenalidomide and dexamethasone), or, in patients initiated on triple therapy (lenalidomide, bortezomib and dexamethasone during treatment cycles 1 up to 8) and are now being treated with treatment cycle 9 or beyond Patient must have previously been authorised with a PBS prescription with this drug for the condition; AND Patient must not have demonstrated progressive disease; AND Patient must not be receiving concomitant PBS-subsidised bortezomib, thalidomide or its analogues; AND The treatment must be in combination with dexamethasone. Progressive disease is defined as at least 1 of the following: (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or (b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or (c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause). Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein. Patients receiving this drug under the PBS listing must be registered in the i-access risk management program. | Compliance with Authority Required procedures |
|  | C10428 |  | Multiple myeloma Initial treatment with triple therapy (lenalidomide, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle The condition must be newly diagnosed; AND The condition must be confirmed by a histological diagnosis; AND Patient must not be receiving concomitant PBS-subsidised carfilzomib, thalidomide or its analogues; AND The treatment must be in combination with bortezomib and dexamethasone; AND Patient must not have been treated with lenalidomide or bortezomib for this condition; AND The treatment must not exceed a total of 4 cycles under this restriction. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Multiple Myeloma lenalidomide Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, and nomination of which disease activity parameters will be used to assess response. To enable confirmation of eligibility for treatment, current pathology results of (for items a, b, c, g), or, a statement that diagnosis was based on (for items d, e, f) at least one of the following must be provided: (a) the level of serum monoclonal protein; or (b) Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or (c) the serum level of free kappa and lambda light chains; or (d) bone marrow aspirate or trephine; or (e) if present, the size and location of lytic bone lesions (not including compression fractures); or (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or (g) if present, the level of hypercalcaemia, corrected for albumin concentration. As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients and kept on the patient’s records. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be stated/declared. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be declared to be held on the patient’s medical records. Patients receiving this drug under the PBS listing must be registered in the i-access risk management program. | Compliance with Written Authority Required procedures |
|  | C10429 |  | Multiple myeloma Continuing treatment of triple therapy (lenalidomide, bortezomib and dexamethasone) for treatment cycles 5 and 6 (administered using 28-day treatment cycles) Patient must have received PBS-subsidised treatment with this drug under the treatment phase covering cycles 1 to 4; AND Patient must not be receiving concomitant PBS-subsidised carfilzomib, thalidomide or its analogues; AND The treatment must be in combination with bortezomib and dexamethasone; AND The treatment must not exceed a total of 2 cycles under this restriction. Patients receiving this drug under the PBS listing must be registered in the i-access risk management program. | Compliance with Authority Required procedures |
|  | C10452 |  | Multiple myeloma Continuing treatment of triple therapy (lenalidomide, bortezomib and dexamethasone) for treatment cycles 5 to 8 inclusive (administered using 21-day treatment cycles) Patient must have received PBS-subsidised treatment with this drug under the treatment phase covering cycles 1 to 4; AND Patient must not be receiving concomitant PBS-subsidised carfilzomib, thalidomide or its analogues; AND The treatment must be in combination with bortezomib and dexamethasone; AND The treatment must not exceed a total of 4 cycles under this restriction. Patients receiving this drug under the PBS listing must be registered in the i-access risk management program. | Compliance with Authority Required procedures |
|  | C10453 |  | Multiple myeloma Initial treatment with triple therapy (lenalidomide, bortezomib and dexamethasone) for the first 4 treatment cycles (cycles 1 to 4) administered in a 21-day treatment cycle The condition must be newly diagnosed; AND The condition must be confirmed by a histological diagnosis; AND Patient must not be receiving concomitant PBS-subsidised carfilzomib, thalidomide or its analogues; AND The treatment must be in combination with bortezomib and dexamethasone; AND Patient must not have been treated with lenalidomide or bortezomib for this condition; AND The treatment must not exceed a total of 4 cycles under this restriction. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Multiple Myeloma lenalidomide Authority Application - Supporting Information Form, which includes details of the histological diagnosis of multiple myeloma, and nomination of which disease activity parameters will be used to assess response. To enable confirmation of eligibility for treatment, current pathology results of (for items a, b, c, g), or, a statement that diagnosis was based on (for items d, e, f) at least one of the following must be provided: (a) the level of serum monoclonal protein; or (b) Bence-Jones proteinuria - the results of 24-hour urinary light chain M protein excretion; or (c) the serum level of free kappa and lambda light chains; or (d) bone marrow aspirate or trephine; or (e) if present, the size and location of lytic bone lesions (not including compression fractures); or (f) if present, the size and location of all soft tissue plasmacytomas by clinical or radiographic examination i.e. MRI or CT-scan; or (g) if present, the level of hypercalcaemia, corrected for albumin concentration. As these parameters will be used to determine response, results for either (a) or (b) or (c) should be provided for all patients and kept on the patient’s records. Where the patient has oligo-secretory or non-secretory multiple myeloma, either (c) or (d) or if relevant (e), (f) or (g) should be stated/declared. Where the prescriber plans to assess response in patients with oligo-secretory or non-secretory multiple myeloma with free light chain assays, evidence of the oligo-secretory or non-secretory nature of the multiple myeloma (current serum M protein less than 10 g per L) must be declared to be held on the patient’s medical records. Patients receiving this drug under the PBS listing must be registered in the i-access risk management program. | Compliance with Written Authority Required procedures |
| Lenograstim | C6502 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in an infant or child with central nervous system tumours. | Compliance with Authority Required procedures - Streamlined Authority Code 6502 |
|  | C6507 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia. | Compliance with Authority Required procedures - Streamlined Authority Code 6507 |
|  | C6516 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma. | Compliance with Authority Required procedures - Streamlined Authority Code 6516 |
|  | C6522 |  | Chemotherapy-induced neutropenia Patient must be receiving standard dose adjuvant chemotherapy for breast cancer; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre); AND The treatment must be used in a patient for whom there is a clinical justification for wishing to continue chemotherapy with the same drug combination, dosage and treatment schedule; AND Patient must be anticipated to have a good response to treatment providing chemotherapy can be delivered as planned. | Compliance with Authority Required procedures - Streamlined Authority Code 6522 |
|  | C6523 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours. | Compliance with Authority Required procedures - Streamlined Authority Code 6523 |
|  | C6532 |  | Chemotherapy-induced neutropenia Patient must be receiving first-line chemotherapy for Hodgkin disease; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre); AND The treatment must be used in a patient for whom there is a clinical justification for wishing to continue chemotherapy with the same drug combination, dosage and treatment schedule; AND Patient must be anticipated to have a good response to treatment providing chemotherapy can be delivered as planned. | Compliance with Authority Required procedures - Streamlined Authority Code 6532 |
|  | C6535 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease. | Compliance with Authority Required procedures - Streamlined Authority Code 6535 |
|  | C6634 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma. | Compliance with Authority Required procedures - Streamlined Authority Code 6634 |
|  | C6644 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma. | Compliance with Authority Required procedures - Streamlined Authority Code 6644 |
|  | C6653 |  | Mobilisation of peripheral blood progenitor cells The treatment must be to facilitate harvest of peripheral blood progenitor cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy. | Compliance with Authority Required procedures - Streamlined Authority Code 6653 |
|  | C6654 |  | Mobilisation of peripheral blood progenitor cells The treatment must be in a normal volunteer for use in allogeneic transplantation. | Compliance with Authority Required procedures - Streamlined Authority Code 6654 |
|  | C6657 |  | Assisting peripheral blood progenitor cell or bone marrow transplantation The treatment must be following marrow-ablative chemotherapy for non-myeloid malignancy prior to the transplantation. | Compliance with Authority Required procedures - Streamlined Authority Code 6657 |
|  | C6673 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade). | Compliance with Authority Required procedures - Streamlined Authority Code 6673 |
|  | C6682 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma. | Compliance with Authority Required procedures - Streamlined Authority Code 6682 |
|  | C9226 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in osteosarcoma. | Compliance with Authority Required procedures - Streamlined Authority Code 9226 |
|  | C9227 |  | Assisting peripheral blood progenitor cell or bone marrow transplantation The treatment must be following marrow-ablative chemotherapy for non-myeloid malignancy prior to the transplantation. | Compliance with Authority Required procedures - Streamlined Authority Code 9227 |
|  | C9229 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in relapsed Hodgkin disease. | Compliance with Authority Required procedures - Streamlined Authority Code 9229 |
|  | C9230 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in an infant or child with central nervous system tumours. | Compliance with Authority Required procedures - Streamlined Authority Code 9230 |
|  | C9231 |  | Mobilisation of peripheral blood progenitor cells The treatment must be to facilitate harvest of peripheral blood progenitor cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy. | Compliance with Authority Required procedures - Streamlined Authority Code 9231 |
|  | C9263 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in germ cell tumours. | Compliance with Authority Required procedures - Streamlined Authority Code 9263 |
|  | C9264 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in non-Hodgkin's lymphoma (intermediate or high grade). | Compliance with Authority Required procedures - Streamlined Authority Code 9264 |
|  | C9265 |  | Chemotherapy-induced neutropenia Patient must be receiving standard dose adjuvant chemotherapy for breast cancer; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre); AND The treatment must be used in a patient for whom there is a clinical justification for wishing to continue chemotherapy with the same drug combination, dosage and treatment schedule; AND Patient must be anticipated to have a good response to treatment providing chemotherapy can be delivered as planned. | Compliance with Authority Required procedures - Streamlined Authority Code 9265 |
|  | C9266 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in neuroblastoma. | Compliance with Authority Required procedures - Streamlined Authority Code 9266 |
|  | C9314 |  | Mobilisation of peripheral blood progenitor cells The treatment must be in a normal volunteer for use in allogeneic transplantation. | Compliance with Authority Required procedures - Streamlined Authority Code 9314 |
|  | C9324 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in acute lymphoblastic leukaemia. | Compliance with Authority Required procedures - Streamlined Authority Code 9324 |
|  | C9325 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in rhabdomyosarcoma. | Compliance with Authority Required procedures - Streamlined Authority Code 9325 |
|  | C9326 |  | Chemotherapy-induced neutropenia Patient must be receiving first-line chemotherapy for Hodgkin disease; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia (neutrophil count of less than 1,000 million cells per litre); AND The treatment must be used in a patient for whom there is a clinical justification for wishing to continue chemotherapy with the same drug combination, dosage and treatment schedule; AND Patient must be anticipated to have a good response to treatment providing chemotherapy can be delivered as planned. | Compliance with Authority Required procedures - Streamlined Authority Code 9326 |
|  | C9327 |  | Chemotherapy-induced neutropenia Patient must be receiving treatment with aggressive chemotherapy with the intention of achieving a cure or substantial remission in Ewing's sarcoma. | Compliance with Authority Required procedures - Streamlined Authority Code 9327 |
| Levodopa with carbidopa | C10138 | P10138 | Advanced Parkinson disease Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND The treatment must be commenced in a hospital‑based movement disorder clinic. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10138 |
|  | C10161 | P10161 | Advanced Parkinson disease Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND The treatment must be commenced in a hospital‑based movement disorder clinic. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10161 |
|  | C10363 | P10363 | Advanced Parkinson disease Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND The treatment must be commenced in a hospital-based movement disorder clinic; AND Patient must require continuous administration of levodopa without an overnight break; OR Patient must require a total daily dose of more than 2000 mg of levodopa. | Compliance with Authority Required procedures - Streamlined Authority Code 10363 |
|  | C10375 | P10375 | Advanced Parkinson disease Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND The treatment must be commenced in a hospital-based movement disorder clinic; AND Patient must require continuous administration of levodopa without an overnight break; OR Patient must require a total daily dose of more than 2000 mg of levodopa. | Compliance with Authority Required procedures - Streamlined Authority Code 10375 |
| Lipegfilgrastim | C7822 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must be at greater than 20% risk of developing febrile neutropenia; OR Patient must be at substantial risk (greater than 20%) of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7822 |
|  | C7843 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7843 |
|  | C9224 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must be at greater than 20% risk of developing febrile neutropenia; OR Patient must be at substantial risk (greater than 20%) of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9224 |
|  | C9322 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9322 |
| Lopinavir with ritonavir | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Lumacaftor with ivacaftor | C9857 |  | Cystic fibrosis Initial treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must be homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; AND The treatment must be given concomitantly with standard therapy for this condition; AND Patient must have either chronic sinopulmonary disease or gastrointestinal and nutritional abnormalities; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition. Patient must be 12 years of age or older. The patient must be registered in the Australian Cystic Fibrosis Database Registry. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. Lumacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort. Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin. Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis lumacaftor with ivacaftor Authority Application Supporting Information Form; and (3) a copy of the pathology report detailing the molecular testing for the patient being homozygous for the F508del mutation on the CFTR gene; and (4) the result of a FEV1measurement performed within a month prior to the date of application. Note: FEV1must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (5) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (6) height and weight measurements at the time of application; and (7) a baseline measurement of the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 12 months. | Compliance with Written Authority Required procedures |
|  | C9891 |  | Cystic fibrosis Continuing treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition; AND The treatment must be given concomitantly with standard therapy for this condition. Patient must be aged between 6 and 11 years inclusive. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. Patients who have an acute infective exacerbation at the time of assessment for continuing therapy may receive an additional one month’s supply in order to enable the assessment to be repeated following resolution of the exacerbation. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. Lumacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort. Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin. Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis lumacaftor with ivacaftor Continuing Authority Application Supporting Information Form; and (3) the result of a FEV1measurement performed within a month prior to the date of application. Note: FEV1, must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (4) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (5) height and weight measurements at the time of application; and (6) the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 6 months. | Compliance with Written Authority Required procedures |
|  | C9920 |  | Cystic fibrosis Initial treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must be homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; AND The treatment must be given concomitantly with standard therapy for this condition; AND Patient must have either chronic sinopulmonary disease or gastrointestinal and nutritional abnormalities; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition. Patient must be aged between 6 and 11 years inclusive. The patient must be registered in the Australian Cystic Fibrosis Database Registry. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. Lumacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort. Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin. Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis lumacaftor with ivacaftor Authority Application Supporting Information Form; and (3) a copy of the pathology report detailing the molecular testing for the patient being homozygous for the F508del mutation on the CFTR gene; and (4) the result of a FEV1measurement performed within a month prior to the date of application. Note: FEV1must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (5) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (6) height and weight measurements at the time of application; and (7) a baseline measurement of the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 12 months. | Compliance with Written Authority Required procedures |
|  | C9943 |  | Cystic fibrosis Continuing treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND The treatment must be given concomitantly with standard therapy for this condition; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition. Patient must be 12 years of age or older. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. Patients who have an acute infective exacerbation at the time of assessment for continuing therapy may receive an additional one month’s supply in order to enable the assessment to be repeated following resolution of the exacerbation. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. Lumacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort. Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin. Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis lumacaftor with ivacaftor Continuing Authority Application Supporting Information Form; and (3) the result of a FEV1measurement performed within a month prior to the date of application. Note: FEV1, must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (4) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (5) height and weight measurements at the time of application; and (6) the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 6 months. | Compliance with Written Authority Required procedures |
|  | C10005 |  | Cystic fibrosis Initial treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must be homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; AND The treatment must be given concomitantly with standard therapy for this condition; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition. Patient must be 2 years of age or older. The patient must be registered in the Australian Cystic Fibrosis Database Registry. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. Lumacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort. Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin. Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis lumacaftor with ivacaftor Authority Application Supporting Information Form; and (3) a copy of the pathology report detailing the molecular testing for the patient being homozygous for the F508del mutation on the CFTR gene; and (4) the result of a FEV1measurement performed within a month prior to the date of application, if aged from 6 years or older. Note: FEV1, must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (5) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (6) height and weight measurements at the time of application; and (7) a baseline measurement of the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 12 months. For patients who have initiated non‑PBS subsidised treatment prior to 1 December 2019, date of initiating treatment, baseline FEV1and hospitalisation dates prior to initiating treatment (where available) should be provided. | Compliance with Written Authority Required procedures |
|  | C10007 |  | Cystic fibrosis Continuing treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition; AND The treatment must be given concomitantly with standard therapy for this condition. Patient must be 2 years of age or older. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. Patients who have an acute infective exacerbation at the time of assessment for continuing therapy may receive an additional one month’s supply in order to enable the assessment to be repeated following resolution of the exacerbation. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. Lumacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort. Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin. Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis lumacaftor with ivacaftor Continuing Authority Application Supporting Information Form; and (3) the result of a FEV1measurement performed within one month prior to the date of application, if aged 6 years or older. Note: FEV1, must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (4) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (5) height and weight measurements at the time of application; and (6) the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 6 months. | Compliance with Written Authority Required procedures |
| Macitentan | C10228 |  | Pulmonary arterial hypertension (PAH) Continuing treatment Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent for this condition; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10236 |  | Pulmonary arterial hypertension (PAH) Initial 2 (change) Patient must have documented WHO Functional Class II PAH, or WHO Functional Class III PAH, or WHO Functional Class IV PAH; AND Patient must have had their most recent course of PBS-subsidised treatment for this condition with a PAH agent other than this agent; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment (monotherapy) with 1 of these 8 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent’s restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap between the 8 PAH agents must be made under the relevant initial treatment (monotherapy) restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10285 |  | Pulmonary arterial hypertension (PAH) Initial 1 (new patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have WHO Functional Class II PAH, or WHO Functional Class III PAH, or WHO Functional Class IV PAH; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C11021 |  | Pulmonary arterial hypertension (PAH) Initial 1 (dual therapy - previously untreated patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must currently have WHO Functional Class III PAH or WHO Functional Class IV PAH; AND The treatment must be in combination with a PBS-subsidised phosphodiesterase-5 inhibitor (PDE-5i) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C11033 |  | Pulmonary arterial hypertension (PAH) Initial 2 (dual therapy - previously treated patients) Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH; AND Patient must have documented a failure to achieve or maintain WHO Functional Class II status with prior PBS-subsidised monotherapy treatment with a phosphodiesterase-5 inhibitor (PDE-5i) for this condition; AND The treatment must be in combination with the PBS-subsidised PDE-5i for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. The results and date of the RHC, ECHO and 6 MWT as applicable must be included in the patient's medical record. Where a RHC cannot be performed on clinical grounds, the written confirmation of the reasons why must also be included in the patient's medical record. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11034 |  | Pulmonary arterial hypertension (PAH) Continuing treatment (dual therapy) Patient must have received their most recent course of PBS-subsidised dual therapy with this PAH agent and a phosphodiesterase-5 inhibitor (PDE-5i) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11043 |  | Pulmonary arterial hypertension (PAH) Initial 3 (dual therapy - change) Patient must have had their most recent course of PBS-subsidised dual therapy with a phosphodiesterase-5 inhibitor (PDE-5i) and an endothelin receptor antagonist (ERA) other than this agent for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once patients are approved dual therapy with a PAH agent from the PDE-5i class; or a PAH agent from the ERA class, they may swap between PAH agents within the same class. This means that patients may commence treatment with another PAH agent in the same class, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap within a PAH agent class must be made under the relevant initial treatment restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11071 |  | Pulmonary arterial hypertension (PAH) Grandfathered patients (dual therapy) Patient must be receiving dual therapy with this non PBS-subsidised pulmonary arterial hypertension (PAH) agent and a non PBS-subsidised phosphodiesterase-5 inhibitor (PDE-5i) for this condition prior to 1 October 2020; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it was not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC could not be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests were able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC could not be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria for dual therapy for this condition. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
| Mannitol | C7362 |  | Cystic fibrosis  The treatment must be as monotherapy; AND  Patient must be intolerant or inadequately responsive to dornase alfa.  Patient must be 6 years of age or older.  Patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved Product Information initiation dose assessment for this drug, prior to therapy with this drug, with a negative result.  Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit.  Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease.  Initial therapy is limited to 3 months treatment with mannitol at a dose of 400 mg twice daily.  To be eligible for continued PBS‑subsidised treatment with this drug following 3 months of initial treatment:  (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND  (2) the patient or the patient’s family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient.  Further reassessments must be undertaken and documented at six‑monthly intervals. Therapy with this drug should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7362 |
|  | C7367 |  | Cystic fibrosis  The treatment must be in combination with dornase alfa; AND  Patient must be inadequately responsive to dornase alfa; AND  Patient must have trialled hypertonic saline for this condition.  Patient must be 6 years of age or older.  Patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved Product Information initiation dose assessment for this drug, prior to therapy with this drug, with a negative result.  Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit.  Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease.  Initial therapy is limited to 3 months treatment with mannitol at a dose of 400 mg twice daily.  To be eligible for continued PBS‑subsidised treatment with this drug following 3 months of initial treatment:  (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND  (2) the patient or the patient’s family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient.  Further reassessments must be undertaken and documented at six‑monthly intervals. Therapy with this drug should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7367 |
|  | C9527 |  | Cystic fibrosis The treatment must be as monotherapy; AND Patient must be intolerant or inadequately responsive to dornase alfa. Patient must be 6 years of age or older. Patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved Product Information initiation dose assessment for this drug, prior to therapy with this drug, with a negative result. Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit. Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease. Initial therapy is limited to 3 months treatment with mannitol at a dose of 400 mg twice daily. To be eligible for continued PBS‑subsidised treatment with this drug following 3 months of initial treatment: (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND (2) the patient or the patient’s family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient. Further reassessments must be undertaken and documented at six‑monthly intervals. Therapy with this drug should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9527 |
|  | C9593 |  | Cystic fibrosis The treatment must be in combination with dornase alfa; AND Patient must be inadequately responsive to dornase alfa; AND Patient must have trialled hypertonic saline for this condition. Patient must be 6 years of age or older. Patient must have been assessed for bronchial hyperresponsiveness as per the TGA approved Product Information initiation dose assessment for this drug, prior to therapy with this drug, with a negative result. Patient must be assessed at a cystic fibrosis clinic/centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis or by a specialist physician or paediatrician in consultation with such a unit. Prior to therapy with this drug, a baseline measurement of forced expiratory volume in 1 second (FEV1) must be undertaken during a stable period of the disease. Initial therapy is limited to 3 months treatment with mannitol at a dose of 400 mg twice daily. To be eligible for continued PBS‑subsidised treatment with this drug following 3 months of initial treatment: (1) the patient must demonstrate no deterioration in FEV1 compared to baseline; AND (2) the patient or the patient’s family (in the case of paediatric patients) and the treating physician(s) must report a benefit in the clinical status of the patient. Further reassessments must be undertaken and documented at six‑monthly intervals. Therapy with this drug should cease if there is not general agreement of benefit as there is always the possibility of harm from unnecessary use. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9593 |
| Maraviroc | C5008 |  | HIV infection Patient must be infected with CCR5‑tropic HIV‑1, AND The treatment must be in addition to optimised background therapy, AND The treatment must be in combination with other antiretroviral agents, AND Patient must have experienced virological failure or clinical failure or genotypic resistance after each of at least 3 different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes. Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment‑limiting toxicity. A tropism assay to determine CCR5 only strain status must be performed prior to initiation. Individuals with CXCR4 tropism demonstrated at any time point are not eligible. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5008 |
| Mepolizumab | C9885 | P9885 | Uncontrolled severe eosinophilic asthma Balance of supply Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must received insufficient therapy with this drug under the Initial 1 (new patients or recommencement of treatment in a new treatment cycle) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Initial 2 (change of treatment) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND The treatment must not provide more than the balance of up to 32 weeks of treatment if the most recent authority approval was made under an Initial treatment restriction; OR The treatment must not provide more than the balance of up to 24 weeks of treatment if the most recent authority approval was made under the Continuing treatment restriction. | Compliance with Authority Required procedures |
|  | C10221 | P10221 | Uncontrolled severe eosinophilic asthma Initial treatment ‑ Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must not have received PBS‑subsidised treatment with a biological medicine for severe asthma; OR Patient must have had a break in treatment from the most recently approved PBS‑subsidised biological medicine for severe asthma; AND Patient must have a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by the following standard clinical features: (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma; AND Patient must have a duration of asthma of at least 1 year; AND Patient must have blood eosinophil count greater than or equal to 300 cells per microlitre in the last 12 months; OR Patient must have blood eosinophil count greater than or equal to 150 cells per microlitre while receiving treatment with oral corticosteroids in the last 12 months; AND Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. Optimised asthma therapy includes: (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long‑acting beta‑2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated; AND (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated. If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA‑approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application. The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application: (a) an Asthma Control Questionnaire (ACQ‑5) score of at least 2.0, as assessed in the previous month, AND (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician. The Asthma Control Questionnaire (5 item version) assessment of the patient’s response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment, which will be used to determine eligibility for the first continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition within the same treatment cycle. A treatment break in PBS‑subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 3 biological medicines within the same treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with a PBS‑subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle. There is no limit to the number of treatment cycles that a patient may undertake in their lifetime. At the time of the authority application, medical practitioners should request up to 7 repeats to provide for an initial course of mepolizumab sufficient for up to 32 weeks of therapy. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Eosinophilic Asthma Initial PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) details of prior optimised asthma drug therapy (date of commencement and duration of therapy); and (ii) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and (iii) the eosinophil count and date; and (iv) Asthma Control Questionnaire (ACQ‑5) score. | Compliance with Written Authority Required procedures |
|  | C10222 | P10222 | Uncontrolled severe eosinophilic asthma Initial treatment ‑ Initial 2 (Change of treatment) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must have received prior PBS‑subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND Patient must not have failed, or ceased to respond to, PBS‑subsidised treatment with this drug for severe asthma during the current treatment cycle; AND Patient must have had a blood eosinophil count greater than or equal to 300 cells per microlitre and that is no older than 12 months immediately prior to commencing PBS‑subsidised biological medicine treatment for severe asthma; OR Patient must have had a blood eosinophil count greater than or equal to 150 cells per microlitre while receiving treatment with oral corticosteroids and that is no older than 12 months immediately prior to commencing PBS‑subsidised biological medicine treatment for severe asthma; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Eosinophilic Asthma (mepolizumab/benralizumab) Initial PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) Asthma Control Questionnaire (ACQ‑5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and (ii) the details of prior biological medicine treatment including the details of date and duration of treatment; and (iii) eosinophil count and date; and (iv) the dose of the maintenance oral corticosteroid (where the response criteria or baseline is based on corticosteroid dose); and (v) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). An application for a patient who has received PBS‑subsidised biological medicine treatment for severe asthma who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ‑5 assessment of the patient’s most recent course of PBS‑subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine. An ACQ‑5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS‑subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment at around 28 weeks, which will be used to determine eligibility for the first continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this biological medicine. At the time of the authority application, medical practitioners should request up to 7 repeats to provide for an initial course sufficient for up to 32 weeks of therapy. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. | Compliance with Written Authority Required procedures |
|  | C10280 | P10280 | Uncontrolled severe eosinophilic asthma Continuing treatment Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must have demonstrated or sustained an adequate response to PBS‑subsidised treatment with this drug for this condition; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma; AND Patient must not receive more than 24 weeks of treatment under this restriction. Patient must be aged 12 years or older. An adequate response to this biological medicine is defined as: (a) a reduction in the Asthma Control Questionnaire (ACQ‑5) score of at least 0.5 from baseline, OR (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ‑5 score from baseline or an increase in ACQ‑5 score from baseline less than or equal to 0.5. All applications for second and subsequent continuing treatments with this drug must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient’s response to the prior course of treatment or the assessment of oral corticosteroid dose, should be made at around 20 weeks after the first dose of PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. The assessment should, where possible, be completed by the same physician who initiated treatment with this drug. This assessment, which will be used to determine eligibility for continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this drug. Where treatment was ceased for clinical reasons despite the patient experiencing improvement, an assessment of the patient’s response to treatment made at the time of treatment cessation or retrospectively will be considered to determine whether the patient demonstrated or sustained an adequate response to treatment. A patient who fails to respond to treatment with this biological medicine for uncontrolled severe asthma will not be eligible to receive further PBS subsidised treatment with this biological medicine for severe asthma within the current treatment cycle. At the time of the authority application, medical practitioners should request the appropriate number of repeats to provide for a continuing course of this drug sufficient for up to 24 weeks of therapy. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Eosinophilic Asthma Continuing PBS Authority Application ‑ Supporting Information Form which includes: (i) details of maintenance oral corticosteroid dose; or (ii) a completed Asthma Control Questionnaire (ACQ‑5) score. | Compliance with Written Authority Required procedures |
|  | C10483 | P10483 | Uncontrolled severe eosinophilic asthma Grandfather treatment - use in a patient initiated with non-PBS subsidised pre-filled syringe or pen device Patient must have received non-PBS-subsidised treatment with this biological medicine’s pre-filled syringe or pen device for this PBS-indication prior to 1 June 2020; AND Patient must have demonstrated or sustained an adequate response to treatment with this biological medicine if the patient has received at least the week 28 dose of this biological medicine; AND Patient must be receiving treatment with this drug for this condition at the time of application; AND Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed with severe asthma by a multidisciplinary severe asthma clinic team; AND Patient must have had, prior to commencement of this drug, a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by the following standard clinical features: (i) Forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR Patient must have had, prior to commencement of this drug, a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma; AND Patient must have had a blood eosinophil count greater than or equal to 300 cells per microlitre prior to commencement of a biological medicine treatment for severe asthma; OR Patient must have had a blood eosinophil count greater than or equal to 150 cells per microlitre while receiving treatment with oral corticosteroids prior to commencement of a biological medicine treatment for severe asthma; AND Patient must have had a duration of asthma of at least 1 year prior to commencement of this biological medicine; AND Patient must have failed to achieve adequate control with optimised asthma therapy prior to commencement of this biological medicine despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma. Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be aged 12 years or older. Optimised asthma therapy includes: (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long-acting beta-2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated; AND (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the 12 months prior to commencing treatment with a biological medicine for severe asthma, unless contraindicated or not tolerated. If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application (if not already provided). The following initiation criteria indicate failure to achieve adequate control with optimised asthma therapy and must be declared to have been met at the time of the application: (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0 prior to commencement with a biological medicine for severe asthma; AND (b) while receiving optimised asthma therapy in the 12 months prior to commencing treatment with a biological medicine for severe asthma, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician. An Asthma Control Questionnaire (5 item version) assessment and/or an assessment of a reduction in the patient’s maintenance oral corticosteroid dose to determine whether the patient has achieved or sustained an adequate response to non-PBS-subsidised treatment, must be conducted immediately (no later than 4 weeks after the last dose of non-PBS-subsidised treatment) prior to this application if the treatment duration has been 28 weeks or greater. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within the same treatment cycle. A treatment break in PBS-subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 3 biological medicines within the same treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with a PBS-subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle. There is no limit to the number of treatment cycles that a patient may undertake in their lifetime. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. An adequate response to this biological medicine is defined as: (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline, OR (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline or an increase in ACQ-5 score from baseline less than or equal to 0.5. A Grandfathered patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the continuing treatment criteria. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Eosinophilic Asthma Grandfather PBS Authority Application - Supporting Information Form which seeks details of the following (if not already provided): (i) prior optimised asthma drug therapy (date of commencement and duration of therapy); and (ii) eosinophil pathology report (eosinophil counts and dates); and (iii) ACQ-5 scores including the date of assessment of the patient’s symptoms, or details of the maintenance oral corticosteroid dose. | Compliance with Written Authority Required procedures |
|  | C10484 | P10484 | Uncontrolled severe eosinophilic asthma Grandfather treatment - use in a patient initiated with non-PBS-subsidised pre-filled syringe or pen device Patient must have received non-PBS-subsidised treatment with this biological medicine’s pre-filled syringe or pen device for this PBS-indication prior to 1 June 2020; AND Patient must have demonstrated or sustained an adequate response to treatment with this biological medicine if the patient has received at least the week 28 dose of this biological medicine; AND Patient must be receiving treatment with this drug for this condition at the time of application; AND Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed with severe asthma by a multidisciplinary severe asthma clinic team; AND Patient must have had, prior to commencement of this drug, a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by the following standard clinical features: (i) Forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR Patient must have had, prior to commencement of this drug, a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma; AND Patient must have had a blood eosinophil count greater than or equal to 300 cells per microlitre prior to commencement of a biological medicine treatment for severe asthma; OR Patient must have had a blood eosinophil count greater than or equal to 150 cells per microlitre while receiving treatment with oral corticosteroids prior to commencement of a biological medicine treatment for severe asthma; AND Patient must have had a duration of asthma of at least 1 year prior to commencement of this biological medicine; AND Patient must have failed to achieve adequate control with optimised asthma therapy prior to commencement of this biological medicine despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND The treatment must not be used in combination with and within 4 weeks of another PBS-subsidised biological medicine prescribed for severe asthma. Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be aged 12 years or older. Optimised asthma therapy includes: (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long-acting beta-2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated; AND (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the 12 months prior to commencing treatment with a biological medicine for severe asthma, unless contraindicated or not tolerated. If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA-approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application (if not already provided). The following initiation criteria indicate failure to achieve adequate control with optimised asthma therapy and must be declared to have been met at the time of the application: (a) an Asthma Control Questionnaire (ACQ-5) score of at least 2.0 prior to commencement with a biological medicine for severe asthma; AND (b) while receiving optimised asthma therapy in the 12 months prior to commencing treatment with a biological medicine for severe asthma, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician. An Asthma Control Questionnaire (5 item version) assessment and/or an assessment of a reduction in the patient’s maintenance oral corticosteroid dose to determine whether the patient has achieved or sustained an adequate response to non-PBS-subsidised treatment, must be conducted immediately (no later than 4 weeks after the last dose of non-PBS-subsidised treatment) prior to this application if the treatment duration has been 28 weeks or greater. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within the same treatment cycle. A treatment break in PBS-subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 3 biological medicines within the same treatment cycle. The length of the break in therapy is measured from the date the most recent treatment with a PBS-subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle. There is no limit to the number of treatment cycles that a patient may undertake in their lifetime. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. An adequate response to this biological medicine is defined as: (a) a reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 0.5 from baseline, OR (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ-5 score from baseline or an increase in ACQ-5 score from baseline less than or equal to 0.5. A Grandfathered patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the continuing treatment criteria. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Eosinophilic Asthma Grandfather PBS Authority Application - Supporting Information Form which seeks details of the following (if not already provided): (i) prior optimised asthma drug therapy (date of commencement and duration of therapy); and (ii) eosinophil pathology report (eosinophil counts and dates); and (iii) ACQ-5 scores including the date of assessment of the patient’s symptoms, or details of the maintenance oral corticosteroid dose. | Compliance with Written Authority Required procedures |
| Methoxsalen | C10971 | P10971 | Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma Initial treatment Patient must have experienced disease progression while on at least one systemic treatment for this PBS indication prior to initiating treatment with this drug; OR Patient must have experienced an intolerance necessitating permanent treatment withdrawal to at least one systemic treatment for this PBS indication prior to initiating treatment with this drug; AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; OR The treatment must be in combination with peginterferon alfa-2a only if used in combination with another drug; AND Patient must be receiving the medical service as described in item 14247 of the Medicare Benefits Schedule; AND Patient must not have previously received PBS-subsidised treatment with this drug for this PBS indication. Must be treated by a haematologist; OR Must be treated by a medical physician working under the supervision of a haematologist. Patient must be aged 18 years or over. | Compliance with Authority Required procedures - Streamlined Authority Code 10971 |
|  | C10985 | P10985 | Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma Initial treatment Patient must have experienced disease progression while on at least one systemic treatment for this PBS indication prior to initiating treatment with this drug; OR Patient must have experienced an intolerance necessitating permanent treatment withdrawal to at least one systemic treatment for this PBS indication prior to initiating treatment with this drug; AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; OR The treatment must be in combination with peginterferon alfa-2a only if used in combination with another drug; AND Patient must be receiving the medical service as described in item 14247 of the Medicare Benefits Schedule; AND Patient must not have previously received PBS-subsidised treatment with this drug for this PBS indication. Must be treated by a haematologist; OR Must be treated by a medical physician working under the supervision of a haematologist. Patient must be aged 18 years or over. | Compliance with Authority Required procedures - Streamlined Authority Code 10985 |
|  | C10988 | P10988 | Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma Continuing treatment Patient must have received PBS-subsidised treatment with this drug for this PBS indication; AND Patient must have demonstrated a response to treatment with this drug if treatment is continuing beyond 6 months of treatment for the first time; AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; OR The treatment must be in combination with peginterferon alfa-2a only if used in combination with another drug; AND Patient must be receiving the medical service as described in item 14249 of the Medicare Benefits Schedule. Must be treated by a haematologist; OR Must be treated by a medical physician working under the supervision of a haematologist. A response, for the purposes of administering this continuing restriction, is defined as attaining a reduction of at least 50% in the overall skin lesion score from baseline, for at least 4 consecutive weeks. Refer to the Product Information for directions on calculating an overall skin lesion score. The definition of a clinically significant reduction in the Product Information differs to the 50% requirement for PBS-subsidy. Response only needs to be demonstrated after the first six months of treatment | Compliance with Authority Required procedures - Streamlined Authority Code 10988 |
|  | C10989 | P10989 | Erythrodermic stage III-IVa T4 M0 Cutaneous T-cell lymphoma Continuing treatment Patient must have received PBS-subsidised treatment with this drug for this PBS indication; AND Patient must have demonstrated a response to treatment with this drug if treatment is continuing beyond 6 months of treatment for the first time; AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; OR The treatment must be in combination with peginterferon alfa-2a only if used in combination with another drug; AND Patient must be receiving the medical service as described in item 14249 of the Medicare Benefits Schedule. Must be treated by a haematologist; OR Must be treated by a medical physician working under the supervision of a haematologist. A response, for the purposes of administering this continuing restriction, is defined as attaining a reduction of at least 50% in the overall skin lesion score from baseline, for at least 4 consecutive weeks. Refer to the Product Information for directions on calculating an overall skin lesion score. The definition of a clinically significant reduction in the Product Information differs to the 50% requirement for PBS-subsidy. Response only needs to be demonstrated after the first six months of treatment | Compliance with Authority Required procedures - Streamlined Authority Code 10989 |
| Methoxy polyethylene glycol‑epoetin beta | C6294 |  | Anaemia associated with intrinsic renal disease Patient must require transfusion; AND Patient must have a haemoglobin level of less than 100 g per L; AND Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6294 |
|  | C9688 |  | Anaemia associated with intrinsic renal disease Patient must require transfusion; AND Patient must have a haemoglobin level of less than 100 g per L; AND Patient must have intrinsic renal disease, as assessed by a nephrologist. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9688 |
| Midostaurin | C8138 | P8138 | Acute Myeloid Leukaemia Maintenance therapy ‑ Continuing treatment Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the initial maintenance or the initial maintenance grandfathering treatment restriction; AND Patient must not have developed disease progression while receiving PBS‑subsidised treatment with this drug for this condition; AND Patient must not be undergoing or have undergone a stem cell transplant. A maximum of 9 cycles will be authorised under this restriction in a lifetime. Progressive disease monitoring via a complete blood count must be taken at the end of each cycle. If abnormal blood counts suggest the potential for relapsed AML, a bone marrow biopsy must be performed to confirm the absence of progressive disease for the patient to be eligible for further cycles. Progressive disease is defined as the presence of any of the following: Leukaemic cells in the CSF; Re‑appearance of circulating blast cells in the peripheral blood, not attributable to overshoot following recovery from myeloablative therapy; Greater than 5 % blasts in the marrow not attributable to bone marrow regeneration or another cause; Extramedullary leukaemia. A patient who has progressive disease when treated with this drug is no longer eligible for PBS‑subsidised treatment with this drug. | Compliance with Authority Required procedures |
|  | C8177 | P8177 | Acute Myeloid Leukaemia Maintenance therapy ‑ Initial treatment Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must not have developed disease progression while receiving PBS‑subsidised treatment with this drug for this condition; AND Patient must have demonstrated complete remission after induction and consolidation chemotherapy in combination with midostaurin; AND Patient must not be undergoing or have undergone a stem cell transplant; AND The condition must have been internal tandem duplication (ITD) or tyrosine kinase domain (TKD) FMS tyrosine kinase 3 (FLT3) mutation positive before initiating this drug for this condition. A maximum of 3 cycles will be authorised under this restriction in a lifetime. Progressive disease monitoring via a complete blood count must be taken at the end of each cycle. If abnormal blood counts suggest the potential for relapsed AML, a bone marrow biopsy must be performed to confirm the absence of progressive disease for the patient to be eligible for further cycles. Progressive disease is defined as the presence of any of the following: Leukaemic cells in the CSF; Re‑appearance of circulating blast cells in the peripheral blood, not attributable to overshoot following recovery from myeloablative therapy; Greater than 5 % blasts in the marrow not attributable to bone marrow regeneration or another cause; Extramedullary leukaemia. A patient who has progressive disease when treated with this drug is no longer eligible for PBS‑subsidised treatment with this drug. The authority application must be made in writing and must include: (1) a completed authority prescription form; (2) a completed Acute myeloid leukaemia PBS Authority Application ‑ Supporting Information Form; and (3) confirmation that the patient is not undergoing or has not undergone a stem cell transplant; and (4) confirmation that the patient does not have progressive disease; and (5) a copy of a recent bone marrow biopsy report demonstrating that the patient is in complete remission; and (6) a copy of the pathology test demonstrating that the condition was FMS tyrosine kinase 3 (FLT3) (ITD or TKD) mutation positive prior to commencing midostaurin. | Compliance with Written Authority Required procedures |
|  | C8193 | P8193 | Acute Myeloid Leukaemia Induction / Consolidation therapy Patient must not have received prior chemotherapy as induction therapy for this condition; OR The treatment must be for consolidation treatment following induction treatment with midostaurin in combination with chemotherapy; AND The condition must be internal tandem duplication (ITD) or tyrosine kinase domain (TKD) FMS tyrosine kinase 3 (FLT3) mutation positive before initiating this drug for this condition; AND The condition must not be acute promyelocytic leukaemia; AND The treatment must be in combination with standard intensive remission induction or consolidation chemotherapy for this condition. A maximum of 6 cycles will be authorised under this restriction in a lifetime. Standard intensive remission induction combination chemotherapy must include cytarabine and an anthracycline. The FLT3 ITD or TKD mutation test result and date of testing must be provided at the time of application. This drug is not PBS‑subsidised if it is prescribed to an in‑patient in a public hospital setting. Progressive disease monitoring via a complete blood count must be taken at the end of each cycle. If abnormal blood counts suggest the potential for relapsed AML, a bone marrow biopsy must be performed to confirm the absence of progressive disease for the patient to be eligible for further cycles. Progressive disease is defined as the presence of any of the following: Leukaemic cells in the CSF; Re‑appearance of circulating blast cells in the peripheral blood, not attributable to overshoot following recovery from myeloablative therapy; Greater than 5 % blasts in the marrow not attributable to bone marrow regeneration or another cause; Extramedullary leukaemia. A patient who has progressive disease when treated with this drug is no longer eligible for PBS‑subsidised treatment with this drug. | Compliance with Authority Required procedures |
|  | C8218 | P8218 | Acute Myeloid Leukaemia Maintenance therapy ‑ Grandfathered treatment Patient must have received non‑PBS subsidised treatment with this drug for this condition prior to 1 December 2018; AND Patient must be receiving treatment with this drug for this condition at the time of application; AND Patient must not have developed disease progression while receiving treatment with this drug for this condition; AND Patient must have demonstrated complete remission after induction and consolidation chemotherapy in combination with midostaurin; AND Patient must not be undergoing or have undergone a stem cell transplant; AND The condition must have been internal tandem duplication (ITD) or tyrosine kinase domain (TKD) FMS tyrosine kinase 3 (FLT3) mutation positive before initiating this drug for this condition. A maximum of 2 cycles will be authorised under this restriction in a lifetime. A patient may qualify for PBS‑subsidised treatment under this restriction once only. For continuing PBS‑subsidised treatment, a Grandfathered patient must qualify under the maintenance therapy continuing treatment criteria. Progressive disease monitoring via a complete blood count must be taken at the end of each cycle. If abnormal blood counts suggest the potential for relapsed AML, a bone marrow biopsy must be performed to confirm the absence of progressive disease for the patient to be eligible for further cycles. Progressive disease is defined as the presence of any of the following: Leukaemic cells in the CSF; Re‑appearance of circulating blast cells in the peripheral blood, not attributable to overshoot following recovery from myeloablative therapy; Greater than 5 % blasts in the marrow not attributable to bone marrow regeneration or another cause; Extramedullary leukaemia. A patient who has progressive disease when treated with this drug is no longer eligible for PBS‑subsidised treatment with this drug. The authority application must be made in writing and must include: (1) a completed authority prescription form; (2) a completed Acute myeloid leukaemia PBS Authority Application ‑ Supporting Information Form; and (3) confirmation that the patient is not undergoing or has not undergone a stem cell transplant; and (4) confirmation that the patient does not have progressive disease; and (5) a copy of a recent bone marrow biopsy report demonstrating that the patient is in complete remission; and (6) a copy of the pathology test demonstrating that the condition was FMS tyrosine kinase 3 (FLT3) (ITD or TKD) mutation positive prior to commencing midostaurin. | Compliance with Written Authority Required procedures |
| Mycophenolic Acid | C4084 |  | Prophylaxis of renal allograft rejection  Management  The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required Procedures – Streamlined Authority Code 4084 |
|  | C4095 |  | WHO Class III, IV or V lupus nephritis  Management  The condition must be proven by biopsy,  Must be treated by a nephrologist or in consultation with a nephrologist.  The name of the consulting nephrologist must be included in the patient medical records. | Compliance with Authority Required Procedures – Streamlined Authority Code 4095 |
|  | C5554 |  | Management of cardiac allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of cardiac allograft rejection, AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5554 |
|  | C5600 |  | Management of cardiac allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of cardiac allograft rejection, AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5600 |
|  | C5653 |  | Management of renal allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of renal allograft rejection, AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5653 |
|  | C5795 |  | Management of renal allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of renal allograft rejection, AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5795 |
|  | C9689 |  | Management of renal allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of renal allograft rejection; AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9689 |
|  | C9690 |  | Management of cardiac allograft rejection Management (initiation, stabilisation and review of therapy ) Patient must be receiving this drug for prophylaxis of cardiac allograft rejection; AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9690 |
|  | C9691 |  | Management of renal allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of renal allograft rejection; AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9691 |
|  | C9692 |  | Prophylaxis of renal allograft rejection Management The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9692 |
|  | C9693 |  | Management of cardiac allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of cardiac allograft rejection; AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9693 |
|  | C9809 |  | WHO Class III, IV or V lupus nephritis Management The condition must be proven by biopsy. Must be treated by a nephrologist or in consultation with a nephrologist. The name of the consulting nephrologist must be included in the patient medical records. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9809 |
| Natalizumab | C9744 |  | Clinically definite relapsing-remitting multiple sclerosis Must be treated by a neurologist. The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must be ambulatory (without assistance or support); AND Patient must have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years of commencing a PBS-subsidised disease modifying therapy for this condition; AND The condition must be confirmed by magnetic resonance imaging of the brain and/or spinal cord; OR Patient must be deemed unsuitable for magnetic resonance imaging due to the risk of physical (not psychological) injury to the patient. The date of the magnetic resonance imaging scan must be included in the patient's medical notes, unless written certification is provided, in the patient's medical notes, by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. Treatment with this drug must cease if there is continuing progression of disability whilst the patient is being treated with this drug. For continued treatment the patient must demonstrate compliance with, and an ability to tolerate, this drug. Neurologists prescribing natalizumab under the PBS listing must be registered with the Tysabri Australian Prescribing Program. | Compliance with Authority Required procedures - Streamlined Authority Code 9744 |
|  | C9818 |  | Clinically definite relapsing-remitting multiple sclerosis Must be treated by a neurologist. The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must be ambulatory (without assistance or support); AND Patient must have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years of commencing a PBS-subsidised disease modifying therapy for this condition; AND The condition must be confirmed by magnetic resonance imaging of the brain and/or spinal cord; OR Patient must be deemed unsuitable for magnetic resonance imaging due to the risk of physical (not psychological) injury to the patient. The date of the magnetic resonance imaging scan must be included in the patient's medical notes, unless written certification is provided, in the patient's medical notes, by a radiologist that an MRI scan is contraindicated because of the risk of physical (not psychological) injury to the patient. Treatment with this drug must cease if there is continuing progression of disability whilst the patient is being treated with this drug. For continued treatment the patient must demonstrate compliance with, and an ability to tolerate, this drug. Neurologists prescribing natalizumab under the PBS listing must be registered with the Tysabri Australian Prescribing Program. | Compliance with Authority Required procedures - Streamlined Authority Code 9818 |
| Nevirapine | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
|  | C4526 |  | HIV infection Initial  Patient must have been stabilised on nevirapine immediate release; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4526 |
| Nusinersen | C11049 |  | Spinal muscular atrophy (SMA) Continuing/maintenance treatment of either symptomatic Type I, II or IIIa SMA or of a patient commenced on this drug under the pre-symptomatic SMA listing Must be treated by a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA; or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA; or initiated by a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA. Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND The treatment must be given concomitantly with standard of care for this condition; AND The treatment must be ceased when invasive permanent assisted ventilation is required in the absence of a potentially reversible cause while being treated with this drug. Recognised hospitals in the management of SMA are Lady Cilento Children's Hospital (Brisbane), Royal Children's Hospital Melbourne, Monash Children's Hospital (Melbourne), John Hunter Hospital (Newcastle), Sydney Children's Hospital Randwick, Children's Hospital at Westmead, Adelaide Women and Children's Hospital and Perth Children's Hospital. Invasive permanent assisted ventilation means ventilation via tracheostomy tube for greater than or equal to 16 hours per day. | Compliance with Authority Required procedures |
|  | C11050 |  | Symptomatic Type I, II or IIIa spinal muscular atrophy (SMA) Initial treatment of symptomatic Type I, II or IIIa SMA - Loading doses Must be treated by a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA; or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA. The condition must have genetic confirmation of 5q homozygous deletion of the survival motor neuron 1 (SMN1) gene; OR The condition must have genetic confirmation of deletion of one copy of the SMN1 gene in addition to a pathogenic/likely pathogenic variant in the remaining single copy of the SMN1 gene; AND Patient must have experienced at least two of the defined signs and symptoms of SMA type I, II or IIIa prior to 3 years of age; AND The treatment must be given concomitantly with standard of care for this condition; AND The treatment must not exceed four loading doses (at days 0, 14, 28 and 63) under this restriction. Patient must be 18 years of age or under. Defined signs and symptoms of type I SMA are: i) Onset before 6 months of age; and ii) Failure to meet or regression in ability to perform age-appropriate motor milestones; or iii) Proximal weakness; or iv) Hypotonia; or v) Absence of deep tendon reflexes; or vi) Failure to gain weight appropriate for age; or vii) Any active chronic neurogenic changes; or viii) A compound muscle action potential below normative values for an age-matched child. Defined signs and symptoms of type II SMA are: i) Onset between 6 and 18 months; and ii) Failure to meet or regression in ability to perform age-appropriate motor milestones; or iii) Proximal weakness; or iv) Weakness in trunk righting/derotation; or v) Hypotonia; or vi) Absence of deep tendon reflexes; or vii) Failure to gain weight appropriate for age; or viii) Any active chronic neurogenic changes; or ix) A compound muscle action potential below normative values for an age-matched child. Defined signs and symptoms of type IIIa SMA are: i) Onset between 18 months and 3 years of age; and ii) Failure to meet or regression in ability to perform age-appropriate motor milestones; or iii) Proximal weakness; or iv) Hypotonia; or v) Absence of deep tendon reflexes; or vi) Failure to gain weight appropriate for age; or vii) Any active chronic neurogenic changes; or viii) A compound muscle action potential below normative values for an age-matched child. Recognised hospitals in the management of SMA are Lady Cilento Children's Hospital (Brisbane), Royal Children's Hospital Melbourne, Monash Children's Hospital (Melbourne), John Hunter Hospital (Newcastle), Sydney Children's Hospital Randwick, Children's Hospital at Westmead, Adelaide Women and Children's Hospital and Perth Children's Hospital. Application for authorisation of initial treatment must be in writing and must include: (a) a completed authority prescription form; and (b) a completed Spinal muscular atrophy PBS Authority Application Form which includes the following: i) specification of SMA type (I, II or IIIa); and (ii) sign(s) and symptom(s) that the patient has experienced; and (iii) patient's age at the onset of sign(s) and symptom(s). | Compliance with Written Authority Required procedures |
|  | C11058 |  | Pre-symptomatic spinal muscular atrophy (SMA) Initial treatment of pre-symptomatic spinal muscular atrophy (SMA) - Loading doses Must be treated by a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA; or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA. The condition must have genetic confirmation of 5q homozygous deletion of the survival motor neuron 1 (SMN1) gene; OR The condition must have genetic confirmation of deletion of one copy of the SMN1 gene in addition to a pathogenic/likely pathogenic variant in the remaining single copy of the SMN1 gene; AND The condition must have genetic confirmation that there are 1 to 2 copies of the survival motor neuron 2 (SMN2) gene; AND The condition must be pre-symptomatic; AND The treatment must be given concomitantly with standard of care for this condition; AND The treatment must not exceed four loading doses (at days 0, 14, 28 and 63) under this restriction. Patient must be aged under 36 months prior to commencing treatment. Application for authorisation of initial treatment must be in writing (lodged via postal service or electronic upload) and must include: (a) a completed authority prescription form; and (b) a completed Spinal muscular atrophy PBS Authority Application Form which includes the following: (i) confirmation of genetic diagnosis of SMA; and (ii) a copy of the results substantiating the number of SMN2 gene copies determined by quantitative polymerase chain reaction (qPCR) or multiple ligation dependent probe amplification (MLPA) Recognised hospitals in the management of SMA are Queensland Children's Hospital (Brisbane), Royal Children's Hospital Melbourne, Monash Children's Hospital (Melbourne), John Hunter Hospital (Newcastle), Sydney Children's Hospital Randwick, Children's Hospital at Westmead, Adelaide Women and Children's Hospital and Perth Children's Hospital. | Compliance with Written Authority Required procedures |
| Ocrelizumab | C7386 |  | Multiple sclerosis Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must not show continuing progression of disability while on treatment with this drug; AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must have demonstrated compliance with, and an ability to tolerate this therapy. Must be treated by a neurologist. | Compliance with Authority Required procedures - Streamlined Authority Code 7386 |
|  | C7699 |  | Multiple sclerosis Initial treatment The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis by magnetic resonance imaging of the brain and/or spinal cord; OR The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis by accompanying written certification provided by a radiologist that a magnetic resonance imaging scan is contraindicated because of the risk of physical (not psychological) injury to the patient; AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years of commencing a PBS-subsidised disease modifying therapy for this condition; AND Patient must be ambulatory (without assistance or support). Must be treated by a neurologist. Where applicable, the date of the magnetic resonance imaging scan must be recorded in the patient's medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 7699 |
|  | C9523 |  | Multiple sclerosis Initial treatment The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis by magnetic resonance imaging of the brain and/or spinal cord; OR The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis by accompanying written certification provided by a radiologist that a magnetic resonance imaging scan is contraindicated because of the risk of physical (not psychological) injury to the patient; AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years of commencing a PBS-subsidised disease modifying therapy for this condition; AND Patient must be ambulatory (without assistance or support). Must be treated by a neurologist. Where applicable, the date of the magnetic resonance imaging scan must be recorded in the patient's medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 9523 |
|  | C9635 |  | Multiple sclerosis Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must not show continuing progression of disability while on treatment with this drug; AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition; AND Patient must have demonstrated compliance with, and an ability to tolerate this therapy. Must be treated by a neurologist. | Compliance with Authority Required procedures - Streamlined Authority Code 9635 |
| Octreotide | C5901 |  | Functional carcinoid tumour Patient must have achieved symptom control on octreotide immediate release injections, AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months’ therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5901 |
|  | C5906 |  | Vasoactive intestinal peptide secreting tumour (VIPoma) Patient must have achieved symptom control on octreotide immediate release injections, AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months’ therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5906 |
|  | C6369 |  | Vasoactive intestinal peptide secreting tumour (VIPoma)  The condition must be causing intractable symptoms; AND  Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti‑histamines, anti‑serotonin agents and anti‑diarrhoea agents; AND  Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND  The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months’ therapy.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6369 |
|  | C6390 |  | Functional carcinoid tumour  The condition must be causing intractable symptoms; AND  Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti‑histamines, anti‑serotonin agents and anti‑diarrhoea agents; AND  Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND  The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months’ therapy.  Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6390 |
|  | C8161 |  | Acromegaly The condition must be controlled with octreotide immediate release injections; AND The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose); AND The treatment must cease if IGF1 is not lower after 3 months of treatment; AND The treatment must not be given concomitantly with PBS‑subsidised lanreotide or pegvisomant for this condition. In a patient treated with radiotherapy, octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8161 |
|  | C8165 |  | Acromegaly The condition must be active; AND Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre; AND The treatment must be after failure of other therapy including dopamine agonists; OR The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; OR The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated; AND The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks; AND The treatment must cease if IGF1 is not lower after 3 months of treatment at a dose of 100 micrograms 3 time daily; AND The treatment must not be given concomitantly with PBS‑subsidised lanreotide or pegvisomant for this condition. In a patient treated with radiotherapy, octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8165 |
|  | C8197 |  | Acromegaly Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND The condition must be controlled with octreotide immediate release injections; AND The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose); AND The treatment must cease if IGF1 is not lower after 3 months of treatment; AND The treatment must not be given concomitantly with PBS‑subsidised lanreotide or pegvisomant for this condition. In a patient treated with radiotherapy, octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8197 |
|  | C8198 |  | Vasoactive intestinal peptide secreting tumour (VIPoma) Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have achieved symptom control on octreotide immediate release injections; AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8198 |
|  | C8208 |  | Functional carcinoid tumour Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have achieved symptom control on octreotide immediate release injections; AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 8208 |
|  | C9232 |  | Vasoactive intestinal peptide secreting tumour (VIPoma) The condition must be causing intractable symptoms; AND Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents; AND Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months’ therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures - Streamlined Authority Code 9232 |
|  | C9233 |  | Acromegaly The condition must be active; AND Patient must have persistent elevation of mean growth hormone levels of greater than 2.5 micrograms per litre; AND The treatment must be after failure of other therapy including dopamine agonists; OR The treatment must be as interim treatment while awaiting the effects of radiotherapy and where treatment with dopamine agonists has failed; OR The treatment must be in a patient who is unfit for or unwilling to undergo surgery and where radiotherapy is contraindicated; AND The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks; AND The treatment must cease if IGF1 is not lower after 3 months of treatment at a dose of 100 micrograms3 times daily; AND The treatment must not be given concomitantly with PBS-subsidised lanreotide or pegvisomant for this condition. In a patient treated with radiotherapy, octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission | Compliance with Authority Required procedures - Streamlined Authority Code 9233 |
|  | C9262 |  | Acromegaly The condition must be controlled with octreotide immediate release injections; AND The treatment must cease in a patient treated with radiotherapy if there is biochemical evidence of remission (normal IGF1) after octreotide has been withdrawn for at least 4 weeks (8 weeks after the last dose); AND The treatment must cease if IGF1 is not lower after 3 months of treatment; AND The treatment must not be given concomitantly with PBS-subsidised lanreotide or pegvisomant for this condition. In a patient treated with radiotherapy, octreotide should be withdrawn every 2 years in the 10 years after radiotherapy for assessment of remission | Compliance with Authority Required procedures - Streamlined Authority Code 9262 |
|  | C9288 |  | Vasoactive intestinal peptide secreting tumour (VIPoma) Patient must have achieved symptom control on octreotide immediate release injections; AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures - Streamlined Authority Code 9288 |
|  | C9289 |  | Functional carcinoid tumour The condition must be causing intractable symptoms; AND Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents; AND Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 2 months’ therapy. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures - Streamlined Authority Code 9289 |
|  | C9313 |  | Functional carcinoid tumour Patient must have achieved symptom control on octreotide immediate release injections; AND The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections. Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose. | Compliance with Authority Required procedures - Streamlined Authority Code 9313 |
|  | C10061 |  | Non‑functional gastroenteropancreatic neuroendocrine tumour (GEP‑NET) The condition must be unresectable locally advanced disease or metastatic disease; AND The condition must be World Health Organisation (WHO) grade 1 or 2; AND The treatment must be the sole PBS‑subsidised therapy for this condition. Patient must be aged 18 years or older. WHO grade 1 of GEP‑NET is defined as a mitotic count (10HPF) of less than 2 and Ki‑67 index (%) of less than or equal to 2. WHO grade 2 of GEP‑NET is defined as a mitotic count (10HPF) of 2‑20 and Ki‑67 index (%) of 3‑20. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10061 |
|  | C10075 |  | Non‑functional gastroenteropancreatic neuroendocrine tumour (GEP‑NET) Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND The condition must be unresectable locally advanced disease or metastatic disease; AND The condition must be World Health Organisation (WHO) grade 1 or 2; AND The treatment must be the sole PBS‑subsidised therapy for this condition. Patient must be aged 18 years or older. WHO grade 1 of GEP‑NET is defined as a mitotic count (10HPF) of less than 2 and Ki‑67 index (%) of less than or equal to 2. WHO grade 2 of GEP‑NET is defined as a mitotic count (10HPF) of 2‑20 and Ki‑67 index (%) of 3‑20. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10075 |
|  | C10077 |  | Non‑functional gastroenteropancreatic neuroendocrine tumour (GEP‑NET) The condition must be unresectable locally advanced disease or metastatic disease; AND The condition must be World Health Organisation (WHO) grade 1 or 2; AND The treatment must be the sole PBS‑subsidised therapy for this condition. Patient must be aged 18 years or older. WHO grade 1 of GEP‑NET is defined as a mitotic count (10HPF) of less than 2 and Ki‑67 index (%) of less than or equal to 2. WHO grade 2 of GEP‑NET is defined as a mitotic count (10HPF) of 2‑20 and Ki‑67 index (%) of 3‑20. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 10077 |
| Omalizumab | C7046 |  | Severe chronic spontaneous urticaria  Continuing treatment  Must be treated by a clinical immunologist; OR  Must be treated by an allergist; OR  Must be treated by a dermatologist; OR  Must be treated by a general physician with expertise in the management of chronic spontaneous urticaria (CSU).  Patient must have demonstrated a response to the most recent PBS‑subsidised treatment with this drug for this condition; AND  Patient must not receive more than 24 weeks per authorised course of treatment under this restriction. | Compliance with Authority Required procedures |
|  | C7055 |  | Severe chronic spontaneous urticaria  Initial treatment  Must be treated by a clinical immunologist; OR  Must be treated by an allergist; OR  Must be treated by a dermatologist; OR  Must be treated by a general physician with expertise in the management of chronic spontaneous urticaria (CSU).  The condition must be based on both physical examination and patient history (to exclude any factors that may be triggering the urticaria); AND  Patient must have experienced itch and hives that persist on a daily basis for at least 6 weeks despite treatment with H1 antihistamines; AND  Patient must have failed to achieve an adequate response after a minimum of 2 weeks treatment with a standard therapy; AND  Patient must not receive more than 12 weeks of treatment under this restriction.  A standard therapy is defined as a combination of therapies that includes H1 antihistamines at maximally tolerated doses in accordance with clinical guidelines, and one of the following:  1) a H2 receptor antagonist (150 mg twice per day); or  2) a leukotriene receptor antagonist (LTRA) (10 mg per day); or  3) doxepin (up to 25 mg three times a day)  If the requirement for treatment with H1 antihistamines and a H2 receptor antagonist, or a leukotriene receptor antagonist or doxepin cannot be met because of contraindications according to the relevant TGA‑approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the authority application.  A failure to achieve an adequate response to standard therapy is defined as a current Urticaria Activity Score 7 (UAS7) score of equal to or greater than 28 with an itch score of greater than 8, as assessed while still on standard therapy.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Chronic Spontaneous Urticaria Omalizumab Initial PBS Authority Application ‑ Supporting Information Form which must include:  (i) demonstration of failure to achieve an adequate response to standard therapy; and  (ii) drug names and doses of standard therapies that the patient has failed; and  (iii) a signed patient acknowledgment that cessation of therapy should be considered after the patient has demonstrated clinical benefit with omalizumab to re‑evaluate the need for continued therapy. Any patient who ceases therapy and whose CSU relapses will need to re‑initiate PBS‑subsidised omalizumab as a new patient. | Compliance with Written Authority Required procedures |
|  | C9855 |  | Uncontrolled severe allergic asthma Balance of supply in a patient aged 12 years or older Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must received insufficient therapy with this drug under the Initial 1 (new patients or recommencement of treatment in a new treatment cycle) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Initial 2 (change of treatment) restriction to complete 32 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND The treatment must not provide more than the balance of up to 32 weeks of treatment if the most recent authority approval was made under an Initial treatment restriction; OR The treatment must not provide more than the balance of up to 24 weeks of treatment if the most recent authority approval was made under the Continuing treatment restriction. | Compliance with Authority Required procedures |
|  | C10219 |  | Uncontrolled severe allergic asthma Initial treatment ‑ Initial 2 (Change of treatment) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must have received prior PBS‑subsidised treatment with a biological medicine for severe asthma in this treatment cycle; AND Patient must not have failed, or ceased to respond to, PBS‑subsidised treatment with this drug for severe asthma during the current treatment cycle; AND Patient must have past or current evidence of atopy, documented by skin prick testing or an in vitro measure of specific IgE in the past 12 months or in the 12 months prior to initiating PBS‑subsidised treatment with a biological medicine for severe asthma; AND Patient must have total serum human immunoglobulin E greater than or equal to 30 IU/mL, measured no more than 12 months prior to initiating PBS‑subsidised treatment with a biological medicine for severe asthma; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Allergic Asthma (omalizumab) Initial PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) Asthma Control Questionnaire (ACQ‑5 item version) score (where a new baseline is being submitted or where the patient has responded to prior treatment); and (ii) the details of prior biological medicine treatment including the details of date and duration of treatment; and (iii) the IgE results; and (iv) the reason for switching therapy (e.g. failure of prior therapy, partial response to prior therapy, adverse event to prior therapy). An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change therapy to this biological medicine, must be accompanied by the results of an ACQ‑5 assessment of the patient’s most recent course of PBS‑subsidised biological medicine treatment. The assessment must have been made not more than 4 weeks after the last dose of biological medicine. Where a response assessment was not undertaken, the patient will be deemed to have failed to respond to treatment with that previous biological medicine. An ACQ‑5 assessment of the patient may be made at the time of application for treatment (to establish a new baseline score), but should be made again around 28 weeks after the first PBS‑subsidised dose of this biological medicine under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment at around 28 weeks, which will be used to determine eligibility for the first continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this biological medicine. At the time of the authority application, medical practitioners should request an appropriate maximum quantity based on IgE level and body weight (refer to the TGA‑approved Product Information) to be administered every 2 to 4 weeks and up to 7 repeats to provide for an initial course sufficient for up to 32 weeks of therapy. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. | Compliance with Written Authority Required procedures |
|  | C10223 |  | Uncontrolled severe allergic asthma Balance of supply in a patient aged 6 to 12 years Must be treated by a paediatric respiratory physician, clinical immunologist, allergist; or paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician. Patient must have received insufficient therapy with this drug under the Initial treatment restriction to complete 28 weeks treatment; OR Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 28 weeks treatment available under the Initial restriction or up to 24 weeks treatment available under the Continuing restriction. | Compliance with Authority Required procedures |
|  | C10226 |  | Uncontrolled severe allergic asthma Continuing treatment Patient must have a documented history of severe allergic asthma; AND Patient must have demonstrated or sustained an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction. Must be treated by a paediatric respiratory physician, clinical immunologist, allergist; or paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician. An adequate response to omalizumab treatment is defined as: (a) a reduction in the Asthma Control Questionnaire (ACQ‑5) or ACQ‑IA score of at least 0.5 from baseline, OR (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ‑5 or ACQ‑IA score from baseline, OR (c) a reduction in the time‑adjusted exacerbation rates compared to the 12 months prior to baseline. All applications for continuing treatment with omalizumab must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) or Asthma Control Questionnaire interviewer administered version (ACQ‑IA) assessment of the patient’s response to the prior course of treatment, the assessment of systemic corticosteroid dose, and the assessment of time‑adjusted exacerbation rate must be made at around 20 weeks after the first dose of PBS‑subsidised omalizumab so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. The first assessment should, where possible, be completed by the same physician who initiated treatment with omalizumab. This assessment, which will be used to determine eligibility for continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with omalizumab. A patient who fails to respond to a course of PBS‑subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS‑subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased. At the time of the authority application, medical practitioners should request the appropriate quantity and number of repeats to provide for a continuing course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA‑approved Product Information), sufficient for 24 weeks of therapy. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Paediatric Severe Allergic Asthma Continuing PBS Authority Application ‑ Supporting Information form which includes details of: (i) maintenance oral corticosteroid dose; and (ii) Asthma Control Questionnaire (ACQ‑5) score; or (iii) Asthma Control Questionnaire interviewer administered version (ACQ‑IA) score. | Compliance with Written Authority Required procedures |
|  | C10265 |  | Uncontrolled severe allergic asthma Initial treatment Patient must have a diagnosis of asthma confirmed and documented by a paediatric respiratory physician, clinical immunologist, or allergist; or paediatrician or general physician experienced in the management of patients with severe asthma in consultation with a respiratory physician, defined by the following standard clinical features: forced expiratory volume (FEV1) reversibility or airway hyperresponsiveness or peak expiratory flow (PEF) variability; AND Patient must have a duration of asthma of at least 1 year; AND Patient must have past or current evidence of atopy, documented by skin prick testing or an in vitro measure of specific IgE; AND Patient must have total serum human immunoglobulin E greater than or equal to 30 IU/mL; AND Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND Patient must not receive more than 28 weeks of treatment under this restriction. Patient must be aged 6 to less than 12 years. Must be treated by a paediatric respiratory physician, clinical immunologist, allergist; or paediatrician or general physician experienced in the management of patients with severe asthma, in consultation with a respiratory physician. Patient must be under the care of the same physician for at least 6 months. Optimised asthma therapy includes: (i) Adherence to optimal inhaled therapy, including high dose inhaled corticosteroid (ICS) and long‑acting beta‑2 agonist (LABA) therapy for at least six months. If LABA therapy is contraindicated, not tolerated or not effective, montelukast, cromoglycate or nedocromil may be used as an alternative; AND (ii) treatment with at least 2 courses of oral or IV corticosteroids (daily or alternate day maintenance treatment courses, or 3‑5 day exacerbation treatment courses), in the previous 12 months, unless contraindicated or not tolerated. If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications (including those specified in the relevant TGA‑approved Product Information) and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application. The initial IgE assessment must be no more than 12 months old at the time of application. The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application: (a) An Asthma Control Questionnaire (ACQ‑5) score of at least 2.0, as assessed in the previous month (for children aged 6 to 10 years it is recommended that the Interviewer Administered version ‑ the ACQ‑IA be used), AND (b) while receiving optimised asthma therapy in the previous 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician. The Asthma Control Questionnaire (5 item version) or ACQ‑IA assessment of the patient’s response to this initial course of treatment, the assessment of oral corticosteroid dose, and the assessment of exacerbation rate should be made at around 24 weeks after the first dose so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. This assessment, which will be used to determine eligibility for continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with omalizumab. A patient who fails to respond to a course of PBS‑subsidised omalizumab for the treatment of uncontrolled severe allergic asthma will not be eligible to receive further PBS‑subsidised treatment with omalizumab for this condition within 6 months of the date on which treatment was ceased. At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab of up to 28 weeks, consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA‑approved Product Information) to be administered every 2 or 4 weeks. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Paediatric Severe Allergic Asthma Initial PBS Authority Application ‑ Supporting Information form, which includes the following: (i) details of prior optimised asthma drug therapy (dosage, date of commencement and duration of therapy); and (ii) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and (iii) the IgE result; and (iv) Asthma Control Questionnaire (ACQ‑5) score; or (v) Asthma Control Questionnaire interviewer administered version (ACQ‑IA) score. | Compliance with Written Authority Required procedures |
|  | C10279 |  | Uncontrolled severe allergic asthma Continuing treatment Patient must have demonstrated or sustained an adequate response to PBS‑subsidised treatment with this drug for this condition; AND Patient must not receive more than 24 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be aged 12 years or older. An adequate response to omalizumab treatment is defined as: (a) a reduction in the Asthma Control Questionnaire (ACQ‑5) score of at least 0.5 from baseline, OR (b) maintenance oral corticosteroid dose reduced by at least 25% from baseline, and no deterioration in ACQ‑5 score from baseline or an increase in ACQ‑5 score from baseline less than or equal to 0.5, OR (c) a reduction in the time‑adjusted exacerbation rates compared to the 12 months prior to baseline (this criterion is only applicable for patients transitioned from the paediatric to the adolescent/adult restriction). All applications for second and subsequent continuing treatments with this drug must include a measurement of response to the prior course of therapy. The Asthma Control Questionnaire (5 item version) assessment of the patient’s response to the prior course of treatment, the assessment of oral corticosteroid dose or the assessment of time adjusted exacerbation rate must be made at around 20 weeks after the first PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for continuing therapy to be processed. The assessment should, where possible, be completed by the same physician who initiated treatment with this drug. This assessment, which will be used to determine eligibility for continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this drug. Where treatment was ceased for clinical reasons despite the patient experiencing improvement, an assessment of the patient’s response to treatment made at the time of treatment cessation or retrospectively will be considered to determine whether the patient demonstrated or sustained an adequate response to treatment. A patient who fails to respond to treatment with this biological medicine for uncontrolled severe asthma will not be eligible to receive further PBS‑subsidised treatment with this biological medicine for severe asthma within the current treatment cycle. At the time of the authority application, medical practitioners should request the appropriate quantity and number of repeats to provide for a continuing course of this biological medicine consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA‑approved Product Information), sufficient for up to 24 weeks of therapy. The authority application must be made in writing and must include: (a) a completed authority prescription form(s); and (b) a completed Severe Allergic Asthma PBS Authority Application and Supporting Information Form which includes details of: (i) maintenance oral corticosteroid dose; or (ii) Asthma Control Questionnaire (ACQ‑5) score including the date of assessment of the patient’s symptoms; or (iii) for patients transitioned from the paediatric to the adolescent/adult restrictions, confirmation that the exacerbation rate has reduced. | Compliance with Written Authority Required procedures |
|  | C10299 |  | Uncontrolled severe allergic asthma Initial treatment ‑ Initial 1 (New patients; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy) Must be treated by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma. Patient must be under the care of the same physician for at least 6 months; OR Patient must have been diagnosed by a multidisciplinary severe asthma clinic team; AND Patient must not have received PBS‑subsidised treatment with a biological medicine for severe asthma; OR Patient must have had a break in treatment from the most recently approved PBS‑subsidised biological medicine for severe asthma; AND Patient must have a diagnosis of asthma confirmed and documented by a respiratory physician, clinical immunologist, allergist or general physician experienced in the management of patients with severe asthma, defined by the following standard clinical features: (i) forced expiratory volume (FEV1) reversibility greater than or equal to 12% and greater than or equal to 200 mL at baseline within 30 minutes after administration of salbutamol (200 to 400 micrograms), or (ii) airway hyperresponsiveness defined as a greater than 20% decline in FEV1 during a direct bronchial provocation test or greater than 15% decline during an indirect bronchial provocation test, or (iii) peak expiratory flow (PEF) variability of greater than 15% between the two highest and two lowest peak expiratory flow rates during 14 days; OR Patient must have a diagnosis of asthma from at least two physicians experienced in the management of patients with severe asthma; AND Patient must have a duration of asthma of at least 1 year; AND Patient must have past or current evidence of atopy, documented by skin prick testing or an in vitro measure of specific IgE, that is no more than 1 year old; AND Patient must have total serum human immunoglobulin E greater than or equal to 30 IU/mL; AND Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND Patient must not receive more than 32 weeks of treatment under this restriction; AND The treatment must not be used in combination with and within 4 weeks of another PBS‑subsidised biological medicine prescribed for severe asthma. Patient must be aged 12 years or older. Optimised asthma therapy includes: (i) Adherence to maximal inhaled therapy, including high dose inhaled corticosteroid (ICS) plus long‑acting beta‑2 agonist (LABA) therapy for at least 12 months, unless contraindicated or not tolerated; AND (ii) treatment with oral corticosteroids, either daily oral corticosteroids for at least 6 weeks, OR a cumulative dose of oral corticosteroids of at least 500 mg prednisolone equivalent in the previous 12 months, unless contraindicated or not tolerated. If the requirement for treatment with optimised asthma therapy cannot be met because of contraindications according to the relevant TGA‑approved Product Information and/or intolerances of a severity necessitating permanent treatment withdrawal, details of the contraindication and/or intolerance must be provided in the Authority application. The initial IgE assessment must be no more than 12 months old at the time of application. The following initiation criteria indicate failure to achieve adequate control and must be demonstrated in all patients at the time of the application: (a) an Asthma Control Questionnaire (ACQ‑5) score of at least 2.0, as assessed in the previous month, AND (b) while receiving optimised asthma therapy in the past 12 months, experienced at least 1 admission to hospital for a severe asthma exacerbation, OR 1 severe asthma exacerbation, requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids) prescribed/supervised by a physician. The Asthma Control Questionnaire (5 item version) assessment of the patient’s response to this initial course of treatment, and the assessment of oral corticosteroid dose, should be made at around 28 weeks after the first PBS‑subsidised dose of this drug under this restriction so that there is adequate time for a response to be demonstrated and for the application for the first continuing therapy to be processed. This assessment, which will be used to determine eligibility for the first continuing treatment, should be submitted within 4 weeks of the date of assessment, and no later than 2 weeks prior to the patient completing their current treatment course, to avoid an interruption to supply. Where a response assessment is not undertaken and submitted, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for severe asthma within the same treatment cycle. A treatment break in PBS‑subsidised biological medicine therapy of at least 12 months must be observed in a patient who has either failed to achieve or sustain a response to treatment with 3 biological medicines for severe asthma within the same treatment cycle. A treatment break in PBS‑subsidised omalizumab therapy of at least 6 months must be observed in a patient with uncontrolled severe allergic asthma, in whom omalizumab is the only appropriate treatment option, and who has either failed to achieve or sustain a response to the most recent PBS‑subsidised omalizumab therapy. The length of the break in therapy is measured from the date the most recent treatment with a PBS‑subsidised biological medicine was administered until the date of the first application for recommencement of treatment with a biological medicine under the new treatment cycle. There is no limit to the number of treatment cycles that a patient may undertake in their lifetime. At the time of the authority application, medical practitioners should request the appropriate maximum quantity and number of repeats to provide for an initial course of omalizumab consisting of the recommended number of doses for the baseline IgE level and body weight of the patient (refer to the TGA‑approved Product Information) to be administered every 2 or 4 weeks. A multidisciplinary severe asthma clinic team comprises of: A respiratory physician; and A pharmacist, nurse or asthma educator. The authority application must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Severe Allergic Asthma PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) details of prior optimised asthma drug therapy (date of commencement and duration of therapy); and (ii) details of severe exacerbation/s experienced in the past 12 months while receiving optimised asthma therapy (date and treatment); and (iii) the IgE result; and (iv) Asthma Control Questionnaire (ACQ‑5) score. | Compliance with Written Authority Required procedures |
| Pamidronic Acid | C4433 |  | Hypercalcaemia of malignancy  Patient must have a malignancy refractory to anti‑neoplastic therapy | Compliance with Authority Required procedures – Streamlined Authority Code 4433 |
|  | C5218 |  | Multiple Myeloma | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5218 |
|  | C5291 |  | Bone metastases  The condition must be due to breast cancer. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5291 |
|  | C9234 |  | Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti‑neoplastic therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9234 |
|  | C9315 |  | Bone metastases The condition must be due to breast cancer. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9315 |
|  | C9335 |  | Multiple myeloma | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9335 |
| Pasireotide | C9088 |  | Acromegaly Initial treatment Patient must not have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have a mean growth hormone (GH) level greater than 1 microgram per litre or 3 mlU/L; OR Patient must have an age‑ and sex‑adjusted insulin‑like growth factor 1 (IGF‑1) concentration greater than the upper limit of normal (ULN); AND The treatment must be after failure to achieve biochemical control with a maximum indicated dose of either 30 mg octreotide LAR or 120 mg lanreotide ATG every 28 days for 24 weeks; unless contraindicated or not tolerated according to the TGA approved Product Information; AND The treatment must not be given concomitantly with PBS‑subsidised pegvisomant. Patient must be aged 18 years or older. If treatment with either octreotide or lanreotide is contraindicated according to the relevant TGA‑approved Product Information, the application must provide details of contraindication. If intolerance to either octreotide or lanreotide treatment developed during the relevant period of use which is of a severity to necessitate withdrawal of the treatment, the application must provide details of the nature and severity of this intolerance. Failure to achieve biochemical control after completion of a prior therapy with either octreotide or lanreotide is defined as: 1) Growth hormone level greater than 1 mcg/L or 3 mIU/L; OR 2) IGF‑1 level is greater than the age‑ and sex‑adjusted ULN. In a patient treated with radiotherapy, pasireotide should be withdrawn every 2 years in the 10 years after completion of radiotherapy for assessment of remission. Pasireotide should be withdrawn at least 8 weeks prior to the assessment of remission. Biochemical evidence of remission is defined as: 1) Growth hormone (GH) levels of less than 1 mcg/L or 3 mlU/L; OR 2) normalisation of sex‑ and age‑ adjusted insulin‑like growth factor 1 (IGF‑1) The authority application must be made in writing and must include: a) a completed authority prescription form; and b) a completed Acromegaly PBS Authority Application ‑ Supporting Information Form; and c) in a patient who has been previously treated with radiotherapy for this condition, the date of completion of radiotherapy must be provided; the date and result of GH or IGF‑1 levels taken at the most recent two yearly assessment in the 10 years after completion of radiotherapy must be provided; and d) a recent result of GH or IGF‑1 levels must be provided. | Compliance with Written Authority Required procedures |
|  | C9089 |  | Acromegaly Continuing treatment Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND The treatment must not be given concomitantly with PBS‑subsidised pegvisomant. Patient must be aged 18 years or older. In a patient treated with radiotherapy, pasireotide should be withdrawn every 2 years in the 10 years after completion of radiotherapy for assessment of remission. Pasireotide should be withdrawn at least 8 weeks prior to the assessment of remission. Biochemical evidence of remission is defined as: 1) Growth hormone (GH) levels of less than 1 mcg/L or 3 mlU/L; OR 2) normalisation of sex‑ and age‑ adjusted insulin‑like growth factor 1 (IGF‑1) In a patient who has been previously treated with radiotherapy for this condition, the date of completion of radiotherapy and the GH and IGF‑1 levels taken at the most recent two yearly assessment in the 10 years after completion of radiotherapy must be provided at the time of approval. | Compliance with Authority Required procedures |
| Pegfilgrastim | C7822 |  | Chemotherapy‑induced neutropenia  Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must be at greater than 20% risk of developing febrile neutropenia; OR Patient must be at substantial risk (greater than 20%) of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7822 |
|  | C7843 |  | Chemotherapy‑induced neutropenia  Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 7843 |
|  | C9235 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must be at greater than 20% risk of developing febrile neutropenia; OR Patient must be at substantial risk (greater than 20%) of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9235 |
|  | C9303 |  | Chemotherapy‑induced neutropenia Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND Patient must have had a prior episode of febrile neutropenia; OR Patient must have had a prior episode of prolonged severe neutropenia for more than or equal to seven days. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9303 |
| Peginterferon  alfa‑2a | C5004 |  | Chronic hepatitis C infection Must be treated in an accredited treatment centre. Patient must be aged 18 years or older; AND Patient must not be pregnant or breastfeeding, and must be using an effective form of contraception if female and of child-bearing age. Patient must have compensated liver disease; AND Patient must not have received prior interferon alfa or peginterferon alfa treatment for hepatitis C; AND Patient must have a contraindication to ribavirin; AND The treatment must cease unless the results of an HCV RNA quantitative assay at week 12 (performed at the same laboratory using the same test) show that plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop; AND The treatment must be limited to a maximum duration of 48 weeks. Evidence of chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive) must be documented in the patient’s medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 5004 |
|  | C9603 |  | Chronic hepatitis C infection Must be treated in an accredited treatment centre. Patient must be aged 18 years or older; AND Patient must not be pregnant or breastfeeding, and must be using an effective form of contraception if female and of child‑bearing age. Patient must have compensated liver disease; AND Patient must not have received prior interferon alfa or peginterferon alfa treatment for hepatitis C; AND Patient must have a contraindication to ribavirin; AND The treatment must cease unless the results of an HCV RNA quantitative assay at week 12 (performed at the same laboratory using the same test) show that plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop; AND The treatment must be limited to a maximum duration of 48 weeks. Evidence of chronic hepatitis C infection (repeatedly anti‑HCV positive and HCV RNA positive) must be documented in the patient’s medical records. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9603 |
| Pegvisomant | C7087 |  | Acromegaly  Continuing treatment  Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND  The treatment must not be given concomitantly with a PBS‑subsidised somatostatin analogue; AND  The treatment must cease if IGF‑1 is not lower after 3 months of pegvisomant treatment at the maximum tolerated dose.  Somatostatin analogues include octreotide, lanreotide and pasireotide  In a patient treated with radiotherapy, pegvisomant should be withdrawn every 2 years in the 10 years after completion of radiotherapy for assessment of remission. Pegvisomant should be withdrawn at least 8 weeks prior to the assessment of remission.  Biochemical evidence of remission is defined as normalisation of sex‑ and age‑ adjusted insulin‑like growth factor 1 (IGF‑1).  In a patient who has been previously treated with radiotherapy for this condition, the date of completion of radiotherapy must be provided; and a copy of IGF‑1 level taken at the most recent two yearly assessment in the 10 years after completion of radiotherapy must be provided at the time of application. | Compliance with Authority Required procedures |
|  | C9041 |  | Acromegaly Initial treatment Patient must not have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have an age‑ and sex‑adjusted insulin‑like growth factor 1 (IGF‑1) concentration greater than the upper limit of normal (ULN); AND The treatment must be after failure to achieve biochemical control with a maximum indicated dose of either 30 mg octreotide LAR or 120 mg lanreotide ATG every 28 days for 24 weeks; unless contraindicated or not tolerated according to the TGA approved Product Information; AND The treatment must not be given concomitantly with a PBS‑subsidised somatostatin analogue. Somatostatin analogues include octreotide, lanreotide and pasireotide Failure to achieve biochemical control after completion of a prior therapy with either octreotide or lanreotide is defined as: 1) Growth hormone level greater than 1 mcg/L or 3 mIU/L; OR 2) IGF‑1 level is greater than the age‑ and sex‑adjusted ULN. If treatment with either octreotide or lanreotide is contraindicated according to the relevant TGA‑approved Product Information, the application must provide details of contraindication. If intolerance to either octreotide or lanreotide treatment developed during the relevant period of use which is of a severity to necessitate withdrawal of the treatment, the application must provide details of the nature and severity of this intolerance. In a patient treated with radiotherapy, pegvisomant should be withdrawn every 2 years in the 10 years after completion of radiotherapy for assessment of remission. Pegvisomant should be withdrawn at least 8 weeks prior to the assessment of remission. Biochemical evidence of remission is defined as normalisation of sex‑ and age‑ adjusted insulin‑like growth factor 1 (IGF‑1). Two completed authority prescriptions should be submitted with the initial application for this drug. One prescription should be for the loading dose of 80 mg for a quantity of 4 vials of 20 mg with no repeats. The second prescription should be for subsequent doses, starting from 10 mg daily, and allowing dose adjustments in increments of 5 mg based on serum IGF‑1 levels measured every 4 to 6 weeks in order to maintain the serum IGF‑1 level within the age‑adjusted normal range based on the dosage recommendations in the TGA‑approved Product Information. The authority application must be made in writing and must include: a) two completed authority prescription forms ; and b) a completed Acromegaly Pegvisomant initial PBS Authority Application ‑ Supporting Information Form; and c) in a patient who has been previously treated with radiotherapy for this condition, the date of completion of radiotherapy, the date and result of IGF‑1 levels taken at the most recent two yearly assessment in the 10 years after completion of radiotherapy; and d) a recent result of the IGF‑1 level and the date of assessment ; and e) demonstration of failure to achieve biochemical control after completion of a prior therapy with either octreotide or lanreotide No increase in the maximum quantity or number of units may be authorised for the loading dose. | Compliance with Written Authority Required procedures |
| Plerixafor | C4549 |  | Mobilisation of haematopoietic stem cells The treatment must be in combination with granulocyte‑colony stimulating factor (G‑CSF); AND Patient must have lymphoma; OR Patient must have multiple myeloma; AND Patient must require autologous stem cell transplantation; AND Patient must have failed previous stem cell collection; OR Patient must be undergoing chemotherapy plus G‑CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per millilitre or less than 10 million per litre on the day of planned collection; OR Patient must be undergoing chemotherapy plus G‑CSF mobilisation and the first apheresis has yielded less than 1 million CD34+ cells/kg. Evidence that the patient meets the PBS restriction criteria must be recorded in the patient’s medical records | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4549 |
|  | C9329 |  | Mobilisation of haematopoietic stem cells The treatment must be in combination with granulocyte‑colony stimulating factor (G‑CSF); AND Patient must have lymphoma; OR Patient must have multiple myeloma; AND Patient must require autologous stem cell transplantation; AND Patient must have failed previous stem cell collection; OR Patient must be undergoing chemotherapy plus G‑CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per millilitre or less than 10 million per litre on the day of planned collection; OR Patient must be undergoing chemotherapy plus G‑CSF mobilisation and the first apheresis has yielded less than 1 million CD34+ cells/kg. Evidence that the patient meets the PBS restriction criteria must be recorded in the patient’s medical records. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9329 |
| Pomalidomide | C7791 |  | Multiple myeloma Continuing treatment Patient must have previously been issued with an authority prescription for this drug; AND Patient must not have progressive disease; AND The treatment must be in combination with dexamethasone; AND Patient must not be receiving concomitant PBS‑subsidised bortezomib, carfilzomib or thalidomide or its analogues. Progressive disease is defined as at least 1 of the following: (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or (b) at least a 25% increase in 24‑hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or (c) in oligo‑secretory and non‑secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause). Patients receiving this drug under the PBS listing must be registered in the i‑access risk management program. | Compliance with Authority Required procedures |
|  | C7952 |  | Multiple myeloma Initial treatment The treatment must be in combination with dexamethasone; AND Patient must have undergone or be ineligible for a primary stem cell transplant; AND Patient must have experienced treatment failure with lenalidomide, unless contraindicated or not tolerated according to the Therapeutic Goods Administration (TGA) approved Product Information; AND Patient must have experienced treatment failure with bortezomib, unless contraindicated or not tolerated according to the Therapeutic Goods Administration (TGA) approved Product Information; AND Patient must not be receiving concomitant PBS‑subsidised bortezomib, carfilzomib or thalidomide or its analogues. Bortezomib treatment failure is the absence of achieving at least a partial response or as progressive disease during treatment or within 6 months of discontinuing treatment with bortezomib. Lenalidomide treatment failure is progressive disease during treatment or within 6 months of discontinuing treatment with lenalidomide. If treatment with either bortezomib or lenalidomide is contraindicated according to the relevant TGA‑approved Product Information, the application must provide details of the contraindication. If intolerance to either bortezomib or lenolidomide treatment develops during the relevant period of use which is of a severity to necessitate withdrawal of the treatment, the application must provide details of the nature and severity of this intolerance. Progressive disease is defined as at least 1 of the following: (a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or (b) at least a 25% increase in 24‑hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or (c) in oligo‑secretory and non‑secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or (d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or (e) an increase in the size or number of lytic bone lesions (not including compression fractures); or (f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or (g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause). Oligo‑secretory and non‑secretory patients are defined as having active disease with less than 10 g per L serum M protein. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Multiple Myeloma pomalidomide Authority Application Supporting Information form; and (3) reports demonstrating the patient has failed treatment with, providing details of the contraindication to or details of the nature and severity of the intolerance to lenalidomide; and (4) reports demonstrating the patient has failed treatment with, providing details of the contraindication to or details of the nature and severity of the intolerance to bortezomib. Patients receiving this drug under the PBS listing must be registered in the i‑access risk management program. | Compliance with Written Authority Required procedures |
| Raltegravir | C4274 |  | HIV infection Continuing The treatment must be in combination with other antiretroviral agents; AND Patient must be antiretroviral experienced with at least 6 months therapy with 2 alternate classes of anti-retroviral therapy; AND Patient must have previously received PBS-subsidised therapy for HIV infection. Patient must be aged 2 years or older. | Compliance with Authority Required procedures - Streamlined Authority Code 4274 |
|  | C4275 |  | HIV infection Initial The treatment must be in combination with other antiretroviral agents; AND Patient must be antiretroviral experienced with at least 6 months therapy with 2 alternate classes of anti-retroviral therapy; AND Patient must have a CD4 count of less than 500 per cubic millimetre; OR Patient must have symptomatic HIV disease. Patient must be aged 2 years or older. | Compliance with Authority Required procedures - Streamlined Authority Code 4275 |
|  | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Ribavirin | C5957 | P5957 | Chronic hepatitis C infection Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 12 weeks. Patient must not be pregnant or breastfeeding. Female partners of male patients must not be pregnant. Patients and their partners must each be using an effective form of contraception if of child‑bearing age. | Compliance with Authority Required procedures |
|  | C5958 | P5958 | Chronic hepatitis C infection Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 24 weeks. Patient must not be pregnant or breastfeeding. Female partners of male patients must not be pregnant. Patients and their partners must each be using an effective form of contraception if of child‑bearing age. | Compliance with Authority Required procedures |
| Rifabutin | C6350 |  | Mycobacterium avium complex infection  Patient must be human immunodeficiency virus (HIV) positive. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6350 |
|  | C6356 |  | Mycobacterium avium complex infection  The treatment must be for prophylaxis; AND  Patient must be human immunodeficiency virus (HIV) positive; AND  Patient must have CD4 cell counts of less than 75 per cubic millimetre. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6356 |
|  | C9560 |  | Mycobacterium avium complex infection Patient must be human immunodeficiency virus (HIV) positive. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9560 |
|  | C9622 |  | Mycobacterium avium complex infection The treatment must be for prophylaxis; AND Patient must be human immunodeficiency virus (HIV) positive; AND Patient must have CD4 cell counts of less than 75 per cubic millimetre. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9622 |
| Rilpivirine | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Riociguat | C6645 |  | Chronic thromboembolic pulmonary hypertension (CTEPH) Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must demonstrate stable or responding disease; AND The treatment must be the sole PBS-subsidised therapy for this condition. Must be treated in a centre with expertise in the management of CTEPH. Patient must be aged 18 years or older. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed CTEPH PBS Continuing Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Test requirements to establish response to treatment for continuation of treatment are as follows: The following list outlines the preferred test combination, in descending order, for the purposes of continuation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments plus 6MWT; (2) RHC plus ECHO composite assessments; (3) RHC composite assessment plus 6MWT; (4) ECHO composite assessment plus 6MWT; (5) RHC composite assessment only; (6) ECHO composite assessment only. The results of the same tests as conducted at baseline should be provided with each written continuing treatment application (i.e., every 6 months), except for patients who were able to undergo all 3 tests at baseline, and whose subsequent ECHO and 6MWT results demonstrate disease stability or improvement, in which case RHC can be omitted. In all other patients, where the same test(s) conducted at baseline cannot be performed for assessment of response on clinical grounds, a patient specific reason why the test(s) could not be conducted must be provided with the application. The test results provided with the application for continuing treatment must be no more than 2 months old at the time of application. Response to this drug is defined as follows: For patients with two or more baseline tests, response to treatment is defined as two or more tests demonstrating stability or improvement of disease. For patients with a RHC composite assessment alone at baseline, response to treatment is defined as a RHC result demonstrating stability or improvement of disease. For patients with an ECHO composite assessment alone at baseline, response to treatment is defined as an ECHO result demonstrating stability or improvement of disease. The assessment of the patient’s response to the continuing 6 month courses of treatment should be made following the preceding 5 months of treatment, in order to allow sufficient time for a response to be demonstrated. The maximum quantity per prescription must be based on the dosage recommendations in the TGA-approved Product Information and be limited to provide sufficient supply for 1 month of treatment. A maximum of 5 repeats will be authorised. Applications for continuing treatment with this drug should be made two weeks prior to the completion of the 6-month treatment course to ensure continuity for those patients who respond to treatment, as assessed by the treating physician. Patients who fail to demonstrate disease stability or improvement to PBS-subsidised treatment with this agent at the time where an assessment is required must cease PBS-subsidised therapy with this agent. | Compliance with Written Authority Required procedures |
|  | C6664 |  | Chronic thromboembolic pulmonary hypertension (CTEPH) Initial treatment Patient must have WHO Functional Class II, III or IV CTEPH; AND The condition must be inoperable by pulmonary endarterectomy; OR The condition must be recurrent or persistent following pulmonary endarterectomy; AND The treatment must be the sole PBS‑subsidised therapy for this condition. Must be treated in a centre with expertise in the management of CTEPH. Patient must be aged 18 years or older. CTEPH that is inoperable by pulmonary endarterectomy is defined as follows: Right heart catheterisation (RHC) demonstrating pulmonary vascular resistance (PVR) of greater than 300 dyn\*sec\*cm‑5measured at least 90 days after start of full anticoagulation; and A mean pulmonary artery pressure (PAPmean) of greater than 25 mmHg at least 90 days after start of full anticoagulation. CTEPH that is recurrent or persistent subsequent to pulmonary endarterectomy is defined as follows: RHC demonstrating a PVR of greater than 300 dyn\*sec\*cm‑5measured at least 180 days following pulmonary endarterectomy. Where a RHC cannot be performed due to right ventricular dysfunction, an echocardiogram demonstrating the dysfunction must be provided at the time of application. Applications for authorisation must be in writing and must include:(1) completed authority prescription forms sufficient for dose titration; and(2) a completed CTEPH PBS Initial Authority Application ‑ Supporting Information form which includes results from the 3 tests below, to establish baseline measurements, where available:(i) RHC composite assessment, and(ii) ECHO composite assessment, and(iii) 6 Minute Walk Test (6MWT); and(3) a signed patient acknowledgment form; and(4) confirmation of evidence of inoperable CTEPH including results of a pulmonary vascular resistance (PVR), a mean pulmonary artery pressure (PAPmean) and the starting date of full anticoagulation; or(5) confirmation of evidence of recurrent or persistent CTEPH including result of PVR and the date that pulmonary endarterectomy was performed; or(6) confirmation of an echocardiogram demonstrating right ventricular dysfunction. Where it is not possible to perform all 3 tests above on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference:(1) RHC plus ECHO composite assessments;(2) RHC composite assessment plus 6MWT;(3) RHC composite assessment only. In circumstance where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference:(1) ECHO composite assessment plus 6MWT;(2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. The test results provided must not be more than 2 months old at the time of application. Prescriptions for dose titration must provide sufficient quantity for dose titrations by 0.5 mg increments at 2‑week intervals to achieve up to a maximum of 2.5 mg three times daily based on the dosage recommendations for initiation of treatment in the TGA‑approved Product Information. No repeats will be authorised for these prescriptions. Approvals for subsequent authority prescription will be limited to 1 month of treatment, the quantity approved must be based on the dosage recommendations in the TGA‑approved Product Information, and a maximum of 3 repeats. The assessment of the patient's response to the initial 20‑week course of treatment should be made following the preceding 16 weeks of treatment, in order to allow sufficient time for a response to be demonstrated. Patients who fail to demonstrate a response to PBS‑subsidised treatment with this agent at the time where an assessment is required must cease PBS‑subsidised therapy with this agent. | Compliance with Written Authority Required procedures |
|  | C7629 |  | Chronic thromboembolic pulmonary hypertension (CTEPH)  Balance of supply  Patient must have received insufficient therapy with this drug under the Initial treatment restriction to complete a maximum of 20 weeks of treatment; OR Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete a maximum of 24 weeks of treatment; AND The treatment must provide no more than the balance of up to 20 or 24 weeks of treatment available under the above respective restriction; AND The treatment must be the sole PBS‑subsidised agent for this condition.  Must be treated in a centre with expertise in the management of CTEPH.  Patient must be aged 18 years or older. | Compliance with Authority Required procedures |
|  | C10231 |  | Pulmonary arterial hypertension (PAH) Continuing treatment Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent for this condition; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10243 |  | Pulmonary arterial hypertension (PAH) Initial 2 (change) Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH; AND Patient must have had their most recent course of PBS-subsidised treatment for this condition with a PAH agent other than this agent; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment (monotherapy) with 1 of these 8 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent’s restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap between the 8 PAH agents must be made under the relevant initial treatment (monotherapy) restriction. Approvals for prescriptions for dose titration will provide sufficient quantity for dose titrations by 0.5 mg increments at 2-week intervals to achieve up to a maximum of 2.5 mg three times daily based on the dosage recommendations for initiation of treatment in the TGA-approved Product Information. No repeats will be authorised for these prescriptions. Approvals for subsequent authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. | Compliance with Authority Required procedures |
|  | C10245 |  | Pulmonary arterial hypertension (PAH) Initial 1 (new patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have WHO Functional Class III PAH or WHO Functional Class IV PAH; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. Approvals for prescriptions for dose titration will provide sufficient quantity for dose titrations by 0.5 mg increments at 2-week intervals to achieve up to a maximum of 2.5 mg three times daily based on the dosage recommendations for initiation of treatment in the TGA-approved Product Information. No repeats will be authorised for these prescriptions. Approvals for subsequent authority prescription will be limited to 1 month of treatment, with the quantity approved based on the dosage recommendations in the TGA-approved Product Information, and a maximum of 4 repeats. | Compliance with Written Authority Required procedures |
| Ritonavir | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Rituximab | C7021 |  | Severe active granulomatosis with polyangiitis (Wegeners granulomatosis) Re‑induction of remission The treatment must be for the re‑induction of remission; AND Patient must have previously received and responded to this drug for this condition; AND The treatment must in combination with glucocorticoids; AND Patient must be at risk of end‑organ damage or mortality; AND Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide. Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti‑neutrophil cytoplasmic antibody (ANCA) positive serology. This drug is not PBS‑subsidised for maintenance of remission The authority application must be made in writing | Compliance with Written Authority Required procedures |
|  | C7022 |  | Severe active microscopic polyangiitis Re‑induction of remission The treatment must be for the re‑induction of remission; AND Patient must have previously received and responded to this drug for this condition; AND The treatment must in combination with glucocorticoids; AND Patient must be at risk of end‑organ damage or mortality; AND Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide. Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti‑neutrophil cytoplasmic antibody (ANCA) positive serology. This drug is not PBS‑subsidised for maintenance therapy. The authority application must be made in writing | Compliance with Written Authority Required procedures |
|  | C9336 |  | Severe active granulomatosis with polyangiitis (Wegeners granulomatosis) Re‑induction of remission The treatment must be for the re‑induction of remission; AND Patient must have previously received and responded to this drug for this condition; AND The treatment must in combination with glucocorticoids; AND Patient must be at risk of end‑organ damage or mortality; AND Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide. Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti‑neutrophil cytoplasmic antibody (ANCA) positive serology. This drug is not PBS‑subsidised for maintenance of remission | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9336 |
|  | C9340 |  | Severe active rheumatoid arthritis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C9344 |  | Severe active granulomatosis with polyangiitis (Wegeners granulomatosis) Induction of remission The treatment must be for the induction of remission; AND Patient must not have previously received this drug for this condition; AND The treatment must in combination with glucocorticoids; AND Patient must be at risk of end‑organ damage or mortality; AND Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide. Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti‑neutrophil cytoplasmic antibody (ANCA) positive serology. This drug is not PBS‑subsidised for maintenance of remission The authority application must be made in writing | Compliance with Written Authority Required procedures |
|  | C9446 |  | Severe active rheumatoid arthritis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9446 |
|  | C9448 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have failed to respond to at least 1 PBS‑subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND Patient must not have failed to respond to previous PBS‑subsidised treatment with this drug for this condition; AND Patient must not have already failed , or ceased to respond to, PBS‑subsidised biological medicine treatment for this condition 5 times; AND Patient must not receive more than 2 infusions of this drug under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). An application for a patient who has received PBS‑subsidised treatment with this drug and who wishes to re‑commence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised treatment with this drug, within the timeframes specified below. Where the most recent course of PBS‑subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. A patient whose most recent course of PBS‑subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment‑free period. | Compliance with Written Authority Required procedures |
|  | C9449 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 24 months or more from the most recent PBS‑subsidised biological medicine for this condition; AND Patient must have failed to respond to at least 1 PBS‑subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND Patient must not have failed to respond to previous PBS‑subsidised treatment with this drug for this condition; AND Patient must not have already failed , or ceased to respond to, PBS‑subsidised biological medicine treatment for this condition 5 times; AND The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; OR The condition must have a C‑reactive protein (CRP) level greater than 15 mg per L; AND The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND Patient must not receive more than 2 infusions of this drug under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. A patient whose most recent course of PBS‑subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment‑free period. | Compliance with Written Authority Required procedures |
|  | C9450 |  | Severe active rheumatoid arthritis First continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 2 infusions of this drug under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C9511 |  | Severe active microscopic polyangiitis Induction of remission The treatment must be for the induction of remission; AND Patient must not have previously received this drug for this condition; AND The treatment must in combination with glucocorticoids; AND Patient must be at risk of end‑organ damage or mortality; AND Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide. Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti‑neutrophil cytoplasmic antibody (ANCA) positive serology. This drug is not PBS‑subsidised for maintenance therapy. The authority application must be made in writing | Compliance with Written Authority Required procedures |
|  | C9512 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 1 (new patient) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have failed to respond to at least 1 PBS‑subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti‑rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)‑approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA‑approved Product Information or cannot be tolerated at the doses specified above, must include at least 3 months continuous treatment with each of at least 2 DMARDs, with one or more of the following DMARDs being used in place of the DMARDS which are contraindicated or not tolerated: (i) azathioprine at a dose of at least 1 mg/kg per day; and/or (ii) cyclosporin at a dose of at least 2 mg/kg/day; and/or (iii) sodium aurothiomalate at a dose of 50 mg weekly; AND Patient must not receive more than 2 infusions of this drug under this restriction; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. If methotrexate is contraindicated according to the TGA‑approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable. The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C‑reactive protein (CRP) level greater than 15 mg per L; AND either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active joints from the following list of major joints: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. A patient whose most recent course of PBS‑subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment‑free period. | Compliance with Written Authority Required procedures |
|  | C9539 |  | Severe active microscopic polyangiitis Re‑induction of remission The treatment must be for the re‑induction of remission; AND Patient must have previously received and responded to this drug for this condition; AND The treatment must in combination with glucocorticoids; AND Patient must be at risk of end‑organ damage or mortality; AND Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide. Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti‑neutrophil cytoplasmic antibody (ANCA) positive serology. This drug is not PBS‑subsidised for maintenance therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9539 |
|  | C9611 |  | Severe active rheumatoid arthritis Subsequent continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have previously received PBS‑subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated an adequate response to treatment with this drug; AND The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The measurement of response to the prior course of therapy must be documented in the patient’s medical notes. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9611 |
|  | C9640 |  | Severe active granulomatosis with polyangiitis (Wegeners granulomatosis) Re‑induction of remission The treatment must be for the re‑induction of remission; AND Patient must have previously received and responded to this drug for this condition; AND The treatment must in combination with glucocorticoids; AND Patient must be at risk of end‑organ damage or mortality; AND Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide. Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti‑neutrophil cytoplasmic antibody (ANCA) positive serology. This drug is not PBS‑subsidised for maintenance of remission | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9640 |
|  | C9641 |  | Severe active microscopic polyangiitis Re‑induction of remission The treatment must be for the re‑induction of remission; AND Patient must have previously received and responded to this drug for this condition; AND The treatment must in combination with glucocorticoids; AND Patient must be at risk of end‑organ damage or mortality; AND Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide. Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti‑neutrophil cytoplasmic antibody (ANCA) positive serology. This drug is not PBS‑subsidised for maintenance therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9641 |
| Romiplostim | C6694 |  | Severe thrombocytopenia  Initial treatment 1 ‑ New patient  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  Patient must have had a splenectomy; AND  Patient must have failed to acheive an adequate response to, or be intolerant to, corticosteroid therapy following the splenectomy; AND  Patient must have failed to acheive an adequate response to, or be intolerant to, immunoglobulin therapy following the splenectomy; AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition.  Patient must be an adult.  The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of initial application;  (a) a platelet count of less than or equal to 20,000 million per L; OR  (b) a platelet count of 20,000 million to 30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.  At the time of the written authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1 microgram/kg. Up to 1 repeat may be requested with the initial written application.  Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be requested by telephone. The dose (microgram/kg/week) must be provided at the time of application.  Once a patient’s dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.  Authority approval will not be given for doses higher than 10 micrograms/kg/week  The authority application must be made in writing and must include:  (1) a completed authority prescription form,  (2) a signed patient acknowledgement,  (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application ‑ Supporting Information Form,  (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and  (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.  The full blood count must be no more than 1 month old at the time of application. | Compliance with Written Authority Required procedures |
|  | C6737 |  | Severe thrombocytopenia  First Continuing treatment or Re‑initiation of interrupted treatment  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  Patient must have previously received PBS‑subsidised initial treatment with this drug for this condition; AND  Patient must have demonstrated a sustained platelet response to PBS‑subsidised treatment with this drug for this condition under the Initial treatment restriction; AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition.  Patient must be an adult.  For the purposes of this restriction, a sustained platelet response is defined as:  (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the initial period of PBS‑subsidised treatment with this drug,  AND either of the following:  (b) a platelet count greater than or equal to 50,000 million per L on at least four (4) occasions, each at least one week apart;  OR  (c) a platelet count greater than 30,000 million per L and which is double the baseline (pre‑treatment) platelet count on at least four (4) occasions, each at least one week apart.  The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.  Authority approval will not be given for doses higher than 10 micrograms/kg/week  Applications for the First continuing PBS‑subsidised treatment or Re‑initiation of interrupted PBS‑subsidised treatment must be made in writing and must include:  (1) a completed authority prescription form, and  (2) a completed Idiopathic Thrombocytopenic Purpura Continuing PBS Authority Application ‑ Supporting Information Form , and  (3) copies of the platelet count pathology reports (unless previously provided for patients re‑initiating therapy).  The platelet count must be no more than one month old at the time of application. | Compliance with Written Authority Required procedures |
|  | C6738 |  | Severe thrombocytopenia  Initial 1, Initial 2, First Continuing treatment or Re‑initiation of interrupted treatment, and Second and Subsequent Continuing treatment ‑ balance of supply  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition; AND  Patient must have received insufficient therapy with this drug for this condition under the Initial 1 restriction to complete 24 weeks treatment; OR  Patient must have received insufficient therapy with this drug for this condition under the Initial 2 restriction to complete 24 weeks treatment; OR  Patient must have received insufficient therapy with this drug for this condition under the First Continuing treatment or Re‑initiation of interrupted treatment restriction to complete 24 weeks treatment; OR  Patient must have received insufficient therapy with this drug for this condition under the Second and subsequent Continuing treatment restriction to complete 24 weeks treatment; AND  The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.  Patient must be an adult. | Compliance with Authority Required procedures |
|  | C6766 |  | Severe thrombocytopenia  Initial treatment 2 ‑ New patient  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  Patient must not have had a splenectomy; AND  Patient must have failed to acheive an adequate response to, or be intolerant to, corticosteroid therapy at a dose equivalent to 0.5‑2 mg/kg/day of prednisone for at least 4‑6 weeks; AND  Patient must have failed to acheive an adequate response to, or be intolerant to, immunoglobulin therapy; AND  Patient must be unsuitable for splenectomy due to medical reasons; AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition.  Patient must be an adult.  The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of initial application;  (a) a platelet count of less than or equal to 20,000 million per L; OR  (b) a platelet count of 20,000 million to 30,000 million per L, where the patient is experiencing significant bleeding or has a history of significant bleeding in this platelet range.  At the time of the written authority application, medical practitioners should request the appropriate quantity of vials of appropriate strength to provide sufficient drug for a single treatment at a dose of 1 microgram/kg. Up to 1 repeat may be requested with the initial written application.  Subsequently during the initial period of dose titration, authority applications for a single dose and up to 1 repeat may be requested by telephone. The dose (microgram/kg/week) must be provided at the time of application.  Once a patient’s dose has been stable for a period of 4 weeks, authority approvals for sufficient vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) for up to 4 weeks of treatment and up to 4 repeats may be granted, as long as the total period of treatment authorised under this restriction does not exceed 24 weeks.  Authority approval will not be given for doses higher than 10 micrograms/kg/week  The authority application must be made in writing and must include:  (1) a completed authority prescription form,  (2) a signed patient acknowledgement,  (3) a completed Idiopathic Thrombocytopenic Purpura Initial PBS Authority Application ‑ Supporting Information Form,  (4) a copy of a full blood count pathology report supporting the diagnosis of ITP, and  (5) where the application is sought on the basis of a medical contraindication to surgery, a signed and dated letter from the clinician making this assessment which includes the date upon which the patient was assessed for surgery and the clinical grounds upon which surgery is contraindicated.  The full blood count must be no more than 1 month old at the time of application. | Compliance with Written Authority Required procedures |
|  | C6789 |  | Severe thrombocytopenia  Second or Subsequent Continuing treatment  The condition must be severe chronic immune (idiopathic) thrombocytopenic purpura (ITP); AND  Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND  Patient must have demonstrated a continuing response to treatment with this drug; AND  The treatment must be the sole PBS‑subsidised thrombopoietin receptor agonist (TRA) for this condition.  Patient must be an adult.  For the purpose of this restriction, a continuing response to treatment with drug is defined as:  (a) use of rescue medication (corticosteroids or immunoglobulins) on no more than one occasion during the most recent 24 week period of PBS‑subsidised treatment with this drug  AND either of the following:  (b) a platelet count greater than or equal to 50,000 million per L  OR  (c) a platelet count greater than 30,000 million per L and which is double the baseline platelet count.  The platelet count must be no more than one month old at the time of application.  The medical practitioner should request sufficient number of vials of appropriate strength based on the weight of the patient and dose (microgram/kg/week) to provide 4 weeks of treatment. Up to a maximum of 5 repeats may be authorised.  Authority approval will not be given for doses higher than 10 micrograms/kg/week  Authority applications for second and subsequent periods of continuing therapy may be made by telephone | Compliance with Authority Required procedures |
| Saquinavir | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Sevelamer | C5530 |  | Hyperphosphataemia Initiation and stabilisation The condition must not be adequately controlled by calcium; AND Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; OR The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy; AND The treatment must not be used in combination with any other non-calcium phosphate binding agents. Patient must be undergoing dialysis for chronic kidney disease. | Compliance with Authority Required procedures - Streamlined Authority Code 5530 |
|  | C9762 |  | Hyperphosphataemia Initiation and stabilisation The condition must not be adequately controlled by calcium; AND Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; OR The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy; AND The treatment must not be used in combination with any other non‑calcium phosphate binding agents. Patient must be undergoing dialysis for chronic kidney disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9762 |
| Sildenafil | C10228 |  | Pulmonary arterial hypertension (PAH) Continuing treatment Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent for this condition; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10234 |  | Pulmonary arterial hypertension (PAH) Initial 2 (change) Patient must have documented WHO Functional Class II PAH, or WHO Functional Class III PAH; AND Patient must have had their most recent course of PBS-subsidised treatment for this condition with a PAH agent other than this agent; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment (monotherapy) with 1 of these 8 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent’s restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap between the 8 PAH agents must be made under the relevant initial treatment (monotherapy) restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10304 |  | Pulmonary arterial hypertension (PAH) Initial 1 (new patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have WHO Functional Class II PAH, or WHO Functional Class III PAH; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C10998 |  | Pulmonary arterial hypertension (PAH) Continuing treatment (dual therapy) Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent and an endothelin receptor antagonist (ERA) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11012 |  | Pulmonary arterial hypertension (PAH) Initial 3 (dual therapy - change) Patient must have had their most recent course of PBS-subsidised dual therapy with an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i) other than this agent for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once patients are approved dual therapy with a PAH agent from the PDE-5i class; or a PAH agent from the ERA class, they may swap between PAH agents within the same class. This means that patients may commence treatment with another PAH agent in the same class, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap within a PAH agent class must be made under the relevant initial treatment restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11020 |  | Pulmonary arterial hypertension (PAH) Initial 2 (dual therapy - previously treated patients) Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH; AND Patient must have documented a failure to achieve or maintain WHO Functional Class II status with prior PBS-subsidised monotherapy treatment with an endothelin receptor antagonist (ERA) for this condition; AND The treatment must be in combination with a PBS-subsidised endothelin receptor antagonist (ERA) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. The results and date of the RHC, ECHO and 6 MWT as applicable must be included in the patient's medical record. Where a RHC cannot be performed on clinical grounds, the written confirmation of the reasons why must also be included in the patient's medical record. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11032 |  | Pulmonary arterial hypertension (PAH) Initial 1 (dual therapy - previously untreated patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must currently have WHO Functional Class III PAH or WHO Functional Class IV PAH; AND The treatment must be in combination with a PBS-subsidised endothelin receptor antagonist (ERA) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C11045 |  | Pulmonary arterial hypertension (PAH) Grandfathered patients (dual therapy) Patient must be receiving dual therapy with this non PBS-subsidised pulmonary arterial hypertension (PAH) agent and a non PBS-subsidised endothelin receptor antagonist (ERA) for this condition prior to 1 October 2020; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it was not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC could not be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests were able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC could not be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria for dual therapy for this condition. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
| Sirolimus | C5795 |  | Management of renal allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of renal allograft rejection, AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5795 |
|  | C9914 |  | Management of renal allograft rejection Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of renal allograft rejection; AND The treatment must be under the supervision and direction of a transplant unit. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9914 |
| Sofosbuvir | C5969 |  | Chronic hepatitis C infection Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 12 weeks. | Compliance with Authority Required procedures |
|  | C5972 |  | Chronic hepatitis C infection Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 24 weeks. | Compliance with Authority Required procedures |
| Sofosbuvir with velpatasvir | C5969 |  | Chronic hepatitis C infection  Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND  Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND  The treatment must be limited to a maximum duration of 12 weeks. | Compliance with Authority Required procedures |
| Sofosbuvir with velpatasvir and voxilaprevir | C10248 |  | Chronic hepatitis C infection Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND Patient must be taking this drug as part of a regimen set out in the matrix in the General Statement for Drugs for the Treatment of Hepatitis C, based on the hepatitis C virus genotype, patient treatment history and cirrhotic status; AND The treatment must be limited to a maximum duration of 12 weeks. The application must include details of the prior treatment regimen containing an NS5A inhibitor. | Compliance with Authority Required procedures |
| Sucroferric oxyhydroxide | C5530 |  | Hyperphosphataemia Initiation and stabilisation The condition must not be adequately controlled by calcium; AND Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; OR The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy; AND The treatment must not be used in combination with any other non-calcium phosphate binding agents. Patient must be undergoing dialysis for chronic kidney disease. | Compliance with Authority Required procedures - Streamlined Authority Code 5530 |
|  | C9762 |  | Hyperphosphataemia Initiation and stabilisation The condition must not be adequately controlled by calcium; AND Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; OR The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy; AND The treatment must not be used in combination with any other non‑calcium phosphate binding agents. Patient must be undergoing dialysis for chronic kidney disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9762 |
| Tacrolimus | C5569 |  | Management of rejection in patients following organ or tissue transplantation The treatment must be under the supervision and direction of a transplant unit, AND The treatment must include initiation, stabilisation, and review of therapy as required. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5569 |
|  | C9697 |  | Management of rejection in patients following organ or tissue transplantation The treatment must be under the supervision and direction of a transplant unit; AND The treatment must include initiation, stabilisation, and review of therapy as required. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9697 |
| Tadalafil | C10228 |  | Pulmonary arterial hypertension (PAH) Continuing treatment Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent for this condition; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10234 |  | Pulmonary arterial hypertension (PAH) Initial 2 (change) Patient must have documented WHO Functional Class II PAH, or WHO Functional Class III PAH; AND Patient must have had their most recent course of PBS-subsidised treatment for this condition with a PAH agent other than this agent; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once these patients are approved initial treatment (monotherapy) with 1 of these 8 drugs, they may swap between PAH agents at any time without having to re-qualify for treatment with the alternate agent. This means that patients may commence treatment with the alternate agent, subject to that agent’s restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap between the 8 PAH agents must be made under the relevant initial treatment (monotherapy) restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C10304 |  | Pulmonary arterial hypertension (PAH) Initial 1 (new patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have WHO Functional Class II PAH, or WHO Functional Class III PAH; AND The treatment must be the sole PBS-subsidised PAH agent for this condition. The term ‘PAH agents’ refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C10998 |  | Pulmonary arterial hypertension (PAH) Continuing treatment (dual therapy) Patient must have received their most recent course of PBS-subsidised treatment with this PAH agent and an endothelin receptor antagonist (ERA) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11012 |  | Pulmonary arterial hypertension (PAH) Initial 3 (dual therapy - change) Patient must have had their most recent course of PBS-subsidised dual therapy with an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i) other than this agent for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. Swapping between PAH agents: Patients can access PAH agents through the PBS according to the relevant restrictions. Once patients are approved dual therapy with a PAH agent from the PDE-5i class; or a PAH agent from the ERA class, they may swap between PAH agents within the same class. This means that patients may commence treatment with another PAH agent in the same class, subject to that agent's restriction, irrespective of the severity of their disease at the time the application to swap therapy is submitted. Applications to swap within a PAH agent class must be made under the relevant initial treatment restriction. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11020 |  | Pulmonary arterial hypertension (PAH) Initial 2 (dual therapy - previously treated patients) Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH; AND Patient must have documented a failure to achieve or maintain WHO Functional Class II status with prior PBS-subsidised monotherapy treatment with an endothelin receptor antagonist (ERA) for this condition; AND The treatment must be in combination with a PBS-subsidised endothelin receptor antagonist (ERA) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. The results and date of the RHC, ECHO and 6 MWT as applicable must be included in the patient's medical record. Where a RHC cannot be performed on clinical grounds, the written confirmation of the reasons why must also be included in the patient's medical record. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Authority Required procedures |
|  | C11032 |  | Pulmonary arterial hypertension (PAH) Initial 1 (dual therapy - previously untreated patients) Patient must not have received prior PBS-subsidised treatment with a pulmonary arterial hypertension (PAH) agent; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must currently have WHO Functional Class III PAH or WHO Functional Class IV PAH; AND The treatment must be in combination with a PBS-subsidised endothelin receptor antagonist (ERA) for this condition. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it is not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC cannot be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests are able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC cannot be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. The test results provided must not be more than 2 months old at the time of application. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
|  | C11045 |  | Pulmonary arterial hypertension (PAH) Grandfathered patients (dual therapy) Patient must be receiving dual therapy with this non PBS-subsidised pulmonary arterial hypertension (PAH) agent and a non PBS-subsidised endothelin receptor antagonist (ERA) for this condition prior to 1 October 2020; AND Patient must have been assessed by a physician with expertise in the management of PAH; AND Patient must have documented WHO Functional Class III PAH or WHO Functional Class IV PAH. The term 'PAH agents' refers to bosentan monohydrate, iloprost trometamol, epoprostenol sodium, sildenafil citrate, ambrisentan, tadalafil, macitentan, and riociguat. For the purposes of PBS subsidy, dual therapy refers to combined use of an endothelin receptor antagonist (ERA) and a phosphodiesterase-5 inhibitor (PDE-5i). (i) An ERA includes ambrisentan, bosentan monohydrate, or macitentan. (ii) A PDE-5i includes sildenafil citrate, or tadalafil. PAH agents are not PBS-subsidised for patients with pulmonary hypertension secondary to interstitial lung disease associated with connective tissue disease, where the total lung capacity is less than 70% of predicted. PAH (WHO Group 1 pulmonary hypertension) is defined as follows: (i) mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest and pulmonary artery wedge pressure (PAWP) less than or equal to 15 mmHg; or (ii) where a right heart catheter (RHC) cannot be performed on clinical grounds, right ventricular systolic pressure (RVSP), assessed by echocardiography (ECHO), greater than 40 mmHg, with normal left ventricular function. Applications for authorisation must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Pulmonary Arterial Hypertension PBS Authority Application - Supporting Information form which includes results from the three tests below, where available: (i) RHC composite assessment; and (ii) ECHO composite assessment; and (iii) 6 Minute Walk Test (6MWT). Where it was not possible to perform all 3 tests on clinical grounds, the following list outlines the preferred test combination, in descending order, for the purposes of initiation of PBS-subsidised treatment: (1) RHC plus ECHO composite assessments; (2) RHC composite assessment plus 6MWT; (3) RHC composite assessment only. In circumstances where a RHC could not be performed on clinical grounds, applications may be submitted for consideration based on the results of the following test combinations, which are listed in descending order of preference: (1) ECHO composite assessment plus 6MWT; (2) ECHO composite assessment only. Where fewer than 3 tests were able to be performed on clinical grounds, a patient specific reason outlining why the particular test(s) could not be conducted must be provided with the authority application. Where a RHC could not be performed on clinical grounds, confirmation of the reason(s) must be provided with the authority application by a second PAH physician or cardiologist with expertise in the management of PAH. A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria for dual therapy for this condition. The maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment, based on the dosage recommendations in the TGA-approved Product Information. A maximum of 5 repeats may be requested. | Compliance with Written Authority Required procedures |
| Teduglutide | C9515 |  | Type III Short bowel syndrome with intestinal failure Initial treatment or initial grandfather treatment ‑ balance of supply Must be treated by a gastroenterologist; OR Must be treated by a specialist within a multidisciplinary intestinal rehabilitation unit. Patient must have previously received PBS‑subsidised initial treatment with this drug for this condition; OR Patient must have received PBS‑subsidised treatment with this drug for this condition as a grandfathered patient; AND Patient must have received insufficient therapy with this drug under the initial or grandfather treatment restriction to complete the maximum duration of 12 months of initial treatment; AND The treatment must provide no more than the balance of up to 12 months of treatment. | Compliance with Authority Required procedures |
|  | C9569 |  | Type III Short bowel syndrome with intestinal failure Initial treatment Must be treated by a gastroenterologist; OR Must be treated by a specialist within a multidisciplinary intestinal rehabilitation unit. Patient must have short bowel syndrome with intestinal failure following major surgery; AND Patient must have a history of dependence on parenteral support for at least 12 months; AND Patient must have received a stable parenteral support regimen for at least 3 days per week in the previous 4 weeks; AND Patient must not have active gastrointestinal malignancy or history of gastrointestinal malignancy within the last 5 years; AND The treatment must not exceed 12 months under this restriction; AND Patient must not have previously received PBS‑subsidised treatment with this drug for this condition. Baseline is the mean number of days of parenteral support per week over the four weeks immediately prior to initiating treatment with teduglutide under the PBS initial treatment restriction or four weeks immediately prior to initiating treatment with non‑PBS subsidised teduglutide for grandfathered patients. A stable parenteral support regimen is defined as a minimum of 3 days of parenteral support (parenteral nutrition with or without IV fluids) per week for 4 consecutive weeks to meet caloric, fluid or electrolyte needs. Baseline number of days of parenteral support should be documented in the patient’s medical records. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Short bowel syndrome with intestinal failure form; and (3) details of baseline mean number of days on parenteral support per week for 4 consecutive weeks immediately preceding this application; and (4) documented duration in months of prior dependence on parenteral support. | Compliance with Written Authority Required procedures |
|  | C9687 |  | Type III Short bowel syndrome with intestinal failure Initial treatment ‑ Grandfathered patients Must be treated by a gastroenterologist; OR Must be treated by a specialist within a multidisciplinary intestinal rehabilitation unit. Patient must have previously received non‑PBS subsidised treatment with this drug for this condition prior to 1 October 2019; AND Patient must have short bowel syndrome with intestinal failure following major surgery; AND Patient must have had a history of dependence on parenteral support for at least 12 months prior to initiating non‑PBS subsidised treatment with this drug for this condition; AND Patient must have received a stable parenteral support regimen for at least 3 days per week in the 4 weeks prior to initiating non‑PBS subsidised treatment with this drug for this condition; AND Patient must not have active gastrointestinal malignancy or history of gastrointestinal malignancy within the last 5 years; AND Patient must have achieved a treatment response if the patient has been on non‑PBS subsidised therapy with this drug for more than 12 months. Baseline is the mean number of days of parenteral support per week over the 4 weeks immediately prior to initiating treatment with non‑PBS subsidised teduglutide for grandfathered patients. A stable parenteral support regimen is defined as a minimum of 3 days of parenteral support (parenteral nutrition with or without IV fluids) per week for 4 consecutive weeks to meet caloric, fluid or electrolyte needs. A patient has met the criteria for treatment response when there is a reduction in the mean number of days of parenteral support of at least 1 day per week since initiating non‑PBS subsidised treatment, or where a patient has completely ceased treatment with parenteral support for a period of at least 4 consecutive weeks prior to application for PBS‑subsidised treatment. The number of days of parenteral support is calculated as the mean number of days in which any parenteral support is required (parenteral nutrition with or without IV fluids) per week to meet caloric, fluid or electrolyte needs between commencement of non‑PBS subsidised teduglutide and application for PBS‑subsidised treatment. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Short bowel syndrome with intestinal failure Grandfather PBS Authority Application ‑ Supporting Information Form; and (3) details of non‑PBS subsidised teduglutide treatment start date; and (4) details of the mean number of days on parenteral support per week for 4 consecutive weeks prior to initiating non‑PBS subsidised therapy; and (5) documented duration in months of dependence on parenteral support prior to initiating non‑PBS subsidised treatment; and (6) details of response to teduglutide treatment if patient has received 12 or more months of non‑PBS subsidised treatment. A patient may qualify for PBS‑subsidised treatment under this restriction once only. For patients who have been on this drug for less than 12 months, the maximum number of repeats that will be approved will be for an amount equivalent to an initial 12 month supply of PBS and non‑PBS subsidised treatment. For patients who have been on this drug for more than 12 months, a maximum of 5 repeats will be approved. For continuing PBS‑subsidised treatment, a Grandfathered patient must qualify under the First continuing treatment criteria. | Compliance with Written Authority Required procedures |
|  | C9740 |  | Type III Short bowel syndrome with intestinal failure Subsequent continuing treatment Must be treated by a gastroenterologist; OR Must be treated by a specialist within a multidisciplinary intestinal rehabilitation unit. Patient must have received PBS‑subsidised first‑continuing treatment with this drug for this condition and achieved a treatment response in the preceding treatment period; OR Patient must have received PBS‑subsidised recommencement of treatment following a trial cessation period and not have previously experienced a failure to respond to treatment with this drug for this condition. Treatment response For applications for subsequent continuing treatment, treatment response is when there was a reduction in the mean number of days of parenteral support of at least 1 day per week since the last assessment for PBS‑subsidised treatment, OR where a patient has completely ceased treatment with parenteral support for a period of at least 4 consecutive weeks. The current mean number of days of parenteral support is calculated as the mean number of days in which any parenteral support is required (parenteral nutrition with or without IV fluids) per week to meet caloric, fluid or electrolyte needs over the immediately preceding 4 week treatment period Treatment failure For applications for subsequent continuing treatment, failure of treatment is defined as an increase in the mean number of days per week of parenteral support requirements of at least 1 day per week over the preceding 4 week period compared to the last assessment for PBS‑subsidised treatment of parenteral support (parenteral nutrition with or without IV fluids) to meet caloric, fluid or electrolyte needs. Patients who experience failure of treatment must permanently discontinue treatment. Treatment stability Patients who neither demonstrate a treatment response nor a treatment failure since the last assessment for PBS‑subsidised treatment are considered to have a stable parenteral support regimen, defined as the same mean number of days of parenteral support (parenteral nutrition with or without IV fluids) per week to meet caloric, fluid or electrolyte needs over the 4 weeks preceding treatment period, where the number of days is greater than zero and the mean number of days of parenteral support is less than baseline. Patients with a stable parenteral support regimen over 6 months must undertake a trial cessation period. Patients who have re‑commenced after a trial cessation period are exempt from further trial cessation. Trial cessation period Patients who demonstrate a stable frequency of mean days per week of parenteral support in a 6‑month period commencing after the initial 12 months of treatment with this drug for this condition are required to undertake a trial of treatment cessation. Patients who have re‑commenced after a trial cessation period are exempt from further trial cessation. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Short bowel syndrome with intestinal failure Form; and (3) details of the mean number of days reduction of parenteral support (parenteral nutrition with or without IV fluids) per week to meet caloric, fluid or electrolyte needs over the preceding treatment period or confirmation the patient has had 4 consecutive weeks without parenteral support (if applicable); and (4) the current mean number of days per week of parenteral support over the preceding 4 week period. | Compliance with Written Authority Required procedures |
|  | C9793 |  | Type III Short bowel syndrome with intestinal failure First continuing treatment Must be treated by a gastroenterologist; OR Must be treated by a specialist within a multidisciplinary intestinal rehabilitation unit. Patient must have previously received PBS‑subsidised initial treatment with this drug for this condition; OR Patient must have received PBS‑subsidised treatment with this drug for this condition as a grandfathered patient; AND Patient must have a reduction in parenteral support frequency of at least one day per week compared to the mean number of days per week at baseline. Baseline is the mean number of days of parenteral support per week over the four weeks immediately prior to initiating treatment with teduglutide under the PBS initial treatment restriction or four weeks immediately prior to initiating treatment with non‑PBS subsidised teduglutide for grandfathered patients. The current mean number of days of parenteral support is calculated as the mean number of days in which any parenteral support is required (parenteral nutrition with or without IV fluids) per week to meet caloric, fluid or electrolyte needs over the immediately preceding 4 week treatment period Treatment failure For applications for first continuing treatment, failure of treatment is defined as no change compared to baseline in the mean number of days per week in parenteral support (parenteral nutrition with or without IV fluids) to meet caloric, fluid or electrolyte needs. Patients who experience failure of treatment must permanently discontinue treatment. Current mean number of days of parenteral support should be documented in the patient’s medical records. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Short bowel syndrome with intestinal failure Form; and (3) details of the mean number of days reduction of parenteral support (parenteral nutrition with or without IV fluids) per week to meet caloric, fluid or electrolyte needs from baseline; and (4) the current mean number of days per week of parenteral support over the preceding 4 week period. | Compliance with Written Authority Required procedures |
|  | C9829 |  | Type III Short bowel syndrome with intestinal failure Recommencement of treatment Must be treated by a gastroenterologist; OR Must be treated by a specialist within a multidisciplinary intestinal rehabilitation unit. Patient must have received PBS‑subsidised treatment with this drug for this condition; AND Patient must have undertaken a trial cessation period due to experiencing a stable parenteral support regimen in the first continuing or subsequent continuing treatment phase, and not due to a treatment failure; AND Patient must have experienced deterioration during a trial cessation period. Trial cessation period Patients who demonstrate a stable frequency of mean days per week of parenteral support in a 6‑month period commencing after the initial 12 months of treatment with this drug for this condition are required to undertake a trial of treatment cessation. Patients who have re‑commenced after a trial cessation period are exempt from further trial cessation. Deterioration during the trial cessation period includes an increase in parenteral support frequency of more than or equal to one day per week from the pre‑cessation level, or other clinical parameters suggestive of deterioration including changes in renal function or urinary sodium levels or changes in body weight. The authority application must be made in writing and must include: (1) a completed authority prescription form; and (2) a completed Short bowel syndrome with intestinal failure Form; and (3) details of the reason for recommencement after trial cessation; and (4) the current mean number of days per week of parenteral support over the preceding 4 week period (5) details of completion of the trial cessation period including the start and end date. | Compliance with Authority Required procedures |
| Tenofovir | C6980 | P6980 | Chronic hepatitis B infection  Patient must have cirrhosis; AND  Patient must be nucleoside analogue naive; AND  Patient must have detectable HBV DNA; AND  The treatment must be the sole PBS‑subsidised therapy for this condition.  Patients with Child’s class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6980 |
|  | C6982 | P6982 | HIV infection  Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND  The treatment must be in combination with other antiretroviral agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6982 |
|  | C6983 | P6983 | Chronic hepatitis B infection  Patient must have cirrhosis; AND  Patient must have failed antihepadnaviral therapy; AND  Patient must have detectable HBV DNA.  Patients with Child’s class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6983 |
|  | C6984 | P6984 | Chronic hepatitis B infection  Patient must not have cirrhosis; AND  Patient must have failed antihepadnaviral therapy; AND  Patient must have repeatedly elevated serum ALT levels while on concurrent antihepadnaviral therapy of greater than or equal to 6 months duration, in conjunction with documented chronic hepatitis B infection; OR  Patient must have repeatedly elevated HBV DNA levels one log greater than the nadir value or failure to achieve a 1 log reduction in HBV DNA within 3 months whilst on previous antihepadnaviral therapy, except in patients with evidence of poor compliance. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6984 |
|  | C6992 | P6992 | Chronic hepatitis B infection  Patient must not have cirrhosis; AND  Patient must be nucleoside analogue naive; AND  Patient must have elevated HBV DNA levels greater than 20,000 IU/mL (100,000 copies/mL) if HBeAg positive, in conjunction with documented hepatitis B infection; OR  Patient must have elevated HBV DNA levels greater than 2,000 IU/mL (10,000 copies/mL) if HBeAg negative, in conjunction with documented hepatitis B infection; AND  Patient must have evidence of chronic liver injury determined by: (i) confirmed elevated serum ALT; or (ii) liver biopsy; AND  The treatment must be the sole PBS‑subsidised therapy for this condition. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6992 |
|  | C6998 | P6998 | HIV infection  Initial  Patient must be antiretroviral treatment naive; AND  The treatment must be in combination with other antiretroviral agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6998 |
|  | C10362 | P10362 | Chronic hepatitis B infection Patient must be in the third trimester of pregnancy; AND Patient must have elevated HBV DNA levels greater than 200,000 IU/mL (1,000,000 copies/mL), in conjunction with documented hepatitis B infection. | Compliance with Authority Required  procedures ‑ Streamlined Authority Code 10362 |
| Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat | C4470 |  | HIV infection Continuing Patient must have previously received PBS‑subsidised therapy for HIV infection. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4470 |
|  | C4522 |  | HIV infection Initial Patient must be antiretroviral treatment naive. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4522 |
| Tenofovir with emtricitabine | C6985 |  | HIV infection  Initial  Patient must be antiretroviral treatment naive; AND  The treatment must be in combination with other antiretroviral agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6985 |
|  | C6986 |  | HIV infection  Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND  The treatment must be in combination with other antiretroviral agents. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 6986 |
| Tenofovir with emtricitabine and efavirenz | C4470 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4470 |
|  | C4522 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4522 |
| Tezacaftor with ivacaftor and ivacaftor | C9880 |  | Cystic fibrosis ‑ homozygous for the F508del mutation Continuing treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition; AND The treatment must be given concomitantly with standard therapy for this condition. Patient must be 12 years of age or older. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. Patients who have an acute infective exacerbation at the time of assessment for continuing therapy may receive an additional one month’s supply in order to enable the assessment to be repeated following resolution of the exacerbation. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. Dosage of tezacaftor with ivacaftor is tezacaftor 100 mg/ivacaftor 150 mg and ivacaftor 150 mg tablets on alternate days if the patient is concomitantly receiving one of the following moderate CYP3A4 drugs inhibitors: amprenavir, aprepitant, atazanavir, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil. Dosage of tezacaftor with ivacaftor is tezacaftor 100 mg/ivacaftor 150 mg twice weekly (approximately 3 or 4 days apart) if the patient is concomitantly receiving one of the following strong CYP3A4 inhibitors: boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole. Tezacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort; Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin; Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis tezacaftor with ivacaftor Continuing Authority Application Supporting Information Form; and (3) the result of a FEV1measurement performed within a month prior to the date of application. Note: FEV1, must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (4) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (5) height and weight measurements at the time of application; and (6) the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 6 months. | Compliance with Written Authority Required procedures |
|  | C9961 |  | Cystic fibrosis ‑ homozygous for the F508del mutation Initial treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must be homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition; AND The treatment must be given concomitantly with standard therapy for this condition; AND Patient must have either chronic sinopulmonary disease or gastrointestinal and nutritional abnormalities. Patient must be 12 years of age or older. The patient must be registered in the Australian Cystic Fibrosis Database Registry. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. Dosage of tezacaftor with ivacaftor is tezacaftor 100 mg/ivacaftor 150 mg and ivacaftor 150 mg tablets on alternate days if the patient is concomitantly receiving one of the following moderate CYP3A4 drugs inhibitors: amprenavir, aprepitant, atazanavir, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil. Dosage of tezacaftor with ivacaftor is tezacaftor 100 mg/ivacaftor 150 mg twice weekly (approximately 3 or 4 days apart) if the patient is concomitantly receiving one of the following strong CYP3A4 inhibitors: boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole. Tezacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort; Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin; Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis tezacaftor with ivacaftor Authority Application Supporting Information Form; and (3) a copy of the pathology report detailing the molecular testing for the patient being homozygous for the F508del mutation on the CFTR gene; and (4) the result of a FEV1measurement performed within a month prior to the date of application. Note: FEV1must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (5) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (6) height and weight measurements at the time of application; and (7) a baseline measurement of the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 12 months. For patients who have initiated non‑PBS subsidised treatment prior to 1 December 2019, date of initiating treatment, baseline FEV1and hospitalisation dates prior to initiating treatment (where available) should be provided. | Compliance with Written Authority Required procedures |
|  | C10064 |  | Cystic fibrosis ‑ one residual function (RF) mutation Initial treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must have at least one residual function (RF) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor with ivacaftor; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition; AND The treatment must be given concomitantly with standard therapy for this condition; AND Patient must have either chronic sinopulmonary disease or gastrointestinal and nutritional abnormalities. Patient must be 12 years of age or older. The patient must be registered in the Australian Cystic Fibrosis Database Registry. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. For the purposes of this restriction, the list of mutations considered to be responsive to tezacaftor with ivacaftor is defined in the TGA approved product information. Dosage of tezacaftor with ivacaftor is tezacaftor 100 mg/ivacaftor 150 mg and ivacaftor 150 mg tablets on alternate days if the patient is concomitantly receiving one of the following moderate CYP3A4 drugs inhibitors: amprenavir, aprepitant, atazanavir, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil. Dosage of tezacaftor with ivacaftor is tezacaftor 100 mg/ivacaftor 150 mg twice weekly (approximately 3 or 4 days apart) if the patient is concomitantly receiving one of the following strong CYP3A4 inhibitors: boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole. Tezacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort; Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin; Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis tezacaftor with ivacaftor Authority Application Supporting Information Form; and (3) a copy of the pathology report detailing the molecular testing for the patient having at least one RF mutation on the CFTR gene; and (4) the result of a FEV1measurement performed within a month prior to the date of application. Note: FEV1, must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (5) CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (6) height and weight measurements at the time of application; and (7) a baseline measurement of the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 12 months. For patients who have initiated non‑PBS subsidised treatment prior to 1 December 2019, date of initiating treatment, baseline FEV1and hospitalisation dates prior to initiating treatment (where available) should be provided. | Compliance with Written Authority Required procedures |
|  | C10069 |  | Cystic fibrosis ‑ one residual function (RF) mutation Continuing treatment Must be treated by a specialist respiratory physician with expertise in cystic fibrosis or in consultation with a specialist respiratory physician with expertise in cystic fibrosis if attendance is not possible due to geographic isolation; AND Must be treated in a centre with expertise in cystic fibrosis or in consultation with a centre with expertise in cystic fibrosis if attendance is not possible due to geographic isolation. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND The treatment must be the sole PBS‑subsidised cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy for this condition; AND The treatment must be given concomitantly with standard therapy for this condition. Patient must be 12 years of age or older. Treatment must not be given to a patient who has an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease in the last 4 weeks prior to commencing this drug. Patients who have an acute infective exacerbation at the time of assessment for continuing therapy may receive an additional one month’s supply in order to enable the assessment to be repeated following resolution of the exacerbation. For the purposes of this restriction, PBS subsidised ‘CFTR modulator’ means ivacaftor, lumacaftor/ivacaftor and tezacaftor/ivacaftor. Dosage of tezacaftor with ivacaftor is tezacaftor 100 mg/ivacaftor 150 mg and ivacaftor 150 mg tablets on alternate days if the patient is concomitantly receiving one of the following moderate CYP3A4 drugs inhibitors: amprenavir, aprepitant, atazanavir, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil. Dosage of tezacaftor with ivacaftor is tezacaftor 100 mg/ivacaftor 150 mg twice weekly (approximately 3 or 4 days apart) if the patient is concomitantly receiving one of the following strong CYP3A4 inhibitors: boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole. Tezacaftor with ivacaftor is not PBS‑subsidised for this condition in a patient who is currently receiving one of the following CYP3A4 inducers: Strong CYP3A4 inducers: avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, St. John’s wort; Moderate CYP3A4 inducers: bosentan, efavirenz, etravirine, modafinil, nafcillin; Weak CYP3A4 inducers: armodafinil, echinacea, pioglitazone, rufinamide. The authority application must be in writing and must include: (1) a completed authority prescription form; and (2) a completed Cystic Fibrosis tezacaftor with ivacaftor Continuing Authority Application Supporting Information Form; and (3) the result of a FEV1measurement performed within a month prior to the date of application. Note: FEV1, must be measured in an accredited pulmonary function laboratory, with documented no acute infective exacerbation at the time FEV1is measured; and (4) current CYP3A4 inhibitors, CYP3A4 inducers and IV antibiotics; and (5) height and weight measurements at the time of application; and (6) the number of days of CF‑related hospitalisation (including hospital‑in‑the home) in the previous 6 months. | Compliance with Written Authority Required procedures |
| Thalidomide | C5914 |  | Multiple myeloma | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5914 |
|  | C9290 |  | Multiple myeloma | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9290 |
| Tipranavir | C5764 |  | HIV infection  The treatment must be in addition to optimised background therapy, AND The treatment must be in combination with other antiretroviral agents, AND Patient must be antiretroviral experienced, AND The treatment must be co‑administered with 200 mg ritonavir twice daily, AND Patient must have experienced virological failure or clinical failure or genotypic resistance after each of at least 3 different antiretroviral regimens that have included one drug from at least 3 different antiretroviral classes. Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment‑limiting toxicity. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5764 |
| Tocilizumab | C8627 |  | Severe active rheumatoid arthritis Continuing Treatment ‑ balance of supply. Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction. | Compliance with Authority Required procedures |
|  | C8635 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 2 (change or re‑commencement of treatment after a break in biological medicine of less than 24 months) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must not have failed to respond to previous PBS‑subsidised treatment with this drug for this condition; AND Patient must not have already failed , or ceased to respond to, PBS‑subsidised biological medicine treatment for this condition 5 times; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). An application for a patient who has received PBS‑subsidised treatment with this drug and who wishes to re‑commence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised treatment with this drug, within the timeframes specified below. Where the most recent course of PBS‑subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. A patient who has demonstrated a response to a course of rituximab must have a PBS‑subsidised biological therapy treatment‑free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine. | Compliance with Written Authority Required procedures |
|  | C8636 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 3 (re‑commencement of treatment after a break in biological medicine of more than 24 months) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 24 months or more from the most recent PBS‑subsidised biological medicine for this condition; AND Patient must not have failed to respond to previous PBS‑subsidised treatment with this drug for this condition; AND Patient must not have already failed , or ceased to respond to, PBS‑subsidised biological medicine treatment for this condition 5 times; AND The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; OR The condition must have a C‑reactive protein (CRP) level greater than 15 mg per L; AND The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be aged 18 years or older. Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C8637 |  | Severe active rheumatoid arthritis Continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient has either failed or ceased to respond to a PBS‑subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS‑subsidised treatment with a biological medicine for this condition. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C8638 |  | Severe active rheumatoid arthritis Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) ‑ balance of supply Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | Compliance with Authority Required procedures |
|  | C8709 |  | Severe active rheumatoid arthritis Initial treatment ‑ Initial 1 (new patient) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must not have received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti‑rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)‑approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA‑approved Product Information or cannot be tolerated at the doses specified above, must include at least 3 months continuous treatment with each of at least 2 DMARDs, with one or more of the following DMARDs being used in place of the DMARDS which are contraindicated or not tolerated: (i) azathioprine at a dose of at least 1 mg/kg per day; and/or (ii) cyclosporin at a dose of at least 2 mg/kg/day; and/or (iii) sodium aurothiomalate at a dose of 50 mg weekly; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be aged 18 years or older. If methotrexate is contraindicated according to the TGA‑approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable. The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C‑reactive protein (CRP) level greater than 15 mg per L; AND either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active joints from the following list of major joints: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) a completed authority prescription form(s); and (2) a completed Rheumatoid Arthritis PBS Authority Application ‑ Supporting Information Form. It is recommended that an assessment of a patient’s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment. To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS‑subsidised treatment with this drug for this condition. Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. | Compliance with Written Authority Required procedures |
|  | C9380 |  | Severe active juvenile idiopathic arthritis Continuing Treatment ‑ balance of supply Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction. | Compliance with Authority Required procedures |
|  | C9384 |  | Severe active juvenile idiopathic arthritis Continuing treatment ‑ balance of supply Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction. | Compliance with Authority Required procedures |
|  | C9386 |  | Severe active juvenile idiopathic arthritis Initial treatment ‑ Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) ‑ balance of supply Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | Compliance with Authority Required procedures |
|  | C9407 |  | Severe active juvenile idiopathic arthritis Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 24 months or more from the most recently approved PBS‑subsidised biological medicine for this condition; OR Patient must not have received PBS‑subsidised biological medicine for at least 5 years if they failed or ceased to respond to PBS‑subsidised biological medicine treatment 3 times in their last treatment cycle; AND The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; OR The condition must have a C‑reactive protein (CRP) level greater than 15 mg per L; AND The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be aged 18 years or older. Active joints are defined as: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). All measures of joint count must be no more than 4 weeks old at the time of this application. At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for one infusion. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application ‑ Supporting Information Form. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C9417 |  | Severe active juvenile idiopathic arthritis Initial treatment ‑ Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) ‑ balance of supply Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) restriction to complete 16 weeks treatment; AND The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | Compliance with Authority Required procedures |
|  | C9494 |  | Severe active juvenile idiopathic arthritis Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; AND Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) an active joint count of fewer than 10 active (swollen and tender) joints; or (b) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or (c) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for one infusion. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application ‑ Supporting Information Form. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient who fails to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS‑subsidised treatment with this drug in this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the initial 3 treatment restriction. If a patient fails to respond to PBS‑subsidised biological medicine treatment 3 times (once with each agent) they will not be eligible to receive further PBS‑subsidised biological medicine therapy in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C9495 |  | Severe active juvenile idiopathic arthritis Continuing treatment Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction. Patient must be aged 18 years or older. An adequate response to treatment is defined as: an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; AND either of the following: (a) an active joint count of fewer than 10 active (swollen and tender) joints; or (b) a reduction in the active (swollen and tender) joint count by at least 50% from baseline; or (c) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application ‑ Supporting Information Form. At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for one infusion. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats will be authorised. Where the most recent course of PBS‑subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. If a patient fails to respond to PBS‑subsidised biological medicine treatment 3 times (once with each agent) they will not be eligible to receive further PBS‑subsidised biological medicine therapy in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C9496 |  | Severe active juvenile idiopathic arthritis Initial treatment ‑ Initial 1 (new patient) Must be treated by a rheumatologist; OR Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. Patient must have a documented history of severe active juvenile idiopathic arthritis with onset prior to the age of 18 years; AND Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti‑rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)‑approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; OR Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA‑approved Product Information or cannot be tolerated at the doses specified above, must include at least 3 months continuous treatment with each of at least 2 DMARDs, with one or more of the following DMARDs being used in place of the DMARDS which are contraindicated or not tolerated: (i) azathioprine at a dose of at least 1 mg/kg per day; and/or (ii) cyclosporin at a dose of at least 2 mg/kg/day; and/or (iii) sodium aurothiomalate at a dose of 50 mg weekly; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be aged 18 years or older. If methotrexate is contraindicated according to the TGA‑approved Product Information or cannot be tolerated at a 20 mg weekly dose, the application must include details of the contraindication or intolerance to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable. The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances. The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance and dose for each DMARD must be provided in the authority application. The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C‑reactive protein (CRP) level greater than 15 mg per L; AND either (a) an active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active joints from the following list: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application ‑ Supporting Information Form. At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for one infusion. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C10532 |  | Systemic juvenile idiopathic arthritis Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months) Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must have had a break in treatment of 12 months or more from this drug for this condition; AND Patient must have polyarticular course disease and the condition must have (a) an active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active joints from the following list of major joints: i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth); OR Patient must have refractory systemic symptoms and the condition must have (a) an active joint count of at least 2 active joints; and (b) persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; and/or (c) a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN); AND Patient must not receive more than 16 weeks of treatment under this restriction. Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must be under 18 years of age. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form which includes the following: (i) the date of assessment of severe active systemic juvenile idiopathic arthritis; (ii) pathology reports detailing C-reactive protein (CRP) level and platelet count where appropriate. The most recent systemic juvenile idiopathic arthritis assessment must be no more than 4 weeks old at the time of application. At the time of authority application, the medical practitioner must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month’s supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below. The assessment of the patient’s response to the most recent course of biological medicine must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed that most recent course of treatment in this treatment cycle. If a patient fails to demonstrate a response to 2 courses of treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition in the current treatment cycle. A serious adverse reaction of a severity requiring permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C10535 |  | Systemic juvenile idiopathic arthritis Initial treatment - Initial 1 (new patient) Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have polyarticular course disease which has failed to respond adequately to oral or parenteral methotrexate at a dose of at least 15 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; OR Patient must have polyarticular course disease and have demonstrated severe intolerance of, or toxicity due to, methotrexate; OR Patient must have refractory systemic symptoms, demonstrated by an inability to decrease and maintain the dose of prednisolone (or equivalent) below 0.5 mg per kg per day following a minimum of 2 months of therapy; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be under 18 years of age. Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. The following criteria indicate failure to achieve an adequate response to prior methotrexate therapy in a patient with polyarticular course disease and must be demonstrated in the patient at the time of the initial application: (a) an active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active joints from the following list of major joints: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The following criteria indicate failure to achieve an adequate response to prior therapy in a patient with refractory systemic symptoms and must be demonstrated in the patient at the time of the initial application: (a) an active joint count of at least 2 active joints; and (b) persistent fever greater than 38 degrees Celsius for at least 5 out of 14 consecutive days; and/or (c) a C-reactive protein (CRP) level and platelet count above the upper limits of normal (ULN). The baseline measurements of joint count, fever and/or CRP level and platelet count must be performed preferably whilst on treatment, but no longer than 4 weeks following cessation of the most recent prior treatment. The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments. Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant non-steroidal anti-inflammatory drugs (NSAIDs) on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours. Toxicity due to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis. If treatment with methotrexate alone or in combination with other treatments is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application. If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, details of this toxicity must be provided at the time of application. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form which includes the following: (i) the date of assessment of severe active systemic juvenile idiopathic arthritis; (ii) details of prior treatment including dose and duration of treatment; (iii) pathology reports detailing CRP and platelet count where appropriate. At the time of authority application, the medical practitioner must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month’s supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. The assessment of the patient’s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C10536 |  | Systemic juvenile idiopathic arthritis Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment under this restriction. Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. An adequate response to treatment is defined as: (a) in a patient with polyarticular course disease: (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%: - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). (b) in a patient with refractory systemic symptoms: (i) absence of fever greater than 38 degrees Celsius in the preceding seven days; and/or (ii) a reduction in the C-reactive protein (CRP) level and platelet count by at least 30% from baseline; and/or (iii) a reduction in the dose of corticosteroid by at least 30% from baseline. Determination of whether a response has been demonstrated to initial and subsequent courses of treatment will be based on the baseline measurements of disease severity submitted with the initial treatment application. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form which includes baseline and current pathology reports detailing CRP and platelet count where appropriate. The most recent systemic juvenile idiopathic arthritis assessment must be no more than 4 weeks old at the time of application. At the time of authority application, the medical practitioner must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month’s supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats will be authorised. The assessment of the patient’s response to the most recent course of biological medicine must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed that most recent course of treatment in this treatment cycle. The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed in the month prior to completing their current course of treatment. If a patient fails to demonstrate a response to 2 courses of treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition in the current treatment cycle. A serious adverse reaction of a severity requiring permanent withdrawal of treatment is not considered as a treatment failure. A patient may re-trial this drug after a minimum of 12 months have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C10541 |  | Severe active juvenile idiopathic arthritis Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND Patient must not receive more than 16 weeks of treatment under this restriction. An adequate response to treatment is defined as: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for one infusion. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient who fails to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. A patient may re-trial this drug after a minimum of 12 months have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the initial 3 treatment restriction. If a patient fails to respond to PBS-subsidised biological medicine treatment 3 times (once with each agent) they will not be eligible to receive further PBS-subsidised biological medicine therapy in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C10542 |  | Severe active juvenile idiopathic arthritis Continuing treatment Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND Patient must have demonstrated an adequate response to treatment with this drug; AND Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction. An adequate response to treatment is defined as: (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (b) a reduction in the number of the following active joints, from at least 4, by at least 50%: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). Determination of whether a response has been demonstrated to initial and subsequent courses of treatment will be based on the baseline measurement of joint count submitted with the initial treatment application. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for one infusion. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 5 repeats will be authorised. Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re-trial this drug after a minimum of 12 months have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. If a patient fails to respond to PBS-subsidised biological medicine treatment 3 times (once with each agent) they will not be eligible to receive further PBS-subsidised biological medicine therapy in this treatment cycle. | Compliance with Written Authority Required procedures |
|  | C10545 |  | Severe active juvenile idiopathic arthritis Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have had a break in treatment of 12 months or more from the most recently approved PBS-subsidised biological medicine for this condition; AND The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND Patient must not receive more than 16 weeks of treatment under this restriction. Active joints are defined as: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). All measures of joint count must be no more than 4 weeks old at the time of this application. Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of active joints, the response must be demonstrated on the total number of active joints. At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for one infusion. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C10567 |  | Systemic juvenile idiopathic arthritis Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) Patient must have received prior PBS-subsidised treatment with this drug for this condition in the previous 12 months; AND Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug more than once during the current treatment cycle; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be under 18 years of age. Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. An adequate response to treatment is defined as: (a) in a patient with polyarticular course disease: (i) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or (ii) a reduction in the number of the following major active joints, from at least 4, by at least 50%: - elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or - shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). (b) in a patient with refractory systemic symptoms: (i) absence of fever greater than 38 degrees Celsius in the preceding seven days; and/or (ii) a reduction in the C-reactive protein (CRP) level and platelet count by at least 30% from baseline; and/or (iii) a reduction in the dose of corticosteroid by at least 30% from baseline. At the time of authority application, the medical practitioner must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for two infusions (one month’s supply). A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Systemic Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form which includes pathology reports detailing C-reactive protein (CRP) level and platelet count where appropriate. An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to retrial or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below. The assessment of the patient’s response to the most recent course of biological medicine must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed that most recent course of treatment in this treatment cycle. If a patient fails to demonstrate a response to 2 courses of treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition in the current treatment cycle. A serious adverse reaction of a severity requiring permanent withdrawal of treatment is not considered as a treatment failure. A patient may re-trial this drug after a minimum of 12 months have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C10570 |  | Systemic juvenile idiopathic arthritis Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under Initial 3 (recommencement of treatment after a break of more than 12 months) restriction to complete 16 weeks treatment; AND The treatment must provide no more than the balance of up to 16 weeks therapy available under Initial 1, 2 or 3 treatment. Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. | Compliance with Authority Required procedures |
|  | C10571 |  | Systemic juvenile idiopathic arthritis Balance of supply - Continuing treatment Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND The treatment must provide no more than the balance of up to 24 weeks therapy available under Continuing treatment. Must be treated by a rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. | Compliance with Authority Required procedures |
|  | C10616 |  | Severe active juvenile idiopathic arthritis Initial treatment - Initial 1 (new patient) Must be treated by a paediatric rheumatologist; OR Patient must be undergoing treatment under the supervision of a paediatric rheumatology treatment centre. Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have demonstrated severe intolerance of, or toxicity due to, methotrexate; OR Patient must have demonstrated failure to achieve an adequate response to 1 or more of the following treatment regimens: (i) oral or parenteral methotrexate at a dose of at least 20 mg per square metre weekly, alone or in combination with oral or intra-articular corticosteroids, for a minimum of 3 months; or (ii) oral methotrexate at a dose of at least 10 mg per square metre weekly together with at least 1 other disease modifying anti-rheumatic drug (DMARD), alone or in combination with corticosteroids, for a minimum of 3 months; AND Patient must not receive more than 16 weeks of treatment under this restriction. Patient must be under 18 years of age. Severe intolerance to methotrexate is defined as intractable nausea and vomiting and general malaise unresponsive to manoeuvres, including reducing or omitting concomitant non-steroidal anti-inflammatory drugs (NSAIDs) on the day of methotrexate administration, use of folic acid supplementation, or administering the dose of methotrexate in 2 divided doses over 24 hours. Toxicity due to methotrexate is defined as evidence of hepatotoxicity with repeated elevations of transaminases, bone marrow suppression temporally related to methotrexate use, pneumonitis, or serious sepsis. If treatment with methotrexate alone or in combination with another DMARD is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application. If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, details of this toxicity must be provided at the time of application. The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: (a) an active joint count of at least 20 active (swollen and tender) joints; OR (b) at least 4 active joints from the following list: (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder, cervical spine and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). The joint count assessment must be performed preferably whilst still on DMARD treatment, but no longer than 4 weeks following cessation of the most recent prior treatment. The authority application must be made in writing and must include: (1) completed authority prescription form(s); and (2) a completed Juvenile Idiopathic Arthritis PBS Authority Application - Supporting Information Form. At the time of authority application, medical practitioners must request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for one infusion. A separate authority prescription form must be completed for each strength requested. Up to a maximum of 3 repeats will be authorised. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
| Ustekinumab | C9655 |  | Severe Crohn disease Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; AND The treatment must not exceed a total of 2 doses to be administered at weeks 0 and 8 under this restriction. Patient must be aged 18 years or older. Applications for authorisation must be made in writing and must include: (a) two completed authority prescription forms; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient’s condition, if relevant; or (ii) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy for patients with short gut syndrome, extensive small intestine disease or an ostomy, if relevant; and (iii) the date of clinical assessment; and (iv) the details of prior biological medicine treatment including the details of date and duration of treatment. Two completed authority prescriptions should be submitted with every initial application for this drug. One prescription should be written under S100 (Highly Specialised Drugs) for a weight‑based loading dose, containing a quantity of up to 4 vials of 130 mg and no repeats. The second prescription should be written under S85 (General) for 2 vials of 45 mg and no repeats. A maximum quantity of a weight based loading dose is up to 4 vials with no repeats and the subsequent first dose of 90 mg (2 vials of 45 mg) with no repeats provide for an initial 16 week course of this drug will be authorised. Where fewer than 6 vials in total are requested at the time of the application, authority approvals for a sufficient number of vials based on the patient’s weight to complete dosing at weeks 0 and 8 may be requested by telephone through the balance of supply restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of biological medicine therapy within the timeframes specified in the relevant restriction. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy for adalimumab or ustekinumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and vedolizumab and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C9656 |  | Severe Crohn disease Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND Patient must have confirmed severe Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician; AND Patient must have a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 that is no more than 4 weeks old at the time of application; OR Patient must have a documented history of intestinal inflammation and have diagnostic imaging or surgical evidence of short gut syndrome if affected by the syndrome or has an ileostomy or colostomy; OR Patient must have a documented history and radiological evidence of intestinal inflammation if the patient has extensive small intestinal disease affecting more than 50 cm of the small intestine, together with a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220 and that is no more than 4 weeks old at the time of application; AND Patient must have evidence of intestinal inflammation; OR Patient must be assessed clinically as being in a high faecal output state; OR Patient must be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of this drug, if affected by short gut syndrome, extensive small intestine disease or is an ostomy patient; AND The treatment must not exceed a total of 2 doses to be administered at weeks 0 and 8 under this restriction. Patient must be aged 18 years or older. Applications for authorisation must be made in writing and must include: (a) two completed authority prescription forms; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient’s condition if relevant; and (ii) the reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and (iii) the date of the most recent clinical assessment. Evidence of intestinal inflammation includes: (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C‑reactive protein (CRP) level greater than 15 mg per L; or (ii) faeces: higher than normal lactoferrin or calprotectin level; or (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery. Two completed authority prescriptions should be submitted with every initial application for this drug. One prescription should be written under S100 (Highly Specialised Drugs) for a weight‑based loading dose, containing a quantity of up to 4 vials of 130 mg and no repeats. The second prescription should be written under S85 (General) for 2 vials of 45 mg and no repeats. A maximum quantity of a weight based loading dose is up to 4 vials with no repeats and the subsequent first dose of 90 mg (2 vials of 45 mg) with no repeats provide for an initial 16 week course of this drug will be authorised. Where fewer than 6 vials in total are requested at the time of the application, authority approvals for a sufficient number of vials based on the patient’s weight to complete dosing at weeks 0 and 8 may be requested by telephone through the balance of supply restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS‑subsidised therapy. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9710 |  | Severe Crohn disease Initial treatment ‑ Initial 1 (new patient) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must be aged 18 years or older. Patient must have confirmed severe Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician; AND Patient must have failed to achieve an adequate response to prior systemic therapy with a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; AND Patient must have failed to achieve adequate response to prior systemic immunosuppressive therapy with azathioprine at a dose of at least 2 mg per kg daily for 3 or more consecutive months; OR Patient must have failed to achieve adequate response to prior systemic immunosuppressive therapy with 6‑mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more consecutive months; OR Patient must have failed to achieve adequate response to prior systemic immunosuppressive therapy with methotrexate at a dose of at least 15 mg weekly for 3 or more consecutive months; AND The treatment must not exceed a total of 2 doses to be administered at weeks 0 and 8 under this restriction; AND Patient must have a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as evidence of failure to achieve an adequate response to prior systemic therapy; OR Patient must have short gut syndrome with diagnostic imaging or surgical evidence, or have had an ileostomy or colostomy; and must have evidence of intestinal inflammation; and must have evidence of failure to achieve an adequate response to prior systemic therapy as specified below; OR Patient must have extensive intestinal inflammation affecting more than 50 cm of the small intestine as evidenced by radiological imaging; and must have a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220; and must have evidence of failure to achieve an adequate response to prior systemic therapy as specified below. Applications for authorisation must be made in writing and must include: (a) two completed authority prescription forms; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient’s condition if relevant; and (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and (iii) the reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and (iv) the date of the most recent clinical assessment. Evidence of failure to achieve an adequate response to prior therapy must include at least one of the following: (a) patient must have evidence of intestinal inflammation; (b) patient must be assessed clinically as being in a high faecal output state; (c) patient must be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of this drug, if affected by short gut syndrome, extensive small intestine disease or is an ostomy patient. Evidence of intestinal inflammation includes: (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C‑reactive protein (CRP) level greater than 15 mg per L; or (ii) faeces: higher than normal lactoferrin or calprotectin level; or (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery. Two completed authority prescriptions should be submitted with every initial application for this drug. One prescription should be written under S100 (Highly Specialised Drugs) for a weight‑based loading dose, containing a quantity of up to 4 vials of 130 mg and no repeats. The second prescription should be written under S85 (General) for 2 vials of 45 mg and no repeats. A maximum quantity of a weight based loading dose is up to 4 vials with no repeats and the subsequent first dose of 90 mg (2 vials of 45 mg) with no repeats provide for an initial 16 week course of this drug will be authorised. Where fewer than 6 vials in total are requested at the time of the application, authority approvals for a sufficient number of vials based on the patient’s weight to complete dosing at weeks 0 and 8 may be requested by telephone through the balance of supply restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application and should be performed preferably whilst still on conventional treatment, but no longer than 1 month following cessation of the most recent prior treatment If treatment with any of the specified prior conventional drugs is contraindicated according to the relevant TGA‑approved Product Information, please provide details at the time of application. If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, details of this toxicity must be provided at the time of application. Details of the accepted toxicities including severity can be found on the Department of Human Services website. Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS‑subsidised therapy. An assessment of a patient’s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
| Valaciclovir | C5975 |  | Cytomegalovirus infection and disease Prophylaxis Patient must have undergone a renal transplant; AND Patient must be at risk of cytomegalovirus disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5975 |
|  | C9267 |  | Cytomegalovirus infection and disease Prophylaxis Patient must have undergone a renal transplant; AND Patient must be at risk of cytomegalovirus disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9267 |
| Valganciclovir | C4980 |  | Cytomegalovirus retinitis Patient must have HIV infection. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4980 |
|  | C4989 |  | Cytomegalovirus infection and disease Prophylaxis Patient must be a solid organ transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4989 |
|  | C9316 |  | Cytomegalovirus infection and disease Prophylaxis Patient must be a solid organ transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9316 |
| Vedolizumab | C9682 |  | Moderate to severe ulcerative colitis Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have previously received PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have had a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND Patient must have a Mayo clinic score greater than or equal to 6; OR Patient must have a partial Mayo clinic score greater than or equal to 6, provided the rectal bleeding and stool frequency subscores are both greater than or equal to 2 (endoscopy subscore is not required for a partial Mayo clinic score); AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment. Patient must be aged 18 years or older. Application for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ulcerative Colitis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Mayo clinic or partial Mayo clinic calculation sheet including the date of assessment of the patient’s condition; and (ii) the details of prior biological medicine treatment including the details of date and duration of treatment. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of one vial of 300 mg per dose, with one dose to be administered at weeks 0, 2 and 6, will be authorised. All tests and assessments should be performed preferably whilst still on treatment, but no longer than 4 weeks following cessation of the most recent prior conventional treatment. The most recent Mayo clinic or partial Mayo clinic score must be no more than 4 weeks old at the time of application. A partial Mayo clinic assessment of the patient’s response to this initial course of treatment must be following a minimum of 12 weeks of treatment for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for golimumab, infliximab and vedolizumab so that there is adequate time for a response to be demonstrated. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. Details of the accepted toxicities including severity can be found on the Department of Human Services website. | Compliance with Written Authority Required procedures |
|  | C9683 |  | Moderate to severe ulcerative colitis Continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have previously received PBS‑subsidised treatment with this drug for this condition; AND Patient must have demonstrated or sustained an adequate response to treatment by having a partial Mayo clinic score less than or equal to 2, with no subscore greater than 1 while receiving treatment with this drug; AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment. Patient must be aged 18 years or older. Patients who have failed to maintain a partial Mayo clinic score less than or equal to 2, with no subscore greater than 1 with continuing treatment with this drug, will not be eligible to receive further PBS‑subsidised treatment with this drug. Patients are eligible to receive continuing treatment with this drug in courses of up to 24 weeks providing they continue to sustain the response. At the time of the authority application, medical practitioners should request the appropriate number of vials, to provide for a single infusion of 300 mg per dose. Up to a maximum of 2 repeats will be authorised. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Authority Required procedures |
|  | C9708 |  | Severe Crohn disease Initial treatment ‑ Initial 1 (new patient) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must be aged 18 years or older. Patient must have confirmed severe Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician; AND Patient must have failed to achieve an adequate response to prior systemic therapy with a tapered course of steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period; AND Patient must have failed to achieve adequate response to prior systemic immunosuppressive therapy with azathioprine at a dose of at least 2 mg per kg daily for 3 or more consecutive months; OR Patient must have failed to achieve adequate response to prior systemic immunosuppressive therapy with 6‑mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more consecutive months; OR Patient must have failed to achieve adequate response to prior systemic immunosuppressive therapy with methotrexate at a dose of at least 15 mg weekly for 3 or more consecutive months; AND The treatment must not exceed a total of 3 doses to be administered at weeks 0, 2 and 6 under this restriction; AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment; AND Patient must have a Crohn Disease Activity Index (CDAI) Score greater than or equal to 300 as evidence of failure to achieve an adequate response to prior systemic therapy; OR Patient must have short gut syndrome with diagnostic imaging or surgical evidence, or have had an ileostomy or colostomy; and must have evidence of intestinal inflammation; and must have evidence of failure to achieve an adequate response to prior systemic therapy as specified below; OR Patient must have extensive intestinal inflammation affecting more than 50 cm of the small intestine as evidenced by radiological imaging; and must have a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220; and must have evidence of failure to achieve an adequate response to prior systemic therapy as specified below. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient’s condition if relevant; and (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]; and (iii) the reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and (iv) the date of the most recent clinical assessment. Evidence of failure to achieve an adequate response to prior therapy must include at least one of the following: (a) patient must have evidence of intestinal inflammation; (b) patient must be assessed clinically as being in a high faecal output state; (c) patient must be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of this drug, if affected by short gut syndrome, extensive small intestine disease or is an ostomy patient. Evidence of intestinal inflammation includes: (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C‑reactive protein (CRP) level greater than 15 mg per L; or (ii) faeces: higher than normal lactoferrin or calprotectin level; or (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery. All assessments, pathology tests and diagnostic imaging studies must be made within 1 month of the date of application and should be performed preferably whilst still on conventional treatment, but no longer than 1 month following cessation of the most recent prior treatment If treatment with any of the specified prior conventional drugs is contraindicated according to the relevant TGA‑approved Product Information, please provide details at the time of application. If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, details of this toxicity must be provided at the time of application. Details of the accepted toxicities including severity can be found on the Department of Human Services website. Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS‑subsidised therapy. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of one vial of 300 mg per dose, with one dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of this drug may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. The assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for the first continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
|  | C9738 |  | Moderate to severe ulcerative colitis Balance of supply Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks of treatment; AND The treatment must provide no more than the balance of up to 3 doses therapy available under Initial 1, 2 or 3 treatment; OR The treatment must provide no more than the balance of up to 24 weeks therapy available under Continuing treatment; AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment. | Compliance with Authority Required procedures |
|  | C9739 |  | Moderate to severe ulcerative colitis Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have already failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment. Patient must be aged 18 years or older. Application for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Ulcerative Colitis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Mayo clinic or partial Mayo clinic calculation sheet including the date of assessment of the patient’s condition if relevant; and (ii) the details of prior biological medicine treatment including the details of date and duration of treatment. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of one vial of 300 mg per dose, with one dose to be administered at weeks 0, 2 and 6, will be authorised. At the time of the authority application, medical practitioners should request the appropriate number of vials, to provide for a single infusion of 300 mg per dose. Up to a maximum of 2 repeats will be authorised. Authority approval for sufficient therapy to complete a maximum of 3 initial doses of treatment may be requested by telephone by contacting the Department of Human Services. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, an assessment of a patient’s response must have been conducted following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for golimumab, infliximab and vedolizumab and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient who fails to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS‑subsidised treatment with this drug in this treatment cycle. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9771 |  | Severe Crohn disease Balance of supply Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete the 3 doses (the initial infusion regimen at 0, 2 and 6 weeks); OR Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks of treatment; AND The treatment must provide no more than the balance of up to 14 weeks therapy available under Initial 1, 2 or 3 treatment; OR The treatment must provide no more than the balance of up to 24 weeks therapy available under Continuing treatment; AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment. | Compliance with Authority Required procedures |
|  | C9792 |  | Moderate to severe ulcerative colitis Initial treatment ‑ Initial 1 (new patient) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have failed to achieve an adequate response to a 5‑aminosalicylate oral preparation in a standard dose for induction of remission for 3 or more consecutive months or have intolerance necessitating permanent treatment withdrawal; AND Patient must have failed to achieve an adequate response to azathioprine at a dose of at least 2 mg per kg daily for 3 or more consecutive months or have intolerance necessitating permanent treatment withdrawal; OR Patient must have failed to achieve an adequate response to 6‑mercaptopurine at a dose of at least 1 mg per kg daily for 3 or more consecutive months or have intolerance necessitating permanent treatment withdrawal; OR Patient must have failed to achieve an adequate response to a tapered course of oral steroids, starting at a dose of at least 40 mg prednisolone (or equivalent), over a 6 week period or have intolerance necessitating permanent treatment withdrawal, and followed by a failure to achieve an adequate response to 3 or more consecutive months of treatment of an appropriately dosed thiopurine agent; AND Patient must have a Mayo clinic score greater than or equal to 6; OR Patient must have a partial Mayo clinic score greater than or equal to 6, provided the rectal bleeding and stool frequency subscores are both greater than or equal to 2 (endoscopy subscore is not required for a partial Mayo clinic score); AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment. Patient must be aged 18 years or older. Application for authorisation of initial treatment must be in writing and must include: (a) a completed authority prescription form; and (b) a completed Ulcerative Colitis PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Mayo clinic or partial Mayo clinic calculation sheet including the date of assessment of the patient’s condition; and (ii) details of prior systemic drug therapy [dosage, date of commencement and duration of therapy]. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of one vial of 300 mg per dose, with one dose to be administered at weeks 0, 2 and 6, will be authorised. All tests and assessments should be performed preferably whilst still on treatment, but no longer than 4 weeks following cessation of the most recent prior conventional treatment. The most recent Mayo clinic or partial Mayo clinic score must be no more than 4 weeks old at the time of application. A partial Mayo clinic assessment of the patient’s response to this initial course of treatment must be following a minimum of 12 weeks of treatment for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for golimumab, infliximab and vedolizumab so that there is adequate time for a response to be demonstrated. If treatment with any of the above‑mentioned drugs is contraindicated according to the relevant TGA‑approved Product Information, details must be provided at the time of application. An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS‑subsidised treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. Details of the accepted toxicities including severity can be found on the Department of Human Services website. | Compliance with Written Authority Required procedures |
|  | C9796 |  | Severe Crohn disease Continuing treatment Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must be aged 18 years or older. Patient must have received this drug as their most recent course of PBS‑subsidised biological medicine treatment for this condition; AND Patient must not receive more than 24 weeks of treatment under this restriction; AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment; AND Patient must have an adequate response to this drug defined as a reduction in Crohn Disease Activity Index (CDAI) Score to a level no greater than 150 if assessed by CDAI or if affected by extensive small intestine disease; OR Patient must have an adequate response to this drug defined as (a) an improvement of intestinal inflammation as demonstrated by: (i) blood: normalisation of the platelet count, or an erythrocyte sedimentation rate (ESR) level no greater than 25 mm per hour, or a C‑reactive protein (CRP) level no greater than 15 mg per L; or (ii) faeces: normalisation of lactoferrin or calprotectin level; or (iii) evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment; or (b) reversal of high faecal output state; or (c) avoidance of the need for surgery or total parenteral nutrition (TPN), if affected by short gut syndrome, extensive small intestine or is an ostomy patient. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient’s condition, if relevant; or (ii) the reports and dates of the pathology test or diagnostic imaging test(s) used to assess response to therapy for patients with short gut syndrome, extensive small intestine disease or an ostomy, if relevant; and (iii) the date of clinical assessment. All assessments, pathology tests, and diagnostic imaging studies must be made within 1 month of the date of application. If the application is the first application for continuing treatment with this drug, an assessment of the patient’s response to the initial course of treatment must be made up to 12 weeks after the first dose so that there is adequate time for a response to be demonstrated. The assessment of the patient’s response to a continuing course of therapy must be made within the 4 weeks prior to completion of that course and posted to the Department of Human Services no less than 2 weeks prior to the date the next dose is scheduled, in order to ensure continuity of treatment for those patients who meet the continuation criterion. Where an assessment is not submitted to the Department of Human Services within these timeframes, patients will be deemed to have failed to respond, or to have failed to sustain a response, to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. Patients are eligible to receive continuing treatment with this drug in courses of up to 24 weeks providing they continue to sustain the response. At the time of the authority application, medical practitioners should request the appropriate number of vials, to provide sufficient for a single infusion of 300 mg vedolizumab per dose. Up to a maximum of 2 repeats will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete 24 weeks treatment may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for continuing authority applications, or for treatment that would otherwise extend the continuing treatment period. | Compliance with Written Authority Required procedures |
|  | C9815 |  | Severe Crohn disease Initial treatment ‑ Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have failed, or ceased to respond to, PBS‑subsidised treatment with this drug for this condition during the current treatment cycle; AND The treatment must not exceed a total of 3 doses to be administered at weeks 0, 2 and 6 under this restriction; AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment. Patient must be aged 18 years or older. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form, which includes the following: (i) the completed current Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of assessment of the patient’s condition if relevant; or (ii) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy for patients with short gut syndrome, extensive small intestine disease or an ostomy, if relevant; and (iii) the date of clinical assessment; and (iv) the details of prior biological medicine treatment including the details of date and duration of treatment. An application for a patient who has received PBS‑subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient’s most recent course of PBS‑subsidised biological medicine treatment, within the timeframes specified below. Where the most recent course of PBS‑subsidised biological medicine treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab or ustekinumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and vedolizumab and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. If the response assessment to the previous course of biological medicine treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of biological medicine. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of one vial of 300 mg per dose, with one dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of this drug may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. The assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
|  | C9825 |  | Severe Crohn disease Initial treatment ‑ Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Patient must have received prior PBS‑subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS‑subsidised biological medicine for this condition; AND Patient must have confirmed severe Crohn disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician; AND Patient must have a Crohn Disease Activity Index (CDAI) Score of greater than or equal to 300 that is no more than 4 weeks old at the time of application; OR Patient must have a documented history of intestinal inflammation and have diagnostic imaging or surgical evidence of short gut syndrome if affected by the syndrome or has an ileostomy or colostomy; OR Patient must have a documented history and radiological evidence of intestinal inflammation if the patient has extensive small intestinal disease affecting more than 50 cm of the small intestine, together with a Crohn Disease Activity Index (CDAI) Score greater than or equal to 220 and that is no more than 4 weeks old at the time of application; AND Patient must have evidence of intestinal inflammation; OR Patient must be assessed clinically as being in a high faecal output state; OR Patient must be assessed clinically as requiring surgery or total parenteral nutrition (TPN) as the next therapeutic option, in the absence of this drug, if affected by short gut syndrome, extensive small intestine disease or is an ostomy patient; AND The treatment must not exceed a total of 3 doses to be administered at weeks 0, 2 and 6 under this restriction; AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment. Patient must be aged 18 years or older. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application ‑ Supporting Information Form which includes the following: (i) the completed current Crohn Disease Activity Index (CDAI) calculation sheet including the date of assessment of the patient’s condition if relevant; and (ii) the reports and dates of the pathology or diagnostic imaging test(s) nominated as the response criterion, if relevant; and (iii) the date of the most recent clinical assessment. Evidence of intestinal inflammation includes: (i) blood: higher than normal platelet count, or, an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour, or, a C‑reactive protein (CRP) level greater than 15 mg per L; or (ii) faeces: higher than normal lactoferrin or calprotectin level; or (iii) diagnostic imaging: demonstration of increased uptake of intravenous contrast with thickening of the bowel wall or mesenteric lymphadenopathy or fat streaking in the mesentery. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of one vial of 300 mg per dose, with one dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than 2 repeats are requested at the time of the application, authority approvals for sufficient repeats to complete the 3 doses of this drug may be requested by telephone and authorised through the Balance of Supply treatment phase PBS restriction. Under no circumstances will telephone approvals be granted for initial authority applications, or for treatment that would otherwise extend the initial treatment period. Any one of the baseline criteria may be used to determine response to an initial course of treatment and eligibility for continued therapy, according to the criteria included in the continuing treatment restriction. However, the same criterion must be used for any subsequent determination of response to treatment, for the purpose of eligibility for continuing PBS‑subsidised therapy. The assessment of the patient’s response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug. If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS‑subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. A patient may re‑trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS‑subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction. | Compliance with Written Authority Required procedures |
| Zidovudine | C4454 |  | HIV infection Continuing  Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4454 |
|  | C4512 |  | HIV infection Initial  Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Authority Required procedures ‑ Streamlined Authority Code 4512 |
| Zoledronic acid | C5605 |  | Bone metastases The condition must be due to breast cancer. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5605 |
|  | C5703 |  | Bone metastases The condition must be due to castration‑resistant prostate cancer. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5703 |
|  | C5704 |  | Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti‑neoplastic therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5704 |
|  | C5735 |  | Multiple myeloma | Compliance with Authority Required procedures ‑ Streamlined Authority Code 5735 |
|  | C9268 |  | Multiple myeloma | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9268 |
|  | C9304 |  | Bone metastases The condition must be due to castration‑resistant prostate cancer. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9304 |
|  | C9317 |  | Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti‑neoplastic therapy. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9317 |
|  | C9328 |  | Bone metastases The condition must be due to breast cancer. | Compliance with Authority Required procedures ‑ Streamlined Authority Code 9328 |

Schedule 3 Part 1—General statement for drugs for the treatment of hepatitis C

**1** Criteria for eligibility for drugs for the treatment of chronic hepatitis C

The criteria for patient eligibility for drugs for the treatment of chronic hepatitis C are that:

(1) the patient has been assessed in accordance with paragraph 2 of this Part; and

(2) the patient is:

(a) treated by a medical practitioner or an authorised nurse practitioner who is experienced in the treatment of patients with chronic hepatitis C infection; or

(b) treated by a medical practitioner or an authorised nurse practitioner in consultation with:

(i) a gastroenterologist; or

(ii) a hepatologist; or

(iii) an infectious diseases physician.

**2** Assessment of patient

For the purpose of subparagraph 1(2) of this Part, the patient has been assessed if the treating medical practitioner has:

(1) documented the following information in the patient’s medical records:

(a) evidence of chronic hepatitis C infection; and

(b) where possible, evidence of the patient’s hepatitis C virus genotype; and

(2) chosen a regimen in accordance with paragraph 3 of this Part; and

(3) collected the following information for the purposes of the authority application:

(a) whether the patient is:

(i) cirrhotic; or

(ii) non-cirrhotic

(b) details of the previous treatment regimen (**only** for requests for sofosbuvir with velpatasvir and voxilaprevir or glecaprevir with pibrentasvir for 16 weeks’ treatment in patients who have previously failed a treatment with a regimen containing an NS5A inhibitor).

(4) In this paragraph, evidence of chronic hepatitis C infection is documentation of:

(a) repeat test results showing antibody to hepatitis C virus (anti-HCV) positive; and

(b) test result showing hepatitis C virus ribonucleic acid (RNA) positive.

**3** Treatment regimen

For the purpose of subparagraph 2(2) of this Part, the treating medical practitioner has chosen a regimen in accordance with this paragraph if the patient:

(1) is a kind of patient mentioned for an Item in column 2 of the following table; and

(2) is to receive one of the regimens mentioned in column 3 of the same Item of the following table.

| **Item** | **Kind of patient** | **Regimen** |
| --- | --- | --- |
| 1 | Patient:  (a) all genotypes (pan-genotypic); and  (b) who is treatment naïve; and  (c) who is non-cirrhotic. | Either:  (a) SOFOSBUVIR with VELPATASVIR for 12 weeks; or  (b) GLECAPREVIR with PIBRENTASVIR for 8 weeks. |
| 2 | Patient:  (a) all genotypes (pan-genotypic); and  (b) who is treatment experienced; and  (c) who is non-cirrhotic. | Either:  (a) SOFOSBUVIR with VELPATASVIR for 12 weeks; or  (b) SOFOSBUVIR with VELPATASVIR and VOXILAPREVIR for 12 weeks; or  (c) GLECAPREVIR with PIBRENTASVIR for 8 weeks; or  (d) GLECAPREVIR with PIBRENTASVIR for 12 weeks; or  (e) GLECAPREVIR with PIBRENTASVIR 16 weeks. |
| 3 | Patient:  (a) with Genotype 1; and  (b) who is treatment naïve; and  (c) who is non-cirrhotic. | Either:  (a) LEDIPASVIR with SOFOSBUVIR for 8 weeks; or  (b) LEDIPASVIR with SOFOSBUVIR for 12 weeks; or  (c) GRAZOPREVIR with ELBASVIR for 12 weeks. |
| 4 | Patient:  (a) with Genotype 1; and  (b) who is treatment experienced; and  (c) who is non-cirrhotic. | Either:  (a) LEDIPASVIR with SOFOSBUVIR for 12 weeks; or  (b) GRAZOPREVIR with ELBASVIR for 12 weeks; or  (c) GRAZOPREVIR with ELBASVIR and RIBAVIRIN for 16 weeks. |
| 5 | Patient:  (a) with Genotype 2; and  (b) who is treatment naïve; and  (c) who is non-cirrhotic. | Refer to item 1 above (pan-genotypic, treatment naïve and non-cirrhotic regimens). |
| 6 | Patient:  (a) with Genotype 2; and  (b) who is treatment experienced; and  (c) who is non-cirrhotic. | Refer to item 2 above (pan-genotypic, treatment experienced and non-cirrhotic regimens). |
| 7 | Patient:  (a) with Genotype 3; and  (b) who is treatment naïve; and  (c) who is non-cirrhotic. | Refer to item 1 above (pan-genotypic, treatment naïve and non-cirrhotic regimens). |
| 8 | Patient:  (a) with Genotype 3; and  (b) who is treatment experienced; and  (c) who is non-cirrhotic. | Refer to item 2 above (pan-genotypic, treatment experienced and non-cirrhotic regimens). |
| 9 | Patient:  (a) with Genotype 4; and  (b) who is treatment naïve; and  (c) who is non-cirrhotic. | GRAZOPREVIR with ELBASVIR for 12 weeks. |
| 10 | Patient:  (a) with Genotype 4; and  (b) who is treatment experienced; and  (c) who is non-cirrhotic. | Either:  (a) GRAZOPREVIR with ELBASVIR for 12 weeks; or  (b) GRAZOPREVIR with ELBASVIR and RIBAVIRIN for 16 weeks. |
| 11 | Patient:  (a) with:  (i) Genotype 5; or  (ii) Genotype 6; and  (b) who is treatment naïve; and  (c) who is non-cirrhotic. | Refer to item 1 above (pan-genotypic, treatment naïve and non-cirrhotic regimens). |
| 12 | Patient:  (a) with:  (i) Genotype 5; or  (ii) Genotype 6; and  (b) who is treatment experienced; and  (c) who is non-cirrhotic. | Refer to item 2 above (pan-genotypic, treatment experienced and non-cirrhotic regimens). |
| 13 | Patient:  (a) all genotypes (pan-genotypic); and  (b) who is treatment naïve; and  (c) who is cirrhotic. | Either:  (a) SOFOSBUVIR with VELPATASVIR for 12 weeks; or  (b) GLECAPREVIR with PIBRENTASVIR for 12 weeks. |
| 14 | Patient:  (a) all genotypes (pan-genotypic); and  (b) who is treatment experienced; and  (c) who is cirrhotic. | Either:  (a) SOFOSBUVIR with VELPATASVIR for 12 weeks; or  (b) SOFOSBUVIR with VELPATASVIR and VOXILAPREVIR for 12 weeks; or  (c) GLECAPREVIR with PIBRENTASVIR for 12 weeks; or  (d) GLECAPREVIR with PIBRENTASVIR 16 weeks. |
| 15 | Patient:  (a) with Genotype 1; and  (b) who is treatment naïve; and  (c) who is cirrhotic. | Either:  (a) LEDIPASVIR with SOFOSBUVIR for 12 weeks; or  (b) GRAZOPREVIR with ELBASVIR for 12 weeks. |
| 16 | Patient:  (a) with Genotype 1; and  (b) who is treatment experienced; and  (c) who is cirrhotic. | Either:  (a) LEDIPASVIR with SOFOSBUVIR for 24 weeks; or  (b) GRAZOPREVIR with ELBASVIR for 12 weeks; or  (c) GRAZOPREVIR with ELBASVIR and RIBAVIRIN for 16 weeks. |
| 17 | Patient:  (a) with Genotype 2; and  (b) who is treatment naïve; and  (c) who is cirrhotic. | Refer to item 13 above (pan-genotypic, treatment naïve and cirrhotic regimens). |
| 18 | Patient:  (a) with Genotype 2; and  (b) who is treatment experienced; and  (c) who is cirrhotic. | Refer to item 14 above (pan-genotypic, treatment experienced and cirrhotic regimens). |
| 19 | Patient:  (a) with Genotype 3; and  (b) who is treatment naïve; and  (c) who is cirrhotic. | Refer to item 13 above (pan-genotypic, treatment naïve and cirrhotic regimens). |
| 20 | Patient:  (a) with Genotype 3; and  (b) who is treatment experienced; and  (c) who is cirrhotic. | Refer to item 14 above (pan-genotypic, treatment experienced and cirrhotic regimens). |
| 21 | Patient:  (a) with Genotype 4; and  (b) who is treatment naïve; and  (c) who is cirrhotic. | GRAZOPREVIR with ELBASVIR for 12 weeks. |
| 22 | Patient:  (a) with Genotype 4; and  (b) who is treatment experienced; and  (c) who is cirrhotic. | Either:  (a) GRAZOPREVIR with ELBASVIR for 12 weeks; or  (b) GRAZOPREVIR with ELBASVIR and RIBAVIRIN for 16 weeks. |
| 23 | Patient:  (a) with:  (i) Genotype 5; or  (ii) Genotype 6; and  (b) who is treatment naïve; and  (c) who is cirrhotic. | Refer to item 13 above (pan-genotypic, treatment naïve and cirrhotic regimens). |
| 24 | Patient:  (a) with:  (i) Genotype 5; or  (ii) Genotype 6; and  (b) who is treatment experienced; and  (c) who is cirrhotic. | Refer to item 14 above (pan-genotypic, treatment experienced and cirrhotic regimens). |

Schedule 4—Patient contributions

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Listed Drug** | **Form (strength, type, size, etc.)** | **Manner of Administration** | **Brand** | **Pack Quantity** | **Approved Ex‑manufacturer Price or Proportional Ex‑manufacturer Price**  **$** | **Claimed price**  **$** |
| Lamivudine | Tablet 100 mg | Oral | Zeffix | 28 | $34.70 | $35.30 |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valtrex | 100 | $44.20 | $44.64 |

Schedule 5—HSD pharmaceutical benefits with modified prescription circumstances during COVID‑19 pandemic

Note: See section 9AA.

| Pharmaceutical items with modified prescription circumstances during COVID-19 pandemic | | |
| --- | --- | --- |
| Listed drug | Form | Manner of administration |
| Abatacept | Powder for I.V. infusion 250 mg | Injection |
| Adalimumab | Injection 20 mg in 0.4 mL pre‑filled syringe | Injection |
| Adalimumab | Injection 40 mg in 0.8 mL pre‑filled syringe | Injection |
| Adalimumab | Injection 40 mg in 0.8 mL pre‑filled pen | Injection |
| Ambrisentan | Tablet 5 mg | Oral |
| Ambrisentan | Tablet 10 mg | Oral |
| Benralizumab | Injection 30 mg in 1 mL single dose pre‑filled syringe | Injection |
| Benralizumab | Injection 30 mg in 1 mL single dose pre‑filled pen | Injection |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral |
| Dornase alfa | Solution for inhalation 2.5 mg (2,500 units) in 2.5 mL | Inhalation |
| Epoprostenol | Powder for I.V. infusion 500 micrograms (as sodium) | Injection |
| Epoprostenol | Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL | Injection |
| Epoprostenol | Powder for I.V. infusion 1.5 mg (as sodium) | Injection |
| Epoprostenol | Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL | Injection |
| Etanercept | Injection set containing 4 vials powder for injection 25 mg and 4 pre‑filled syringes solvent 1 mL | Injection |
| Etanercept | Injection 50 mg in 1 mL single use auto‑injector, 4 | Injection |
| Etanercept | Injections 50 mg in 1 mL single use pre‑filled syringes, 4 | Injection |
| Iloprost | Solution for inhalation 20 micrograms (as trometamol) in 2 mL | Inhalation |
| Infliximab | Powder for I.V. infusion 100 mg | Injection |
| Ivacaftor | Sachet containing granules 50 mg | Oral |
| Ivacaftor | Sachet containing granules 75 mg | Oral |
| Ivacaftor | Tablet 150 mg | Oral |
| Lenalidomide | Capsule 5 mg | Oral |
| Lenalidomide | Capsule 10 mg | Oral |
| Lenalidomide | Capsule 15 mg | Oral |
| Lenalidomide | Capsule 25 mg | Oral |
| Lumacaftor with  ivacaftor | Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg | Oral |
| Lumacaftor with  ivacaftor | Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg | Oral |
| Lumacaftor with  ivacaftor | Tablet containing lumacaftor 100 mg with ivacaftor 125 mg | Oral |
| Lumacaftor with ivacaftor | Tablet containing lumacaftor 200 mg with ivacaftor 125 mg | Oral |
| Macitentan | Tablet 10 mg | Oral |
| Mannitol | Pack containing 280 capsules containing powder for inhalation 40 mg and 2 inhalers | Inhalation by mouth |
| Mepolizumab | Powder for injection 100 mg | Injection |
| Mepolizumab | Injection 100 mg in 1 mL single dose pre-filled pen | Injection |
| Omalizumab | Injection 75 mg in 0.5 mL single dose pre‑filled syringe | Injection |
| Omalizumab | Injection 150 mg in 1 mL single dose pre‑filled syringe | Injection |
| Pomalidomide | Capsule 3 mg | Oral |
| Pomalidomide | Capsule 4 mg | Oral |
| Riociguat | Tablet 500 micrograms | Oral |
| Riociguat | Tablet 1 mg | Oral |
| Riociguat | Tablet 1.5 mg | Oral |
| Riociguat | Tablet 2 mg | Oral |
| Riociguat | Tablet 2.5 mg | Oral |
| Rituximab | Solution for I.V. infusion 500 mg in 50 mL | Injection |
| Sildenafil | Tablet 20 mg (as citrate) | Oral |
| Tadalafil | Tablet 20 mg | Oral |
| Tezacaftor with ivacaftor and ivacaftor | Pack containing 28 tablets tezacaftor 100 mg with ivacaftor 150 mg and 28 tablets ivacaftor 150 mg | Oral |
| Tocilizumab | Concentrate for injection 80 mg in 4 mL | Injection |
| Tocilizumab | Concentrate for injection 200 mg in 10 mL | Injection |
| Tocilizumab | Concentrate for injection 400 mg in 20 mL | Injection |
| Ustekinumab | Solution for I.V. infusion 130 mg in 26 mL | Injection |
| Vedolizumab | Powder for injection 300 mg | Injection |

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Editorial changes**

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = *Legislation Act 2003* | Sch = Schedule(s) |
| LIA = *Legislative Instruments Act 2003* | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |

Endnote 3—Legislation history

| Name | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| PB 116 of 2010 | 29 Nov 2010 (F2010L03140) | 1 Dec 2010 (s 2) |  |
| PB 122 of 2010 | 17 Dec 2010 (F2010L03308) | 1 Jan 2010 (s 2) | — |
| PB 2 of 2011 | 31 Jan 2011 (F2011L00168) | 1 Feb 2011 (s 2) | — |
| PB 16 of 2011 | 28 Feb 2011 (F2011L00316) | 1 Mar 2011 (s 2) | — |
| PB 28 of 2011 | 31 Mar 2011 (F2011L00546) | 1 Apr 2011 (s 2) | — |
| PB 34 of 2011 | 27 Apr 2011 (F2011L00643) | 1 May 2011 (s 2) | — |
| PB 38 of 2011 | 31 May 2011 (F2011L00893) | 1 June 2011 (s 2) | — |
| PB 46 of 2011 | 24 June 2011 (F2011L01221) | 1 July 2011 (s 2) | — |
| PB 53 of 2011 | 27 July 2011 (F2011L01543) | 1 Aug 2011 (s 2) | — |
| PB 62 of 2011 | 31 Aug 2011 (F2011L01777) | 1 Sept 2011 (s 2) | — |
| PB 69 of 2011 | 28 Sept 2011 (F2011L01978) | 1 Oct 2011 (s 2) | — |
| PB 76 of 2011 | 26 Oct 2011 (F2011L02130) | 1 Nov 2011 (s 2) | — |
| PB 86 of 2011 | 30 Nov 2011 (F2011L02501) | 1 Dec 2011 (s 2) | — |
| PB 99 of 2011 | 15 Dec 2011 (F2011L02694) | 1 Jan 2011 (s 2) | — |
| PB 5 of 2012 | 23 Feb 2012 (F2012L00380) | 1 Mar 2012 (s 2) | — |
| PB 20 of 2012 | 29 Mar 2012 (F2012L00716) | 1 Apr 2012 (s 2) | — |
| PB 31 of 2012 | 30 Apr 2012 (F2012L00952) | 1 May 2012 (s 2) | — |
| PB 35 of 2012 | 30 May 2012 (F2012L01122) | 1 June 2012 (s 2) | — |
| PB 39 of 2012 | 29 June 2012 (F2012L01458) | 1 July 2012 (s 2) | — |
| PB 47 of 2012 | 26 July 2012 (F2012L01615) | 1 Aug 2012 (s 2) | — |
| PB 64 of 2012 | 29 Aug 2012 (F2012L01783) | 1 Sept 2012 (s 2) | — |
| PB 76 of 2012 | 28 Sept 2012 (F2012L01971) | 1 Oct 2012 (s 2) | — |
| PB 96 of 2012 | 30 Oct 2012 (F2012L02107) | 30 Oct 2012 (s 2) | — |
| PB 106 of 2012 | 29 Nov 2012 (F2012L02286) | 1 Dec 2012 (s 2) | — |
| PB 110 of 2012 | 17 Dec 2012 (F2012L02508) | 1 Jan 2013 (s 2) | — |
| PB 10 of 2013 | 21 Feb 2013 (F2013L00245) | 1 Mar 2013 (s 2) | — |
| PB 16 of 2013 | 27 Mar 2013 (F2013L00562) | 1 Apr 2013 (s 2) | — |
| PB 30 of 2013 | 30 May 2013 (F2013L00874) | 1 June 2013 (s 2) | — |
| PB 42 of 2013 | 31 July 2013 (F2013L01483) | 1 Aug 2013 (s 2) | — |
| PB 56 of 2013 | 27 Aug 2013 (F2013L01630) | 1 Sept 2013 (s 2) | — |
| PB 63 of 2013 | 24 Sept 2013 (F2013L01736) | 1 Oct 2013 (s 2) | — |
| PB 70 of 2013 | 18 Oct 2013 (F2013L01812) | 1 Nov 2013 (s 2) | — |
| PB 78 of 2013 | 29 Nov 2013 (F2013L02011) | 1 Dec 2013 (s 2) | — |
| PB 92 of 2013 | 24 Dec 2013 (F2013L02191) | 1 Jan 2014 (s 2) | — |
| PB 4 of 2014 | 28 Jan 2014 (F2014L00098) | 1 Feb 2014 (s 2) | — |
| PB 11 of 2014 | 25 Feb 2014 (F2014L00183) | 1 Mar 2014 (s 2) | — |
| PB 20 of 2014 | 31 Mar 2014 (F2014L00372 | 1 Apr 2014 (s 2) | — |
| PB 30 of 2014 | 29 Apr 2014 (F2014L00449) | 1 May 2014 (s 2) | — |
| PB 40 of 2014 | 21 May 2014 (F2014L00577) | 1 June 2014 (s 2) | — |
| PB 48 of 2014 | 20 June 2014 (F2014L00766) | 1 July 2014 (s 2) | — |
| PB 55 of 2014 | 31 July 2014 (F2014L01065) | 1 Aug 2014 (s 2) | — |
| PB 63 of 2014 | 25 Aug 2014 (F2014L01126) | 1 Sept 2014 (s 2) | — |
| PB 93 of 2014 | 1 Dec 2014 (F2014L01610) | 1 Dec 2014 (s 2) | — |
| PB 102 of 2014 | 24 Dec 2014 (F2014L01834) | 1 Jan 2015 (s 2) | — |
| PB 3 of 2015 | 30 Jan 2015 (F2015L00087) | 1 Feb 2015 (s 2) | — |
| PB 30 of 2015 | 1 Apr 2015 (F2015L00457) | 1 Apr 2015 (s 2) | — |
| PB 43 of 2015 | 29 Apr 2015 (F2015L00607) | 1 May 2015 (s 2) | — |
| PB 50 of 2015 | 1 June 2015 (F2015L00770) | 1 June 2015 (s 2) | — |
| PB 58 of 2015 | 1 July 2015 (F2015L01073) | 1 July 2015 (s 2) | — |
| PB 72 of 2015 | 31 July 2015 (F2015L01214) | 1 Aug 2015 (s 2) | — |
| PB 83 of 2015 | 1 Sept 2015 (F2015L01370) | 1 Sept 2015 (s 2) | — |
| PB 94 of 2015 | 1 Oct 2015 (F2015L01619) | 1 Oct 2015 (s 2) | — |
| PB 104 of 2015 | 30 Oct 2015 (F2015L01723) | 1 Nov 2015 (s 2) | — |
| PB 111 of 2015 | 1 Dec 2015 (F2015L01908) | 1 Dec 2015 (s 2) | — |
| PB 121 of 2015 | 18 Dec 2015 (F2015L02085) | 18 Dec 2015 (s 2) | — |
| PB 129 of 2015 | 24 Dec 2015 (F2015L02138) | 1 Jan 2016 (s 2) | — |
| PB 5 of 2016 | 1 Feb 2016 (F2016L00076) | 1 Feb 2016 (s 2) | — |
| PB 13 of 2016 | 1 Mar 2016 (F2016L00216) | 1 Mar 2016 (s 2) | — |
| PB 22 of 2016 | 1 Apr 2016 (F2016L00473) | 1 Apr 2016 (s 2) | — |
| PB 33 of 2016 | 29 Apr 2016 (F2016L00607) | 1 May 2016 (s 2) | — |
| PB 45 of 2016 | 31 May 2016 (F2016L00924) | 1 June 2016 (s 2) | — |
| PB 55 of 2016 | 28 June 2016 (F2016L01091) | 1 July 2016 (s 2) | — |
| PB 67 of 2016 | 28 July 2016 (F2016L01240) | 1 Aug 2016 (s 2) | — |
| PB 76 of 2016 | 30 Aug 2016 (F2016L01365) | 1 Sept 2016 (s 2) | — |
| PB 84 of 2016 | 30 Sept 2016 (F2016L01559) | 1 Oct 2016 (s 2) | — |
| PB 93 of 2016 | 31 Oct 2016 (F2016L01664) | 1 Nov 2016 (s 2) | — |
| PB 100 of 2016 | 30 Nov 2016 (F2016L01842) | 1 Dec 2016 (s 2) | — |
| PB 113 of 2016 | 22 Dec 2016 (F2016L02027) | 1 Jan 2017 (s 2) | — |
| PB 5 of 2017 | 25 Jan 2017 (F2017L00066) | 1 Feb 2017 (s 2) | — |
| PB 20 of 2017 | 31 Mar 2017 (F2017L00378) | 1 Apr 2017 (s 2) | — |
| PB 30 of 2017 | 28 Apr 2017 (F2017L00489) | 1 May 2017 (s 2) | — |
| PB 39 of 2017 | 31 May 2017 (F2017L00634) | 1 June 2017 (s 2) | — |
| PB 47 of 2017 | 30 June 2017 (F2017L00856) | 1 July 2017 (s 2) | — |
| PB 57 of 2017 | 27 July 2017 (F2017L00959) | 1 Aug 2017 (s 2) | — |
| PB 66 of 2017 | 31 Aug 2017 (F2017L01117) | 1 Sept 2017 (s 2) | — |
| PB 75 of 2017 | 26 Sept 2017 (F2017L01271) | 1 Oct 2017 (s 2) | — |
| PB 88 of 2017 | 30 Oct 2017 (F2017L01399) | 1 Nov 2017 (s 2) | — |
| PB 95 of 2017 | 1 Dec 2017 (F2017L01555) | 1 Dec 2017 (s 2) | — |
| PB 104 of 2017 | 15 Dec 2017 (F2017L01626) | 1 Jan 2018 (s 2) | — |
| PB 6 of 2018 | 30 Jan 2018 (F2018L00068) | 1 Feb 2018 (s 2) | — |
| PB 16 of 2018 | 28 Feb 2018 (F2018L00162) | 1 Mar 2018 (s 2) | — |
| PB 22 of 2018 | 28 Mar 2018 (F2018L00428) | 1 Apr 2018 (s 2) | — |
| PB 40 of 2018 | 1 June 2018 (F2018L00704) | 1 June 2018 (s 2) | — |
| PB 54 of 2018 | 29 June 2018 (F2018L00951) | 1 July 2018 (s 2) | — |
| PB 67 of 2018 | 31 July 2018 (F2018L01069) | 1 Aug 2018 (s 2) | — |
| PB 77 of 2018 | 30 Aug 2018 (F2018L01211) | 1 Sept 2018 (s 2) | — |
| PB 85 of 2018 | 27 Sept 2018 (F2018L01361) | 1 Oct 2018 (s 2) | — |
| PB 94 of 2018 | 30 Oct 2018 (F2018L01508) | 1 Nov 2018 (s 2) | — |
| PB 102 of 2018 | 30 Nov 2018 (F2018L01646) | 1 Dec 2018 (s 2) | — |
| PB 107 of 2018 | 6 Dec 2018 (F2018L01673) | 21 Dec 2018 (s 2(1) item 1) | Sch 2 |
| PB 111 of 2018 | 20 Dec 2018 (F2018L01814) | 1 Jan 2019 (s 2) | — |
| PB 3 of 2019 | 31 Jan 2019 (F2019L00081) | 1 Feb 2019 (s 2) | — |
| PB 13 of 2019 | 28 Feb 2019 (F2019L00216) | 1 Mar 2019 (s 2) | — |
| PB 20 of 2019 | 29 Mar 2019 (F2019L00459) | 1 Apr 2019 (s 2) | — |
| PB 31 of 2019 | 30 Apr 2019 (F2019L00661) | 1 May 2019 (s 2) | — |
| PB 39 of 2019 | 30 May 2019 (F2019L00697) | 1 June 2019 (s 2) | — |
| PB 48 of 2019 | 28 June 2019 (F2019L00919) | 1 July 2019 (s 2) | — |
| PB 61 of 2019 | 31 July 2019 (F2019L01023) | 1 Aug 2019 (s 2) | — |
| PB 70 of 2019 | 30 Aug 2019 (F2019L01123) | 1 Sept 2019 (s 2) | — |
| PB 78 of 2019 | 30 Sept 2019 (F2019L01295) | 1 Oct 2019 (s 2) | — |
| PB 87 of 2019 | 31 Oct 2019 (F2019L01395) | 1 Nov 2019 (s 2) | — |
| PB 95 of 2019 | 28 Nov 2019 (F2019L01518) | 1 Dec 2019 (s 2) | — |
| PB 106 of 2019 | 23 Dec 2019 (F2019L01688) | 1 Jan 2020 (s 2) | — |
| PB 4 of 2020 | 31 Jan 2020 (F2020L00080) | 1 Feb 2020 (s 2) | — |
| PB 17 of 2020 | 28 Feb 2020 (F2020L00185) | 1 Mar 2020 (s 2) | — |
| PB 24 of 2020 | 31 Mar 2020 (F2020L00356) | 1 Apr 2020 (s 2) | — |
| PB 26 of 2020 | 31 Mar 2020 (F2020L00366) | 1 Apr 2020 (s 2(1) item 1) | — |
| PB 32 of 2020 | 30 Apr 2020 (F2020L00531) | Sch 1 (items 4–6): 1 May 2020 (s 2(1) item 1) | — |
| PB 37 of 2020 | 30 Apr 2020 (F2020L00538) | 1 May 2020 (s 2) | — |
| PB 46 of 2020 | 29 May 2020 (F2020L00646) | 1 June 2020 (s 2) | — |
| PB 72 of 2020 | 31 July 2020 (F2020L00971) | 1 Aug 2020 (s 2) | — |
| PB 82 of 2020 | 28 Aug 2020 (F2020L01090) | 1 Sept 2020 (s 2) | — |
| PB 100 of 2020 | 29 Sept 2020 (F2020L01247) | Sch 1 (item 3):30 Sept 2020 (s 2(1) item 1) | — |
| PB 93 of 2020 | 30 Sept 2020 (F2020L01267) | 1 Oct 2020 (s 2) | — |
| PB 109 of 2020 | 30 Oct 2020 (F2020L01366) | Sch 1 (item 6): 1 Nov 2020 (s 2(1) item 3) | — |
| PB 106 of 2020 | 30 Oct 2020 (F2020L01368) | 1 Nov 2020 (s 2) | — |
| PB 115 of 2020 | 27 Nov 2020 (F2020L01497) | 1 Dec 2020 (s 2) | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| **Part 1** |  |
| **Division 1** |  |
| s 1 | am PB 58 of 2015 |
| s 2 | rep LA s 48D |
| s 3 | rep LA s 48C |
| s 4 | am PB 122 of 2010; PB 2, 16, 28, 46, 62 and 99 of 2011; PB 20, 31, 35, 39 and 76 of 2012; PB 20, 63 and 93 of 2014; PB 3, 30 and 58 of 2015; PB 72 of 2015 (Sch 1 item 1 md); PB 33, 67, 76, 84 and 113 of 2016; PB 30 of 2017; PB 66 of 2017; PB 75 of 2017; PB 104 of 2017; PB 40 of 2018 |
|  | ed C82 |
|  | am PB 85 of 2018; PB 102 of 2018; PB 107 of 2018; PB 3 of 2019; PB 13 of 2019; PB 78 of 2019; PB 95 of 2019; PB 17 of 2020; PB 24 of 2020; PB 26 of 2020 |
|  | ed C105 |
|  | am PB 46 of 2020 |
| s 4A | ad PB 26 of 2020 |
|  | am PB 93 of 2020; PB 106 of 2020 |
|  | ed C112 |
| **Division 2** |  |
| s 7 | am PB 87 of 2019 |
| s 8 | am PB 26 of 2020; PB 109 of 2020; PB 115 of 2020 |
| s 9 | am PB 32 of 2020 |
|  | (3) rep 1 Apr 2021 (s 9AA(3)) |
| s 9AA | ad PB 32 of 2020 |
|  | am PB 100 of 2020 |
|  | rep 1 Apr 2021 (s 9AA(3)) |
| s 9A | ad PB 93 of 2014 |
| **Division 3** |  |
| Division 3 heading | rs PB 30 of 2015 |
| Division 3 | am PB 30 of 2015 |
| s 10 | am PB 62 of 2011; PB 30 of 2015; PB 33 of 2016 |
| s 11 | am PB 62 of 2011 |
|  | rep PB 30 of 2015 |
| s 12 | am PB 62 of 2011 |
|  | rep PB 30 of 2015 |
| s 13 | am PB 62 of 2011 |
|  | rep PB 30 of 2015 |
| **Division 4** |  |
| s 14 | am PB 87 of 2019; PB 26 of 2020 |
| s 15 | am PB 26 of 2020 |
| **Part 2** |  |
| **Division 1** |  |
| s 17A | ad PB 93 of 2014 |
| s 18 | am PB 30 and 58 of 2015 |
|  | rs PB 33 of 2016 |
| s 18A | ad PB 58 of 2015 |
| **Division 2** |  |
| s 19 | am PB 30 of 2015; PB 58 of 2015 |
|  | rs PB 107 of 2018 |
| s 20 | am PB 26 of 2020 |
| **Division 3** |  |
| s 21 | am PB 30 of 2015; PB 107 of 2018; PB 26 of 2020 |
| s 22 | rep PB 30 of 2015 |
| s 22A | ad PB 93 of 2014 |
|  | am PB 26 of 2020 |
| **Division 4** |  |
| s 23 | am PB 30 of 2015; PB 107 of 2018; PB 26 of 2020 |
| s 23A | ad PB 93 of 2014 |
|  | am PB 26 of 2020 |
| s 24 | am PB 2, 28, 46 and 99 of 2011; PB 5, 20 and 31 of 2012 |
|  | rs PB 63 of 2013 |
|  | am PB 113 of 2016; PB 5 of 2017; PB 66 of 2017 |
|  | ed C74 |
|  | am PB 75 of 2017; PB 88 of 2017; PB 40 of 2018; PB 26 of 2020 |
| s 25 | am PB 2, 28, 46 and 99 of 2011; PB 20 and 31 of 2012 |
|  | rs PB 63 of 2013 |
|  | am PB 113 of 2016; PB 5 of 2017; PB 66 of 2017 |
|  | ed C74 |
|  | am PB 75 of 2017; PB 88 of 2017; PB 40 of 2018 |
|  | ed C82 |
|  | am PB 26 of 2020 |
| s 26 | rs PB 30 of 2015; PB 107 of 2018 |
| Part 3 | rep PB 30 of 2015 |
| s 27 | rep PB 30 of 2015 |
| **Part 4** |  |
| Division 1 | rep PB 30 of 2015 |
| s 28 | am PB 62 of 2011; PB 76 of 2012 |
|  | rep PB 30 of 2015 |
| s 29 | rep PB 30 of 2015 |
| **Division 2** |  |
| **Subdivision 1** |  |
| s 30 | am PB 30 of 2015; PB 87 of 2019 |
| Subdivision 2 | rep PB 30 of 2015 |
| s 32 | rep PB 30 of 2015 |
| s 33 | am PB 39 of 2012 |
|  | rep PB 30 of 2015 |
| s 34 | rep PB 30 of 2015 |
| **Division 3** |  |
| Division 3 heading | am PB 58 of 2015 |
| s 36 | am PB 58 of 2015 |
| **Part 5** |  |
| **Division 1** |  |
| s 37 | am PB 76 and 96 of 2012 |
| s 38 | rs PB 76 of 2012 |
| **Division 2** |  |
| Division 2 heading | am PB 58 of 2015 |
| s 39 | am PB 122 of 2010; PB 76 of 2012; PB 58 of 2015; PB 104 of 2017; PB 4 of 2020 |
| s 40 | am PB 76 and 96 of 2012 |
| s 41 | rs PB 76 of 2012 |
| s 42 | rs PB 26 of 2020 |
| **Division 3** |  |
| s 43 | am PB 122 of 2010 |
|  | rep PB 76 of 2012 |
| **Part 6** |  |
| s 45 | am PB 122 of 2010; PB 5 and 106 of 2012 |
|  | rep PB 30 of 2015 |
| s 46 | am PB 106 of 2012; PB 30 of 2015 |
| s 47 | am PB 106 of 2012; PB 30 and 58 of 2015 |
| s 48 | am PB 76 of 2012 |
|  | rs PB 106 of 2012 |
|  | am PB 30 of 2015 |
| **Part 7** |  |
| s 49 | am PB 62 of 2011 |
|  | rs PB 58 of 2015 |
| s 50 | am PB 30 and 58 of 2015 |
| s 51 | am PB 20 of 2012; PB 30 and 58 of 2015; PB 107 of 2018; PB 87 of 2019 |
| **Part 8** |  |
| s 52 | am PB 62 of 2011; PB 107 of 2018 |
| **Part 9** |  |
| s 54 | rep PB 30 of 2015 |
|  | ad PB 30 of 2015 |
|  | am PB 107 of 2018 |
| s 55 | rep PB 30 of 2015 |
|  | ad PB 30 of 2015 |
| s 56 | ad PB 58 of 2015 |
| **Schedule 1** |  |
| Schedule 1 | am PB 122 of 2010; PB 2, 28, 34, 38, 46, 53, 62, 69, 76, 86 and 99 of 2011; PB 5, 20, 31, 35, 39, 47, 64, 76, 106 and 110 of 2012; PB 10, 16, 30, 42, 56, 63, 70, 78 and 92 of 2013; PB 4, 11, 20, 30, 40, 48, 55 and 63 of 2014; PB 93 of 2014 (Sch 1 items 13, 14 md); PB 102 of 2014; PB 3, 30, 43, 50, 58, 72, 83, 94, 104, 111, 121 and 129 of 2015; PB 5 and 13 of 2016; PB 22 of 2016 (Sch 1 items 1–3, 6 md); PB 33, 45, 55, 67 and 76 of 2016; PB 84 of 2016 (Sch 1 item 8 md); PB 93, 100 and 113 of 2016; PB 5 of 2017; PB 20 of 2017; PB 30 of 2017; PB 39 of 2017; PB 47 of 2017; PB 57 of 2017; PB 66 of 2017; PB 75 of 2017; PB 88 of 2017; PB 95 of 2017; PB 104 of 2017; PB 6 of 2018; PB 16 of 2018; PB 22 of 2018; PB 40 of 2018 |
|  | ed C82 |
|  | am PB 54 of 2018; PB 67 of 2018 |
|  | ed C84 |
|  | am PB 77 of 2018 |
|  | ed C85 |
|  | am PB 85 of 2018; PB 94 of 2018; PB 102 of 2018; PB 111 of 2018; PB 3 of 2019; PB 13 of 2019; PB 20 of 2019; PB 31 of 2019; PB 39 of 2019; PB 48 of 2019; PB 61 of 2019; PB 70 of 2019; PB 78 of 2019 |
|  | ed C99 |
|  | am PB 87 of 2019; PB 95 of 2019; PB 106 of 2019; PB 4 of 2020; PB 17 of 2020; PB 24 of 2020; PB 26 of 2020; PB 37 of 2020; PB 46 of 2020; PB 72 of 2020; PB 82 of 2020; PB 93 of 2020; PB 106 of 2020; PB 115 of 2020 |
| **Schedule 2** |  |
| Schedule 2 | am PB 122 of 2010; PB 34, 46, 53 and 69 of 2011; PB 5, 20, 31, 47, 76, 106 and 110 of 2012; PB 16 of 2013 |
|  | rs PB 63 of 2013 |
|  | am PB 11, 93 and 102 of 2014; PB 30, 72, 94 and 104 of 2015; PB 5, 22, 67, 93 and 113 of 2016; PB 20 of 2017 |
|  | rs PB 104 of 2017 |
|  | am PB 16 of 2018; PB 22 of 2018; PB 40 of 2018; PB 85 of 2018; PB 94 of 2018; PB 102 of 2018; PB 111 of 2018; PB 3 of 2019; PB 31 of 2019; PB 61 of 2019; PB 87 of 2019; PB 95 of 2019; PB 4 of 2020; PB 24 of 2020; PB 37 of 2020; PB 72 of 2020; PB 82 of 2020; PB 106 of 2020; PB 115 of 2020 |
| **Schedule 3** |  |
| Schedule 3 | am PB 122 of 2010; PB 16, 28, 34, 38, 46, 62, 76, 86 and 99 of 2011; PB 5, 20, 31, 35, 39, 47 and 106 of 2012; PB 16, 56, 63, 70, 78 and 92 of 2013; PB 4, 20, 30, 40, 48 and 63 of 2014; PB 93 of 2014 (Sch 1 item 24 md); PB 3, 30, 43, 50, 58, 72, 83, 94, 104, 111, 121 and 129 of 2015; PB 5, 13, 22, 33, 45, 55, 67, 76, 84, 93, 100 and 113 of 2016; PB 5 of 2017; PB 30 of 2017; PB 39 of 2017; PB 47 of 2017; PB 57 of 2017; PB 66 of 2017; PB 75 of 2017; PB 88 of 2017; PB 95 of 2017; PB 104 of 2017; PB 6 of 2018; PB 16 of 2018; PB 22 of 2018; PB 40 of 2018 |
|  | ed C82 |
|  | am PB 54 of 2018; PB 67 of 2018; PB 77 of 2018; PB 85 of 2018; PB 94 of 2018; PB 102 of 2018; PB 111 of 2018; PB 3 of 2019; PB 13 of 2019; PB 20 of 2019; PB 31 of 2019; PB 48 of 2019 |
|  | ed C96 |
|  | am PB 61 of 2019; PB 70 of 2019; PB 78 of 2019 (Sch 1 par 46(a) md not incorp) |
|  | ed C99 |
|  | am PB 87 of 2019; PB 95 of 2019; PB 106 of 2019; PB 4 of 2020; PB 17 of 2020; PB 24 of 2020; PB 37 of 2020 |
|  | ed C106 |
|  | am PB 46 of 2020; PB 72 of 2020; PB 82 of 2020; PB 93 of 2020; PB 106 of 2020; PB 115 of 2020 |
| **Part 1** |  |
| Part 1 | rs PB 24 of 2020; PB 106 of 2020 |
| c 1 | ad PB 13 of 2016 |
|  | rs PB 113 of 2016; PB 39 of 2017; PB 24 of 2020; PB 106 of 2020 |
| c 2 | ad PB 13 of 2016 |
|  | rs PB 113 of 2016; PB 24 of 2020; PB 106 of 2020 |
| c 3 | ad PB 13 of 2016 |
|  | rs PB 113 of 2016 |
|  | am PB 5 of 2017; PB 66 of 2017; PB 75 of 2017; PB 77 of 2018 |
|  | ed C85 |
|  | am PB 3 of 2019 |
|  | ed C91 |
|  | am PB 20 of 2019 |
|  | rs PB 24 of 2020; PB 106 of 2020 |
| **Schedule 4** |  |
| Schedule 4 | am PB 28 of 2011 |
|  | rs PB 38 of 2011 |
|  | am PB 47 of 2012 |
|  | rs PB 76 of 2012; PB 16 of 2013; PB 84 and 100 of 2016; PB 20 of 2017; PB 75 of 2017 |
| **Schedule 5** |  |
| Schedule 5 | ad PB 32 of 2020 |
|  | am PB 46 of 2020 |
|  | rep 1 Apr 2021 (s 9AA(3)) |